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 I 
Abstract 
 
Integrated Data Analytics  
of Germline Mutation Classes in Human Cancers 
An Integrated Bioinformatics Analysis to Investigate Associations between 
Germline Mutation Classes and Human Cancers 
Keywords: 
Cancer, Mutation, Gene, Chromosomes, Pathways. 
 
Biological and environmental factors contribute collectively to the 
development of human cancers. The primary focus of this research project 
was to investigate the impact of germline gene mutations, as a significant 
biological factor, on 29 major primary human cancers. For this I obtained 
data from multiple databases, including the Genetic Association Database 
(GAD), Sanger database (COSMIC), HGMD database, OMIM data and 
PubMed literature. Using the Extraction Transform and Load (ETL) 
process, 424 genes were obtained with 8,879 cancer mutation records. By 
integrating these gene mutation records a Human Cancer Map (HCM) was 
constructed, from which several sub-maps were derived based on 
particular mutation classes. Furthermore, a Protein-Protein Interaction 
Map (PPIM) was constructed based on the encoded proteins of the 424 
gene set.  
  
Several key questions were addressed using the HCM and its sub-maps 
including the following: (i) Are individual groups of primary cancers 
associated with specific subset of genes (within the 424 full set)? (ii) Are 
groups of primary cancers associated with particular mutation classes? (iii) 
If both questions prove to be true, are groups of cancers associated with 
particular mutation class of target genes? This project also explored 
whether a corresponding Protein-Protein Interaction Map, derived from the 
Missense/Non-sense Mutation portion of the HCM gene set, would provide 
further information on gene associations between primary cancers in 
terms of the consequent identical amino acid changes involved.   
 
Results showed that: (1) closely-connected human cancers in the HCM 
exhibited a strong association with a particular mutation class;  (2) 
Missense /Nonsense and Regulatory mutations played a central role in 
connecting cancers (i.e. via primary nodes) and so significantly influenced 
the construction of the HCM; (3) Genes with Missense/Nonsense and 
Regulatory mutations tended to be involved in cancer-associated 
pathways; (4) Using the kappa test to measure the extent of agreement 
between two connected primary cancers in the sub-HCMs, BRCA1, 
BRCA2, PALB2, MSH2, MSH6, MLH1, CDKN2A, and TP53 showed 
   
 II 
highest agreement for 5 of 10 mutation classes; (5) From the PIPM, it was 
evident that BRCA1, MSH6, BARD1, TP53, MSH2 and CHEK2 proteins 
best connected Breast, Ovarian, Prostate and Bowel primary cancers, and 
so the latter could represent ‘driver proteins’ for these cancers.   
 
In summary, this project has approached the analysis of gene involvement 
in human primary cancers from the starting position of the mutation class 
that harbours the specific gene mutation. Together with their downstream 
resultant alterations in the associated proteins, this analysis can provide 
insights into the relatedness of primary human cancers and their potential 
gene hierarchies. These data may therefore help us to understand more 
fully the etiology, diagnosis and potentially personalized treatments for 
cancer.  
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Chapter One  
 
1. Fundamentals of Genes in Health and Disease 
 
Until recently the approach most widely used to investigate the 
fundamentals of human genetic variations in relation to the progression of 
human health and diseases has been focused primarily on identifying the 
variations of an individual candidate gene with the described patterns of 
Mendelian inheritance disease. The origin of Mendelian patterns of 
inheritance disease was first proposed by Gregor Mendel in 1865, on the 
basis of dominant and recessive genes (Mendel, 2008). Humans carry two 
copies of the same gene, each one of these copies is inherited from both 
parents. If one of the inherited gene copies is mutated on one of the 
autosomal chromosomes  (chromosomes 1-22) it can lead to the 
development of diseases, such as Huntington’s disease (Griffiths, 2005), 
neurofibromatosis type 1,2 and hereditary non-polyposis colorectal cancer 
etc. This is known as autosomal dominant. if both copies of the inherited 
genes from both parents are mutated then this can be called autosomal 
recessive, which is evident in newly born babies and certain rare 
conditions like cystic fibrosis (Flotte and Laube, 2001), sickle-cell disease 
and Tay-Sachs disease. Otherwise, if one copy of the mutated gene 
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occurs on the X chromosome, this can be called ‘X-linked dominant’ when 
the mutated gene is acting in dominant manner. The impact of the mutated 
gene can have influence on causing a disease in both males and females 
(as both genders have an X-chromosome), like Incontinentia pigment 
disease (Meuwissen and Mancini, 2012). If both gene copies are mutated 
this is known to be ‘X-linked recessive’ leading to disorders including 
Duchenne muscular dystrophy (Moat et al., 2013), or the less serious red-
green colour blindness (Lenaers et al., 2012) and male pattern baldness. 
Finally, if the mutated gene occurs on the Y chromosome, this can be 
called ‘Y-linked’, which is implicated for males only, and is known to be 
associated with male infertility (Yang and Zhang, 2010).  
Secondly, genetic heterogeneity influenced by environmental 
factors, i.e., etiologic heterogeneity, is associated with multiple groups of 
diseases that occur in populations e.g., breast cancers (Ford et al., 1998). 
Identifying the etiologic heterogeneity can be an important step toward 
detecting the possible impacts of gene-gene and gene-environment 
interactions on disease progression.  A third approach for consideration is 
to identify the influence caused by a group of genes on each other leading 
to the presentation or expression of diseases. Systems biologists have 
shown that diseases that share phenotypic similarity are often associated 
with genes with strong functional associations (Oti et al., 2008). Also, 
genes associated with similar functions tend to have similar expression 
patterns (Chu et al., 1998), which provide us with an opportunity to gain 
insight into the functional association of genes. These valuable insights 
have opened up the potential for a virtual roadmap for physicians, genetic 
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counsellors and biomedical researchers for the further study of disease 
associations and will help our understanding of how diseases are caused 
and so may be successfully treated. 
1.1. Chromosomes 
 
There are 23 pairs of different chromosomes in human cells, with 
one member of each pair inherited from each parent. One of these pairs 
represents the so-called sex chromosomes, with either two X or one X and 
one Y chromosome. Only the father can contribute the Y chromosome to 
produce a male offspring, while both parents can contribute an X 
chromosome to produce a female child discussed in (Pasternak, 2005).  
Eukaryotic chromosomes are mixtures of DNA and proteins, which 
together are called chromatin (Figure 1.1). A small amount of RNA is also 
present. Two classes of proteins, called histones and non-histone (or 
acidic) proteins are present to play a central role in chromatin structure. 
Proteins that form histones have a highly conserved amino acid sequence, 
suggesting that these molecules are very important. The basic building 
block of chromatin structure is called the nucleosome (Parry, 2001; Brown, 
1992).  
Nucleosomes consist of a core of histones around which DNA is wound. 
The core of DNA consists of two discs arranged in parallel, each 
composed of four histone molecules. The linker length between the 
nucleosomes varies. In humans it is about 60 base pairs (bp), giving a 
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total length of DNA per nucleosome of approximately 200 bp (Parry, 2001; 
Brown, 1992). 
 
 
Figure 1.1: An Illustration of a Chromosome. Each chromosome is divided into 
two parts by a point known as a ‘Centromere’. Chromosomes consist of four 
arms, two is known as short arms, labelled as ‘p,’ and the other two known as 
long arms, labelled as ‘q’. From (Leja, 2010) 
 
1.2. DNA 
 
The DNA molecule consists of three basic components: pentose 
sugar, (i.e, deoxyribose) and a phosphate group, as well as four types of 
nitrogenous bases, of which cytosine and thymine are single carbon-
nitrogen rings (called pyrimidines), and adenine and guanine are double 
carbon-nitrogen rings (called purines). It is important to note that the four 
bases combine with hydrogen ions in acidic solutions (Parry, 2001; 
Roberts and Pembrey, 1970; Brown, 1992). The chemical structure of the 
four bases that constitute the DNA molecule is shown in figure 1.2. There 
 
CHAPTER ONE 
   
 
5 
 
are three hydrogen bonds between the cytosine-guanine pairs, whereas 
there are two hydrogen bonds between the adenine-thymine pairs (Parry, 
2001; Roberts and Pembrey, 1970; Brown, 1992).  
 
 
Figure 1.2: Chemical structure of the DNA molecule. From (Wikipedia, 
http://en.wikipedia.org/wiki/File:DNA_chemical_structure.svg). 
 The double helix DNA molecule contains sugar-phosphates, which are held 
together in order to form the backbone of the polynucleotide strands. It is 
important to note that the polynucleotide chains run in opposite directions so that 
the polynucleotide has a free 5’ phosphate at one end and a free 3’ OH at the 
other end. The sequence of bases encoding the genetic information is read as 5’ 
to 3’ or 3’ to 5’. The four nitrogenous bases face the inner surface of each strand; 
hydrogen ties the four nitrogenous bases in the DNA strands, which creates the 
double helix. Each DNA subunit consists of one deoxyribose, one phosphate 
group and one base, called a nucleotide. Different sequences of nucleotide 
bases (ACCAAGTGC) specify a code for different proteins. Every 10 nitrogenous 
bases is executed to form the double helix. The sequence of base paring is 
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restricted such that adenine can only pair with thymine and guanine, can only 
pair with cytosine. This is called Complementary Base Pairing. This allows 
genetic information to be preserved during replication of the DNA and expression 
of the gene (Parry, 2001; Roberts and Pembrey, 1970; Brown, 1992; Lodish et 
al., 2000), as shown in figure 1.3. 
 
Figure 1.3: DNA and its building blocks. From (Lodish et al., 2000). 
1.3. Genes 
 
The DNA provides biological information for the organism, which 
will be encoded in a base sequence of the DNA and structured as an 
enormous number of genes. Individually these contain the instructions for 
the synthesis of a polypeptide (i.e. protein). From a physical perspective, a 
gene is a distinct segment of DNA with a base sequence that instructs the 
amino acid sequence of a polypeptide (Brown, 1992).  
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Genes differ significantly in size (the number of base pairs), ranging from 
less than 100 base pairs to several million base pairs. In higher-level 
organisms, the genes are run in a sequence of extremely long DNA 
molecules, named chromosomes. In humans there are around 20,000 to 
25,000 genes, organized in 23 chromosomes (Quackenbush, 2011).  
Biological information is carried by one of the two strands of the DNA 
double helix, which is known as the template/non coding/antisense strand, 
and can be used to generate an RNA molecule of the matching sequence, 
to direct the synthesis of the corresponding polypeptide. Whereas the term 
‘gene’ is often applied to the non-template/coding/sense strand, which 
allow the RNA polymerase reads and transcribes into mRNA, for a 
transcription into mRNA to occur a promoter sequence must be in the 
correct orientation position (Pasternak, 2005). 
1.4. Genetic Code 
The genetic code, as shown in Figure 1.4, illustrates how base 
sequences are transformed into amino acid sequences, where the DNA 
sequence of a gene is separated into units of three nucleotides. A 
nucleotide is composed of a base, a five-carbon sugar (either ribose or 2'-
deoxyribose) and a phosphate group. Each triplet nucleotide is called a 
codon and is indicative of a particular amino acid. Exceptions include 
methionine and tryptophan, which can be encoded by more than one 
codon (Figure 1.4). 
Codons that specify the same amino acid are called synonym codons and 
tend to be very similar; for example ACU, ACC, ACA and ACG, where the 
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changes are all at the third position of the codon  - called the “wobble 
position” (Brown, 1992; Hames and Hooper, 2000). Uracil is one of the 4 
bases in the nucleic acid of RNA. 
The genetic code is said to exhibit degeneracy. This is a description of 
redundancy, but without ambiguity. For example, although codons GAA 
and GAG both specify glutamic acid (an example of redundancy), neither 
of them specifies any other amino acid (therefore no ambiguity). 
Degeneracy of the genetic code minimizes the effects of mutations so that 
alterations to the base sequence are less likely to change the amino acid 
encoded with possible deleterious effects on protein function. It is 
important to note that there are 64 possible codons. 61 of these encode 
amino acids, while the remaining three codons (TAA, TAG, and TGA) act 
as signals for protein synthesis, which are known as termination codons or 
stop codons. The codon for methionine signals protein synthesis to start, 
and is known as the initiation codon (Brown, 1992) (Figure 1.4). 
 
Figure 1.4: Genetic codes, where the letters T, C, A and G are the actual base  
letters and the abbreviation letters after the codons is the produced amino acid 
from each codon (Brown, 1992). 
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1.5. Mutations 
The term Genotype describes the genetic or specific allele makeup 
of an individual and so also can inform the mutation types of specific 
genes under assessment. The Phenotype describes the individual’s 
observable characteristics or traits (e.g. morphology or other biochemical 
or physiological properties, behaviour etc.). Thus, genetic mutation can 
result in phenotypic change. Different forms of mutations include: 
Regulatory, Complex rearrangements, Gross deletions, Gross 
Insertions, Missense/Nonsense, Repeat Variations, Small deletions, 
Small indels, Small insertions and Splicing variants (Joshi, 1997). 
These genetic mutations can give rise to several possibilities of human 
diseases when function is negatively affected.  
Mutations can occur due to errors during DNA replication or be caused by 
environmental factors, such as a chemical mutagen, cosmic radiation, 
chemical carcinogenic, virogenic and ionic radiation. Environmental factors 
can have effects on human health and cause variance at the gene level, 
especially in cases of somatic cell mutation (Figure 1.5). This figure 
illustrates the intrinsic factors that cause genetic mutations in the human 
genome; either via an error occurring during DNA replication or 
methylation or via a transposable genetic element. By contrast, extrinsic 
factors (e.g., physical, chemical and cosmic radiation) can also cause 
gene mutations.   
Besides errors in a DNA replication, gene mutations can be caused by 
various events: - 
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 If the gene-coding region is affected this could lead to alteration of the 
amino acid sequence in the resultant polypeptide chain of a specific 
protein (Kimball, 2003).  
 Methylation, known as the biochemical process for adding the methyl 
group to the cytosine or adenine DNA nucleotides. Whereas the 
Transposable Genetic Element is the DNA sequence that can change 
its position within the genome. These two terms can also give rise to 
abnormal gene products, which can behave like gene mutations. 
However both sometimes only provide temporary prevention of normal 
gene expression, that leads to modification of phenotypic performance, 
known as the epigenetic effect (Kimball, 2003). 
 Epigenetics is the modification to the genome of cancer cells, which is 
caused by a number of factors (e.g., methylation), and usually occurs 
due to methylation at the cytosine base (CpG). The epigenetic change 
does not involve nucleotide sequence changes, and it is as important 
as genetic mutations in a cell’s transformation to cancers (Novak, 
2004).  
Furthermore, a gene mutation is a change in DNA sequence away from 
‘normal’ to abnormal genetic variance. In contrast, a polymorphism is a 
common variation in DNA sequence among individuals in a population. To 
distinguish a mutation from a polymorphism, there is an arbitrary cut-off 
point observed as ≥ 1% prevalence in a population. If this found to be < 
1% then the allele is regarded as a mutation (Ahmadian et al., 2000). 
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Figure 1.5: Causes of Genetic mutations. 
 
1.6. Gene Mutation Classes 
1.6.1. Frame Shift Mutation (Insertions and Deletions) 
 
A frame shift mutation involves the deletion or insertion of a single 
nucleotide, which results in extra or missing amino acids in a polypeptide 
chain of a protein, with the possibility of having a deleterious effect. 
Deletions and insertions tend to be especially harmful when the number of 
missing or extra base pairs is not a multiple of three. This is due to the fact 
that codons consist of groups of three base pairs and such insertions or 
deletions can alter all of the downstream codons (Bell et al., 2003). See 
the example figures 1.6 and 1.7 for single base insertion and deletion. 
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Figure 1.6: The insertion of single base (an A in the second codon) would convert 
the DNA sequence so it reads as 5’-CAT CAT CATCATCATCAT CAT-3’ To 5’-
CAT CAT CAT ACA TCA TCA TCA-3’. This would change the amino acid 
sequence from His-His-His-His-His-His-His to His-His-His-Thr-Ser-Ser-Ser. 
Image  from (Medicine, 2013b) 
 
 
Figure 1.7: The deletion of single base (an A in the second codon) would convert 
the DNA sequence so it reads as 5’-CAT CAT CATCATCATCAT CAT-3’ To 5’-
CAT CAT CAT CTC ATC ATC ATC-3’. This would change the amino acid 
sequence from His-His-His-His-His-His-His to His-His-His-leu-lle-lle-lle.  Image 
taken from (Medicine, 2013a) 
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1.6.2. Missense/Nonsense Mutation 
Missense mutations involve a change in a single amino acid that 
may affect a protein’s structure or function, and is thus likely to lead to a 
harmful effect in the individual and to generate a mutant phenotype 
(Kozak, 1986). Nonsense mutations can produce, in error, one of three 
stop codons (UAA, UAG or UGA) in messenger RNA (mRNA). The stop 
codons can terminate both mRNA transcription and translation and so 
result in premature termination of the polypeptide chain. On the other 
hand, if a correct stop codon is altered to now encode for an amino acid, 
an abnormally elongated polypeptide is then produced (Welch et al., 2007) 
(Figure 1.8).  
 
Figure 1.8: Missense mutations, of single base (an A in the 4th codon) would 
convert a DNA sequence so it reads as 5’-CAT CAT CAT CAT CAT CAT CAT-3’ 
to 5’-CAT CAT CAT CCT CAT CAT CAT-3’. This would change the amino acid 
sequence from His-His-His-His-His-His-His to His-His-His-Pro-His-His-His. 
Image Taken from (Medicine, 2013c) 
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1.6.3. Splice Site Mutation 
Various types of RNA molecules play key roles in making proteins. 
The gene transcript (mRNA) transfers information from DNA in the 
nucleus to the ribosome in the cytoplasm that makes protein. The mRNA 
molecule is used in protein formation via a process called RNA splicing via 
the excision of Introns (non-coding elements) and re-connecting the Exons 
together (see figure 1.9). Arranging Exons in different patterns, called 
alternative splicing, enables the cells to make different proteins from a 
single gene (Norvell and Machalek, 2000). Splicing has to be extremely 
accurate; any errors in the splicing process, even one that results in the 
deletion of just one nucleotide in an Exon or the addition of just one 
nucleotide in an Intron, will throw the whole sequence out of alignment. 
The result is usually an abnormal protein or no protein at all (Norvell and 
Machalek, 2000). For example, splicing error mutations are the causative 
factor of one form of Alzheimer's disease (Kinzler and Vogelstein, 1998).  
 
Figure 1.9: Mutation of normal Splicing (Norvell and Machalek, 2000). 
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1.6.4. Repeat Variations Mutation 
 
Genetic variation is important source of genetic material for natural 
selection. The natural selection is the result of the interactions between 
genetic variations in a population and the environment.  A variation 
mutation in the alleles of genes can occur within and among populations, 
which can lead to a permanent change in the primary structure of a gene. 
However there are three primary factors of genetic variation (i) a single 
nucleotide change in the DNA sequence of genes, (ii) A transfer of a gene 
or alleles from one population to another i.e gene flow (gene migration). 
For example, the mixed populations of humans in the USA has proved the 
transfer of malaria resistant gene from the migrant population to the native 
population among whom the gene was absent originally , (iii) introducing a 
new gene combination into a population i.e sex and genetic shuffling. 
(Conrad et al., 2011) 
 
1.6.5. Small Indels Mutation 
The databases used in this study additionally defines a mutation 
class as ‘small indels’ and represent different records from those included 
in the frame shift mutation (see above). ‘Indel’ stands for mutations with 
either an insertion or a deletion, i.e., a mutation class that includes both 
insertions and deletions (Kondrashov and Rogozin, 2004; Ogurtsov et al., 
2004).  Indels differ from point mutations; where an Indel inserts and 
deletes nucleotides from a sequence, a point mutation is a form of 
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substitution that replaces one of the nucleotides (Figure 1.10). Indels can 
also be contrasted with Tandem Base Mutations (TBM), which may result 
from fundamentally different mechanisms (Hill et al., 2003). (See figure 
1.10). 
 
Figure 1.10: Small Indels, where line 1 shows the standard moose sequence, 
with 5th, 6th, & 7th triplets highlighted, Lines 2 & 3 show a single-nucleotide 
insertion (T) or deletion (g) at the sixth triplet, Lines 4 & 5 show a double-
nucleotide insertion (TT) or deletion (gg) at the sixth triplet and Lines 6 & 7 
show a triplet insertion (TTA) or deletion (gga) of the sixth triplet (Hill et al., 
2003). 
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1.6.6. Regulatory Mutation 
Cis-regulatory element is a region of DNA or RNA that regulates the 
expression of genes located on that same DNA molecule. The word ‘cis’ 
means “on the same side as” (Wray, 2007).  Regulatory mutations 
represent a significant cause of human disease. According to April 2009 
statistics compiled by the Human Gene Mutation Database, 1459 
regulatory mutations have been identified in over 700 genes that cause 
human-inherited disorders. The majority of these regulatory mutations are 
located in proximal and distal promoter elements (a region of DNA that 
facilitates the transcription of a particular gene) that map within 1 kb of the 
transcript start site (TSS). Cis-regulatory mutations affect a broad range of 
morphological, physiological and neurological phenotypes (Epstein, 2009). 
(Figure 1.11). 
 
 
Figure 1.11: Regulatory Mutation: two different promoters are located next to the 
two different genes. By binding to Promoter 1, an enhancer actively regulates 
Gene 1 and leads to its transcription, as indicated by the black arrow above Gene 
1. An insulator prevents this enhancer from activating Gene 2, which is not 
transcribed due to regulation by the silencer (Worsley-Hunt et al., 2011; Epstein, 
2009). 
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1.6.7. Chromosome Rearrangement Mutations 
1.6.7.1. Translocation  
Chromosomal translocation, a chromosome abnormality or 
aberration caused by rearrangement of parts. The mutation is caused by a 
rearrangement of two different non-homologous chromosomes breaking 
and re-joining, where genes in one part of the one chromosome is 
replaced with another genes in part of different chromosome. A fusion 
gene might be creating as a result of the translocation which knows to be 
a common type for causing cancers (Kinzler and Vogelstein, 1998).  
1.6.7.2. Complex Rearrangements (Inversion) 
This class represents a process where a part of the chromosome is 
reversed end-to-end, and inversions are most likely to happen when 
individual chromosome suffer a break and are then rearranged. There are 
two types of Inversion, the first one can happen in one arm of the 
chromosome which knows to be as ‘Paracentric’ and the other one can 
happened in both of the chromosome arms with the involvement of the 
centromere breaking point which is knowing as ‘Pericentric’ (Kinzler and 
Vogelstein, 1998). 
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1.6.7.3. Genetic Duplications/Amplification 
Gene duplication is a mechanism to generate new genetic material 
i.e., molecular evolution. Duplications occurs in chromosomes contains a 
proto-oncogene within them where the number of copies of proto-
oncogene is increased in that chromosome. However these newly 
introduced copies of the proto-oncogene produce protein that is involved 
in stimulating cell growth. Therefore the amount of the produced proteins 
can be increased, which might lead to the cause of cancers (Kinzler and 
Vogelstein, 1998).  
1.6.7.4. Gene Deletion/Deficiencies 
 
Genetic aberration is the process where a part of chromosome or 
DNA sequence is deleted resulting a loss in a genetic material. The 
deletion could be errors in the exchange of genetic material between 
homologous chromosomes (crossing over) during the cell division 
(meiosis), which can cause serious disorders such as cancers (Kinzler and 
Vogelstein, 1998). 
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1.7. Literature Review of Gene Mutations in Human 
Cancers 
Various attempts and approaches have been made in order to 
understand genetic mutations classes and the related human cancers 
arising from these mutations. A review of the most cited literature studies 
related to this field is discussed in this section.    
1.7.1. Relationship between Gene Mutations Classes and Human 
Cancer 
During the past decade biomedical researchers have examined a 
small number of cancers sharing commonalities in both etiology and 
pathology. The latest growth in genetics and genomics studies has 
enabled us to interrogate the entire genome for the influence of genes in 
causes of human cancers (Jimenez-Sanchez et al., 2001; Cooper et al., 
2010).  These impressive studies have opened the gates wide for cancer 
genomic research to investigate the implications of mutation classes in 
human cancers.  
Many authors have been able to identify cancers based on mutation 
classes, starting with the Missense/Nonsense mutations, where detection 
of a single nucleotide changes leading the genetic sequence to encode for 
different amino acid. For example in studies of (Sweet et al., 2010; Sluiter 
and van Rensburg, 2011; Bonadona et al., 2011) some cancers (such as 
Breast, Lung and Bowel) were considered as a consequence of altered 
amino acid, that occurred due to dozens of single base-pair substitutions, 
 
CHAPTER ONE 
   
 
21 
 
in a group of genes (e.g., ATM, BRCA1, BRCA2, MSH2, MSH6 and 
MLH1).  
Others have detected how a change of nucleotides during splicing of an 
intron could transform the precursor messenger RNA into mature 
messenger RNA, leading to unusual production of proteins. For example, 
altered distributions of the exonic splicing enhancer motif in ATM gene 
resulted in a change in protein function that are associated to breast 
cancer (Brunet et al., 2008; La Paglia et al., 2010).  
Remaining with the single base-pair substitutions, a regulatory mutation in 
the FAS gene promoter affects gene expression and modulates apoptotic 
signalling and can cause Acute Myeloid Leukaemia (Sibley et al., 2003). 
Yang and co-workers examined 1,840 lung cancer patients and found two 
single nucleotide polymorphisms (SNPs) located in the FEN1 promoter, 
which causes the reduction of FEN1 expression level, leading to the 
development of lung cancer (Yang et al., 2009).  
Small insertions and deletions can alter human genetic sequences and 
can result in cancer formation. One of the most common human genetic 
cancers, breast cancer, is frequently caused by a small coding insertion or 
deletion within the MSH2, MSH6 and MLH1 genes that eliminates a single 
amino acid (Kim et al., 2010; Nilbert et al., 2009). Another form of deletion 
and insertion, include gross deletions for the entire FH gene and gross 
insertions or duplications for the FH gene in two different patients; both 
processes can cause kidney cancer (Bardella et al., 2011; Ahvenainen et 
al., 2008). Others  (Vaughn et al., 2010) have further proposed how the 
whole deletion of the Mismatch repair gene (PMS2) in 22 out 53 patients is 
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principally responsible for a form of bowel cancer (Walsh et al., 2010). 
Discovery of the inheritance patterns for mutations of large 
rearrangements (Gross Insertion) in the BRCA1 gene has revealed the 
importance of this gene in breast cancer. A study of large genomic 
rearrangements (complex rearrangement mutations) in breast cancer 
cases (Engert et al., 2008), has revealed that BRCA1 can harbour cancer-
causing mutations. An analysis of 1,506 German families carrying breast 
and ovarian cancers detected a total of 32 pathogenic rearrangements in 
the BRCA1 genes. BRAC1 gene screening has been carried out on 283 
ovarian cancer patients to detect large genomic alterations, with the 
finding that 12 of these patients exhibit complex rearrangements mutations 
(Ramus et al., 2007). 
A small indel have also been found to be a cancer-causing mutation. It 
tends to have a deletion of a single base or double nucleotide insertions 
affecting the genetic sequence, such as the finding of a small indel 
mutation in HLA-DQA1 causing  lung cancers  (Qiu et al., 1996). Finally, a 
reported study of the MUC6 gene, which is a highly expressed gene in 
stomach and gall bladder, has been carried out on 470 gastric cancer 
patients, which showed that five of these cancer patients are known to 
have repeat variations mutations in this gene (Kwon et al., 2010).  
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1.7.2. The Analysis of Genetic Data in Cancer Research 
The past few decades has witnessed a rapid development in 
technologies that can analyze cancer genomes. These have focused on  a 
single platform or type of genetic alteration such as High Resolution Melt 
(HRM) analysis for the detection of novel oncogenes (Nanjundan et al., 
2007). Similarly, the technology of DNA Sequencing (i.e., directed 
sequencing, shotgun sequencing) has been used widely to detect novel 
genes involved in specific cancer types e.g., direct sequencing to detect 
mutations in BRAF causing human cancers (Davies et al., 2002). More 
recently, a combination of genome sequencing and bioinformatics tools 
has been used, e.g., by The Cancer Genome Atlas (TCGA), to catalogue 
genetic mutations associated with cancers. All these developments have 
opened the road widely for new genetic analysis tools. For example, a new 
technique has been implemented to sequence DNA, named as the 
Second-generation sequencing. This new technique offers several 
advantages over previous technologies; (i) allows the whole genome to be 
sequenced, (ii) offers structural information, which has never been 
available before using other platforms, (iii) enables for the first time a 
global assessment of chromosomal rearrangements in cancer. A good 
example of next generation sequencing can be found in (Mardis et al., 
2009). 
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1.8. Method for the Analysis of Biological Networks 
A network is a graphical representation of relations between 
objects, where these objects potentially interact with each other. In human 
genome research, graphs or networks have been used to represent 
various complex biological processes such as regulatory networks, 
disease networks, and various types of pathway interactions such as 
protein- or gene-interactions. The development of molecular networks was 
begun over 40 years ago using classical molecular tools (Dagley and 
Nicholson, 1970). With the rapid increase genome data, scientists now are 
able to construct more informative molecular networks, such as protein-
protein interaction networks and gene regulatory networks. These 
molecular networks have similarities in terms of their structures. For 
example, the yeast transcription regulatory network (Guelzim et al., 2002), 
the metabolic networks (Wagner and Fell, 2001), and the yeast protein 
interaction network (Wagner, 2001), all have approximately power-law 
degree distribution, where most nodes in the networks interact with one 
other node, and a few can interact with tens or hundreds of others. 
Various mathematical approaches have been used to investigate the 
structure of biological networks including (i) degree distributions of nodes 
(k), (ii) clustering coefficient. The degree distribution (Newman, 2003) is 
used to quantify the properties of each node connecting to other nodes 
within the network. The clustering coefficient is to observe the connections 
of a node and connections made by its neighbours, this observation can 
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only be applied to a large fragment of the network (Newman, 2003). See 
figure 1.12 
 
Figure 1.12: Theoretic illustration of a network (Proulx et al., 2005) (a) divided 
into three components A, B and C outlined with dash line. Each component node 
is represented by circles or squares. These nodes are connected via edges (solid 
black lines). The degree of connectivity for each node varies between 0 and 4, for 
example the central node with degree 4 is shaded darker green. In component 
(A) the shortest path between square node 1 and square node 2 consists of 4 
steps. Whereas component (B) has a high clustering coefficient, due to the 
connectivities of its neighbour (i.e, every set of three nodes is connected within a 
triangle of edges). (b) Comparison of the node degree and frequency 
distributions produced by models of network formation, displayed on a log-log 
plots. Poisson random networks and Power-law degree distributions that appear 
linear are shown in the Figure 1.12 (Proulx et al., 2005).     
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1.9. Aims and Objectives 
The main aim of this study is to investigate the influence of various 
germline mutation classes on different human cancers, by means of (i) 
constructing a Human Cancer Map (HCM) based on a knowledge of 
genes and on their associated mutation classes, (ii) investigating the 
distribution of mutation classes over the newly constructed Human Cancer 
Map (HCM), (iii) constructing a Genome-wide Distribution Map to identify 
the involved genes in the constructed Human Cancers Map, (iv) identifying 
pathways associated with the involved genes in the constructed Genome-
wide Distribution Map, (v) identifying the relatedness of the involved genes 
in the Genome-wide Distribution Map based on their biological roles and, 
(vii)  associating genes with cancer based on the corresponding encoded 
proteins and the protein-protein interactions (PPI) followed by their 
interrogation for Missense/Nonsense mutations.  
This study was conducted in several phases: First, I investigated the 
properties of gene mutation classes in relation to human cancers; second, 
I gathered information about the ten classes of germline mutations 
involved. Third, I prepared the gathered biological data and established 
associations between gene mutations and human cancers. Thereafter, I 
build a human cancer map and a Genome-wide Distribution map based on 
the associations of specific mutation classes. 
The objectives in order to achieve this aim included: 
 Integrating the complementary data sources such as Genome 
database, OMIM, HUGO Gene Nomenclature Committee, Entrez 
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Gene, GeneCards, GenAtlas, GeneClinics, UniGene, SwissPort, 
Human Protein Reference Database, Human Gene Mutation 
Database (HGMD), Genetic Association Database and Sanger 
Database. 
 Designing constructing and analysing networks using various 
bioinformatics tools including R and bioconductor, Cytoscape and 
Gephi network visualization tools. R is a programming language 
that has been widely used for statistical computation, graphics and 
bioinformatics. Cytoscape is an open-source bioinformatics 
software platform for visualizing molecular interaction networks and 
biological pathways and integrating these networks with 
annotations, gene expression profiles and other state data. Gephi 
visualization is a network analysis tool that has been used widely by 
bioinformatics.   
 Designing and constructing a Genome-wide Distribution Map using 
CIRCOS visualizing software package (Krzywinski et al., 2009) and 
Perl Programming Language.  
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Chapter Two  
 
2. Material and Methods 
The aims of this chapter are four-fold: (i) to investigate the 
properties of genetics in relation to human cancers, by accessing various 
complementary data sources, including Genome Database (Grzybowska 
et al., 2002), Database of Human Genes and Genetic Disorders (OMIM) 
(Amberger et al., 2009), GeneCards (Safran et al., 2002a), Genetic 
Association Database (GAD) (Becker et al., 2004), Sanger Database 
(Futreal et al., 2004) and the Human Gene Mutation Database (HGMD) 
(Stenson et al., 2009); (ii) to extract genes associated with cancers and 
their associated classes of germline mutations including; Regulatory, 
Complex rearrangements, Gross deletions, Gross Insertions, 
Missense/Nonsense, Repeat Variations, Small deletions, Small indels, 
Small insertions, and Splicing;  (iii) to extract the associated biological 
aspects of these data, with reference to Cancer Research UK and 
PubMed, (iv) to apply the appropriate statistical methods for analysing the 
data. 
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2.1. Data Integration 
Data integration can be defined as a process of combining data 
obtained from different sources, with ‘cleaning-up’ the data so as to 
provide a unified view for users. This process is a significant in this study, 
as it involves complex data mining procedures to combine research results 
and findings from different depositories (Halevy, 2001). This process 
results in a new ‘data warehouse’, via procedures of Extracting data from 
various sources, and then Transforming it to construct a database suitable 
for a particular  operation, and Loading it to be in a useable format (ETL) 
for data mining and analytics (Chaudhuri and Dayal, 1997). My aim here is 
to apply the ETL process to perform data extraction from three 
complementary data sources, including Genetic association database 
(GAD), Sanger database (COSMIC) and human gene mutation database 
(HGMD), and then transforming it (e.g cleaning, reformatting, 
standardization, aggregation) into a suitable data set as specific tables 
layout (See figure 2.1). The data described in the next two sections 2.2 
and 2.3 will be manipulated based on the ETL process.  
 
Figure 2.1: Extraction, Transform, and Load (ETL). On the left hand side is the 
list of three main biological databases to be used in this project. The ETL is the 
process to apply for the extracted data, and the data warehouse is when the data 
is ready to be suitable for the project needs. 
 
CHAPTER TWO 
 
30 
2.2. Source of Data and Genetic Records Used in this 
Thesis  
 
2.2.1. The Genetic Association Database (GAD)   
The Genetic association Database (GAD) (Becker et al., 2004), is 
an online library archive of published genetic association studies that 
provides a comprehensive, public, web-based repository of molecular, 
clinical and study parameters for more than 130,000 entries of human 
genetic association studies. These includes 19 different disease classes, 
such as cancer, aging, cardiovascular, chemdependency, developmental, 
haematological, immune, infection, metabolic, mitochondrial, neurological, 
normal variation, pharmacogenomics, psychiatric, renal, reproduction, and 
vision. Each entry of the GAD is saved as an independent record and is 
composed of 22 fields (or attributes), including gene symbol, entrez 
GeneID, chromosomal location, associated tag between genes and 
disorders (“Y”, N), DNA position, P-value, reference and its corresponding 
PubMed is and OMIM id, etc.  
The GAD data file was downloaded on 30 November 2011. Out of 21,444 
cancer-related entries, 1,908 were selected based on their positive 
associations with cancers. The selected entries contained 486 unique 
genes and 480 duplicated primary or subtype cancer disorder names. 
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2.2.2. The Cancer Gene Census Database (COSMIC)   
The Cancer Gene Census Database (COSMIC) (Futreal et al., 
2004) is a collection of somatic and germline mutations with classes of 
mutations from  the published literature. The mutation information is based 
on those mutations implicated in the development of particular cancers. 
The COSMIC database stores a total of 1,324 mutations entries. Table 2.1  
summarise the characteristics of COSMIC data. Each entry of COSMIC is 
saved as a unique independent record and is composed of sixteen fields 
(attributes), including gene symbol, name of gene, geneID, chromosome, 
chromosome band, somatic mutation, germline mutation, tumour type 
(somatic mutation), tumour type (germline mutation), cancer syndrome, 
tissue type, cancer molecular genetics, mutation subclasses, 
translocation, other syndromes.  
We downloaded the COSMIC database file on 1st of February 2012. Out of 
487 cancer-related genes, 76 genes were selected with germline 
mutations.  
Table 2.1: Total number of entries for each mutation type, mutation class, gene, 
and chromosome. 
Category Number 
Amplification Mutation 16 
Chromosome location 487 
Frameshift mutation 100 
Germline Mutation 76 
Large deletions 37 
Missense Mutation 141 
Nonsense Mutation 92 
Other mutation 26 
Somatic Mutation 447 
Splicing Mutation 63 
Gene Symbol 487 
Translocation Mutation 326 
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2.2.3. The Human Gene Mutation Database (HGMD) 
The Human Gene Mutation Database (HGMD) (Stenson et al., 
2009) is a large depository of broad data on human germline mutations 
with its sub-categories of mutation classes. The mutation data includes 
point mutations of a single base pair with insertions and deletions, 
regulatory and splicing-relevant regions of human nuclear genes, micro-
deletions (indels), repeat variants, gross lesions (deletions, insertions and 
duplications) and complex rearrangements (including inversions, see table 
2.2 for a summary of mutation data). The mutation data was stored as 
independent records and presented on a gene-wise basis, with access to 
the mutation classes data via a hypertext link, including additional data 
sources (i.e., Genome Database (GDB), Online Mendelian inheritance in 
Man (OMIM), HUGO Gene Nomenclature Committee (HGNC), Entrez 
Gene, GeneCards, GeneAtlas, GeneClinics, UniGene, SwissProt and the 
Human Protein Reference Database from each gene page. 
 
Table 2.2: Total number of mutation classes held by HGMD [3] 
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In order to extract data from the HGMD Web-based application a 
gene symbol is needed. The gene symbols used here were based on 
merging the GAD and COSMIC gene data, then performing a filtering 
process to remove duplicated genes. In total 520 unique genes were 
selected which represent the cancer-associated genes. The HGMD was 
then extracted manually by entering each of the gene symbols into the 
HGMD Web-based applications. The result of the search included gene 
symbol, gene descriptions, chromosome location, cDNA sequence ID, 
mutation classes, total number of mutations for each gene, total number of 
specific class of mutation for each of the gene, related phenotypes, unique 
mutation ID, PubMed references, and some additional information about 
the gene. I further expanded the search by using cancer names obtained 
from the GAD to increase the chance of finding new cancer-related gene 
and mutation records. As a result a total of 15,264 records were collected, 
with a combination of cancers and some non-cancers disorders for each of 
the 10 different mutation classes. Table 2.3 summarises the total number 
for each manually-curated mutation record. 
Table 2.3: Classes of mutation; with total number of collected records for cancers 
and non-cancer disorders.  
Class of mutation Total number of mutation records 
Missense nonsense 7456 
Small Deletion 3280 
Splicing 1465 
Gross Deletions 1227 
Small Insertions 1111 
Regulatory 280 
Small Indels 177 
Gross Insertions 150 
Complex Rearrangements 82 
Repeat Variations 36 
Total 15264 
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For further investigation the entries were cross-checked twice manually to 
ensure there was no duplication of the data and to double-check that the 
collected information is accurate and that none of the records were 
eliminated by the extraction process. As I was only interested in the 
cancer entries, a separation of the data on the basis of cancers and non-
cancers entries was carried out in the data preparation part for each of the 
10 classes. 
2.2.4. DAVID Bioinformatics Database 
Database, Annotation, Visualization and Integrated Discovery 
(DAVID) is an online functional annotation tools program. The tool aims to 
group a list of genes from different organism/species based on measuring 
the agreement of genetic biological functions (annotations). DAVID web-
based tools tend to deliver other services, such as identifying the genetic 
pathways for a given list of genes, using bio-pathways, KEGG pathways 
and more (Sherman et al., 2007). My interest in DAVID online tools is to 
group our genes based on annotation associations using the functional 
classification tools.  
2.2.5. The BioGRID Database 
The Biological General Repository for Interaction Datasets 
(BioGRID) is a public database for genetic and proteomics interactions 
(http://thebiogrid.org/). The BioGRID contains 684,996 physical and 
genetic interaction records, of which 381,026 are about human cells 
(access date:01/10/2012). The BioGRID supplies an important plugin for 
Cytoscape visualization network tools, known as BioGRID Plugin, to allow 
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access of interaction data. This plugin was used in this research to search 
for the Physical Protein-Protein interactions related to the 424 selected 
genes (Stark et al., 2011). 
2.3. Data Preparation 
In the original HGMD, the 15,264-curated mutation records have 
much complexity with the data. For example the data was a combination 
of cancers and non-cancer disorder records. Also, many of the cancer 
entries are duplicated using different names/terms or the subtypes of 
cancer disorders are listed together with primary cancer names/categories 
etc. To deal with such data complexity, the non-cancer disorder records 
were eliminated from the list by investigating on a manual basis each of 
the disorders for the 15,264 records and the eliminations informed by the 
published literature studies (e.g., PubMed, OMIM and other online 
libraries) (Amberger et al., 2009). As a result 6,717 non-cancer records 
were eliminated from the 15,264 list (see table 2.4).  
Table 2.4: The total number of eliminations for each of the mutation class for 
cancers and non-cancers disorders. 
Mutation Non-cancer Mutations Cancers 
Mutations 
Missense nonsense 4371 3085 
Small Deletion 1181 2099 
Small Insertions 374 816 
Gross Deletion 325 902 
Splicing 295 1091 
Regulatory 91 189 
Small Indels 34 143 
Gross Insertions 19 131 
Repeat Variations 16 25 
Complex Rearrangements 11 66 
Total 6717 8547 
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Secondly, the remaining 8,547 cancer records exhibited some 
naming/nomenclature complexity i.e., the primary cancer name had sub-
classification names. For example, Leukaemia has two subclasses - Acute 
Leukaemia and Chronic Leukaemia, and each one of these a variety of 
subtypes. On the other hand many of the cancers were duplicated using 
‘different’ names; e.g., Bowel cancer, Colorectal cancer and Colon cancer. 
These entries with duplicated names should be merged into the cancer 
term “Bowel cancer” etc. To solve this critical issue, a hierarchy list for 
each of the primary cancer names was manually created, followed by 
primary cancer subclass names and sub-subclass cancer names. In other 
words, constructing a family tree for each of the cancers, starting from 
primary, secondary, tertiary and so on. This family tree of cancers 
informed the re-arrangement of the data to be used for further 
development in the project in order to achieve our aims and objectives. 
See table 2.5 for an Illustration of the hierarchy of human cancers, 
constructed based on the terms applied in Cancer Research UK-accepted 
terms (Grzybowska et al., 2002). Moving further and to ensure no more 
complexity of the cancers disorder naming, I cross-checked each of the 
entries using the naming structure of table 2.5. This is to associate each 
cancer with its primary named cancer. While assigning each of the 
individual cancer entries into their ‘primary’ cancer designation (e.g, all 
cancers affecting the bowel designated as ‘Bowel Cancer’ as primary 
name), in some cases several cancers were found to be associated with 
the same mutation. For example,  a Missense/Nonsense mutation in the 
MLH1 gene (i.e. ‘CGG’ to ‘TGG’) resulting in an ‘Arg’ to ‘Trp’ change at 
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position 389 was found in both Breast and Colorectal cancer (Jensen et 
al., 2010), see table 2.6. Therefore, this mutation record was split into two, 
though both retained the same unique mutation ID. This approach allowed 
me to look at each of the cancer disorders as independent records when 
applying the statistical analysis for each gene mutation and cancer (see 
Tables 2.6 and 2.7). After the required data pre-processing (eliminations, 
merging and splitting) 8,879 mutation records were remained, containing 
424 unique genes and a total of 26 primary unique cancer disorders. Each 
entry was stored as an independent record (see figure 2.2). 
Finally, the data was manipulated to construct a table containing the 
following entries: gene symbol, unique mutation ID, sub class of mutation, 
cancers disorder name, total number of mutations for each gene, total 
number of mutations for each of the 10 different classes of mutations, and 
PubMed references (Table 2.8).   
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Figure 2.2: Algorithmic framework for the extractions and preparation of mutations data. The start point at the top of the image shows the two 
extracted databases for finding the cancer-associated genes. Moving to the middle of the image the HGMD database shows the extractions of 
mutation records, while moving down the image shows the split of the data for cancers and non-cancers. This is followed by filtering the data 
on the basis of primary cancer names. 
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Table 2.5: The hierarchy of human cancer disorders (family tree of cancers), 
where the red text represents the primary cancer name, the green text the 
subtype (secondary level) and the black text the tertiary level name. In total there 
are 29 primary cancer names, each one followed by its subtypes. 
 
Hierarchy of cancers  
1 Leukaemia 
1.1 Acute leukaemia 
1.1.1 Acute Myeloid Leukaemia 
1.1.2 Acute Lymphoblastic Leukaemia 
1.2 Chronic leukaemia 
1.2.1 Chronic myeloid leukaemia 
1.2.2 Chronic lymphocytic leukaemia 
1.2.3 Hairy cell leukaemia 
2 Brain Tumour 
2.1 Gliomas 
2.1.1 Astrocytoma 
2.1.2 Ependymoma 
2.1.3 Oligodendroglioma 
2.1.4 Mixed glioma 
2.2 Astrocytomas 
2.3 Ependymomas 
2.4 Acoustic neuromas 
2.5 Craniopharyngiomas 
2.6 Haemangioblastomas 
2.7 Primary cerebral lymphoma 
2.8 Meningiomas 
2.9 Germ cell tumours 
2.10 Pineal region tumours 
2.11 Pituitary tumours 
2.12 Primitive neuroectodermal tumours (PNETs) 
2.13 Spinal cord tumours 
3 Breast Cancer 
3.1 DCIS- Ductal carcinoma in situ 
3.2 LCIS- Lobular carcinoma in situ 
3.4 Invasive ductal breast cancer 
3.5 Invasive lobular breast cancer 
3.6 Inflammatory breast cancer 
3.7 Paget's disease 
3.8 Rare types of breast cancer 
3.9 Breast Cancer in men 
4 Bowel Cancer 
4.1 Adenocarcinoma 
4.1.1 Colorectal Cancer 
4.1.2 Colon Cancer 
4.2 Squamous cell cancers of bowel 
4.3 Carcinoid tumours 
4.5 Sarcomas of colon 
4.6 Cancers of the lymphatic system in colon 
5 Anal Cancer 
5.1 Epidermoid cancers. 
5.1.1 Large cell keratinising 
5.1.2 Large cell non keratinising (also called transitional) 
5.1.3 Basaloid 
5.2 Non Epidermoid cancer 
5.3 Adenocarcinoma of glandular cells 
5.4 Basal cell carcinoma of anal origin 
5.5 Melanoma of anal origin 
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5.6 Rectal cancer or cancer of the rectum 
6 Womb Cancer 
6.1 Endometrial cancer 
6.1.1 Endometrioid adenocarcinomas 
6.1.2 Papillary serous carcinomas 
6.1.3 Clear cell carcinoma 
6.2 Adenocarcinoma with squamous cells of womb 
6.3 Sarcoma of the womb 
6.4 Cancer of the neck of the womb (cervix) 
7 Cervical Cancer 
7.1 Squamous cell cancer of cervical 
7.2 Adenocarcinoma of cervical 
8 Ocular cancer or Eye cancer 
8.1 Melanoma of the eye 
8.2 Lymphoma of the eye 
8.3 Rare cancers in children 
9 Gall bladder cancer 
9.1 Adenocarcinoma Gallbladder 
9.2 Squamous cell cancer of the gallbladder 
9.3 Adenosquamous cancer of the gallbladder 
9.4 Small cell cancer of the gallbladder 
9.5 Sarcoma of the gallbladder 
9.6 Neuroendocrine tumour of the gallbladder 
9.7 Lymphoma and melanoma of the gallbladder 
10 Stomach Cancer 
10.1 Adenocarcinoma of the stomach 
10.2 Squamous cell cancers of stomach 
10.3 Lymphoma of the stomach 
10.4 Gastrointestinal stromal tumour (GIST) 
10.5 Neuroendocrine tumours 
11 Kidney cancer 
11.1 Renal cell cancer 
11.1.1 Clear cell 
11.1.2 Papillary (Type 1 and 2) 
11.1.3 Chromophobe 
11.1.4 Oncocytic 
11.1.5 Collecting duct 
11.2 Transitional cell cancer (TCC) of the renal pelvis 
12 Larynx or Laryngeal cancer 
12.1 Squamous cell cancer of larynx 
12.2 Adenocarcinoma of larynx 
12.3 Sarcoma of larynx 
12.4  Myeloma of larynx 
13 Liver cancer 
13.1 Hepatocellular carcinoma (HCC) 
13.2 Cholangiocarcinoma 
13.3 Angiosarcoma 
13.4 Hepatoblastoma 
14 Lung cancer 
14.1 Small cell lung cancer 
14.2 Non small cell lung cancer 
14.2.1 Squamous cell carcinoma of lung 
14.2.2 Adenocarcinoma of lung 
14.2.3 Large cell carcinoma of Lung 
14.3 Mesothelioma 
15 Lymphoma 
15.1 Hodgkin Lymphoma 
15.1.1 Classical types 
15.1.1.1 Nodular sclerosing 
15.1.1.2 Mixed cellularity 
15.1.1.3 Lymphocyte rich 
15.1.1.4 Lymphocyte depleted 
15.1.2 Nodular lymphocyte predominant type 
15.2 Non Hodgkin lymphoma (NHL) 
15.2.1 Cutaneous T cell lymphoma 
15.2.2 Mucosa associated lymphoid tissue (MALT) lymphoma 
15.2.3 Mantle cell lymphoma 
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16 Melanoma skin cancer 
16.1 Superficial spreading melanoma 
16.2 Nodular melanoma 
16.3 Lentigo maligna melanoma 
16.4 Acral lentiginous melanoma 
16.5 Other types of melanoma 
16.5.1 Internal organs melanoma 
16.5.2  Melanoma of the eye 
17 Mouth and oropharyngeal cancer 
17.1 Mouth and oropharyngeal cells 
17.2 Squamous cell cancers of the mouth and oropharynx 
17.3 Other types of mouth and oropharyngeal cancer 
17.3.1 Salivary gland cancer 
17.3.1.1 Adenoid cystic cancer 
17.3.1.2 Lymphoma 
17.3.1.3 Melanoma 
18 Myeloma 
18.1 Light chain myeloma 
18.2 Non secretory myeloma 
19 Oesophageal cancer 
19.1 Squamous cell carcinoma of oesophageal 
19.2 Adenocarcinoma  oesophageal 
19.3 Undifferentiated cancer 
19.4 Rare types of oesophageal cancer 
20 Ovarian cancer 
20.1 Epithelial ovarian cancer 
20.2 Germ cell and other rare ovarian tumours 
21 Pancreatic cancer 
21.1 Exocrine cancers 
21.1.1 Cystic tumours 
21.1.2 Cancer of the acinar cells 
21.1.3 Sarcomas of the pancreas 
21.2 Endocrine pancreatic tumours 
21.3 Lymphoma of the pancreas 
22 Penile (penis) cancer 
22.1 Squamous cell cancer of the penis 
22.2 Adenocarcinoma 
22.3 Melanoma of the penis 
22.4 Basal cell cancer of the penis 
22.5 Sarcoma of the penis 
23 Salivary gland cancer 
23.1 Cells of the salivary gland 
23.2 Benign tumours 
23.3 Mucoepidermoid cancer 
23.4 Acinic cell carcinoma 
23.5 Adenoid cystic cancers 
23.6 Adenocarcinoma 
23.7 Malignant mixed cancers 
23.8 Low grade polymorphous cancers 
23.9 Other types 
23.9.1 Squamous cell carcinoma 
23.9.2 Lymphoepithelioma 
23.9.3 Anaplastic carcinoma 
23.9.4 Poorly differentiated carcinoma 
23.9.5 And other even rarer cancers 
24 Skin cancer (non melanoma) 
24.1 Basal cell skin cancer 
24.1.1 Nodular 
24.1.2 Superficial 
24.1.3 Morphoeic 
24.1.4 Pigmented 
24.2 Squamous cell skin cancer 
24.3 Rarer types of non melanoma skin cancer 
24.3.1 Merkel cell carcinoma 
24.3.2 Kaposi’s sarcoma 
24.3.3 T cell lymphoma of the skin 
25 Soft tissue sarcomas 
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25.1 Fibrosarcomas 
25.2 Leiomyosarcomas and rhabdomyosarcomas 
25.3 Liposarcomas 
25.4 Synovial sarcomas 
25.5 Angiosarcomas 
25.6 Malignant peripheral nerve sheath tumours 
25.7 Gastrointestinal Stromal Tumours (GISTs) 
25.8 Kaposi's sarcomas 
25.9 Ewings sarcomas and PNETs 
25.10 Fibromatosis 
26 Testicular cancer 
26.1 Seminomas 
26.2 Non seminomas 
27 Thyroid cancer 
27.1 Papillary thyroid cancer 
27.2 Follicular thyroid cancer 
27.3 Medullary thyroid cancer 
27.4 Anaplastic thyroid cancer 
27.5 Rare types of thyroid cancer 
28 Vaginal cancer 
28.1 Squamous cell carcinoma of vaginal 
28.2 Adenocarcinoma of the vagina 
28.2.1 Clear cell adenocarcinoma 
28.2.2 Papillary adenocarcinoma 
28.2.3 Mucinous adenocarcinoma 
28.2.4 Adenosquamous carcinoma 
28.3 Sarcoma of the vagina 
28.4 Melanoma of the vagina 
28.5 Small cell vaginal cancer 
29 Vulval cancer 
29.1 Squamous cell carcinoma of vulval cancer 
29.2 Vulval melanoma 
29.3 Adenocarcinoma 
29.4 Basal cell carcinoma of vulval 
29.5 Verrucous carcinoma of vulval 
29.6 Sarcomas of vulval 
30 Bone cancer 
30.1 Osteosarcoma 
30.2 Ewing’s sarcoma 
20.3 Chondrosarcoma 
30.4 Spindle cell sarcoma 
30.5 Chordoma 
31 Bladder cancer 
31.1 Transitional cell (Urothelial cancer) 
31.2 Non Muscle Invasive 
31.3 Squamous cell bladder cancer 
31.4 Invasive bladder cancer 
31.5 Adenocarcinoma of the bladder 
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The following three tables, 2.6, 2.7 and 2.8 are the example tables related to section 2.3 Data preparation part. 
Table 2.6: Example of two cancers entries based on one Mutation class. 
HGMD ID Genes Locations Cancer Mutations Types Number of 
mutations in 
that gene 
Number of 
Specific 
mutation 
Mutation Descriptions amino acid changes Ref 
CM103943 MLH1 3p21.3 Breast & 
Colorectal_Cancer 
Missense/Nonsense 875 285 cCGG-TGG Arg389Trp Jensen (2010) Breast Cancer Res Treat 120, 777 
 
 
Table 2.7: Example of Split for the two cancers entries using same Mutation HGMD ID. 
HGMD ID Genes Locations Cancer Mutations Types Number of 
mutations in 
that gene 
Number of 
Specific 
mutation 
Mutation Descriptions amino acid changes Ref 
CM103943 MLH1 3p21.3 Colorectal_Cancer Missense/Nonsense 875 285 cCGG-TGG Arg389Trp Jensen (2010) Breast Cancer Res Treat 120, 777 
CM103943 MLH1 3p21.3 Breast_Cancer Missense/Nonsense 875 285 cCGG-TGG Arg389Trp Jensen (2010) Breast Cancer Res Treat 120, 777 
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Table 2.8: Example for the filtered data table layout, i.e. an example for one cancer only, “Bladder cancer”, where the phenotype is the cancer 
name, gene is a gene symbols, Mutation classes, total number of mutations for each gene including cancers and non-cancers, total number of 
mutation classes including cancers and non-cancers as well, location of the gene in the chromosome, the collected HGMD unique ID and 
finally a PubMed reference for each mutation and cancer records.  
 
Phenotype Gene Mutation classes Total 
Number of 
gene 
mutations 
Total number 
of mutation 
class for  
Chromosome 
location 
HGMD 
Accession 
References 
Bladder Cancer ARL6IP5 Regulatory 1 1 3p14 CR057790 Wu (2005) Zhonghua Yi Xue Yi Chuan Xue Za Zhi 22, 64 
Bladder Cancer DDX20 Missense nonsense 1 1 1p21.1-p13.2 CM086198 Yang (2008) Cancer Res 68, 2530 
Bladder Cancer ERCC4 Regulatory 22 1 16p13.3-p13.11 CR102187 Wang (2010) Oncogene 29, 1920 
Bladder Cancer ERCC6 Missense nonsense 74 35 10q11.23 CM0910264 Chang (2009) Anticancer Res 29, 5121 
Bladder Cancer HRAS Missense nonsense 18 13 11p15.5 CM035804 Johne (2003) Cancer Epidemiol Biomarkers Prev 12,68 
Bladder Cancer MDM2 Regulatory 3 3 12q14.3-q15 CR082025 Wang (2008) Clin Cancer Res 14, 3633 
Bladder Cancer OGG1 Regulatory 17 4 3p26.2 CR072322 Figueroa (2007) Hum Genet 121, 233 
Bladder Cancer PTGS2 Regulatory 8 5 1q25.2-q25.3 CR050013 Kang (2005) Cancer Lett 217, 11 
Bladder Cancer TNFRSF10A Regulatory 3 1 8p21 CR117979 Wang (2009) Mutat Res 661, 85 
Bladder Cancer UGT2B7 Missense nonsense 7 2 4q13 CM057512 Lin (2005) Toxicol Sci 85, 502 
Bladder Cancer XPC Missense nonsense 55 21 3p25 CM112197 Qiao (2011) Carcinogenesis 32, 516 
Bladder Cancer XPC Missense nonsense 55 21 3p25 CM112198 Qiao (2011) Carcinogenesis 32, 516 
Bladder Cancer XPC Regulatory 55 2 3p25 CR112196 Qiao (2011) Carcinogenesis 32, 516 
Bladder Cancer XRCC4 Splicing 4 1 5q13-q14 CS075240 Figueroa (2007) Carcinogenesis 28, 1788 
Bladder Cancer XRCC5 Repeat Variations 1 1 2q35 CE075931 Wang (2008) Mutat Res 638, 26 
Bladder Cancer ZNF350 Missense nonsense 1 1 19q13.33 CM074642 Figueroa (2007) Carcinogenesis 28, 1788 
Bladder Cancer MLH1 Small Deletion 875 195 3p21.3 CD105829 van der Post (2010) J Med Genet 47, 464 
Bladder Cancer MSH2 Splicing 860 92 2p22-p21 CS104167 van der Post (2010) J Med Genet 47, 464 
Bladder Cancer MSH2 Gross Deletions 860 190 2p22-p21 CG104168 van der Post (2010) J Med Genet 47, 464 
Bladder Cancer MSH2 Gross Deletions 860 190 2p22-p21 CG104166 van der Post (2010) J Med Genet 47, 464 
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2.4. Statistical Methods   
 
2.4.1. Cohen’s Kappa (κ) Coefficient 
Cohen’s kappa coefficient was originally proposed by (Carletta, 
1996; Cohen, 1960) to quantify the inter-rater agreement or inter-annotator 
agreement between two individuals. This is thought to be more robust a 
measure than simple percent agreement calculation, since k takes into 
account the agreement occurring by chance. The agreement is calculated 
between two raters, which each classify N items into C mutually exclusive 
categories. The equation for quantifying     
  ( )    ( )
     ( )
  
Where Pr(a) is the relative observed agreement among raters, and Pr(e) is 
the hypothetical probability of chance agreement, using the observed data 
to calculate the probabilities of each observer randomly classifying each 
category randomly. If the raters are in complete agreement then κ = 1. If 
there is no agreement among the raters other than what would be 
expected by chance [as defined by Pr(e)], κ = 0.  
However Kappa’s strength lies in its ability to take into account chance 
agreement between two or more observers. A second strength of Kappa 
lies in its known sampling distribution. Kappa’s weakness is that it takes 
no account of the degree of disagreement, i.e., all disagreements are 
treated equally. 
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Weighted Kappa Statistic 
The weighted kappa coefficient is a generalization of the simple kappa 
coefficient, using weights to quantify the relative difference between 
categories. The weighted kappa is useful in programming, when codes are 
sequential in order (Cohen, 1968).  
The equation for weighted      
∑    ∑           
 
 
∑     ∑   
 
       
 
Where k = number of codes and   ,     , and     are elements in the 
weight, observed, and expected matrices, respectively. When diagonal 
cells contain weights of 0 and all off-diagonal cells weights of 1, this 
formula produces the same value of Kappa as the calculation given above. 
Interclass Correlation Class (ICC) 
The interclass correlation coefficient is useful for measuring the 
degree of dependence of observations within a group (Koch, 1983) to 
determine how similar are the values of some variables within the same 
group. Essentially, it is a measure of the within subject (group) variability. 
Within each group, the mean of a value can be computed, and if values 
are similar then the difference between the mean and a single value will 
be small. The ICC is particularly relevant for work with families and 
siblings because of the possibility of having more than two siblings within a 
family (group). 
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The hypothesis of the current project is to quantify the degree (κ) of 
agreement between two or more connected cancers on the basis of the 
shared genes. In this study, I distinguished the association degree if two 
cancer into four classes: “very connected”, “highly connected”, and 
moderate connected” and “low connected”. Two cancers are defined as 
very connected if k = (0.75 to 1), highly connected if k = (0.5 to 0.75), 
Moderate connected if k = (0.25 to 0.5) or with low connectivity of k = 
(<0.25).  
Theoretical example  
 
Table 2.9: Theoretical example table. Set of five genes and four cancer types. If a 
gene and cancer are related the number 1 will be added to the table and if they 
are not related the number 0 is added. 
 
 
 
 
 
Table 2.10:  This 3 x 3 table, based on table 2.9 above, shows the scoring of 
cancer entries where ‘1’ represents a positive gene association and 0 represents 
a no gene association between Cancer A and Cancer B.  
 
 
 
 
 
 
 
 Gene1 Gene 2 Gene 3 Gene 4 Gene n 
Cancer A 1 1 1 0 0 
Cancer B 1 1 1 1 0 
Cancer C 0 0 1 0 1 
Cancer D 1 0 1 0 1 
  Cancer A  
Row total 
 
 
Cancer B 
  1 0 
1 3 
(    ) 
1 
(    ) 
4 
(    ) 
0  0 
(    ) 
1 
(    ) 
1 
(    ) 
Column total  3 
(    ) 
 2 
(    ) 
 5 
(    ) 
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Three steps are needed to derive the value of k; 
1. Calculate the observed percentage agreement,     
          
    
 = 
   
 
     
2. Calculate the probability of random agreement 
     
                    
       
  
       
   
      
3.  Calculate the degree of k,     
       
      
  
         
      
       
 
2.4.2. Density 
In this study, I am interested in investigating the density of cancer-
associated genes in each chromosome as this may provide some 
measure structural insight. The method of mass density (density) is a 
measure of mass contained per unit volume. Mathematically, density is a 
mass divided by volume   
 
 
 , where   signify density,   signify mass, 
and   signify volume (S Dole, 2009). Here, the density formula that is 
going to be used to calculates the density of the collected cancer genes in 
each chromosome, where  the number of cancer genes is assigned to a 
particular chromosome and   is the total number of the identified genes on 
the associated chromosome. 
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2.5. Conclusion 
The 3 complementary data sources, (i) Genetic Association 
database (GAD) (Becker et al., 2004), (ii) The Cancer Gene Census 
Database (COSMIC) (Futreal et al., 2004), (iii) Human Gene Mutation 
Database (HGMD) (Stenson et al., 2009), were successfully extracted and 
integrated in this study. In the GAD a total of 1,908 cancer-related entries 
was selected and 1,324 entries selected from COSMIC. Filtering these 
extracted 3,232 cancer-related gene records from both databases resulted 
in a list of 520 genes. Based on these filtered 520 genes, a subsequent 
manual extraction of 15,264-germline mutation class records were 
obtained including; Missense nonsense, Splicing, Regulatory, Small 
deletions, Small Insertions, Small Indels. Gross deletions, Gross 
Insertions, Complex rearrangements and Repeat variations, from the 
HGMD, for cancer and non-cancer disorders.  
The newly constructed database was achieved by performing a splitting 
process to clarify two groups of mutation records; the first consisted of a 
total of 8,547 cancer mutation records and the second 6,717 non-cancer 
mutation records. The clarified 8,547-cancer mutation records, was 
successfully screened further by introducing a ‘hierarchy’ to cancer 
disorder names (family tree of cancers) using the Cancer Research UK 
and PubMed literature. The introduced hierarchy consisted of 31 primary 
cancer name terms and 206 secondary and tertiary cancer names. The 
newly screened data was stored in a table as an independent record for 
each gene symbol. Each record consisted of Primary cancer name, Gene 
symbol, the implicated mutation class name involved in the cancer, the 
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total number of evident mutations for each gene including cancers and 
non-cancers mutations, the total number of mutations for each of the 
implicated class, gene chromosome location and PubMed literature 
reference. In total I achieved 8,879 Mutations records including 424 
unique genes and 29 primary cancer disorder names.  
The method Choen’s Kappa Coefficient was used to measure the 
agreements between two cancers in order to determine if there can be 
connected nodes in the to-be constructed Human cancer map.  
These achieved our objectives in relation to the biological data and 
detected mathematical methods were then used in the next two chapters 
to extract some biological meaning in order to increase our understanding 
of how mutation can impact on cancer development. 
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Chapter Three  
 
3. Association of Human Cancers, Genes and 
Mutations Classes 
Cancers can develop in response to multiple contributory factors 
and can be associated through various factors (principally genetic ones). 
Many authors have shown the value of revealing cancer associations 
based on cancer-causing genes (Goh et al., 2007; Barabási et al., 2011). 
Others have assessed cancer development based on an analysis of gene 
expression to identify the proteins that may act on similar disease-causing 
pathway(s) (Dreze et al., 2010; Goehler et al., 2004). The aim of the work 
presented in this chapter is to investigate the associations of cancers 
based on the involvement or usage of particular genetic mutation classes. 
Using this approach, I intend to explore whether genetic mutation classes 
vary from one to another in terms of their associations to cancers. The 
curated mutation data shows that the association of various cancers 
correspond to gene mutation(s) very differently. For example, Breast 
cancer is associated to ten different types of mutations in each of several 
genes, while Bone cancer is associated to just two different types of 
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mutation based on the same causing gene. In order to gain greater insight 
into the nature of the associations between cancers, and the association 
of gene mutation type and the target cancers, I conducted a series of 
investigations, including: (i) constructing and analysing a Human Cancers 
Map (HCM) based on genetic mutations in human genome, (ii) 
investigation into the distribution of mutations classes over the HCM (iii) 
constructing a Genome-wide Distribution Map to identify the involved 
genes in the HCM   (IV) identifying pathways for the involved target genes, 
(V) to cluster genes based on the relatedness of their  biological factors. 
 
3.1. A Human Cancer Map Based on Genes and Their 
Associated Mutation Classes 
The map connecting human cancers for investigating the association 
between cancer disorders was manipulated by running a string (loop 
statement) in R, to loop the 8,879 curated mutation records based on table 
2.8 (see chapter 2). Two cancer disorders are connected if they involve a 
common gene due to same mutation class and not only with associated 
gene itself (Figure 3.1). 
The Human Cancer Map (HCM) displayed many connections between 
cancer nodes, with each of these connections corresponding to an 
implicated gene and a contributing mutation class. Of 26 primary cancers, 
20 had at least one link to other cancers in the HCM. Sixty-nine genes 
(from total gene set of 424) underpinned these links between cancers. 
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This suggests that the genetic origin and associated mutation class plays 
a central role in associations between cancer nodes.  
 
Next, the degree of connectivity (k) of nodes distributed in the HCM was 
assessed. Seven cancers, representing one particular hub in the HCM, 
were found to be connected to a large number of other cancers as 
indicated by their high k value. For example, Bowel cancer (k = 18), Lung 
cancer (k =17), Breast cancer (k = 16), Brain tumours (k = 13), Ovarian 
cancer (k =13), Stomach cancers (k = 12), and Melanoma (k = 11). This 
finding indicates that each of these cancers is associated with several 
other cancers via the same gene and mutation classes (Figure 3.1).  
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Figure 3.1: Human Cancer Map (HCM). Each node corresponds to a primary 
cancer and a link between two nodes represents the presence of shared cancer 
genes and mutation class. 
Key to Figures 3.1 to 3.12. The size of each node is proportional to the number of 
interconnections shared by that node i.e., number of distinct primary cancers 
connecting to it. The colours assigned to the node represent the number of 
interconnected links between primary cancer types, and the width of the link-lines 
reflects the number of genes linking each cancer nodes.  
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3.1.1. Investigations into the Distribution of Mutation Classes in a 
Constructed Human Cancer Map 
The distribution of mutation classes behind the Human Cancer Map 
(HCM) was next investigated, to gain a clearer understanding of the 
impact of the underlying mutation class to various cancers.  This 
investigation was based on extracting a mutation-based classes-HCM 
(CM-HCM) from the main HCM (Figure 3.1), with each map corresponding 
to a specific mutation type (see figures 3.2~3.11) and the corresponding 
tables (A1.1~A1.10). 
 
The ratio for the distribution of each mutation class was calculated based 
on the total number of the interconnections (links) between cancers nodes 
for each of the CM-HCMs divided by the total number of interconnections 
for the whole HCM. In total there are 171 interconnections in the HCM. Of 
these 44% were for Missense/Nonsense; 14% small deletion, 9% splicing, 
10% regulatory, 10% small insertion, 6% gross deletion, 3% small indels, 
1% gross insertion, 1% complex rearrangement and finally 2% repeat 
variation (Figure 3.12).  
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Figure 3.2: Missense/Nonsense CM-HCM. Each node corresponds to a primary 
cancer with a total of 19 notes and 76 links. The size of the node is proportional 
to the number of links. Two cancer nodes are connected if there is at least one 
identical gene implicated in both nodes.  The width of the links (connections) is 
proportional to the number of genes implicated in both cancer nodes. For a full 
list of cancer nodes and associated genes please see Appendix 1 table A1.1. 
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Figure 3.3: Small deletion CM-HCM. Each node corresponds to a primary cancer, 
totalling 12 nodes with 24 links. Full lists of cancer nodes and associated genes 
please see Appendix 1 table A1.2. 
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Figure 3.4: Splicing CM-HCM. Each node corresponds to a primary cancer in 
which there are a total of 12 nodes with 16 links. For full lists of cancer nodes and 
associated genes please see Appendix 1 table A1.3. 
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Figure 3.5: Small Insertions CM-HCM. Each node corresponds to a primary 
cancer and a total of 11 nodes with were detected for this SM-HCM. 18 links For 
full lists of cancer nodes and associated genes please see Appendix 1 table 
A1.4. 
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Figure 3.6: Regulatory CM-HCM. Each node corresponds to a primary cancer, 
with a total of 11 nodes with; 17 links for the regulatory SM-HCM network. For a 
full list of cancer nodes and associated genes please see Appendix 1 table A1.5.  
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Figure 3.7: Gross deletion CM-HCM. Each node corresponds to a primary 
cancer, with 8 nodes and a total of 10 links for this SM-HCM. For a full list of 
cancer nodes and associated genes please see Appendix 1 table A1.6. 
 
 
Figure 3.8: Small Indels CM-HCM. Each node corresponds to a primary cancer, 
with a total of 8 nodes with, 5 links for this small indels network. For a full list of 
cancer nodes and associated genes please see Appendix 1 table A1.7. 
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Figure 3.9: Repeat Variation CM-HCM. Each node corresponds to a primary 
cancer with a total of 3 nodes and 3 links for this, gross deletion network. For a 
full list of cancer nodes and associated genes please refer to Appendix 1 table 
A1.8. 
 
 
 
 
Figure 3.10: Complex Rearrangement HCM. Each node corresponds to a primary 
cancer in which there is a total of 2 nodes with a single link. See Appendix 1 table 
A1.9.or a full list of cancer nodes and associated genes. 
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Figure 3.11: Gross Insertion HCM. Each node corresponds to a primary cancer, 
with a total of 2 nodes with a single link. For a full list of cancer nodes and 
associated genes please refer to Appendix 1 table A1.10. 
 
 
 
Figure 3.12: Distribution of mutation classes. The pie chart shows the % 
distribution of interconnections for each of the 10 mutation subclasses within the 
HCM. 
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3.1.2. The Extent of Agreement between Cancers interconnected 
Nodes Classes Mutation- Human Cancer Map. 
The method of Choen’s Kappa was applied to quantify the 
agreement between two connected cancer nodes in the CM-HCMs. The 
agreement revealed a number of interesting relationships between cancer 
nodes across the SM-HCMs (Figure 3.13): (1) Missense/Nonsense 
mutations, which formed 44% of the CM-HCM and regulatory mutation that 
formed 10% of the CM-HCM both showed low to moderate agreements 
between their connected nodes; (2) Small deletions, splicing, small 
insertions, gross deletions and small indels, which formed between 3% to 
14% of the CM-HCM exhibited low to very high agreements. (3) Repeat 
variation, complex rearrangement and cross insertion mutations, which 
formed only 1% to 2% of the CM-HCM showed very low agreements 
between their interconnected cancer nodes, Refer to appendix 1 tables 
(A1.1, A1.2, A1.3, A1.4, A1.5, A1.6, A1.7, A1.8, A1.9 and A1.10) for the 
full cancer node agreements details. 
 
Subsequently, two of the connected cancer nodes i.e., breast and ovarian 
cancers, appeared to be highly agreed for splicing, small insertions and 
small indels mutations for the following six genes (BRCA1, BRCA2, 
BRIP1, RAD51C, RAD51D, TP53). This finding confirms the results of 
several previous studies (Welcsh and King, 2001; Grzybowska et al., 
2002), showing that germline mutations predisposes to breast and ovarian 
cancer in the BRCA2 and BRCA1 genes. Similarly, the current study found 
that brain tumours tend to be highly linked to melanoma, womb and bowel 
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cancer in terms of their associated splicing, small insertion, gross deletion 
and small indels mutations for three genes (MLH1, CDKN2A and BRAC2). 
On the other hand, it was evident that melanoma and pancreatic cancer 
nodes were highly agreed in terms of their associated splicing and small 
insertion mutations for two genes (CDKN2A, BRAC2). This is supported by 
several scientific reports (Whelan et al., 1995; Goldstein, 2004; de Snoo et 
al., 2008) showing strong associations between pancreatic and 
melanoma. The current study also revealed that melanoma exhibited very 
high agreement with the head and neck cancer at the small indels 
mutations by the CDKN2A gene, which have been shown by (Cabanillas 
et al., 2011) in their  study of a novel germline mutation in the CDKN2A 
gene in head and neck squamous cell carcinomas and melanoma. The 
gene CDKN2A is therefore an active gene as its mutations tends affact 
many cancers. Similarly, prostate cancers agreed too many other cancers 
such as melanoma, pancreatic cancer and lung cancer in terms of their 
shared small insertion mutation in the BRAC2 gene.  
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Figure 3.13: Agreement Distributions in CM-HCM. Blue shows low agreements (<0.25), purple represents moderate agreements 
((0.25 to 0.50), green reflects all high agreement (0.50 to 0.75), while red refers to the very high agreement (0.75 – 1). The 
mutations subclasses names are placed under each bar. 
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3.2. A Genome-Wide Distribution Map for Cancer Genes 
A Genome-wide Distribution Map for Cancer Genes was 
constructed, based on the data described in table 2.8 of chapter 2, in order 
to explore the association between the identified 424 cancer genes and 
the 26 primary cancers mutation class and distributions as well as their 
positions in the human genome. In order to probe the genome for these 
424 genes the start and end position of the corresponding genes in the 
human genome are needed. One of the most comprehensive genetic 
sequence databases, i.e. GeneCards, (Rebhan et al., 1997; Safran et al., 
2002b) was used to extract the start and end position of each gene in 
genome. The Genome-wide Map was constructed using CIRCOS 
visualizing software package, which was used to construct a distribution of 
Genome-wide mutations in humans (Figure 3.14).   
Subsequently, the density is mass divided by volume    
 
 
, where   
signify density,  signify mass, and   signify volume. Here the density of 
the explored genes was calculated for each chromosome as well as the 
distributions of the ten mutation classes explored in this study (see figure 
3.15).  
The following interesting characteristics were revealed: (1) Chromosome 
17 is a highly represented chromosome for cancer-associated genes, 
whereas chromosome X is the lowest chromosome for adopting cancer-
associated genes, (2) Chromosomes 2,3,7,10,17 and 22 all contained 
genes represented in all the 10 different mutation classes, (3) Missense 
nonsense mutations were a highly spread mutation class over the entire 
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human genome, whereas the complex rearrangement mutation class 
exhibited the lowest spread of mutations over the human genome (see 
figure 3.15). Please note, these observations apply only to the 424 gene 
set used here that relates to 26 primary cancers (includes the top 10 most 
common cancers to affect humans worldwide) and 10 mutation classes.  
However, these data cannot be used to infer relevance to other cancers 
and other disorders. For statically significance evaluation, subsequent 
studies will need to interrogate clinical data and include more genes, 
cancers and mutation recorders to gain a fully comprehensive view of the 
impact of both mutation class and individual chromosome involvement. 
This was not within the scope of this work. 
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Figure 3.14: Genome-wide Distribution map for cancer genes. Blocks in the outer 
circle, to which are attached the 424 cancer genes, reflect chromosomes. 
Between chromosomes blocks and chromosome number are black bars 
representing the total number of mutations for each gene. The inner circle 
contains the abbreviations for cancers names for each chromosome. For full 
details of genes, cancers and mutations see table A.2.1 Appendix 2. 
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Figure 3.15: Distributions of genes and genetic mutations over all human chromosomes. Here the bars represent cancer mutations in each of 
the 23 chromosomes. The component colours of the blocks on these bars reflect a different subclass of mutations. The blue line across the 
chart represents the density of cancer genes in each of the chromosomes. Written below the chart are the densities for each of the mutation 
subclasses. 
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3.2.1. Identification of Genes Involved in a Human Cancer Map, 
Using their Genome-Wide Distribution  
Identification of genes involved in the Human Cancer Map (Figure 
3.1) was performed based on the gathered underlying gene records and 
the mutation classes records involved in driving the connections between 
cancer nodes in the HCM. In this way 69 genes were discovered from 
4,964 mutation records, which are involved in 20 primary cancers. Based 
on these 4,964 mutation recorders, a string in R was run to associate 
genes to each other. Two or more genes were associated if they are both 
involved with the same cancer via the same mutation class. For example 
the genes XPC, ERCC6 are considered to be associated each other 
because both tended to be causative genes for Bladder cancer at the 
same Missense/Nonsense mutation. Meanwhile the gene MLH1, will be 
excluded from an association for this particular cancer because it is 
associated by a different type of mutation class (i.e., small deletions), 
whereas Bowel cancer can associated the three genes (XPC, ERCC6 and 
MLH1) based on missense nonsense mutation. As a result a total of 1,158 
associations/connections between the 69 cancer genes were extracted. 
These were further explored in CIRCOS to construct a genome-wide 
distribution map of human cancer, and so present the 1,158 associations 
between cancer genes and their positions in the human genome (Figure 
3.16). 
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Figure 3.16: Genome-wide mutations, where the blocks in the outer circle reflect 
particular chromosomes and 69 genes attached to each chromosomes position. 
The inner interconnections represent associations between two or more genes 
connected if they contribute to same cancer and the same mutation class. The 
colours of the interconnections represent the colours of the corresponding 
chromosome. 
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3.2.2. Investigations on the Distribution of Chromosomes, Mutation 
Classes and Genes in a Genome-Wide Distribution Map 
The investigation of the distribution of chromosomes, mutation 
classes and genes in the constructed genome-wide distributions (Figure 
3.16) was done by extracting data of Figure 3.16 into eight genome-wide 
distribution figures, each of which represents a mutation subclass with 
interconnections of the genes cross the human genome (Figures 3.17 to 
3.24). Thereafter the distributions of the 69 associated genes in each 
chromosome were calculated (Figure 3.25) to show the number of 
implicated genes on each chromosome.  Ch17, Ch1, Ch15, Ch2 and Ch3 
tended to contribute to cancer genes disproportionally compared with 
others, whereas Ch22 and Chy did not show any contribution to any of the 
cancer –associated genes.  
As outlined in eight sub-genome-wide mutation diagrams (figures 3.17 to 
3.24), it was clear that Missense/Nonsense mutations has the highest 
impact to human cancer as contributing broadly across the human 
chromosomes, as well in the interconnections between genes. This 
indicates that Missense/Nonsense mutations could be ‘driver mutation’ in 
these interconnecting genes, followed by other mutation classes (i.e., 
regulatory, small deletions, splicing, gross deletions, small insertions, 
small indels and repeated variations). Surprisingly gross insertion and 
complex rearrangement mutations had no impact on the interconnecting 
genes.    
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Figure 3.17: Missense/Nonsense distribution of Genome-wide mutations, where 
the blocks in the outer circle reflect the chromosomes with the 54 genes attached 
to their corresponding chromosomes. The inner interconnections represent 
associations between two or more genes connected if they contribute to same 
cancer. The colours of the interconnections represent the corresponding colour of 
the chromosome. 
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Figure 3.18: Small deletion distribution of Genome-wide mutations, where the 
blocks in the outer circle reflect the chromosomes, with 14 genes attached to 
their corresponding chromosomes. The inner interconnections represent 
associations between two or more genes connected if they contribute to same 
cancer. The colours of the interconnections represent the corresponding 
chromosome. 
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Figure 3.19: Splicing distribution of Genome-wide mutations, where the blocks in 
the outer circle reflect the chromosomes, with the 12 genes attached to their 
corresponding chromosome the inner interconnections represent associations 
between two or more genes connected if they contribute to same cancer.  The 
colours of the interconnections represent the corresponding chromosome.  
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Figure 3.20: Small Insertions distribution of Genome-wide mutations, where the 
blocks in the outer circle reflect the chromosomes, with 9 genes attached to their 
corresponding chromosome positions. The inner interconnections representing 
associations between two or more genes connected if they contribute to same 
cancer. The colours of the interconnections represent the colours of the 
corresponding chromosome.  
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Figure 3.21: Regulatory mutation distribution of Genome-wide mutations, where 
the blocks in the outer circle reflect the chromosomes, with 14 genes attached to 
their corresponding chromosomes. The inner interconnections represent 
associations between two or more genes connected if they contribute to same 
cancer. The colours of the interconnections represent the colours of the 
corresponding chromosome.  
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Figure 3.22: Gross Deletion distribution of Genome-wide mutations, where the 
blocks in the outer circle reflect the chromosomes, with the 7 genes attached to 
their corresponding chromosomes. The inner interconnections represent 
associations between two or more genes connected if they contribute to same 
cancer. The colours of the interconnections represent the colours of the 
chromosome. 
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Figure 3.23: Small Indels distribution of Genome-wide mutations, where the 
blocks in the outer circle reflect the chromosomes, with 4 genes attached to their 
corresponding chromosomes. The inner interconnections represent associations 
between two or more genes connected if they contribute to same cancer. The 
colours of the interconnections represent the colours of the corresponding 
chromosome.  
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Figure 3.24: Repeated Variation distribution of Genome-wide mutations, where 
the blocks in the outer circle reflect the chromosomes, with the 2 genes attached 
to their corresponding chromosome. The inner interconnections representing 
associations between two or more genes connected if they contribute to same 
cancer. The colours of the interconnections represent the colours of the 
chromosome.  
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Figure 3.25: Distribution of the 69 involved genes in the Ggenome-wide 
distributions map for cancer genes over all human chromosomes. 
 
3.2.3. KEGG pathways for the 69 linked Genes Identified in Genome-
Wide Distribution sub-MAPs for each Mutation Class 
The Kyoto Encyclopedia of Genes and Genome (KEGG) pathway 
database (Kanehisa et al., 2006) was used to identify the pathways 
represented in the Genome-wide Distributions sub-maps for each mutation 
class (Figures 3.17 to 3.24). This was carried by entering individual gene 
subsets of each Genome-wide Distribution sub-map (i.e. 10 mutation 
classes) into the pathway database.  
The results showed that 66% of the missense nonsense and 71% of 
regulatory Genome-wide Distribution Map genes were mapped into 
pathways (Figure 3.26) and (Table 3.1), whereas other genome wide 
distribution genes showed no tendency to be in any pathways, and so the 
result was zero.  
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These findings indicate that missense nonsense and the regulatory 
mutation genes are involved in eight relevant pathways (1) Pathways in 
cancer, (2) Colorectal cancer, (3) Endometrial cancer, (4) Bladder cancer, 
(5) Mismatch repair, (6) P53 signalling pathways, (7) Cell cycle, and (8) 
Prostate cancer. Correspondingly, the missense nonsense and regulatory 
mutations showed for six identical cancers (1) Bladder cancer, (2) Bowel 
cancer, (3) Breast cancer, (4) Lung cancer, (5) Ovarian cancer, and (6) 
Prostate cancers in the constructed Genome-wide Distributions diagrams. 
This is an indication that these two classes of mutations could be the 
driver mutations in their interconnected genes to cause cancer (see table 
3.1).    
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Figure 3.26: Pathways (KEGG) for Missense/Nonsense and regulatory mutations. The bar represents the percentage of genes involved in each 
pathway. The red is regulatory mutations and the yellow is a Missense/Nonsense mutation gene. 
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Table 3.1: Identified pathways for Missense/Nonsense and Regulatory mutation classes. For the involved genes in the construction of the 
Genome-wide Distribution Maps, The 1st column represents the identified pathway names (from KEGG). The 2nd column is the number of 
genes involved on the particular pathway for Missense/Nonsense mutation. The 3rd column is the number of genes involved in the particular 
pathway for regulatory mutation. The 4th column shows the gene symbols for the involved genes in the particular pathway for missense 
mutation. The 5th column shows the gene symbols for the involved genes in the particular pathway for regulatory mutation. The ‘0’ means no 
genes were involved in that pathway, while ‘NA’ mean no available genes are reported for this KEGG pathway. 
Pathway Term 
Number of genes 
involved in a pathway 
(Missense/Nonsense) 
Number of genes 
involved in a 
pathway 
(Regulatory) 
Missense/Nonsense involved genes 
 
 
Regulatory involved genes  
 
 
Pathways in cancer 16 9 
BMP4, EGFR, MSH6, AR, PTGS2, MSH2, VHL, 
ERBB2, MET, TP53, PML, MLH1, BRCA2, CDH1, 
CDKN2A, AXIN2 
PTGS2, KLK3, MSH2, BCL2, TP53, 
MLH1, MDM2, BRCA2, MYC 
Coloursectal cancer 7 5 EGFR, MSH6, MSH2, MET, TP53, MLH1, AXIN2 MSH2, BCL2, TP53, MLH1, MYC 
Endometrial cancer 6 3 EGFR, ERBB2, TP53, MLH1, CDH1, AXIN2 TP53, MLH1, MYC 
Bladder cancer 5 3 EGFR, CDKN2A, ERBB2, TP53, CDH1 TP53, MDM2, MYC 
Mismatch repair 4 2 MSH6, MSH2, MLH1, MLH3 MSH2, MLH1 
Homologous recombination 4 0 RAD51C, MRE11A, BRCA2, RAD50 NA 
Melanoma 5 0 EGFR, CDKN2A, MET, TP53, CDH1 NA 
Pancreatic cancer 5 0 EGFR, CDKN2A, ERBB2, TP53, BRCA2 NA 
Non-homologous end-joining 3 0 XRCC4, MRE11A, RAD50 NA 
Non-small cell lung cancer 4 0 EGFR, CDKN2A, ERBB2, TP53 NA 
p53 signalling pathway 4 3 CDKN2A, TP53, CHEK2, ATM TP53, MDM2, CHEK2 
Cell cycle 5 4 CDKN2A, TP53, BUB1B, CHEK2, ATM TP53, MDM2, CHEK2, MYC 
Renal cell carcinoma 4 0 VHL, MET, FLCN, PTPN11 NA 
Adherens junction 4 0 EGFR, ERBB2, MET, CDH1 NA 
Base excision repair 3 0 XRCC1, PARP1, OGG1 NA 
Prostate cancer 4 4 EGFR, AR, ERBB2, TP53 KLK3, BCL2, TP53, MDM2 
Nucleotide excision repair 3 0 ERCC6, XPC, ERCC2 NA 
Steroid hormone biosynthesis 3 0 CYP1B1, CYP1A1, CYP19A1 NA 
Basal cell carcinoma 3 0 BMP4, TP53, AXIN2 NA 
Glioma 3 0 EGFR, CDKN2A, TP53 NA 
Small cell lung cancer 0 4 NA PTGS2, BCL2, TP53, MYC 
Chronic myeloid leukaemia 0 3 NA TP53, MDM2, MYC 
Thyroid cancer 0 0 NA TP53, MYC 
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3.2.4. Functional Analytics of the Clustered Genes Groups  
The 69 linked genes in the Genome-wide Distribution Map were 
clustered into three gene groups, based on the similarities of their shared 
biological functions (within DAVID; (Da Wei Huang and Lempicki, 2008). 
This generated gene-to-gene annotations, and outputted the result into a 
group of functionally-related genes. Using the kappa statistics method, 
only kappa agreement ≥0.35 is considered to reach the required threshold 
for biological function similarity.  
 
Results from these analyses indicated:  
(1) Clustered genes in Group 1 (i.e., RAD50, MRE11A, NBN, 
MLH3, MSH6 and MLH1) show high interconnectivity as they are a) 
functionally-related genes (by DAVID), b) are shared by four cancers (i.e., 
Bowel, Breast, Ovarian and Womb by my Genome-wide Distribution Map), 
c) appear in the sub-maps of each of three mutation classes (i.e., 
missense/nonsense, small deletion and small indel mutations). In this way 
these genes are not just functionally-related but may also be cancer-
related (see figure 3.27).  
(2) Clustered Group 2 genes (i.e., ERBB2, EGFR, MET and 
ERBB4) while a) functionally-related (Via DAVID), b) less interconnected 
in terms of cancer-relatedness within my Genome-wide Distribution sub-
maps, and c) only 2 genes (i.e. EGFR and ERBB2) were found to be 
cancer-related by sharing the same Missense/Nonsense mutation by 
Breast and Lung cancer (see figure 3.28),  
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(3) The clustered Group 3 genes (i.e., CYP11A1, CYP19A1, 
CYP1A1, CYP1B1) are a) functionally-related (via DAVID), b) three of 
these 4 genes (i.e. CYP19A1, CYP1A1, CYP1B1) show good 
interconnectivity in my Genome-wide Distribution sub-map, and c) were 
found to be cancer-related by sharing the same Missense/Nonsense 
mutation by Lung and Prostate cancers (see figure 3.29).  
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Figure 3.27: Functional clustering Group 1: Grey circles represent genes; black arrows connecting these genes on the bases of similarity 
threshold (i.e.     ), for shared biological function; coloured arrows leaving each gene (black circles) and entering an oval (mutations) show 
the mutation class affecting that particular gene; arrows leaving an oval to enter a square show the cancer type associated with this specific 
mutation class. 
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Figure 3.28: Functional clustering Group 2: Grey circles represent genes; black 
arrows connecting these genes on the bases of similarity threshold (i.e.     ), 
for shared biological function; coloured arrows leaving each gene (black circles) 
and entering an oval (mutations) show the mutation class affecting that particular 
gene; arrows leaving an oval to enter a square show the cancer type associated 
with this specific mutation class. 
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Figure 3.29: Functional clustering Group 3: Grey circles represent genes; black 
arrows connecting these genes on the bases of similarity threshold (i.e.     ), 
for shared biological function; coloured arrows leaving each gene (black circles) 
and entering an oval (mutations) show the mutation class affecting that particular 
gene; arrows leaving an oval to enter a square show the cancer type associated 
with this specific mutation class. 
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3.3. Discussions/Conclusions 
This chapter performed 
(i) investigation into the influence of gene mutation classes, as a 
major biological factor in human cancers,  
(ii) development of a human cancer map (HCM) based on genetic 
mutation classes data, and investigate the level of agreement 
(kappa) between interconnected cancer nodes 
(iii) construction of a Genome-wide Distribution Map for cancer 
genes to identify KEGG pathways and thereafter to cluster 
genes into functionally-related groups based on their biological 
function.  
Based on HCM, I explored the interconnectivity between cancer nodes in 
HCM sub-maps and noted some interesting features: 
1. Bowel, Lung, Breast cancers presented as 3 central hubs that all 
connected to many other cancers (incl. melanoma, ovarian, 
stomach, prostate and brain cancers). Therefore, these three 
primary cancers represent major connecting cancer types in the 
HCM and may reflect the dominant position in these disorders in 
the human cancers. This is reflected by their position in the top 3 of 
most common cancers with a combined total lifetime risk of 1:15 as 
stated by Cancer Research UK 
(http://www.cancerresearchuk.org/cancer-
info/cancerstats/incidence/risk/statistics-on-the-risk-of-developing-
cancer). 
 
CHAPTER THREE 
     
 
92 
 
2. The Missense/Nonsense class of mutations dominated the HCM, 
comprising a full 44% of all HCM interactions. By contrast, the 
remaining 9 mutation classes accounted for only 1%-14% of the 
HCM. However, while a Missense/Nonsense mutation appears to 
represent the most common cancer-inducing form of mutations, the 
kappa value for their interconnectivity was generally low.    
3. By contrast, 5 other mutation classes (i.e., small deletions, splicing, 
small insertions, gross deletions and small indels) exhibited high 
kappa values (i.e., level of agreement) between connected nodes. 
This suggests that mutations of these types could be an important 
focus for future investigation into both the nature of cancer 
etiologies and associated potential therapeutic interventions.  
4. The highest kappa values were found for 8 genes (i.e., BRCA1, 
BRCA2, BRIP1, RAD51C, RAD51D, TP53, MLH1, and CDKN2A), 
suggesting that these genes are particularly important connecting 
genes for 10 of the 29 (i.e., 34%) primary cancer nodes in HCM. 
 
Based on Genome Wide Distribution Map,I explored the nature of the 
interconnected 69 cancer genes sub-maps (derived from the full 424 gene 
set), and found some interesting features: 
1. Chromosome 17 carried the highest number of cancer-related 
genes (14% of total), with chromosome X carrying the fewest (1%).  
2. Chromosomes 2,3,7,10,17 and 22 exhibited cancer-related gene 
mutations all the 10 classes.   
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3. The Missense/Nonsense Mutation type was the most common of 
all mutation classes, and was detected in all 22 chromosomes. 
Moreover, a mutation of the Regulatory Mutation type was 
detected in 11 of 22 chromosomes. Together these mutation types 
were most commonly associated with cancer-pathway genes.  
4. By contrast, mutations of the Gross Insertion and Complex 
Rearrangement classes were not associated with cancer. 
5. Six genes (i.e., RAD50, MRE11A, NBN, MLH3, MSH6 and MLH1) 
exhibited similar biological functions, and were causative genes for 
Bowel, Breast, Ovarian and Womb cancer. All 4 cancers were 
associated with mutations of the same mutation classes. 
6. Four genes (i.e., ERBB4, MET, EGFR and ERBB2) exhibited 
similar biological functions, and 2 of these (i.e., EGFR and ERBB2) 
were causative Breast and Lung cancers and were associated with 
mutations of the same mutation classes (i.e. Missense/Nonsense). 
7. Four genes (i.e., CYP11A1, CYP19A, CYP1A1 and CYP1B1) 
exhibited similar biological functions, and are causative genes for 
Lung and Prostate cancers.  
 
In summary, the Missense/Nonsense mutation class may be a priority for 
researchers as this class is over-represented in the Human Cancer Map 
(HCM), Genome Wide Distribution Map, KEGG Pathway, Human genome, 
functional clustering of David Bioinformatics, and has a significant impact 
on human cancers. 
 
CHAPTER FOUR 
     
 
94 
 
 
 
 
 
 
 
Chapter Four  
 
4. Integrated Data Analytics of a Protein-Protein 
Interaction Map with Missense/ Nonsense Mutations 
of corresponding Genes 
Determination of the molecular cause of cancers has been a major 
focus of human genetic research since the early 1960s. The availability of 
advanced high-throughput genomic technologies and data has permitted 
large-scale genome-wide association studies (Cardon et al., 2007; 
Johnson and O'Donnell, 2009), and the analysis of complete DNA 
sequences of large numbers of cancer genomes to be conducted in order 
to gain understanding of how individual cancers develop (Stratton et al., 
2009).  
 
The aim of the work presented in this chapter was to associate 
genes based on the interactions of their encoded proteins. Specifically, 
gene sequences were interrogated for single base substitutions, which led 
to both a codon and amino acid change that was associated with cancer. 
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This approach was adopted to identify whether or not identical codon 
changes in two or more genes were associated with the same or different 
primary cancer type. For example, a codon change in the ATM gene, a 
switch from leucine to serine resulted in breast cancer, whereas the same 
codon change in the MSH2 gene resulted in bowel cancer.  
In order to gain greater knowledge of the associations between 
multiple genes related to cancer, and their single base substitutions I 
sought to:   
(i) Construct a Protein-Protein Interaction Map (PPIM) derived 
from 424 cancer-associated gene set using the Biological 
General Repository for Interaction Datasets (BioGRID) 
(www.thebiogrid.org).  
(ii) Extract Missense/Nonsense mutations (i.e. from codons with 
resultant amino acid change) for cancers.  
(iii) Investigate the distribution of changes in all 21 amino acids 
in relation to cancers  
 
 
 
 
 
 
 
 
CHAPTER FOUR 
     
 
96 
 
4.1. Protein-Protein Interaction Map (PPIM) 
 
A PPIM was constructed to investigate single base substitutions for 
the 424 gene set using BioGRID (Stark et al., 2011) and the GeneMANIA 
Cytoscape plugin (Montojo et al., 2010). Two genes were associated if 
they were found to interact with each other in a protein-protein interaction 
study. Here only the physical interactions of proteins were considered. 
These associating genes were then visualized using Gephi tools (Bastian 
et al., 2009) (see figure 4.1). The PPIM contains nodes that correspond to 
genes, the size of which (nodes) is proportional to the number of distinct 
genes connecting to it, while interconnected links (also called ‘edges’) 
represent the physical interaction of genes. The PPIM I obtained consisted 
of 292 genes with a total of 4,024 physical interactions among the 
corresponding proteins of genes. Certain genes tend to form a central hub 
connecting many other genes, where the distribution degree (k) is high. 
For example, TP53 (k=72), BRCA1 (k=55), CREBBP (k=56), ESR1 
(k=58), AR (k=27), ATM (k=22), BRCA2 (k=13) and RAD41 (k=28) all 
connect many other genes. These data indicate that each of these genes 
is highly interacted with others genes that encode proteins in the PPIM. 
However, a focus here was to identify Missense/Nonsense mutations in 
the DNA for every gene (that encoded a PPIM protein), whereby a single 
nucleotide causes a codon change, with a resultant unexpected amino 
acid alteration, that was associated with cancer.  
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Figure 4.1: Protein–Protein Interaction Map (PPIM): Nodes represent unique 
proteins, and the links (edges) identify the protein-protein physical interactions. 
The colour of the link indicates the originating or source node in the physical 
protein-protein interaction.    
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4.1.1. Interrogation of Missense/Nonsense Mutations of Codons and 
their encoded Amino Acid Changes in a PPIM-Informed 292 Cancer-
Associated Gene set  
The extraction of Missense/Nonsense mutations involving single 
nucleotide changes, which resulted in cancer-associated amino acid 
changes, was investigated manually for the 292-gene set informed by the 
PPIM. This was conducted one base at a time within the mutation using 
complementary data sources e.g., PubMed, OMIM (Amberger et al., 
2009), UniProtKB/Swiss-Port (Boutet et al., 2007) and HGMD(Stenson et 
al., 2009). The purpose of this Missense/Nonsense mutations data 
extraction was to detect:  
(i) the single base change in the affected codon  
(ii) the amino acid resulting from the altered codon  
(iii) the peptide position of the altered amino acid  
(iv) the associated cancer disorder(s) resulting from the altered 
amino acid using PubMed for every gene.  
In total, 2,851 Missense/Nonsense mutation records were found for 161 of 
the 292 interrogated genes and were stored as independent records for 
each gene symbol (see appendix 3 table 3.1). Thus, 131 genes informed 
by the PPIM did not have associated Missense/Nonsense mutation 
records. Thus, I was interested in next assessing whether identical amino 
acid alterations (e.g., a Ser to Leu, Ala to Leu, Tyr to Leu…. etc switch) for 
two or more genes within the 161-gene set were associated with the same 
primary cancer type.  
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4.1.2. Do Identical Amino Acid Alterations for two or more Genes 
Associated with the same Primary Cancer Type?  
 
To address whether identical amino acid alterations for two or more 
genes within the 161 genes set associate with the same primary cancer 
type, I combined the Missense/Nonsense mutation records with the map 
of interconnected gene nodes that informed the PPIM. This was achieved 
by: 
(i) Dividing the extracted Missense/Nonsense mutation records 
(table 3.1 appendix 3) into sub-tables, each consisting of 
records for one altered amino acid that was related to a 
primary cancer type. In total 21 tables were constructed for 
each of the 21 amino acid by running a string using R 
language.  
 
(ii) Associating the newly-constructed amino acid sub-table 
records with the PPIM connected nodes. This association 
was verified as follows. For two or more genes to be 
considered connected they must exhibit a physical 
interaction in the PPIM (recognized in BioGrid) and have an 
identically-altered amino acid that is also associated with the 
same primary cancer type. For example, the following two 
genes (TP53 and MSH2) are said to be associated where a 
single nucleotide change in TP53 changes the ‘GGC’ codon 
to ‘GAC’ resulting in a Glycine’ to ‘Aspartate’ amino acid 
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alteration to cause ‘Bowel cancer’, and a single nucleotide 
change in MSH2, resulting in a codon change from ‘TAT’ to 
‘GAT’, resulting in a ‘Tyrosine’ to ‘Aspartate’ amino acid 
change also causes ‘Bowel cancer’.  
(iii) Tagging the associated gene records by 0,1 or 2 where ‘0’ 
represents the same altered amino acid, ‘1’ the identical 
change in codon, and ‘2’ for the identical encoded amino 
acid change in the identical sequence position of the 
resultant peptide (appendix 3 table A.3.2).  
Due to the complex nature of biological data a manual verification 
process was carried out for combining and verifying each record 
successively, using the Gephi visualizing tools. This generated 21 
‘altered amino acid’ network maps involving 57 genes associated 
with 8 primary cancers (figures 4.2 to 4.22). 
 
As a navigation guide to the following 21 maps, the reader should note 
that:  
a) The colour of gene nodes represents the number of links (edges 
i.e. physical interactions). For any connecting two genes a blue 
edge represents the same altered amino acid (regardless of the 
nature of the codon change); a red edge represents identical 
codon change; and a green edge represents identical peptide 
sequence position of the altered amino acid.  
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Figure 4.2: PPIM of an Alanine altered amino acid and associated with the same 
primary cancer. 59% of the edges (red) show identical codon changes, while 
41% of the edges (blue) show non-identical codon changes. The width of the 
edge is proportional to the number of associated cancers between the two nodes. 
The name on the edge is the abbreviation of the primary cancer involved (e.g, 
Breast cancer (BRE) involves 59% of the connected edges, Bowel cancer (BOW) 
involves 36% of the connected edges and Lung (LU) involves 6% of the 
connected edges). 
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Figure 4.3: PPIM of an Arginine altered amino acid and associated with the 
same primary cancer. 52% of the edges (red) show identical codon changes, 
while 43% of the edges (blue) show non-identical codon changes and the 
remaining 5% of the edges (green) show identical peptide position of the altered 
amino acid. The width of the edge is proportional to the number of associated 
cancers between the two nodes. The name on the edge is the abbreviation of the 
primary cancer involved (e.g, Breast cancer (BRE) involves 38% of the 
connected edges, Bowel cancer (BOW) involves 43% of the connected edges, 
Lung cancer (LU) involves 4% of the connected edges, Ovarian cancer (OV) 
involves 9% of the connected edges and Stomach cancer (ST) involves 4% of 
the connected edges). 
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Figure 4.4: PPIM of an Asparagine altered amino acid and associated with the 
same primary cancer. 60% of the edges (red) show identical codon changes, 
while 40% of the edges (blue) show non-identical codon changes. The width of 
the edge is proportional to the number of associated cancers between the two 
nodes. The name on the edge is the abbreviation of the primary cancer involved 
(e.g, Breast cancer (BRE) involves 53% of the connected edges, Bowel cancer 
(BOW) involves 33% of the connected edges, Ovarian cancer (OV) involves 7% 
of the connected edges and Melanoma (ME) involves 7% of the connected 
edges). 
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Figure 4.5: PPIM of a Glutamate altered amino acid and associated with the 
same primary cancer. 88% of the edges (red) show identical codon changes, 
while 12% of the edges (blue) show non-identical codon changes. The width of 
the edge is proportional to the number of associated cancers between the two 
nodes. The name on the edge is the abbreviation of the primary cancer involved 
(e.g, Breast cancer (BRE) involves 44% of the connected edges and Bowel 
cancer (BOW) involves 56% of the connected edges). 
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Figure 4.6: PPIM of a Glycine altered amino acid and associated with the same 
primary cancer. 63% of the edges (red) show identical codon changes, while 
37% of the edges (blue) show non-identical codon changes. The width of the 
edge is proportional to the number of associated cancers between the two nodes. 
The name on the edge is the abbreviation of the primary cancer involved (e.g, 
Breast cancer (BRE) involves 63% of the connected edges, Bowel cancer (BOW) 
involves 32% of the connected edges and Ovarian cancer (OV) involves 5% of 
the connected edges). 
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Figure 4.7: PPIM of a Histidine altered amino acid and associated with the same 
primary cancer. 55% of the edges (red) show identical codon changes, while 
36% of the edges (blue) show non-identical codon changes and the remaining 
9% of the edges (green) show identical peptide position of the altered amino 
acid. The width of the edge is proportional to the number of associated cancers 
between the two nodes. The name on the edge is the abbreviation of the primary 
cancer involved (e.g, Breast cancer (BRE) involves 68% of the connected edges, 
Bowel cancer (BOW) involves 27% of the connected edges and Melanoma (ME) 
involves 5% of the connected edges). 
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Figure 4.8: PPIM of an Isoleucine altered amino acid and associated with the 
same primary cancer. 48% of the edges (red) show identical codon changes, 
while 48% of the edges (blue) show non-identical codon changes and the 
remaining 4% of the edges (green) show identical peptide position of the altered 
amino acid. The width of the edge is proportional to the number of associated 
cancers between the two nodes. The name on the edge is the abbreviation of the 
primary cancer involved (e.g, Breast cancer (BRE) involves 48% of the 
connected edges, Bowel cancer (BOW) involves 48% of the connected edges 
and Ovarian cancer (OV) involves 4% of the connected edges). 
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Figure 4.9: PPIM of a Lysine altered amino acid and associated with the same 
primary cancer. 77% of the edges (red) show identical codon changes, while 
23% of the edges (blue) show non-identical codon changes. The width of the 
edge is proportional to the number of associated cancers between the two nodes. 
The name on the edge is the abbreviation of the primary cancer involved (e.g, 
Breast cancer (BRE) involves 46% of the connected edges, Bowel cancer (BOW) 
involves 31% of the connected edges and Ovarian cancer (OV) involves 23% of 
the connected edges). 
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Figure 4.10: PPIM of a Methionine altered amino acid and associated with the 
same primary cancer. 50% of the edges (red) show identical codon changes, 
while 50% of the edges (blue) show non-identical codon changes. The width of 
the edge is proportional to the number of associated cancers between the two 
nodes. The name on the edge is the abbreviation of the primary cancer involved 
(e.g, Breast cancer (BRE) involves 63% of the connected edges, Bowel cancer 
(BOW) involves 31% of the connected edges and Ovarian cancer (OV) involves 
6% of the connected edges). 
 
 
CHAPTER FOUR 
     
 
110 
 
 
Figure 4.11: PPIM of a Proline altered amino acid and associated with the same 
primary cancer. 53% of the edges (red) show identical codon changes, while 
40% of the edges (blue) show non-identical codon changes and the remaining 
7% of the edges (green) show identical peptide position of the altered amino 
acid. The width of the edge is proportional to the number of associated cancers 
between the two nodes. The name on the edge is the abbreviation of the primary 
cancer involved (e.g, Breast cancer (BRE) involves 54% of the connected edges, 
Bowel cancer (BOW) involves 40% of the connected edges and Ovarian cancer 
(OV) involves 6% of the connected edges). 
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Figure 4.12: PPIM of a Termination (stop codon) altered amino acid and 
associated with the same primary cancer. 50% of the edges (red) show identical 
codon changes, while 31% of the edges (blue) show non-identical codon 
changes and the remaining 19% of the edges (green) show identical peptide 
position of the altered amino acid. The width of the edge is proportional to the 
number of associated cancers between the two nodes. The name on the edge is 
the abbreviation of the primary cancer involved (e.g, Breast cancer (BRE) 
involves 63% of the connected edges, Bowel cancer (BOW) involves 25% of the 
connected edges, Ovarian cancer (OV) involves 6% of the connected edges and 
Prostate cancer (PR) involves 6% of the connected edges). 
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Figure 4.13: PPIM of a Threonine altered amino acid and associated with the 
same primary cancer. 73% of the edges (red) show identical codon changes, 
while 20% of the edges (blue) show non-identical codon changes and the 
remaining 7% of the edges (green) show identical peptide position of the altered 
amino acid. The width of the edge is proportional to the number of associated 
cancers between the two nodes. The name on the edge is the abbreviation of the 
primary cancer involved (e.g, Breast cancer (BRE) involves 53% of the 
connected edges, Bowel cancer (BOW) involves 40% of the connected edges 
and Ovarian cancer (OV) involves 7% of the connected edges). 
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Figure 4.14: PPIM of a Tyrosine altered amino acid and associated with the 
same primary cancer. 73% of the edges (red) show identical codon changes, 
while 27% of the edges (blue) show non-identical codon changes. The width of 
the edge is proportional to the number of associated cancers between the two 
nodes. The name on the edge is the abbreviation of the primary cancer involved 
(e.g, Breast cancer (BRE) involves 45% of the connected edges, Bowel cancer 
(BOW) involves 45% of the connected edges and Ovarian cancer (OV) involves 
5% of the connected edges). 
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Figure 4.15: PPIM of a Serine altered amino acid and associated with the same 
primary cancer. 67% of the edges (red) show identical codon changes, while 
33% of the edges (blue) show non-identical codon changes. The width of the 
edge is proportional to the number of associated cancers between the two nodes. 
The name on the edge is the abbreviation of the primary cancer involved (e.g, 
Breast cancer (BRE) involves 47% of the connected edges, Bowel cancer (BOW) 
involves 37% of the connected edges, Ovarian cancer (OV) involves 3% of the 
connected edges and Prostate cancer (PR) involves 3% of the connected 
edges). 
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Figure 4.16: PPIM of an Aspartate altered amino acid and associated with the 
same primary cancer. 71% of the edges (red) show identical codon changes, 
while 29% of the edges (blue) show non-identical codon changes. The width of 
the edge is proportional to the number of associated cancers between the two 
nodes. The name on the edge is the abbreviation of the primary cancer involved 
(e.g, Breast cancer (BRE) involves 50% of the connected edges, Bowel cancer 
(BOW) involves 36% of the connected edges and Ovarian cancer (OV) involves 
14% of the connected edges). 
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Figure 4.17: PPIM of a Cysteine altered amino acid and associated with the 
same primary cancer. 77% of the edges (red) show identical codon changes, 
while 23% of the edges (blue) show non-identical codon changes. The width of 
the edge is proportional to the number of associated cancers between the two 
nodes. The name on the edge is the abbreviation of the primary cancer involved 
(e.g, Breast cancer (BRE) involves 53% of the connected edges, Bowel cancer 
(BOW) involves 23% of the connected edges, Ovarian cancer (OV) involves 9% 
of the connected edges, Stomach cancer (ST) involves 5% of the connected 
edges, Melanoma  (ME) involves 5% of the connected edges and Prostate 
cancer (PR) involves 5% of the connected edges). 
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Figure 4.18: PPIM of a Glutamine altered amino acid and associated with the 
same primary cancer. 65% of the edges (red) show identical codon changes, 
while 32% of the edges (blue) show non-identical codon changes and the 
remaining 3% of the edges (green) show identical peptide position of the altered 
amino acid. The width of the edge is proportional to the number of associated 
cancers between the two nodes. The name on the edge is the abbreviation of the 
primary cancer involved (e.g, Breast cancer (BRE) involves 58% of the 
connected edges, Bowel cancer (BOW) involves 30% of the connected edges, 
Ovarian cancer (OV) involves 3% of the connected edges, Stomach cancer (ST) 
involves 3% of the connected edges and Prostate cancer (PR) involves 3% of the 
connected edges). 
. 
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Figure 4.19: PPIM of a Leucine altered amino acid and associated with the same 
primary cancer. 44% of the edges (red) show identical codon changes, while 
56% of the edges (blue) show non-identical codon changes. The width of the 
edge is proportional to the number of associated cancers between the two nodes. 
The name on the edge is the abbreviation of the primary cancer involved (e.g, 
Breast cancer (BRE) involves 56% of the connected edges, Bowel cancer (BOW) 
involves 31% of the connected edges, Ovarian cancer (OV) involves 5% of the 
connected edges, Stomach cancer (ST) involves 3% of the connected edges and 
Prostate cancer (PR) involves 5% of the connected edges). 
. 
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Figure 4.20: PPIM of a Phenylalanine altered amino acid and associated with 
the same primary cancer. 58% of the edges (red) show identical codon changes, 
while 42% of the edges (blue) show non-identical codon changes. The width of 
the edge is proportional to the number of associated cancers between the two 
nodes. The name on the edge is the abbreviation of the primary cancer involved 
(e.g, Breast cancer (BRE) involves 75% of the connected edges, Bowel cancer 
(BOW) involves 10% of the connected edges, Ovarian cancer (OV) involves 10% 
of the connected edges and Prostate cancer (PR) involves 5% of the connected 
edges). 
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Figure 4.21: PPIM of a Tryptophan altered amino acid and associated with the 
same primary cancer. 61% of the edges (red) show identical codon changes, 
while 39% of the edges (blue) show non-identical codon changes. The width of 
the edge is proportional to the number of associated cancers between the two 
nodes. The name on the edge is the abbreviation of the primary cancer involved 
(e.g, Breast cancer (BRE) involves 42% of the connected edges, Bowel cancer 
(BOW) involves 48% of the connected edges and Ovarian cancer (OV) involves 
10% of the connected edges). 
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Figure 4.22: PPIM of a Valine altered amino acid and associated with the same 
primary cancer. 36% of the edges (red) show identical codon changes, while 
56% of the edges (blue) show non-identical codon changes and the remaining 
8% of the edges (green) show identical peptide position of the altered amino 
acid. The width of the edge is proportional to the number of associated cancers 
between the two nodes. The name on the edge is the abbreviation of the primary 
cancer involved (e.g, Breast cancer (BRE) involves 60% of the connected edges, 
Bowel cancer (BOW) involves 24% of the connected edges, Ovarian cancer (OV) 
involves 8% of the connected edges, Lung cancer (LU) involves 4% of the 
connected edges and Womb cancer (WO) involves 4% of the connected edges). 
. 
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4.1.3. Investigating the Connectivity of the 21 Individual PPIM Altered 
Amino Acid Networks. 
The ‘altered amino acid networks’ revealed several interesting 
points. Identical single nucleotide changes, identical altered amino acid, 
and identical peptide positions of the altered amino acids were found in 
several connected gene nodes. These data may be best presented in four 
parts on the basis of their sub-network connectivity. For example in the 
first part two fully-disconnected sub-networks occur with no bridging node, 
while in the second these disjointed sub-networks are bridged by BRCA1 
and MSH6, the third bridged by TP53 and MSH2, and finally the fourth 
bridged by CHEK2 and MSH2. 
  
1. a) Fig. 4.2-4.14 shows two fully disconnected sub-networks, 
where one sub-network corresponds to connected genes 
associated with Bowel cancer and the other sub-network to Breast 
cancer. Both sub-networks also contain, a minor constituent 
ovarian, prostate, lung and melanoma cancers. Connected gene 
nodes in these networks were associated with the same amino acid 
alteration and/or the identical change of codon. Surprisingly some 
of these changes occurred at identical peptide positions in the 
proteins encoded by the connected genes. For example, Figure 4.7 
shows that the amino acid encoded by the BRCA1 gene altered 
from ‘Asn564’ to ‘His564’, the amino acid change for the protein 
encoded by the BARD1 gene was from ‘Gln564’ to ‘His564’. Both 
amino acid alterations are associated with Breast cancer. This 
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finding was agreed by a previous report showing interactions of 
these two genes in Breast cancer (Wu et al., 1996), indicating that 
the BARD1/BRCA1 interaction is interrupted by BRCA1 Missense 
mutations. Others have reported that BRCA1 DNA-binding activity 
is stimulated by BARD1 (Simons et al., 2006).  I also detected 
another amino acid alteration in BRCA1 i.e., ‘Gln1785’ to ‘His1785’ that 
was also found in the ATM i.e., ‘Pro1785’ to ‘His1785’ both associated 
with Breast cancer. It has been reported that DNA damage can lead 
to ATM-dependent phosphorylation of BRCA1 leading to Breast 
cancer (Gatei et al., 2000; Cortez et al., 1999).  
 
1.b) Fig 4.13 and 4.8 shows where BRCA1 and BRCA2 have an 
identically changed codon (i.e. ‘ATG’ to ‘ACG’) that alters the 
resultant amino acid from ‘Met’ to ‘Thr’ in the same peptide 
sequence position 1. This change is associated with Ovarian 
cancer. An identical codon change from ‘ATG’ to ‘ATA’ produced a 
‘Met’ to ‘Ile’ alteration in same peptide also at position ‘1’. In this 
case the change was associated with Breast cancer. It has 
previously been reported that BRCA1 and BRCA2 proteins interact 
in pathways that lead to the activation of double-strand break repair 
and homologous recombination (Chen et al., 1998).  
 
1. c) Fig 4.11 reveals an amino acid alteration ‘Ala636’ to ‘Pro636’ in 
MSH2, while a ‘Leu636’ to ‘Pro636’ amino acid alteration was 
apparent for MLH1. Both changes are associated with Bowel 
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cancer. Both genes also exhibit another identical amino acid 
alteration ‘Gly751’ to ‘Arg751’ in MSH2 and ‘Lys751’ to ‘Arg751’ in 
MLH1, again both associated with Bowel cancer. According to 
previous reports these two genes are pathway genes for bowel 
cancer (Arends, 2013).  
2. a) Fig 4.15, 4.20, 4.21 and 4.22 illustrate how two disjointed sub-
networks can be connected by an identical codon or amino acid alteration.  
These network’s ‘bridges’ may be a cross point for the clustering of breast 
and bowel cancers. For example, BRCA1 and MSH6 have 4 identical 
codon changes each resulting in an amino acid change. These include: (i) 
Fig 4.15 shows a ‘TCT’ to ‘TTT’ codon change resulting in an amino acid 
alteration from ‘Ser’ to ‘Phe’, which is associated with Breast cancer; (ii) 
Fig 4.20 shows a ‘GCC’ to ‘TCC’ codon change resulting in an ‘Ala’ to ‘Ser’ 
amino acid change also leading to Breast cancer; (iii) Fig 4.21 showing a 
‘CGG’ to ‘TGG’ codon change leading to a ‘Arg’ to ‘Trp’ amino acid change 
that in this case is associated Bowel cancer. Fig 4.22 shows a change in 
amino acid from ‘Ile’ to ‘Val’ for BRCA1 and MSH6 that is associated with 
Breast cancer.  
BRCA1 is connected with two other genes (MSH2 and MLH1) as 
they are associated with Bowel cancer. The literature reports that MSH6, 
MSH2 and MLH1 genes are associated with BRCA1 to form a large 
protein complex for the recognition of abnormal/damaged DNA structures 
(Wang et al., 2000).  
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3) Fig 4.16, 4.17 and 4.19 reveal networks with two disjoined sub-
networks that are bridged with a TP53 and MSH2 connection. Both genes 
share an identical codon change that produces different amino acids. In 
Fig 4.16 this is ‘GGC’ to ‘GAC’ resulting in ‘Gly’ to ‘Asp’ switch, while in Fig 
4.19 the change of codon is from ‘CCC’ to ‘CTC’, with resultant ‘Pro’ to 
‘Leu’ switch. Both changes are associated with Bowel cancer. By contrast, 
Fig 4.17 shows another sub-network linked this time by TP53 and MSH2. 
The encoded protein TP53 is altered via the amino acid change ‘Arg’ to 
‘Cys’, while for MSH2 ‘Tyr’ is altered to ‘Cys’; both changes are associated 
with Stomach cancer. The literature reports that these two genes bind 
together during the DNA synthesis phase of the cell cycle (Zink et al., 
2002).  
4) Fig 4.18 shows an identical codon change in CHEK2 and MSH2 
that connect the two disjoined sub-networks. Here the codon has changed 
from ‘CGG’ to ‘CAG’ in both genes, resulting in a ‘Arg’ to ‘Gln’ switch and 
is associated with Bowel cancer. The literature reports that MSH2 binds  
CHEK2  (Brown et al., 2002). 
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4.2. Discussion/Conclusions 
The main objectives of this chapter were as follows: (i) associating 
genes based on the physical interactions of their encoded proteins and 
thereby construct a protein-protein interaction map (PPIM), (ii) extracting 
Missense/Nonsense mutations in codons and determine their associated 
amino acid changes, and relating these to associated cancers within the 
PPIM, (iii) merging the extracted Missense/Nonsense mutation records 
with the PPIM data to construct “21 amino acid alteration networks”, and 
lastly; (iv) investigating the influence of a single nucleotide change, amino 
acid change and the peptide position of the changed amino acid in the 
altered amino acid networks.  
 
The amino acid alteration networks revealed:   
1. Mutation-derived alterations in Alanine, Arginine, Asparagine, 
Glutamate, Histidine, Isoleucine, Lysine, Methionine, Proline, 
Termination, Threonine and Tyrosine were associated with two 
fully-disjoint sub-networks; the first sub-network associated with 
genes linked to Bowel cancer and the second sub-network 
associated with genes leading to Breast cancer. 
2. Mutation-derived alterations in Serine, Aspartate, Cysteine, 
Glutamine, Leucine, Phenylalanine, Tryptophan and Valine 
connected the two disjoint sub-networks and linked the clusters of 
Bowel, Breast or Stomach cancers. 
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3. BRCA1 and MSH6 appear to play a central role in connecting the 
disjoint sub-networks of mutation-derived alterations in Serine, 
Phenylalanine, Tryptophan and Valine, where both genes are 
associated with Breast and Bowel cancers. 
4. TP53 and MSH2 connect disjointed sub-networks by the encoded 
amino acid alterations in Leucine and Aspartate, resulting in Bowel 
cancer, while the encoded amino acid alteration leading to Cysteine 
was associated with Stomach cancer. 
5. CHEK2 and MSH2 genes connect genes in the disjointed sub-
networks, but the encoded amino acid change to Glutamine, 
resulting in Bowel cancer. 
6. Identical encoded amino acid change at identical peptide sequence 
positions for two associated genes leading to same cancer. 
 
It may be useful to further investigate the groups of associated genes 
in these altered amino acid networks, and especially those gene nodes 
that connect disjointed gene node clusters in the network. Areas of 
potential relevant research could be around their enzyme binding, gene 
ontology, damaged DNA binding and DNA repair etc.  
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Chapter Five  
 
5. Overall Discussion and Future Work 
 
5.1. General Conclusions 
The aim of this project was to assess the involvement of germline 
mutation classes in developing human cancers. This aim was progressed 
via several specific objectives/questions as follows: (i) Are individual 
groups of primary cancers associated with specific gene subsets groups 
(within the 424 cancer genes)? (ii) Are there any specific groups of primary 
cancers associated with particular mutation classes? (iii) If both questions 
prove true, are groups of cancers associated with particular mutation 
classes of target gene groups? This project also explored whether a 
corresponding Protein-Protein Interaction Map, derived from the 
Missense/Non-sense Mutation portion of the HCM gene set, would provide 
further information on gene associations between primary cancers in 
terms of the consequent identical amino acid changes involved.   
Results showed that: (1) Closely-connected human cancers in the 
HCM exhibited a strong association with particular mutation class.  (2) 
Missense /Nonsense and Regulatory mutations played a central role in 
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connecting cancers (i.e. via primary cancer nodes) and so significantly 
influenced the construction of the HCM. (3) Group of genes with 
Missense/Nonsense and Regulatory mutations tended to be cancer-
associated pathway genes. (4) BRCA1, BRCA2, PALB2, MSH2, MSH6, 
MLH1, CDKN2A, and TP53 showed the highest agreement for 5 of 10 
mutation classes. (5) From the PPIM, it was evident that BRCA1, MSH6, 
BARD1, TP53, MSH2 and CHEK2 proteins best connected Breast, 
Ovarian, Prostate and Bowel primary cancers and so could represent 
‘driver proteins’ for these cancers.   
In summary, this project has approached the analysis of gene 
involvement in human primary cancers from the starting position of the 
mutation class that harbours the specific gene mutation. Together with 
their downstream resultant alterations in the associated proteins, this 
analysis provides great insights into the relatedness of primary human 
cancers and their associated potential gene hierarchies. The data 
produced in this study may therefore help us to understand further the 
aetiology, diagnosis and potentially personalized treatments for cancer. 
For example, the amino acids connecting the disjoined networks via 
different genes and cancers at the missense/nonsense mutation might be 
a point where one gene is affected leading to an effect on all linked genes 
in the networks, which could then lead to the development of other 
cancers.  
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5.2. General Discussion  
The Human Cancer Map (HCM) revealed a significant variation in 
the dominance of different mutation class involved in cancer. 
Missense/Nonsense mutation (44%) represented almost half of the 
interconnections in the HCM, followed by small deletion mutations at 14%. 
The remaining mutation classes ranged from 10% to 1%. This means that 
cancer associations vary from one mutation class to another. For example, 
a total of 19 primary cancers with Missense/Nonsense mutation were 
found to be associated to each other, whereas only 12 primary cancers 
were represented by splicing mutations.  
The agreements between the connected nodes (cancers) in the 
HCM and sub-HCMs (i.e. sub-MAPs for each mutation class) were 
examined and quantified using Choen’s kappa test (Carletta, 1996; 
Cohen, 1960), and revealed some interesting results. Cancer node 
connectivity levels involving Missense/Nonsense and the Regulatory 
mutation classes ranged from low for 80% of the nodes (k<0.25) to 
moderate for 20% (k=0.25-0.5). This suggests that although this mutation 
class dominates the HCM, it may be less important mutations in terms of 
connectivity between cancer nodes in the constructed HCM (Chapter 3, 
Figure 3.13). However, many more of these genes are involved in 
pathways (KEGG) for cancers and other disorders than for other mutation 
classes, even if the later show higher levels of kappa agreement (Chapter 
3, Figure 3.26 and Table 3.1).  By contrast, mutations involving Repeat 
variations, Complex rearrangement and Gross insertions showed low 
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agreement values for all the connected nodes, which make them less 
important mutations in terms of connectivity between cancer nodes in the 
constructed HCM. (Chapter 3, Figure 3.13 and Appendix 1 Tables A.1.8, 
A.1.9 and A.1.10). Furthermore, these gene nodes were not represented 
in the KEGG pathways for cancer. Surprisingly, while the remaining five 
mutation classes showed some high kappa agreement values between 
interconnected gene nodes, the mutation class was represented in only a 
small proportion of all nodes (Fig. 3.13). For example, while Small Indels 
mutations represented only a mere 2% of the total HCM, their 
corresponding inter-node connectivity revealed 100% high or very high 
kappa values (agreement) (Chapter 3, Figure 3.13 and Appendix 1 Tables 
A.1.2, A.1.3, A.1.4, A.1.6 and A.1.7).   
From a biological perspective, what does the above finding mean? I 
would like to suggest two potential hypotheses. The first indicates that a 
Missense/Nonsense and Regulatory mutation has a large impact on how 
cancer nodes associate with each other in a HCM. Without the 
involvement of these two mutation classes the HCM would fragment, and 
almost 50% of cancer nodes would be disconnected. This then may 
suggest that mutations of these 2 classes may contain driver mutations 
connecting cancer gene nodes. Alternatively, mutations of the following 
types (i.e. Small Deletions, Splicing, Small Insertions, Gross Deletions, 
and Small Indels), with their high to very high agreements (kappa values) 
between some of their connected cancer nodes, may make them more 
deleterious as they would have greater impact on cancer gene 
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connectivity in the HCM. For example, Small deletion mutations tend to be 
a target mutation connecting Womb cancer to Lymphoma and Brain 
cancer nodes via small deletion mutations in the BRCA2, BRCA1 and 
PALB2 genes, while at the same time connecting Lymphoma to Brain 
cancer nodes via small deletion mutations in MSH2, MSH6, BRCA1 and 
MLH1 (figure 3.3 and Appendix 1 Table A1.2). Splicing mutations tend to 
be target mutations for connecting Melanoma to Brain and Pancreatic 
cancer nodes via splicing mutations in the CDKN2A gene, and for 
connecting Breast to Ovarian cancer nodes via splicing mutations in 
BRCA1, BRCA2, RAD51C, RAD51D and TP53 genes. They also connect 
Kidney to Bladder cancer nodes via splicing mutations in MSH2 (Figure 
3.4 and Appendix 1 Table A1.3). 
Small Insertion mutations tend to be more engaged in the HCM by 
targeting more high to very high agreements (kappa values) between their 
inter-connected cancer nodes. For example, Stomach cancer connected 
to Bowel and Kidney cancers via small Insertion mutations in CDH1 and 
MSH2, while Breast cancer connected to Ovarian cancer via small 
Insertion mutations BRCA1, BRIP1 and RAD51C. Melanoma was 
connected to Lung, Prostate and Pancreatic cancers via small Insertion 
mutations of BRCA2 and CDKN2A, while Pancreatic cancer was connect 
to Prostate and Lung by small Insertion mutations in BRCA2 ( Figure 3.5 
and Appendix 1 Table A1.4). 
Finally, Small Indels mutation tend to have a high to very high 
agreements (100%) between all its connected cancer nodes, such as 
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Bowel connected to the Brain and Womb cancer nodes via MLH1 and 
MSH6, Ovarian connected to Breast and Pancreatic cancer node via 
BRCA1 and BRCA2, Melanoma connected to the Head and Neck cancer 
node via CDKN2A (Figure 3.8 and Appendix 1 Table A1.7). 
The above five mutation classes may share some similarities in 
terms of their genetics implications via associated mutations in BRCA1, 
BRCA1, PALB2, MSH6, MSH2, MLH1, CDKN2A, RAD51C, RAD51D, 
TP53, CDH1 and BRIP1. These 12 genes were also connected in the 
Genome-wide Distribution Maps and also at the protein interaction as 
shown in the Protein-Protein Interactions Map (PPI). DAVID analysis 
revealed that 2 of these twelve genes (i.e., MSH6 and MLH1) tended to 
have similar biological functions. All these revealed information suggesting 
these groups of genes could be the main driver genes, which are 
responsible for many types of cancers as shown in this study. These 
relations can be seen in Chapter 3, figures 3.16 to 3.24 and Chapter 4 
figure 4.1. 
The results of this study suggested that Missense/Nonsense 
mutations have a large influence in interconnecting cancer nodes, and 
interrogation of these Missense/Nonsense mutation records provided new 
insights. One of these is that cancers caused by different amino acid 
alterations involving all 21 amino acids of the human body. The 
interrogation results targeted two groups of interconnected genes; each 
one formed a network associated with a specific cancer. The first group of 
connected genes (MSH2, PMS2, MLH1, MSH6 and MUTYH) associated 
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with Bowel cancer, while the second group of genes (PALB2, BRCA1, 
BRCA2, ATM, TP53 and CHEK2) associated with Breast cancer. These 
PPIM networks occur when their nucleotide changes encode alterations in 
one of the following 13 amino acids (i.e., Alanine, Arginine, Asparagine, 
Glutamate, Glycine, Histidine, Isoleucine, Lysine, Methionine, Proline, 
Termination, Threonine and Tyrosine) (Chapter 4 figures 4.2 to 4.14). But 
when these two groups of genes undergo nucleotide change to encode 
one of the following 8 amino acids (i.e., Serine, Aspartate, Cysteine, 
Glutamine, Leucine, Phenylalanine, Tryptophan and Valine) we see 
merging of the two disjointed node clusters in the network. The bridging is 
either by Breast, Bowel or Ovarian cancer (figures 4.15 to 4.22), and could 
be a interesting subject for further research as these 12 genes appeared 
to be significant throughout this study, ie are over represented in cancers. 
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5.3. Future Work 
It would be potentially very useful to extending the current study 
presented in this thesis by considering the following important points: 
1. Extending current work on the HCM, which currently includes 20 
primary human cancers and their associated 424 genes (of a total of 
29 primary human cancers), by including updated information of 
genes, cancers and mutation records. This will allow us to produce a 
global HCM.  
2. Extending the current interrogation protocol used for 
Missense/Nonsense mutation class to the remaining nine mutation 
classes i.e. Splicing, Small deletions, Small Insertion, Small Indels, 
Complex Rearrangement, Gross deletion, Gross Insertion, 
Regulatory and Repeat variation. 
3. Investigating the environmental factors that have impact on gene 
behaviour, which will address unanswered questions in relation to 
genetic mutations. This will allow us to produce a modified Global 
Human Cancer Map. 
4. Integrating somatic cell mutations and germline mutations. 
5. Investigating further the following highly represented cancer-related 
genes i.e. MSH2, PMS2, MLH1, MSH6, MUTYH, PALB2, BRCA1, BRCA2, 
ATM, TP53 and CHEK2) in terms of their associated biological 
activities e.g., enzyme binding, gene ontology, Damage DNA binding 
and DNA repair etc. 
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6. Expands the current work presented in chapter three (figure 3.15), to 
include a patient based clinical data and increase to the number of 
gene, mutation and cancer records.  
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Appendix 
Appendix 1 
  
Table A.1.1: Missense/Nonsense SM-HCM. The first column represents cancer 
node one, the second column is the associated cancer node for cancers in 
column one, the third column is the shared gene for each of the two associated 
cancer nodes, the fourth column is the kappa agreement test results where low 
agreements <0.25, moderate agreement 0.25 to 0.50, high agreement 0.50 to 
0.75 and the very high agreement 0.75 – 1. In total there are 56 genes and 19 
primary cancer nodes.  
Cancer Node1 Cancer Node 2 Shared Genes Kappa 
Lung Cancer Prostate Cancer CYP1B1 -0.20 
Bowel Cancer Breast Cancer NBN,TP53,MSH6,PML,BRCA
1,BRCA2,CHEK2,PARP1 
-0.17 
Bowel Cancer Ovarian Cancer TP53,BRCA1,BRCA2,CHEK2 -0.14 
Lung Cancer Bowel Cancer ABCB1,AXIN2,CYP1A1,NBN,
OGG1,TP53,XPC 
-0.14 
Lung Cancer Ovarian Cancer BARD1,TNFRSF10A,TP53 -0.14 
Lung Cancer Melanoma NBN -0.14 
Bowel Cancer Pancreatic Cancer BRCA2 -0.13 
Lung Cancer Breast Cancer ATM,BARD1,EGFR,ERBB2,N
BN,TP53,XRCC1 
-0.09 
Breast Cancer Melanoma NBN,BRCA2 -0.07 
Lung Cancer Stomach Cancer TP53 -0.07 
Melanoma Ovarian Cancer BRCA2 -0.07 
Bowel Cancer Skin Cancer (Non Melanoma) TP53 -0.06 
Bowel Cancer Kidney Cancer FLCN,MSH2 -0.05 
Kidney Cancer Ovarian Cancer GEMIN4 -0.05 
Skin Cancer(Non Melanoma) Breast Cancer TP53 -0.05 
Breast Cancer Pancreatic Cancer BRCA2,FANCA -0.04 
Bowel Cancer Brain tumours TP53,MSH2 -0.02 
Breast Cancer Head and neck cancer EGFR -0.02 
Breast Cancer Oesophageal Cancer AURKA -0.02 
Melanoma Prostate Cancer BRCA2 -0.02 
Ovarian Cancer Brain tumours TP53 -0.02 
Womb Cancer Ovarian Cancer BRCA1 -0.02 
Bowel Cancer Melanoma NBN,BMP4,BRCA2 -0.01 
Breast Cancer Stomach Cancer TP53,CDH1 0.00 
Breast Cancer Brain tumours TP53,PTPN11 0.00 
Breast Cancer Womb Cancer MSH6,BRCA1 0.00 
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Prostate Cancer Pancreatic Cancer BRCA2 0.01 
Skin Cancer(Non Melanoma) Ovarian Cancer TP53 0.01 
Lung Cancer Brain tumours TP53,BAP1 0.02 
Stomach Cancer Prostate Cancer CDH1 0.03 
Womb Cancer Prostate Cancer BRCA1 0.03 
Bowel Cancer Soft Tissue Sarcomas TP53 0.04 
Kidney Cancer Melanoma CDKN2A 0.04 
Lung Cancer Bladder Cancer XPC 0.04 
Ovarian Cancer Lymphoma TP53 0.04 
Bowel Cancer Lymphoma TP53,MET 0.05 
Bowel Cancer Leukaemia BUB1B,MYO18B 0.05 
Bowel Cancer Oesophageal Cancer MLH3,PTGS2 0.05 
Lung Cancer Soft Tissue Sarcomas TP53 0.06 
Lung Cancer Mouth Oropharyngeal Cancer XRCC4 0.06 
Breast Cancer Lymphoma ATM,TP53 0.07 
Pancreatic Cancer Ovarian Cancer BRCA2,PALB2 0.07 
Bowel Cancer Bladder Cancer XPC,ERCC6 0.08 
Bowel Cancer Prostate Cancer BRCA1,BRCA2,CHEK2,EPHB
2,PARP1 
0.08 
Lung Cancer Lymphoma ATM,TP53 0.09 
Lung Cancer Head and neck cancer EGFR,PTPN13 0.09 
Lung Cancer Womb Cancer MGMT 0.09 
Skin Cancer(Non Melanoma) Melanoma MC1R 0.10 
Ovarian Cancer Soft Tissue Sarcomas TP53 0.11 
Stomach Cancer Ovarian Cancer TP53,CDH1 0.11 
Stomach Cancer Brain tumours TP53 0.12 
Stomach Cancer Womb Cancer MLH1 0.12 
Bowel Cancer Stomach Cancer TP53,MET,NUDT1,MLH1 0.14 
Bowel Cancer Womb Cancer MSH6,BRCA1,MLH3,MLH1 0.14 
Head and neck cancer Melanoma P14ARF 0.14 
Melanoma Leukaemia RMI1 0.14 
Lung Cancer Skin Cancer(Non Melanoma) TP53,TP53BP1 0.15 
Skin Cancer(Non Melanoma) Lung Cancer ERCC2 0.15 
Head and neck cancer Pancreatic Cancer P14ARF 0.16 
Skin Cancer(Non Melanoma) Stomach Cancer TP53 0.16 
Skin Cancer(Non Melanoma) Brain tumours TP53 0.16 
Brain tumours Lymphoma TP53 0.20 
Womb Cancer Oesophageal Cancer MLH3 0.20 
Prostate Cancer Ovarian Cancer BRCA1,BRCA2,CHEK2,CDH1 0.21 
Skin Cancer(Non Melanoma) Lymphoma TP53 0.24 
Kidney Cancer Pancreatic Cancer VHL,CDKN2A 0.25 
Breast Cancer Prostate Cancer BRCA1,BRCA2,CHEK2,PARP
1,AR,CDH1,CYP19A1 
0.27 
Kidney Cancer Brain tumours MSH2,SDHB 0.29 
Breast Cancer Soft Tissue Sarcomas TP53 0.31 
Soft Tissue Sarcomas Brain tumours TP53 0.31 
Stomach Cancer Soft Tissue Sarcomas TP53 0.31 
Breast Cancer Ovarian Cancer BARD1,TP53,BRCA1,BRCA2,
CHEK2,CDH1,MRE11A,RAD
50,RAD51C,RAD51D 
0.37 
Skin Cancer(Non Melanoma) Soft Tissue Sarcomas TP53 0.38 
Melanoma Pancreatic Cancer BRCA2,P14ARF,CDKN2A 0.39 
Stomach Cancer Lymphoma TP53,MET 0.46 
Soft Tissue Sarcomas Lymphoma TP53 0.49 
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Table A.1.2: Small Deletions SM-HCM. The first column represents cancer node 
one, the second column is the associated cancer node for cancers in column 
one, the third column is the shared gene for each of the two associated cancer 
nodes, the fourth column is the kappa agreement test results where low 
agreements <0.25, moderate agreement 0.25 to 0.50, high agreement 0.50 to 
0.75 and the very high agreement 0.75 – 1. In total there are 19 genes and 12 
primary cancer nodes. 
 
 
 
 
 
 
 
 
 
 
Cancer Node 1 Cancer Node 2 Genes Kappa 
Bowel Cancer Breast Cancer CDKN2A -0.51 
Bowel Cancer Ovarian Cancer MSH2 -0.24 
Bowel Cancer Pancreatic Cancer BRCA2,BRCA1,PALB2 -0.14 
Breast Cancer Pancreatic Cancer MSH2,MSH6,BRCA1,MLH1 -0.08 
Lung Cancer Breast Cancer MSH2 -0.04 
Lung Cancer Ovarian Cancer BRCA2 -0.04 
Prostate Cancer Ovarian Cancer CDKN2A -0.04 
Womb Cancer Ovarian Cancer MSH2,MSH6 -0.04 
Lung Cancer Bowel Cancer MSH2,MSH6 0.10 
Breast Cancer Stomach Cancer BRCA2,SERCA2B 0.11 
Lung Cancer Pancreatic Cancer BRCA2,BRCA1,PALB2 0.18 
Prostate Cancer Pancreatic Cancer MSH2 0.18 
Pancreatic Cancer Ovarian Cancer BRCA2,SERCA2B 0.19 
Breast Cancer Prostate Cancer MSH2,MSH6 0.22 
Bowel Cancer Lymphoma 
BRCA2,BRCA1,BRIP1,CDH1,CHEK2,RA
D50,RAD51C,TP53 0.24 
Bowel Cancer Brain tumours BRCA2,SERCA2B 0.24 
Bowel Cancer Bladder Cancer BRCA2 0.24 
Melanoma Pancreatic Cancer 
BRCA2,BRCA1,BRIP1,CDH1,CHEK2,RA
D50,RAD51C,TP53 0.32 
Breast Cancer Ovarian Cancer 
BRCA2,BRCA1,BRIP1,CDH1,CHEK2,RA
D50,RAD51C,TP53 0.42 
Lung Cancer Prostate Cancer CDKN2A 0.42 
Bowel Cancer Womb Cancer MSH2,MSH6,BRCA1,MLH1 0.46 
Womb Cancer Lymphoma BRCA2,BRCA1,PALB2 0.63 
Womb Cancer Brain tumours BRCA2 0.63 
Lymphoma Brain tumours MSH2,MSH6,BRCA1,MLH1 1.00 
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Table A.1.3: Splicing SM-HCM. The first column represents cancer node one, the 
second column is the associated cancer node for cancers in column one, the 
third column is the shared gene for each of the two associated cancer nodes, the 
fourth column is the kappa agreement test results where low agreements <0.25, 
moderate agreement 0.25 to 0.50, high agreement 0.50 to 0.75 and the very high 
agreement 0.75 – 1. In total there are 12 genes and 12 primary cancer nodes. 
Cancer Node 1 Cancer Node 2 Genes Kappa 
Prostate Cancer Ovarian Cancer BRCA2 -0.09 
Breast Cancer Pancreatic Cancer BRCA2 0.00 
Pancreatic Cancer Ovarian Cancer BRCA2 0.06 
Breast Cancer Prostate Cancer BRCA2,CHEK2 0.17 
Bowel Cancer Stomach Cancer MUTYH 0.25 
Prostate Cancer Pancreatic Cancer BRCA2 0.25 
Stomach Cancer Prostate Cancer CDH1 0.25 
Brain tumours Pancreatic Cancer CDKN2A 0.40 
Bowel Cancer Womb Cancer MSH6 0.43 
Bowel Cancer Kidney Cancer MSH2 0.43 
Bowel Cancer Bladder Cancer MSH2 0.43 
Melanoma Brain tumours CDKN2A 0.63 
Melanoma Pancreatic Cancer CDKN2A 0.63 
Skin Cancer(Non Melanoma) Brain tumours SUFU 0.63 
Breast Cancer Ovarian Cancer 
BRCA1,BRCA2,RAD5
1C,RAD51D,TP53 0.83 
Kidney Cancer Bladder Cancer MSH2 1.00 
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Table A.1.4: Small Insertion SM-HCM. The first column represents cancer node 
one, the second column is the associated cancer node for cancers in column 
one, the third column is the shared gene for each of the two associated cancer 
nodes, the fourth column is the kappa agreement test results where low 
agreements <0.25, moderate agreement 0.25 to 0.50, high agreement 0.50 to 
0.75 and the very high agreement 0.75 – 1. In total there are 9 genes and 10 
primary cancer nodes. 
Cancer Node 1 Cancer Node 2 Genes Kappa 
Bowel Cancer Breast Cancer CDH1 -0.35 
Breast Cancer Stomach Cancer CDH1 0.05 
Melanoma Ovarian Cancer BRCA2 0.05 
Pancreatic Cancer Ovarian Cancer BRCA2 0.05 
Bowel Cancer Brain tumours TP53 0.27 
Bowel Cancer Kidney Cancer MSH2 0.27 
Bowel Cancer Womb Cancer MSH6 0.27 
Lung Cancer Ovarian Cancer BRCA2 0.27 
Prostate Cancer Ovarian Cancer BRCA2 0.27 
Bowel Cancer Stomach Cancer CDH1,MSH2 0.53 
Breast Cancer Ovarian Cancer BRCA1,BRIP1,RAD51C 0.55 
Lung Cancer Melanoma BRCA2 0.61 
Lung Cancer Pancreatic Cancer BRCA2 0.61 
Melanoma Prostate Cancer BRCA2 0.61 
Prostate Cancer Pancreatic Cancer BRCA2 0.61 
Stomach Cancer Kidney Cancer MSH2 0.61 
Lung Cancer Prostate Cancer BRCA2 1 
Melanoma Pancreatic Cancer BRCA2,CDKN2A 1 
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Table A.1.5: Regulatory SM-HCM. The first column represents cancer node one, 
the second column is the associated cancer node for cancers in column one, the 
third column is the shared gene for each of the two associated cancer nodes, the 
fourth column is the kappa agreement test results where low agreements <0.25, 
moderate agreement 0.25 to 0.50, high agreement 0.50 to 0.75 and the very high 
agreement 0.75 – 1. In total there are 14 genes and 11 primary cancer nodes. 
Cancer Node 1 Cancer Node 2 Gene Kappa 
Breast Cancer Bowel Cancer DNMT3B, ERBB4 -0.29 
Bladder Cancer Breast Cancer MDM2 -0.14 
Bowel Cancer Bladder Cancer PTGS2 -0.09 
Breast Cancer Prostate Cancer KLK3 -0.08 
Lung Cancer Bladder Cancer PTGS2 -0.02 
Breast Cancer Ovarian Cancer BRCA2 0.00 
Lung Cancer Breast Cancer DNMT3B, MIR30C1 0.00 
Lung Cancer Ovarian Cancer CHEK2 0.10 
Skin Cancer (Non 
Melanoma) Breast Cancer TP53 0.14 
Bowel Cancer Oesophageal Cancer PTGS2 0.19 
Bowel Cancer Womb Cancer MSH2 0.19 
Prostate Cancer Bowel Cancer MYC 0.22 
Lung Cancer Oesophageal Cancer PTGS2 0.24 
Lung Cancer Bowel Cancer 
DNMT3B, MLH1, 
PTGS2 0.26 
Bladder Cancer Oesophageal Cancer PTGS2 0.44 
Bladder Cancer Stomach Cancer OGG1 0.44 
Cervical Cancer Prostate Cancer BCL2 0.44 
 
 
 
 
 
 
 
 
 
 
APPENDIX 
 
 
 
154 
 
Table A.1.6: Gross Deletions SM-HCM. The first column represents cancer node 
one, the second column is the associated cancer node for cancers in column 
one, the third column is the shared gene for each of the two associated cancer 
nodes, the fourth column is the kappa agreement test results where low 
agreements <0.25, moderate agreement 0.25 to 0.50, high agreement 0.50 to 
0.75 and the very high agreement 0.75 – 1. In total there are 8 genes and 8 
primary cancer nodes. 
Cancer Node 1 Cancer Node 2 Genes Kappa 
Bowel Cancer Ovarian Cancer BRCA1 -0.07 
Breast Cancer Prostate Cancer CHEK2 0.00 
Prostate Cancer Ovarian Cancer BRCA2 0.14 
Bowel Cancer Breast Cancer BRCA1, TP73 0.25 
Breast Cancer Ovarian Cancer BRCA1, TP53 0.25 
Bowel Cancer Womb Cancer MSH2 0.38 
Bowel Cancer Bladder Cancer MSH2 0.38 
Melanoma Brain tumours CDKN2A 1.00 
Womb Cancer Bladder Cancer MSH2 1.00 
 
 
Table A.1.7: Small Indels SM-HCM. The first column represents cancer node 
one, the second column is the associated cancer node for cancers in column 
one, the third column is the shared gene for each of the two associated cancer 
nodes, the fourth column is the kappa agreement test results where low 
agreements <0.25, moderate agreement 0.25 to 0.50, high agreement 0.50 to 
0.75 and the very high agreement 0.75 – 1. In total there are 5 genes and 8 
primary cancer nodes. 
Cancer Node 1 Cancer Node 2 Gene Kappa 
Bowel Cancer Brain tumours MLH1 0.55 
Bowel Cancer Womb Cancer MSH6 0.55 
Breast Cancer Ovarian Cancer BRCA1 0.55 
Pancreatic Cancer Ovarian Cancer BRCA2 0.55 
Head and neck cancer Melanoma CDKN2A 1 
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Table A.1.8: Repeated Variations SM-HCM. The first column represents cancer 
node one, the second column is the associated cancer node for cancers in 
column one, the third column is the shared gene for each of the two associated 
cancer nodes, the fourth column is the kappa agreement test results where low 
agreements <0.25, moderate agreement 0.25 to 0.50, high agreement 0.50 to 
0.75 and the very high agreement 0.75 – 1. In total there are 2 genes and 3 
primary cancer nodes. 
Cancer Node 1 Cancer Node 2 Gene Kappa 
Breast Cancer Prostate Cancer CYP11A1 0 
Lung Cancer Prostate Cancer TERT 0 
 
Table A.1.9: Complex Rearrangement SM-HCM. The first column represents 
cancer node one, the second column is the associated cancer node for cancers 
in column one, the third column is the shared gene for each of the two associated 
cancer nodes, the fourth column is the kappa agreement test results where low 
agreements <0.25, moderate agreement 0.25 to 0.50, high agreement 0.50 to 
0.75 and the very high agreement 0.75 – 1. In total there are 1 genes and 2 
primary cancer nodes. 
Cancer Node 1 Cancer Node 2 Shared Genes Kappa 
Breast Cancer Ovarian Cancer BRCA1 0 
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Table A.1.10: Gross Insertions SM-HCM. The first column represents cancer 
node one, the second column is the associated cancer node for cancers in 
column one, the third column is the shared gene for each of the two associated 
cancer nodes, the fourth column is the kappa agreement test results where low 
agreements <0.25, moderate agreement 0.25 to 0.50, high agreement 0.50 to 
0.75 and the very high agreement 0.75 – 1. In total there are 1 gene and 2 
primary cancer nodes. 
Cancer Node 1 Cancer Node 2 Shared Genes Kappa 
Breast Cancer Ovarian Cancer BRCA1 0 
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Appendix 2 
Table A.2.11: Chromosome gene mutations and associated cancers. The first column represents the chromosome number, the second column 
shows the genes symbols for gene on this particular chromosome, the third column contains the mutation class for genes on the chromosome 
in column one, and the fourth column shows is the cancers associated with that particular chromosome. 
Chromosomes Genes Mutations Cancers 
Ch 5 MIR146A,AMACR,GHR,DROSHA,CDH12,ROPN1L,MTRR,T
ERT,MSH3,XRCC4,PIK3R1,VCAN,APC,LOX,RAD50,IL12B 
Regulatory,Missense 
nonsense,Splicing,Repeat Variations,Small 
Deletion,Gross Deletions 
Prostate cancer,Lung Cancer,Ovarian Cancer,Breast 
Cancer,Pancreatic Cancer,Leukaemia,Bowel 
Cancer,Bladder Cancer,Mouth Oropharyngeal 
Cancer,Stomach Cancer 
Ch 19 MIR125A,JAK3,B3GNT3,GDF15,MIR27A,TYK2,ICAM5,STK
11,INSR,ICAM1,CEBPA,RHPN2,XRCC1,ERCC1,ERCC2,CD
3EAP,GLTSCR1,ZNF350,ZNF600,KLK3,ZNF577 
Regulatory,Missense nonsense,Splicing,Small 
Deletion,Small Insertions 
Leukaemia,Lymphoma,Prostate cancer,Stomach 
Cancer,Bowel Cancer,Ovarian Cancer,Lung 
Cancer,Skin Cancer(Non Melanoma),Brain 
tumours,Bladder Cancer 
Ch 10 KLF6,AKR1C3,RET,MSMB,ERCC6,PRF1,SFTPD,BMPR1A,
ANXA11,PTEN,HIF1AN,FAS,CYP17A1,SUFU,GSTO2,GPA
M,DMBT1,MGMT,FGFR2,C10ORF137,PAK7,DNMT3B,GHR
H,MIR499,NCOA3,AURKA 
Missense nonsense,Splicing,Small 
Insertions,Small Indels,Comples 
Rearrangements,Regulatory,Small 
Deletion,Gross Deletions,Repeat Variations 
Lung Cancer,Thyroid Cancer,Bowel Cancer,Bladder 
Cancer,Lymphoma,Breast Cancer,Head and neck 
cancer,Leukaemia,Skin Cancer(Non Melanoma),Brain 
tumours,Ovarian Cancer,Womb Cancer,Oesophageal 
Cancer 
Ch 11 ACCS,SPI1,PTPRJ,WT1,RAG1,NAV2,CSNK2A1P,HRAS,M
UC2,MUC6,INS,GTF2H1,FEN1,MS4A64,YAP1,GSTP1,TBX
10,MYO7A,MRE11A,MMP7,ATM,PGR,NPAT,CASP5,IL10R
A,PPP2R1B,HSPA8 
Missense nonsense,Regulatory,Small 
Insertions,Small Indels,Splicing,Small 
Deletion,Gross Deletions,Repeat Variations 
Leukaemia,Thyroid Cancer,Wilms 
Tumour,Lymphoma,Bowel Cancer,Bladder 
Cancer,Stomach Cancer,Prostate cancer,Mouth 
Oropharyngeal Cancer,Melanoma,Breast 
Cancer,Ovarian Cancer,Womb Cancer 
Ch 12 KRAS,CDKN1B,WNK1,DCP1B,KRT5,ATF1,ITGA7,VDR,MIR
196A2,CDK4,MDM2,IGF1,SERCA2B,MYBPC1,PTPN11,SET
D8,CHFR 
Regulatory,Missense 
nonsense,Splicing,Repeat Variations,Small 
Deletion,Gross Insertions 
Melanoma,Prostate cancer,Bowel Cancer,Ovarian 
Cancer,Skin Cancer(Non Melanoma),Bladder 
Cancer,Breast Cancer,Brain tumours 
Ch 13 FLT3,LNX2,BRCA2,FREM2,SETDB2,LPAR6,RB1,EDNRB,M
IR17,ERCC5,LIG4 
Missense nonsense,Regulatory,Small 
Deletion,Small Insertions,Splicing,Gross 
Deletions,Small Indels,Gross 
Insertions,Comples Rearrangements 
Lymphoma,Lung Cancer,Bowel Cancer,Breast 
Cancer,Melanoma,Prostate cancer,Pancreatic 
Cancer,Ovarian Cancer,Ocular Cancer,Brain tumours 
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Ch 14 APEX1,BCL2L2,NFKBIA,NKX2-
1,LGALS3,BMP4,MTHFD1,MLH3,GPR68,GOLGA5,DICER1,
XRCC3,CDC42BPB 
Regulatory,Missense nonsense,Small 
Deletion,Small Indels,Small Insertions,Splicing 
Bowel Cancer,Head and neck cancer,Stomach 
Cancer,Lymphoma,Thyroid Cancer,Breast 
Cancer,Melanoma,Womb Cancer,Oesophageal 
Cancer,Wilms Tumour,Soft Tissue Sarcomas,Brain 
tumours,Ovarian Cancer 
Ch 15 SPRED1,RYR3,BUB1B,TP53BP1,RAD51,CYP19A1,PML,C
YP1A1,ITGA11,CYP11A1,CHRNA3,AKAP13,BCL2A1,IQGA
P1 
Missense nonsense,Splicing,Small 
Deletion,Small Insertions,Regulatory,Repeat 
Variations 
Breast Cancer,Bowel Cancer,Leukaemia,Lung 
Cancer,Skin Cancer(Non Melanoma),Prostate cancer 
Ch 16 SULT1A1,PALB2,SLX4,UBE2I,CREBBP,ERCC4,LOC64371
4,TOX3,MMP2,NOD2,NQO1,CDH1,ZFHX3,C16ORF61,WW
OX,MC1R,FANCA 
Missense nonsense,Splicing,Small 
Deletion,Gross Deletions,Regulatory,Small 
Insertions,Small Indels 
Pancreatic Cancer,Ovarian Cancer,Breast 
Cancer,Lung Cancer,Bladder Cancer,Bowel 
Cancer,Stomach Cancer,Prostate 
cancer,Lymphoma,Skin Cancer(Non 
Melanoma),Melanoma 
Ch 17 AKAP10,ZNF624,FLCN,MAP2K4,ELAC2,DNAH9,ITGAE,GE
MIN4,SHBG,GUCY2D,PFAS,TP53,PLD2,WRAP53,MYH8,C
AMKK1,RPH3AL,ATP2A3,RAD51D,NF1,NOS2,BRCA1,PHB,
ACACA,ERBB2,CDC6,MPP3,CDK5RAP3,RAD51C,BRIP1,A
XIN2,EPX,SSTR2,GH1,BIRC5,FASN 
Missense nonsense,Splicing,Regulatory,Small 
Deletion,Small Insertions,Gross 
Deletions,Repeat Variations,Small 
Indels,Gross Insertions,Comples 
Rearrangements 
Bowel Cancer,Kidney Cancer,Prostate cancer,Ovarian 
Cancer,Breast Cancer,Skin Cancer(Non 
Melanoma),Stomach Cancer,Soft Tissue 
Sarcomas,Myxoma,Brain tumours,Lymphoma,Head 
and neck cancer,Leukaemia,Womb Cancer,Pancreatic 
Cancer 
Ch 18 MEP1B,SMAD7,SMAD4,DCC,BCL2 Missense nonsense,Regulatory Breast Cancer,Cervical Cancer,Prostate cancer 
Ch 1 GSTM1,GSTM3,DDX20,MSH4,IL23R,RAD54L,JUN,PTCH2,
MIR30C1,MYCL1,MUTYH,PLA2G2A,RUNX3,EPHB2,SDHB,
LIN28A,CA6,MIIP,TP73,CHD1L,ARHGEF11,MUC1,S100A14
,DUSP23,MPZ,RNASEL,CDC73,PTGS2,CHIT1,MDM4,ESR
RG,TGFB2,PARP1,EXO1,FH 
Regulatory,Gross Deletions,Missense 
nonsense,Splicing,Small Deletion,Small 
Indels,Small Insertions,Repeat 
Variations,Gross Insertions 
Stomach Cancer,Head and neck cancer,Bladder 
Cancer,Lung Cancer,Bowel Cancer,Skin Cancer(Non 
Melanoma),Kidney Cancer,Prostate cancer,Brain 
tumours,Ovarian Cancer,Oesophageal Cancer,Soft 
Tissue Sarcomas,Parathyroid carcinoma 
Ch 21 NRIP1,GRIK1,IFNGR2,RUNX1,RRP1B,COL18A1 Missense nonsense,Small Deletion Head and neck cancer,Leukaemia,Breast 
Cancer,Prostate cancer 
Ch 22 SMARCB1,MYO18B,COMT,MIF,CABIN1,CHEK2,NF2,PDGF
B,SUN2,TNFRSF13C,SMC1B 
Missense nonsense,Gross Deletions,Small 
Insertions,Regulatory,Repeat 
Variations,Splicing,Small Deletion,Small 
Indels,Gross Insertions,Comples 
Rearrangements 
Kidney Cancer,Bowel Cancer,Leukaemia,Breast 
Cancer,Stomach Cancer,Soft Tissue Sarcomas,Lung 
Cancer,Prostate cancer,Ovarian 
Cancer,Lymphoma,Head and neck cancer 
Ch 2 MSH6,CYP1B1,EPCAM,LHCGR,FSHR,MSH2,DNMT3A,SR
D5A2,IL1R1,IL1B,ERCC3,IFIH1,LRP2,RNASEL,PMS1,PDE1
1A,CTLA4,CASP8,CFLAR,IGFBP5,ERBB4,BARD1,XRCC5,
SLC11A1 
Missense nonsense,Splicing,Small 
Deletion,Regulatory,Small Insertions,Small 
Indels,Gross Deletions,Gross 
Insertions,Comples Rearrangements,Repeat 
Variations 
Breast Cancer,Womb Cancer,Ovarian Cancer,Lung 
Cancer,Prostate cancer,Stomach Cancer,Kidney 
Cancer,Bladder Cancer,Lymphoma,Brain 
tumours,Head and neck cancer,Cervical 
Cancer,Oesophageal Cancer 
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Ch 3 DHX36,ARL6IP5,IL17RB,GPX1,MLH1,RASSF1,MIR191,KLH
DC8B,BAP1,TGFBR2,PLCD1,RAF1,XPC,PPARG,FANCD2,
VHL,OGG1,NR1I2,CD86,GTF2E1,DIRC2,GATA2,TOPBP1,I
L12A,TNFSF10,SERPINI2,SST,MFI2 
Missense nonsense,Regulatory,Small 
Insertions,Splicing,Small Deletion,Small 
Indels,Gross Deletions,Gross 
Insertions,Comples Rearrangements,Repeat 
Variations 
Bladder Cancer,Lung Cancer,Brain tumours,Stomach 
Cancer,Womb Cancer,Ovarian 
Cancer,Lymphoma,Melanoma,Leukaemia,Head and 
neck cancer,Breast Cancer,Oesophageal 
Cancer,Kidney Cancer,Pancreatic Cancer 
Ch 4 TLR1,TLR10,TLR6,BST1,KCNIP4,RAB28,FGFRL1,KIT,PPA
T,IGFBP7,UGT2B7,IL8,SULT1E1,TMPRSS11A,PTPN13,AB
CG2,BMPR1B,ADH7,AGXT2L1,EGF,CCNA2,MAD2L1,EDN
RA,TLR2,PDGFC,PALLD,CASP3 
Missense nonsense,Comples 
Rearrangements,Regulatory,Small 
Deletion,Gross Deletions,Splicing 
Prostate cancer,Lymphoma,Kidney Cancer,Breast 
Cancer,Lung Cancer,Leukaemia,Head and neck 
cancer,Bladder Cancer,Stomach Cancer,Oesophageal 
Cancer,Melanoma,Ovarian Cancer,Pancreatic Cancer 
Ch 6 VEGFA,POLH,TRERF1,CDKN1A,BAG6,DHX16,HLA-
DQA1,PSMB9,MICA,CCHCR1,C6ORF15,PRRC2A,FANCE,
DTNBP1,NQO2,COL12A1,SNORD50A,ASCC3,HACE1,LIN2
8B,REV3L,ESR1,SOD2 
Regulatory,Missense nonsense,Small 
Indels,Repeat Variations,Small 
Insertions,Small Deletion,Comples 
Rearrangements,Splicing 
Melanoma,Bowel Cancer,Breast Cancer,Lung 
Cancer,Mouth Oropharyngeal 
Cancer,Lymphoma,Oesophageal Cancer,Wilms 
Tumour,Ovarian Cancer 
Ch 7 EGFR,IGFBP3,GHRHR,BBS9,AOAH,POU6F2,MAD1L1,NU
DT1,PMS2,CYP2W1,POR,HSPB1,PMS2P3,AKAP9,ABCB1,
CYP3A5,HGF,CYP3A4,PON1,SHFM1,MET,CPA4,EPHB6,P
RKAG2,XRCC2 
Missense nonsense,Repeat 
Variations,Regulatory,Comples 
Rearrangements,Gross 
Deletions,Splicing,Small Deletion,Small 
Insertions,Small Indels,Gross Insertions 
Breast Cancer,Head and neck cancer,Bowel 
Cancer,Wilms Tumour,Stomach Cancer,Pancreatic 
Cancer,Prostate cancer,Lymphoma 
Ch 8 TNFRSF10A,NKX3-
1,MTUS1,LZTS1,MSR1,TNFRSF10B,NAT1,NBN,POP1,CS
MD3,RNF139,TG,PVT1,EIF2C2,EIF3H,EXT1,PSCA,POU5F
1B,MYC,PYCRL 
Missense nonsense,Regulatory,Gross 
Deletions,Splicing,Small Insertions,Small 
Indels,Comples Rearrangements,Small 
Deletion 
Bladder Cancer,Prostate cancer,Ovarian 
Cancer,Breast Cancer,Head and neck cancer,Bowel 
Cancer,Melanoma,Kidney Cancer,Thyroid 
Cancer,Bone Cancer,Stomach Cancer 
Ch 9 CDKN2A,P14ARF,CDKN2B,CDKN2AI3,SMARCA2,CER1,R
MI1,TGFBR1,HSD17B3,PTCH1,PTCH1AM,GALNT12,RAD2
3B,DEC1,TNC,TNFSF8,EHMT1 
Small Indels,Missense 
nonsense,Splicing,Regulatory,Small 
Deletion,Small Insertions,Gross 
Deletions,Gross Insertions,Repeat Variations 
Kidney Cancer,Melanoma,Brain tumours,Pancreatic 
Cancer,Lung Cancer,Leukaemia,Bowel Cancer,Breast 
Cancer,Prostate cancer,Skin Cancer(Non Melanoma) 
Ch X KDM6A,FAM123B,AR,SH2D1A,FMR1 Missense nonsense,Regulatory,Repeat 
Variations,Gross Deletions 
Wilms Tumour,Breast Cancer,Prostate 
cancer,Lymphoma,Ovarian Cancer 
Ch 20 DNMT3B,GHRH,PAK7,AURKA,DNMT3B,MIR499,NCOA3 Splicing,Regulatory,Missense_nonsense, 
Repeat Variations 
Lung_Cancer, 
Bowel_Cancer,Breast_Cancer,Oesophageal_Cancer 
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Appendix 3 
 
Table A.3.1: A sample table of 2,851 collected Missense/Nonsense mutation 
records, where the first column represents the genes , the second column the 
chromosome location, the third column the cancer disorder, the fourth column the 
encoded amino acid (the letters before the hyphen indicates the original codon 
sequence and the letters after the hyphen the incorrect codon sequence), the fifth 
column shows the encoded amino acid (the first three letters is the abbreviation 
of the original amino acid and the second three letters is the abbreviation for the 
iniquitous encoded amino acid; the numbers in the middle represent the peptide 
position of the changed amino acid, and the sixth column provides the PubMed 
literatures for each of the mutation record.  
Genes Locations Cancer Codon 
Change 
Amino acid 
changes 
Reference  
ATM 11q22-q23 Breast_Cancer gAGC-CGC Ser788Arg Atencio (2001) Environ Mol Mutagen 
38, 200 
ATM 11q22-q23 Breast_Cancer tCAT-TAT His1380Tyr Atencio (2001) Environ Mol Mutagen 
38, 200 
ATM 11q22-q23 Breast_Cancer GAC-GGC Asp1467Gly Atencio (2001) Environ Mol Mutagen 
38, 200 
ATM 11q22-q23 Breast_Cancer cATT-GTT Ile2030Val Atencio (2001) Environ Mol Mutagen 
38, 200 
ATM 11q22-q23 Breast_Cancer GCA-GTA Ala2466Val Atencio (2001) Environ Mol Mutagen 
38, 200 
BRCA
1 
17q21 Breast_Cancer aCAA-TAA Gln12Term Adem (2003) Cancer 97, 1 
BRCA
1 
17q21 Breast 
_&_Ovarian_Can
cer 
gTGT-CGT Cys61Arg Al-Mulla (2009) J Clin Pathol 62, 350 
BRCA
1 
17q21 Ovarian_cancer ACA-AGA Thr276Arg Akbari (2011) J Med Genet 48, 783 
BRCA
1 
17q21 Ovarian_cancer tGAT-AAT Asp330Asn Akbari (2011) J Med Genet 48, 783 
BRCA
1 
17q21 Breast_Cancer AGGc-AGC Arg331Ser Asadi (2008) Scand J Clin Lab Invest 
68, 563 
BRCA
1 
17q21 Breast 
_&_Ovarian_Can
cer 
TCA-TGA Ser603Term Al-Mulla (2009) J Clin Pathol 62, 350 
BRCA
1 
17q21 Breast 
_&_Ovarian_Can
cer 
cAAG-CAG Lys918Gln Al-Mulla (2009) J Clin Pathol 62, 350 
BRCA
1 
17q21 Breast_Cancer tGGA-TGA Gly972Term Ahn (2007) Cancer Lett 245, 90 
BRCA
1 
17q21 Breast_Cancer TTG-TAG Leu1198Ter
m 
Ahn (2007) Cancer Lett 245, 90 
BRCA
1 
17q21 Ovarian_cancer CAT-CTT His1421Leu Akbari (2011) J Med Genet 48, 783 
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BRCA
1 
17q21 Ovarian_cancer AGG-ATG Arg1495Met Aziz (2001) Gynecol Oncol 80, 341 
BRCA
1 
17q21 Ovarian_cancer GAT-GTT Asp1692Val Akbari (2011) J Med Genet 48, 783 
BRCA
1 
17q21 Ovarian_cancer aGGT-AGT Gly1748Ser Aktas (2010) Gynecol Oncol epub, 
epub 
BRCA
2 
13q12.3 Breast 
_&_Ovarian_Can
cer 
aGAT-TAT Asp23Tyr Al-Mulla (2009) J Clin Pathol 62, 350 
BRCA
2 
13q12.3 Breast_Cancer CGT-CAT Arg2034His Awadelkarim (2007) Breast Cancer 
Res Treat 102, 189 
BRCA
2 
13q12.3 Ovarian_cancer aCTT-TTT Leu2686Phe Akbari (2011) J Med Genet 48, 783 
BRCA
2 
13q12.3 Breast_Cancer TATt-TAG Tyr2997Ter
m 
Ahn (2007) Cancer Lett 245, 90 
BRCA
2 
13q12.3 Ovarian_cancer GAT-GGT Asp3142Gly Akbari (2011) J Med Genet 48, 783 
CDH1 16q22.1 Gastric_cancer tGCA-ACA Ala617Thr Ascano (2001) Mod Pathol 14, 942 
RB1 13q14.2 Retinoblastoma AGG-AAG Arg46Lys Abouzeid (2009) Mol Vis 15, 771 
RB1 13q14.2 Retinoblastoma aGAA-TAA Glu280Term Babenko (2002) Mol Biol (Mosk) 36, 
623 
RB1 13q14.2 Retinoblastoma CTT-CAT Leu303His Babenko (2002) Mol Biol (Mosk) 36, 
623 
RB1 13q14.2 Retinoblastoma AAA-AGA Lys319Arg Babenko (2002) Mol Biol (Mosk) 36, 
623 
RB1 13q14.2 Retinoblastoma aCAG-TAG Gln436Term Abouzeid (2009) Mol Vis 15, 771 
RB1 13q14.2 Retinoblastoma TGCg-TGA Cys489Term Babenko (2002) Mol Biol (Mosk) 36, 
623 
RB1 13q14.2 Retinoblastoma TATa-TAA Tyr498Term Babenko (2002) Mol Biol (Mosk) 36, 
623 
RB1 13q14.2 Retinoblastoma gAAA-TAA Lys615Term Abouzeid (2009) Mol Vis 15, 771 
RB1 13q14.2 Retinoblastoma aGAA-TAA Glu746Term Babenko (2002) Mol Biol (Mosk) 36, 
623 
RB1 13q14.2 Retinoblastoma TTA-TAA Leu797Term Ata-ur-Rasheed (2002) Ophthalmic 
Genet 23, 121 
RB1 13q14.2 Retinoblastoma TTCc-TTA Phe845Leu Babenko (2002) Mol Biol (Mosk) 36, 
623 
RET 10q11.2 Thyroid_cancer cAAG-GAG Lys666Glu Ahmed (2005) J Mol Diagn 7, 283 
MLH1 3p21.3 Colorectal_cancer GTG-GAG Val49Glu Auclair (2006) Hum Mutat 27, 145 
MLH1 3p21.3 Colorectal_cancer AGCa-AGA Ser106Arg Auclair (2006) Hum Mutat 27, 145 
MLH1 3p21.3 Colorectal_cancer GTT-GAT Val113Asp Auclair (2006) Hum Mutat 27, 145 
MLH1 3p21.3 Colorectal_cancer gGGG-CGG Gly454Arg Auclair (2006) Hum Mutat 27, 145 
MLH1 3p21.3 Colorectal_cancer GCC-GAC Ala586Asp Auclair (2006) Hum Mutat 27, 145 
MSH2 2p22-p21 Colorectal_cancer cACA-GCA Thr33Ala Auclair (2006) Hum Mutat 27, 145 
MSH2 2p22-p21 Colorectal_cancer TAT-TGT Tyr43Cys Auclair (2006) Hum Mutat 27, 145 
MSH2 2p22-p21 Colorectal_cancer CTT-CGT Leu187Arg Auclair (2006) Hum Mutat 27, 145 
MSH2 2p22-p21 Colorectal_cancer CGG-CAG Arg243Gln Auclair (2006) Hum Mutat 27, 145 
MSH2 2p22-p21 Colorectal_cancer TCT-TGT Ser323Cys Akiyama (1997) Biochem Biophys 
Res Commun 236, 248 
MSH2 2p22-p21 Colorectal_cancer CTT-CCT Leu341Pro Auclair (2006) Hum Mutat 27, 145 
MSH2 2p22-p21 Colorectal_cancer tGGT-TGT Gly548Cys Auclair (2006) Hum Mutat 27, 145 
MSH2 2p22-p21 Colorectal_cancer tGAA-AAA Glu561Lys Auclair (2006) Hum Mutat 27, 145 
MSH2 2p22-p21 Colorectal_cancer AAAg-AAC Lys627Asn Auclair (2006) Hum Mutat 27, 145 
TP53 17p13.1 Breast_&_Colore
ctal_Cancer 
GGC-GAC Gly244Asp Achatz (2007) Cancer Lett 245, 96 
TP53 17p13.1 Choroid_Plexus_
Tumours 
AAC-ATC Asn131Ile Agarwalla (2008) Pediatr Neurosurg 
44, 501 
TP53 17p13.1 Colorectal_cancer aGTG-ATG Val197Met Achatz (2007) Cancer Lett 245, 96 
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Table A.3.2: The 21 altered amino acid network tables, where the first column is 
node one gene, the second column is the associated node two gene, the third 
column is the cancer disorder name, the fourth column is a match column where 
‘0’ is equal to identical altered amino acid in both genes, ‘1’ is the identical codon 
change in both genes and ‘2’ is the identical altered amino acid occurs in same 
peptide position of the two altered amino acid. Fifth and sixth columns are the 
encoded codon and amino acid for node gene one, and the seventh and eight 
columns are the encoded codon and amino acid for node gene two.  
Alanine 
Node1 Node2 Cancer Match Node1 codon 
change 
Node1 Amino acid 
changes 
Node2 codon 
change 
Node2 Amino acid 
changes 
ATM TP53 Breast Cancer 0 GTT-GCT 
GTT-GCT 
GGA-GCA 
GTA-GCA 
Val1570Ala 
Val1729Ala 
Gly2287Ala 
Val2439Ala 
aCCC-GCC 
tCCT-GCT 
Pro151Ala 
Pro278Ala 
BRCA1 TP53 Breast Cancer 1 GTA-GCA 
gCCT-GCT 
aCCC-GCC 
tTCT-GCT 
GGT-GCT 
aACA-GCA 
aACG-GCG 
GTA-GCA 
GTA-GCA 
GCAt-GCG 
aCCA-GCA 
tACT-GCT 
aACA-GCA 
gACA-GCA 
GGA-GCA 
GTA-GCA 
GTC-GCC 
tCCA-GCA 
GTT-GCT 
gCCA-GCA 
Val11Ala 
Pro58Ala 
Pro142Ala 
Ser186Ala 
Gly263Ala 
Thr557Ala 
Thr582Ala 
Val772Ala 
Val1047Ala 
Ala1142Ala 
Pro1491Ala 
Thr1685Ala 
Thr1691Ala 
Thr1700Ala 
Gly1706Ala 
Val1713Ala 
Val1736Ala 
Pro1749Ala 
Val1809Ala 
Pro1812Ala 
aCCC-GCC 
tCCT-GCT 
Pro151Ala 
Pro278Ala 
BRCA1 BRIP1 Breast Cancer 1 GTA-GCA 
gCCT-GCT 
aCCC-GCC 
tTCT-GCT 
GGT-GCT 
aACA-GCA 
aACG-GCG 
GTA-GCA 
GTA-GCA 
GCAt-GCG 
aCCA-GCA 
tACT-GCT 
aACA-GCA 
gACA-GCA 
GGA-GCA 
GTA-GCA 
GTC-GCC 
tCCA-GCA 
GTT-GCT 
gCCA-GCA 
Val11Ala 
Pro58Ala 
Pro142Ala 
Ser186Ala 
Gly263Ala 
Thr557Ala 
Thr582Ala 
Val772Ala 
Val1047Ala 
Ala1142Ala 
Pro1491Ala 
Thr1685Ala 
Thr1691Ala 
Thr1700Ala 
Gly1706Ala 
Val1713Ala 
Val1736Ala 
Pro1749Ala 
Val1809Ala 
Pro1812Ala 
tCCC-GCC Pro47Ala 
BRCA1 ATM Breast Cancer 1 GTA-GCA 
gCCT-GCT 
aCCC-GCC 
tTCT-GCT 
GGT-GCT 
aACA-GCA 
aACG-GCG 
GTA-GCA 
GTA-GCA 
GCAt-GCG 
aCCA-GCA 
tACT-GCT 
aACA-GCA 
gACA-GCA 
GGA-GCA 
GTA-GCA 
GTC-GCC 
tCCA-GCA 
GTT-GCT 
gCCA-GCA 
Val11Ala 
Pro58Ala 
Pro142Ala 
Ser186Ala 
Gly263Ala 
Thr557Ala 
Thr582Ala 
Val772Ala 
Val1047Ala 
Ala1142Ala 
Pro1491Ala 
Thr1685Ala 
Thr1691Ala 
Thr1700Ala 
Gly1706Ala 
Val1713Ala 
Val1736Ala 
Pro1749Ala 
Val1809Ala 
Pro1812Ala 
GTT-GCT 
GTT-GCT 
GGA-GCA 
GTA-GCA 
Val1570Ala 
Val1729Ala 
Gly2287Ala 
Val2439Ala 
BRCA1 PALB2 Breast Cancer 1 GTA-GCA 
gCCT-GCT 
aCCC-GCC 
tTCT-GCT 
GGT-GCT 
aACA-GCA 
aACG-GCG 
GTA-GCA 
Val11Ala 
Pro58Ala 
Pro142Ala 
Ser186Ala 
Gly263Ala 
Thr557Ala 
Thr582Ala 
Val772Ala 
GGT-GCT Gly1043Ala 
 
APPENDIX 
 
 
 
163 
 
GTA-GCA 
GCAt-GCG 
aCCA-GCA 
tACT-GCT 
aACA-GCA 
gACA-GCA 
GGA-GCA 
GTA-GCA 
GTC-GCC 
tCCA-GCA 
GTT-GCT 
gCCA-GCA 
Val1047Ala 
Ala1142Ala 
Pro1491Ala 
Thr1685Ala 
Thr1691Ala 
Thr1700Ala 
Gly1706Ala 
Val1713Ala 
Val1736Ala 
Pro1749Ala 
Val1809Ala 
Pro1812Ala 
BRCA2 ATM Breast Cancer 1 GTA-GCA 
gCCT-GCT 
aCCC-GCC 
tTCT-GCT 
GGT-GCT 
aACA-GCA 
aACG-GCG 
GTA-GCA 
GTA-GCA 
GCAt-GCG 
aCCA-GCA 
tACT-GCT 
aACA-GCA 
gACA-GCA 
GGA-GCA 
GTA-GCA 
GTC-GCC 
tCCA-GCA 
GTT-GCT 
gCCA-GCA 
Val11Ala 
Pro58Ala 
Pro142Ala 
Ser186Ala 
Gly263Ala 
Thr557Ala 
Thr582Ala 
Val772Ala 
Val1047Ala 
Ala1142Ala 
Pro1491Ala 
Thr1685Ala 
Thr1691Ala 
Thr1700Ala 
Gly1706Ala 
Val1713Ala 
Val1736Ala 
Pro1749Ala 
Val1809Ala 
Pro1812Ala 
GTT-GCT 
GTT-GCT 
GGA-GCA 
GTA-GCA 
Val1570Ala 
Val1729Ala 
Gly2287Ala 
Val2439Ala 
BRCA2 BRCA1 Breast Cancer 1 GTC-GCC 
tACT-GCT 
aACA-GCA 
GAT-GCT 
tACT-GCT 
aCCC-GCC 
GAT-GCT 
GAG-GCG 
tACC-GCC 
Val211Ala 
Thr225Ala 
Thr598Ala 
Asp1990Ala 
Thr2031Ala 
Pro2283Ala 
Asp2723Ala 
Glu2856Ala 
Thr3349Ala 
GTA-GCA 
gCCT-GCT 
aCCC-GCC 
tTCT-GCT 
GGT-GCT 
aACA-GCA 
aACG-GCG 
GTA-GCA 
GTA-GCA 
GCAt-GCG 
aCCA-GCA 
tACT-GCT 
aACA-GCA 
gACA-GCA 
GGA-GCA 
GTA-GCA 
GTC-GCC 
tCCA-GCA 
GTT-GCT 
gCCA-GCA 
Val11Ala 
Pro58Ala 
Pro142Ala 
Ser186Ala 
Gly263Ala 
Thr557Ala 
Thr582Ala 
Val772Ala 
Val1047Ala 
Ala1142Ala 
Pro1491Ala 
Thr1685Ala 
Thr1691Ala 
Thr1700Ala 
Gly1706Ala 
Val1713Ala 
Val1736Ala 
Pro1749Ala 
Val1809Ala 
Pro1812Ala 
BRCA2 PALB2 Breast Cancer 0 GTC-GCC 
tACT-GCT 
aACA-GCA 
GAT-GCT 
tACT-GCT 
aCCC-GCC 
GAT-GCT 
GAG-GCG 
tACC-GCC 
Val211Ala 
Thr225Ala 
Thr598Ala 
Asp1990Ala 
Thr2031Ala 
Pro2283Ala 
Asp2723Ala 
Glu2856Ala 
Thr3349Ala 
GGT-GCT Gly1043Ala 
BRCA2 TP53 Breast Cancer 1 GTC-GCC 
tACT-GCT 
aACA-GCA 
GAT-GCT 
tACT-GCT 
aCCC-GCC 
GAT-GCT 
GAG-GCG 
tACC-GCC 
Val211Ala 
Thr225Ala 
Thr598Ala 
Asp1990Ala 
Thr2031Ala 
Pro2283Ala 
Asp2723Ala 
Glu2856Ala 
Thr3349Ala 
aCCC-GCC 
tCCT-GCT 
Pro151Ala 
Pro278Ala 
CHEK2 BRCA2 Breast Cancer 1 tACA-GCA 
GGG-GCG 
Thr172Ala 
Gly306Ala 
GTC-GCC 
tACT-GCT 
aACA-GCA 
GAT-GCT 
tACT-GCT 
aCCC-GCC 
GAT-GCT 
GAG-GCG 
tACC-GCC 
Val211Ala 
Thr225Ala 
Thr598Ala 
Asp1990Ala 
Thr2031Ala 
Pro2283Ala 
Asp2723Ala 
Glu2856Ala 
Thr3349Ala 
CHEK2 ATM Breast Cancer 0 tACA-GCA 
GGG-GCG 
Thr172Ala 
Gly306Ala 
GTT-GCT 
GTT-GCT 
GGA-GCA 
GTA-GCA 
Val1570Ala 
Val1729Ala 
Gly2287Ala 
Val2439Ala 
CHEK2 TP53 Breast Cancer 0 tACA-GCA 
GGG-GCG 
Thr172Ala 
Gly306Ala 
aCCC-GCC 
tCCT-GCT 
Pro151Ala 
Pro278Ala 
CHEK2 BRCA1 Breast Cancer 1 tACA-GCA 
GGG-GCG 
Thr172Ala 
Gly306Ala 
GTA-GCA 
gCCT-GCT 
aCCC-GCC 
tTCT-GCT 
GGT-GCT 
aACA-GCA 
aACG-GCG 
GTA-GCA 
GTA-GCA 
GCAt-GCG 
aCCA-GCA 
tACT-GCT 
aACA-GCA 
gACA-GCA 
GGA-GCA 
GTA-GCA 
GTC-GCC 
tCCA-GCA 
GTT-GCT 
gCCA-GCA 
Val11Ala 
Pro58Ala 
Pro142Ala 
Ser186Ala 
Gly263Ala 
Thr557Ala 
Thr582Ala 
Val772Ala 
Val1047Ala 
Ala1142Ala 
Pro1491Ala 
Thr1685Ala 
Thr1691Ala 
Thr1700Ala 
Gly1706Ala 
Val1713Ala 
Val1736Ala 
Pro1749Ala 
Val1809Ala 
Pro1812Ala 
ERCC5 ERCC3 Lung Cancer 0 aACG-GCG Thr971Ala cACT-GCT Thr232Ala 
EXO1 MLH1 Bowel Cancer 0 GTA-GCA 
cCCC-GCC 
Val27Ala 
Pro640Ala 
GGG-GCG 
tACT-GCT 
aCCA-GCA 
GTG-GCG 
aACA-GCA 
GTT-GCT 
GAT-GCT 
Gly22Ala 
Thr82Ala 
Pro141Ala 
Val326Ala 
Thr364Ala 
Val506Ala 
Asp631Ala 
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GAG-GCG Glu663Ala 
EXO1 MSH2 Bowel Cancer 0 GTA-GCA 
cCCC-GCC 
Val27Ala 
Pro640Ala 
cACA-GCA 
GGA-GCA 
tACC-GCC 
GGT-GCT 
GAG-GCG 
Thr33Ala 
Gly162Ala 
Thr564Ala 
Gly674Ala 
Glu853Ala 
EXO1 MSH3 Bowel Cancer 0 GTA-GCA 
cCCC-GCC 
Val27Ala 
Pro640Ala 
cACA-GCA Thr1045Ala 
MSH2 MLH1 Bowel Cancer 1 cACA-GCA 
GGA-GCA 
tACC-GCC 
GGT-GCT 
GAG-GCG 
Thr33Ala 
Gly162Ala 
Thr564Ala 
Gly674Ala 
Glu853Ala 
GGG-GCG 
tACT-GCT 
aCCA-GCA 
GTG-GCG 
aACA-GCA 
GTT-GCT 
GAT-GCT 
GAG-GCG 
Gly22Ala 
Thr82Ala 
Pro141Ala 
Val326Ala 
Thr364Ala 
Val506Ala 
Asp631Ala 
Glu663Ala 
MSH3 MLH1 Bowel Cancer 0 cACA-GCA Thr1045Ala GGG-GCG 
tACT-GCT 
aCCA-GCA 
GTG-GCG 
aACA-GCA 
GTT-GCT 
GAT-GCT 
GAG-GCG 
Gly22Ala 
Thr82Ala 
Pro141Ala 
Val326Ala 
Thr364Ala 
Val506Ala 
Asp631Ala 
Glu663Ala 
MSH3 MSH2 Bowel Cancer 1 cACA-GCA Thr1045Ala cACA-GCA 
GGA-GCA 
tACC-GCC 
GGT-GCT 
GAG-GCG 
Thr33Ala 
Gly162Ala 
Thr564Ala 
Gly674Ala 
Glu853Ala 
MSH6 MLH1 Bowel Cancer 1 GGG-GCG 
gCCA-GCA 
GTG-GCG 
GGT-GCT 
GTT-GCT 
Gly54Ala 
Pro202Ala 
Val509Ala 
Gly685Ala 
Val878Ala 
GGG-GCG 
tACT-GCT 
aCCA-GCA 
GTG-GCG 
aACA-GCA 
GTT-GCT 
GAT-GCT 
GAG-GCG 
Gly22Ala 
Thr82Ala 
Pro141Ala 
Val326Ala 
Thr364Ala 
Val506Ala 
Asp631Ala 
Glu663Ala 
MSH6 MSH2 Bowel Cancer 1 GGG-GCG 
gCCA-GCA 
GTG-GCG 
GGT-GCT 
Gly54Ala 
Pro202Ala 
Val509Ala 
Gly685Ala 
cACA-GCA 
GGA-GCA 
tACC-GCC 
GGT-GCT 
GAG-GCG 
Thr33Ala 
Gly162Ala 
Thr564Ala 
Gly674Ala 
Glu853Ala 
Arginine 
Node1 Node2 Cancer Match Node1 codon 
change 
Node1 Amino acid 
changes 
Node2 codon 
change 
Node2 Amino acid 
changes 
ATM TP53 Breast Cancer 0 gAGC-CGC 
CAG-CGG 
CAT-CGT 
aTGT-CGT 
aGGA-AGA 
tGGA-AGA 
CCT-CGT 
Ser788Arg 
Gln1128Arg 
His2111Arg 
Cys2464Arg 
Gly2772Arg 
Gly2023Arg 
Pro1054Arg 
cTGC-CGC Cys242Arg 
BRCA1 PALB2 Breast Cancer 1 gTGT-CGT 
ACA-AGA 
gTGT-CGT 
CAC-CGC 
tTGC-CGC 
AAA-AGA 
gTGT-CGT 
aTGT-CGT 
AGCc-AGA 
ACG-AGG 
aGGT-CGT 
AGTt-AGG 
CAG-CGG 
tGGG-AGG 
gTGT-CGT 
CAG-CGG 
AGCa-AGG 
AAA-AGA 
aGGG-CGG 
CCT-CGT 
CAC-CGC 
ATG-AGG 
ACA-AGA 
AGCt-AGA 
tAGC-CGC 
aGGA-AGA 
CCA-CGA 
ATG-AGG 
CAG-CGG 
gTGG-CGG 
Cys24Arg 
Thr37Arg 
Cys39Arg 
His41Arg 
Cys44Arg 
Lys56Arg 
Cys61Arg 
Cys64Arg 
Ser72Arg 
Thr77Arg 
Gly98Arg 
Ser264Arg 
Gln356Arg 
Gly462Arg 
Cys805Arg 
Gln867Arg 
Ser1024Arg 
Lys1183Arg 
Gly1205Arg 
Pro1238Arg 
His1284Arg 
Met1689Arg 
Thr1691Arg 
Ser1715Arg 
Ser1715Arg 
Gly1738Arg 
Pro1749Arg 
Met1775Arg 
Gln1811Arg 
Trp1837Arg 
CCA-CGA 
AAG-AGG 
Pro207Arg 
Lys1048Arg 
BRCA2 BUB1B Leukaemia 1 CAA-CGA Gln1396Arg CAA-CGA Gln349Arg 
BRCA2 BRCA1 Breast Cancer 1 AAA-AGA 
CAT-CGT 
CCA-CGA 
AGCa-AGA 
CAG-CGG 
ACA-AGA 
AAG-AGG 
CTT-CGT 
cGGG-AGG 
AAA-AGA 
AGTa-AGA 
tGGT-CGT 
aTGG-CGG 
CTT-CGT 
ACA-AGA 
Lys53Arg 
His150Arg 
Pro201Arg 
Ser326Arg 
Gln499Arg 
Thr1011Arg 
Lys1057Arg 
Leu1114Arg 
Gly1529Arg 
Lys1530Arg 
Ser2006Arg 
Gly2353Arg 
Trp2626Arg 
Leu2721Arg 
Thr2722Arg 
gTGT-CGT 
ACA-AGA 
gTGT-CGT 
CAC-CGC 
tTGC-CGC 
AAA-AGA 
gTGT-CGT 
aTGT-CGT 
AGCc-AGA 
ACG-AGG 
aGGT-CGT 
AGTt-AGG 
CAG-CGG 
tGGG-AGG 
gTGT-CGT 
CAG-CGG 
AGCa-AGG 
AAA-AGA 
aGGG-CGG 
CCT-CGT 
CAC-CGC 
ATG-AGG 
ACA-AGA 
gTGT-CGT 
AGCt-AGA 
tAGC-CGC 
aGGA-AGA 
CCA-CGA 
Cys24Arg 
Thr37Arg 
Cys39Arg 
His41Arg 
Cys44Arg 
Lys56Arg 
Cys61Arg 
Cys64Arg 
Ser72Arg 
Thr77Arg 
Gly98Arg 
Ser264Arg 
Gln356Arg 
Gly462Arg 
Cys805Arg 
Gln867Arg 
Ser1024Arg 
Lys1183Arg 
Gly1205Arg 
Pro1238Arg 
His1284Arg 
Met1689Arg 
Thr1691Arg 
Cys1697Arg 
Ser1715Arg 
Ser1715Arg 
Gly1738Arg 
Pro1749Arg 
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ATG-AGG 
CAG-CGG 
gTGG-CGG 
Met1775Arg 
Gln1811Arg 
Trp1837Arg 
BRCA2 BRCA1 Ovarian 
Cancer 
1 CAG-CGG 
cGGG-AGG 
AAA-AGA 
AGTa-AGA 
CAC-CGC 
tGGT-CGT 
Gln499Arg 
Gly1529Arg 
Lys1530Arg 
Ser2006Arg 
His2116Arg 
Gly2353Arg 
ATG-AGG 
ACA-AGA 
gTGT-CGT 
CAC-CGC 
AAA-AGA 
gTGT-CGT 
AGCc-AGA 
ACA-AGA 
CAG-CGG 
tGGG-AGG 
CCT-CGT 
ATG-AGG 
ACA-AGA 
AGCt-AGA 
tAGC-CGC 
aGGA-AGA 
CAG-CGG 
Met1Arg 
Thr37Arg 
Cys39Arg 
His41Arg 
Lys56Arg 
Cys61Arg 
Ser72Arg 
Thr276Arg 
Gln356Arg 
Gly462Arg 
Pro1238Arg 
Met1689Arg 
Thr1691Arg 
Ser1715Arg 
Ser1715Arg 
Gly1738Arg 
Gln1811Arg 
BRCA2 PALB2 Breast Cancer 1 AAA-AGA 
CAT-CGT 
CCA-CGA 
AGCa-AGA 
CAG-CGG 
ACA-AGA 
AAG-AGG 
CTT-CGT 
cGGG-AGG 
AAA-AGA 
AGTa-AGA 
CAC-CGC 
tGGT-CGT 
aTGG-CGG 
CTT-CGT 
ACA-AGA 
Lys53Arg 
His150Arg 
Pro201Arg 
Ser326Arg 
Gln499Arg 
Thr1011Arg 
Lys1057Arg 
Leu1114Arg 
Gly1529Arg 
Lys1530Arg 
Ser2006Arg 
His2116Arg 
Gly2353Arg 
Trp2626Arg 
Leu2721Arg 
Thr2722Arg 
CCA-CGA 
AAG-AGG 
Pro207Arg 
Lys1048Arg 
CHEK2 BRCA2 Breast Cancer 0 CCT-CGT Pro85Arg AAA-AGA 
CCA-CGA 
AGCa-AGA 
ACA-AGA 
AAG-AGG 
CTT-CGT 
aTGG-CGG 
CTT-CGT 
ACA-AGA 
Lys53Arg 
Pro201Arg 
Ser326Arg 
Thr1011Arg 
Lys1057Arg 
Leu1114Arg 
Trp2626Arg 
Leu2721Arg 
Thr2722Arg 
CHEK2 ATM Breast Cancer 1 CCT-CGT Pro85Arg gAGC-CGC 
CAG-CGG 
CAT-CGT 
aTGT-CGT 
aGGA-AGA 
tGGA-AGA 
CCT-CGT 
Ser788Arg 
Gln1128Arg 
His2111Arg 
Cys2464Arg 
Gly2772Arg 
Gly2023Arg 
Pro1054Arg 
CHEK2 TP53 Breast Cancer 0 CCT-CGT Pro85Arg cTGC-CGC Cys242Arg 
CHEK2 BRCA1 Breast Cancer 1 CCT-CGT Pro85Arg gTGT-CGT 
ACA-AGA 
gTGT-CGT 
CAC-CGC 
tTGC-CGC 
AAA-AGA 
gTGT-CGT 
aTGT-CGT 
AGCc-AGA 
ACG-AGG 
aGGT-CGT 
AGTt-AGG 
CAG-CGG 
tGGG-AGG 
gTGT-CGT 
CAG-CGG 
AGCa-AGG 
AAA-AGA 
aGGG-CGG 
CCT-CGT 
CAC-CGC 
ATG-AGG 
ACA-AGA 
gTGT-CGT 
aCGG-AGG 
AGCt-AGA 
tAGC-CGC 
aGGA-AGA 
CCA-CGA 
ATG-AGG 
CAG-CGG 
gTGG-CGG 
Cys24Arg 
Thr37Arg 
Cys39Arg 
His41Arg 
Cys44Arg 
Lys56Arg 
Cys61Arg 
Cys64Arg 
Ser72Arg 
Thr77Arg 
Gly98Arg 
Ser264Arg 
Gln356Arg 
Gly462Arg 
Cys805Arg 
Gln867Arg 
Ser1024Arg 
Lys1183Arg 
Gly1205Arg 
Pro1238Arg 
His1284Arg 
Met1689Arg 
Thr1691Arg 
Cys1697Arg 
Arg1699Arg 
Ser1715Arg 
Ser1715Arg 
Gly1738Arg 
Pro1749Arg 
Met1775Arg 
Gln1811Arg 
Trp1837Arg 
CHEK2 BRCA1 Ovarian 
Cancer 
1 CAC-CGC His143Arg ATG-AGG 
ACA-AGA 
gTGT-CGT 
CAC-CGC 
AAA-AGA 
gTGT-CGT 
AGCc-AGA 
ACA-AGA 
CAG-CGG 
tGGG-AGG 
CCT-CGT 
ATG-AGG 
ACA-AGA 
AGCt-AGA 
tAGC-CGC 
aGGA-AGA 
CAG-CGG 
Met1Arg 
Thr37Arg 
Cys39Arg 
His41Arg 
Lys56Arg 
Cys61Arg 
Ser72Arg 
Thr276Arg 
Gln356Arg 
Gly462Arg 
Pro1238Arg 
Met1689Arg 
Thr1691Arg 
Ser1715Arg 
Ser1715Arg 
Gly1738Arg 
Gln1811Arg 
ERCC2 ERCC3 Lung Cancer 0 CGCt-CGA Arg156Arg AAG-AGG Lys449Arg 
EXO1 MLH1 Bowel Cancer 1 CTC-CGC Leu410Arg ATG-AGG 
ATG-AGG 
cGGG-AGG 
cGGG-CGG 
aTGT-CGT 
tGGC-CGC 
AGCa-AGA 
ATA-AGA 
ACG-AGG 
aGGG-CGG 
Met1Arg 
Met35Arg 
Gly67Arg 
Gly67Arg 
Cys77Arg 
Gly98Arg 
Ser106Arg 
Ile107Arg 
Thr117Arg 
Gly147Arg 
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CTT-CGT 
CTC-CGC 
CAT-CGT 
gGGG-CGG 
CTG-CGG 
CTT-CGT 
CCC-CGC 
aGGG-AGG 
CTG-CGG 
tTGG-CGG 
CTC-CGC 
aTGC-CGC 
CAG-CGG 
AAA-AGA 
Leu155Arg 
Leu260Arg 
His264Arg 
Gly454Arg 
Leu559Arg 
Leu585Arg 
Pro603Arg 
Gly634Arg 
Leu653Arg 
Trp666Arg 
Leu676Arg 
Cys680Arg 
Gln689Arg 
Lys751Arg 
EXO1 PMS2 Bowel Cancer 0 CTC-CGC Leu410Arg CCT-CGT Pro404Arg 
EXO1 MSH2 Bowel Cancer 0 CTC-CGC Leu410Arg tAGA-CGA 
tGGA-AGA 
tGGA-CGA 
tGGG-AGG 
CTT-CGT 
CTT-CGT 
gTGT-CGT 
aGGA-AGA 
CCT-CGT 
cAGC-CGC 
aGGC-CGC 
CAA-CGA 
CAT-CGT 
tGGC-CGC 
aGGT-CGT 
tGGG-AGG 
ATG-AGG 
tGGG-CGG 
aTGT-CGT 
gGGA-AGA 
CAT-CGT 
ACA-AGA 
CTA-CGA 
Arg99Arg 
Gly162Arg 
Gly162Arg 
Gly164Arg 
Leu187Arg 
Leu310Arg 
Cys333Arg 
Gly338Arg 
Pro349Arg 
Ser554Arg 
Gly587Arg 
Gln629Arg 
His639Arg 
Gly669Arg 
Gly674Arg 
Gly683Arg 
Met688Arg 
Gly692Arg 
Cys697Arg 
Gly751Arg 
His839Arg 
Thr905Arg 
Leu911Arg 
MLH3 MLH1 Bowel Cancer 1 aTGG-CGG Trp1276Arg ATG-AGG 
ATG-AGG 
cGGG-AGG 
cGGG-CGG 
aTGT-CGT 
tGGC-CGC 
AGCa-AGA 
ATA-AGA 
ACG-AGG 
aGGG-CGG 
CTT-CGT 
CTC-CGC 
CAT-CGT 
gGGG-CGG 
CTG-CGG 
CTT-CGT 
CCC-CGC 
aGGG-AGG 
CTG-CGG 
tTGG-CGG 
CTC-CGC 
aTGC-CGC 
CAG-CGG 
AAA-AGA 
Met1Arg 
Met35Arg 
Gly67Arg 
Gly67Arg 
Cys77Arg 
Gly98Arg 
Ser106Arg 
Ile107Arg 
Thr117Arg 
Gly147Arg 
Leu155Arg 
Leu260Arg 
His264Arg 
Gly454Arg 
Leu559Arg 
Leu585Arg 
Pro603Arg 
Gly634Arg 
Leu653Arg 
Trp666Arg 
Leu676Arg 
Cys680Arg 
Gln689Arg 
Lys751Arg 
MSH2 MLH1 Gastric Cancer 0 CTA-CGA Leu173Arg AGCa-AGG Ser106Arg 
MSH2 MLH1 Bowel Cancer 2 tAGA-CGA 
tGGA-AGA 
tGGA-CGA 
tGGG-AGG 
CTT-CGT 
CTT-CGT 
gTGT-CGT 
aGGA-AGA 
CCT-CGT 
cAGC-CGC 
aGGC-CGC 
CAA-CGA 
CAT-CGT 
tGGC-CGC 
aGGT-CGT 
tGGG-AGG 
ATG-AGG 
tGGG-CGG 
aTGT-CGT 
gGGA-AGA 
CAT-CGT 
ACA-AGA 
CTA-CGA 
Arg99Arg 
Gly162Arg 
Gly162Arg 
Gly164Arg 
Leu187Arg 
Leu310Arg 
Cys333Arg 
Gly338Arg 
Pro349Arg 
Ser554Arg 
Gly587Arg 
Gln629Arg 
His639Arg 
Gly669Arg 
Gly674Arg 
Gly683Arg 
Met688Arg 
Gly692Arg 
Cys697Arg 
Gly751Arg 
His839Arg 
Thr905Arg 
Leu911Arg 
ATG-AGG 
ATG-AGG 
cGGG-AGG 
cGGG-CGG 
aTGT-CGT 
tGGC-CGC 
AGCa-AGA 
ATA-AGA 
ACG-AGG 
aGGG-CGG 
CTT-CGT 
CTC-CGC 
CAT-CGT 
gGGG-CGG 
CTG-CGG 
CTT-CGT 
CCC-CGC 
aGGG-AGG 
CTG-CGG 
tTGG-CGG 
CTC-CGC 
aTGC-CGC 
CAG-CGG 
AAA-AGA 
Met1Arg 
Met35Arg 
Gly67Arg 
Gly67Arg 
Cys77Arg 
Gly98Arg 
Ser106Arg 
Ile107Arg 
Thr117Arg 
Gly147Arg 
Leu155Arg 
Leu260Arg 
His264Arg 
Gly454Arg 
Leu559Arg 
Leu585Arg 
Pro603Arg 
Gly634Arg 
Leu653Arg 
Trp666Arg 
Leu676Arg 
Cys680Arg 
Gln689Arg 
Lys751Arg 
MSH6 MLH1 Bowel Cancer 1 AAA-AGA 
CAG-CGG 
gGGA-AGA 
tGGG-AGG 
Lys295Arg 
Gln522Arg 
Gly566Arg 
Gly670Arg 
ATG-AGG 
ATG-AGG 
cGGG-AGG 
cGGG-CGG 
aTGT-CGT 
tGGC-CGC 
AGCa-AGA 
ATA-AGA 
ACG-AGG 
aGGG-CGG 
CTT-CGT 
CTC-CGC 
CAT-CGT 
gGGG-CGG 
CTG-CGG 
CTT-CGT 
CCC-CGC 
aGGG-AGG 
CTG-CGG 
tTGG-CGG 
CTC-CGC 
aTGC-CGC 
CAG-CGG 
AAA-AGA 
Met1Arg 
Met35Arg 
Gly67Arg 
Gly67Arg 
Cys77Arg 
Gly98Arg 
Ser106Arg 
Ile107Arg 
Thr117Arg 
Gly147Arg 
Leu155Arg 
Leu260Arg 
His264Arg 
Gly454Arg 
Leu559Arg 
Leu585Arg 
Pro603Arg 
Gly634Arg 
Leu653Arg 
Trp666Arg 
Leu676Arg 
Cys680Arg 
Gln689Arg 
Lys751Arg 
MSH6 MSH2 Bowel Cancer 1 AAA-AGA 
CAG-CGG 
Lys295Arg 
Gln522Arg 
tAGA-CGA 
tGGA-AGA 
Arg99Arg 
Gly162Arg 
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gGGA-AGA 
tGGG-AGG 
Gly566Arg 
Gly670Arg 
tGGA-CGA 
tGGG-AGG 
CTT-CGT 
CTT-CGT 
gTGT-CGT 
aGGA-AGA 
CCT-CGT 
cAGC-CGC 
aGGC-CGC 
CAA-CGA 
CAT-CGT 
tGGC-CGC 
aGGT-CGT 
tGGG-AGG 
ATG-AGG 
tGGG-CGG 
aTGT-CGT 
gGGA-AGA 
CAT-CGT 
ACA-AGA 
CTA-CGA 
Gly162Arg 
Gly164Arg 
Leu187Arg 
Leu310Arg 
Cys333Arg 
Gly338Arg 
Pro349Arg 
Ser554Arg 
Gly587Arg 
Gln629Arg 
His639Arg 
Gly669Arg 
Gly674Arg 
Gly683Arg 
Met688Arg 
Gly692Arg 
Cys697Arg 
Gly751Arg 
His839Arg 
Thr905Arg 
Leu911Arg 
MSH6 MSH2 Bowel Cancer 1 AAA-AGA 
CAG-CGG 
gGGA-AGA 
tGGG-AGG 
Lys295Arg 
Gln522Arg 
Gly566Arg 
Gly670Arg 
tAGA-CGA 
tGGA-AGA 
tGGA-CGA 
tGGG-AGG 
CTT-CGT 
CTT-CGT 
gTGT-CGT 
aGGA-AGA 
CCT-CGT 
cAGC-CGC 
aGGC-CGC 
CAA-CGA 
CAT-CGT 
tGGC-CGC 
aGGT-CGT 
tGGG-AGG 
ATG-AGG 
tGGG-CGG 
aTGT-CGT 
gGGA-AGA 
CAT-CGT 
ACA-AGA 
CTA-CGA 
Arg99Arg 
Gly162Arg 
Gly162Arg 
Gly164Arg 
Leu187Arg 
Leu310Arg 
Cys333Arg 
Gly338Arg 
Pro349Arg 
Ser554Arg 
Gly587Arg 
Gln629Arg 
His639Arg 
Gly669Arg 
Gly674Arg 
Gly683Arg 
Met688Arg 
Gly692Arg 
Cys697Arg 
Gly751Arg 
His839Arg 
Thr905Arg 
Leu911Arg 
MUTYH MSH6 Bowel Cancer 1 gTGG-AGG 
CAG-CGG 
Trp131Arg 
Gln338Arg 
CAG-CGG 
gGGA-AGA 
tGGG-AGG 
Gln522Arg 
Gly566Arg 
Gly670Arg 
PARP1 TP53 Breast Cancer 0 cCGA-AGA Arg452Arg cTGC-CGC Cys242Arg 
PMS1 MLH1 Bowel Cancer 0 gGGA-AGA Gly501Arg ATG-AGG 
ATG-AGG 
cGGG-AGG 
cGGG-CGG 
aTGT-CGT 
tGGC-CGC 
AGCa-AGA 
ATA-AGA 
ACG-AGG 
aGGG-CGG 
CTT-CGT 
CTC-CGC 
CAT-CGT 
gGGG-CGG 
CTG-CGG 
CTT-CGT 
CCC-CGC 
aGGG-AGG 
CTG-CGG 
tTGG-CGG 
CTC-CGC 
aTGC-CGC 
CAG-CGG 
AAA-AGA 
Met1Arg 
Met35Arg 
Gly67Arg 
Gly67Arg 
Cys77Arg 
Gly98Arg 
Ser106Arg 
Ile107Arg 
Thr117Arg 
Gly147Arg 
Leu155Arg 
Leu260Arg 
His264Arg 
Gly454Arg 
Leu559Arg 
Leu585Arg 
Pro603Arg 
Gly634Arg 
Leu653Arg 
Trp666Arg 
Leu676Arg 
Cys680Arg 
Gln689Arg 
Lys751Arg 
PMS2 MSH2 Bowel Cancer 1 CCT-CGT Pro404Arg tAGA-CGA 
tGGA-AGA 
tGGA-CGA 
tGGG-AGG 
CTT-CGT 
CTT-CGT 
gTGT-CGT 
aGGA-AGA 
CCT-CGT 
cAGC-CGC 
aGGC-CGC 
CAA-CGA 
CAT-CGT 
tGGC-CGC 
aGGT-CGT 
tGGG-AGG 
ATG-AGG 
tGGG-CGG 
aTGT-CGT 
gGGA-AGA 
CAT-CGT 
ACA-AGA 
CTA-CGA 
Arg99Arg 
Gly162Arg 
Gly162Arg 
Gly164Arg 
Leu187Arg 
Leu310Arg 
Cys333Arg 
Gly338Arg 
Pro349Arg 
Ser554Arg 
Gly587Arg 
Gln629Arg 
His639Arg 
Gly669Arg 
Gly674Arg 
Gly683Arg 
Met688Arg 
Gly692Arg 
Cys697Arg 
Gly751Arg 
His839Arg 
Thr905Arg 
Leu911Arg 
PMS2 MLH1 Bowel Cancer 0 CCT-CGT Pro404Arg ATG-AGG 
ATG-AGG 
cGGG-AGG 
cGGG-CGG 
aTGT-CGT 
tGGC-CGC 
AGCa-AGA 
ATA-AGA 
ACG-AGG 
aGGG-CGG 
CTT-CGT 
CTC-CGC 
CAT-CGT 
gGGG-CGG 
CTG-CGG 
CTT-CGT 
CCC-CGC 
aGGG-AGG 
CTG-CGG 
Met1Arg 
Met35Arg 
Gly67Arg 
Gly67Arg 
Cys77Arg 
Gly98Arg 
Ser106Arg 
Ile107Arg 
Thr117Arg 
Gly147Arg 
Leu155Arg 
Leu260Arg 
His264Arg 
Gly454Arg 
Leu559Arg 
Leu585Arg 
Pro603Arg 
Gly634Arg 
Leu653Arg 
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tTGG-CGG 
CTC-CGC 
aTGC-CGC 
CAG-CGG 
AAA-AGA 
Trp666Arg 
Leu676Arg 
Cys680Arg 
Gln689Arg 
Lys751Arg 
PTEN TP53 Breast Cancer 0 AGTg-AGG Ser207Arg cTGC-CGC Cys242Arg 
Asparagine 
Node1 Node2 Cancer Match Node1 codon 
change 
Node1 Amino acid 
changes 
Node2 codon 
change 
Node2 Amino acid 
changes 
BRCA1 TP53 Breast Cancer 1 AAGt-AAT 
AAAt-AAT 
AAAg-AAT 
tGAC-AAC 
AGT-AAT 
cGAT-AAT 
AGC-AAC 
AGT-AAT 
AGC-AAC 
cCAC-AAC 
AGT-AAT 
Lys38Asn 
Lys45Asn 
Lys56Asn 
Asp96Asn 
Ser264Asn 
Asp695Asn 
Ser1040Asn 
Ser1389Asn 
Ser1715Asn 
His1746Asn 
Ser1841Asn 
aGAC-AAC Asp281Asn 
BRCA1 BARD1 Breast Cancer 1 AAGt-AAT 
AAAt-AAT 
AAAg-AAT 
tGAC-AAC 
AGT-AAT 
cGAT-AAT 
AGC-AAC 
AGT-AAT 
AGC-AAC 
cCAC-AAC 
AGT-AAT 
Lys38Asn 
Lys45Asn 
Lys56Asn 
Asp96Asn 
Ser264Asn 
Asp695Asn 
Ser1040Asn 
Ser1389Asn 
Ser1715Asn 
His1746Asn 
Ser1841Asn 
AAAt-AAT Lys312Asn 
BRCA1 ATM Breast Cancer 1 AAGt-AAT 
AAAt-AAT 
AAAg-AAT 
tGAC-AAC 
AGT-AAT 
cGAT-AAT 
AGC-AAC 
AGT-AAT 
AGC-AAC 
cCAC-AAC 
AGT-AAT 
Lys38Asn 
Lys45Asn 
Lys56Asn 
Asp96Asn 
Ser264Asn 
Asp695Asn 
Ser1040Asn 
Ser1389Asn 
Ser1715Asn 
His1746Asn 
Ser1841Asn 
AGT-AAT 
gGAC-AAC 
AAAa-AAC 
aGAT-AAT 
Ser759Asn 
Asp1099Asn 
Lys1454Asn 
Asp1853Asn 
BRCA2 BARD1 Breast Cancer 0 tGAT-AAT 
tGAT-AAT 
AGC-AAC 
AAAa-AAC 
aCAC-AAC 
AAAg-AAC 
ACT-AAT 
AAGg-AAT 
Asp244Asn 
Asp935Asn 
Ser1179Asn 
Lys1690Asn 
His2074Asn 
Lys2128Asn 
Thr2310Asn 
Lys2950Asn 
AAAt-AAT Lys312Asn 
BRCA2 ATM Breast Cancer 1 AAGt-AAT 
AAAt-AAT 
AAAg-AAT 
tGAC-AAC 
AGT-AAT 
cGAT-AAT 
AGC-AAC 
AGT-AAT 
AGC-AAC 
cCAC-AAC 
AGT-AAT 
Lys38Asn 
Lys45Asn 
Lys56Asn 
Asp96Asn 
Ser264Asn 
Asp695Asn 
Ser1040Asn 
Ser1389Asn 
Ser1715Asn 
His1746Asn 
Ser1841Asn 
AGT-AAT 
gGAC-AAC 
AAAa-AAC 
aGAT-AAT 
Ser759Asn 
Asp1099Asn 
Lys1454Asn 
Asp1853Asn 
BRCA2 BRCA1 Breast Cancer 1 tGAT-AAT 
tGAT-AAT 
AGC-AAC 
AAAa-AAC 
aCAC-AAC 
AAAg-AAC 
ACT-AAT 
AAGg-AAT 
Asp244Asn 
Asp935Asn 
Ser1179Asn 
Lys1690Asn 
His2074Asn 
Lys2128Asn 
Thr2310Asn 
Lys2950Asn 
AAGt-AAT 
AAAt-AAT 
AAAg-AAT 
tGAC-AAC 
AGT-AAT 
cGAT-AAT 
AGC-AAC 
AGT-AAT 
AGC-AAC 
cCAC-AAC 
AGT-AAT 
Lys38Asn 
Lys45Asn 
Lys56Asn 
Asp96Asn 
Ser264Asn 
Asp695Asn 
Ser1040Asn 
Ser1389Asn 
Ser1715Asn 
His1746Asn 
Ser1841Asn 
BRCA2 BRCA1 Ovarian 
Cancer 
1 tGAT-AAT 
AAAa-AAC 
aCAC-AAC 
AAGg-AAT 
Asp935Asn 
Lys1690Asn 
His2074Asn 
Lys2950Asn 
AAGt-AAT 
AAAt-AAT 
tGAC-AAC 
tGAT-AAT 
AGC-AAC 
cCAC-AAC 
AGT-AAT 
Lys38Asn 
Lys45Asn 
Asp96Asn 
Asp330Asn 
Ser1715Asn 
His1746Asn 
Ser1841Asn 
BRCA2 TP53 Breast Cancer 0 tGAT-AAT 
tGAT-AAT 
AGC-AAC 
AAAa-AAC 
aCAC-AAC 
AAAg-AAC 
ACT-AAT 
AAGg-AAT 
Asp244Asn 
Asp935Asn 
Ser1179Asn 
Lys1690Asn 
His2074Asn 
Lys2128Asn 
Thr2310Asn 
Lys2950Asn 
aGAC-AAC Asp281Asn 
CDKN2A CDK4 Melanoma 0 gCAC-AAC 
cGAC-AAC 
cGAT-AAT 
His83Asn 
Asp84Asn 
Asp108Asn 
AGC-AAC Ser52Asn 
MSH2 MLH1 Bowel Cancer 1 aGAT-AAT 
AAAg-AAC 
ATC-AAC 
Asp603Asn 
Lys627Asn 
Ile708Asn 
ATT-AAT 
aGAC-AAC 
ATC-AAC 
aTAC-AAC 
gCAC-AAC 
AGT-AAT 
Ile36Asn 
Asp63Asn 
Ile68Asn 
Tyr126Asn 
His329Asn 
Ser406Asn 
MSH6 MLH1 Bowel Cancer 1 AAGa-AAT 
ATT-AAT 
ACT-AAT 
AGT-AAT 
Lys99Asn 
Ile745Asn 
Thr764Asn 
Ser1188Asn 
ATT-AAT 
aGAC-AAC 
ATC-AAC 
aTAC-AAC 
gCAC-AAC 
AGT-AAT 
Ile36Asn 
Asp63Asn 
Ile68Asn 
Tyr126Asn 
His329Asn 
Ser406Asn 
MSH6 MSH2 Bowel Cancer 0 AAGa-AAT 
ATT-AAT 
ACT-AAT 
AGT-AAT 
Lys99Asn 
Ile745Asn 
Thr764Asn 
Ser1188Asn 
aGAT-AAT 
AAAg-AAC 
ATC-AAC 
Asp603Asn 
Lys627Asn 
Ile708Asn 
PMS2 MSH2 Bowel Cancer 0 AGT-AAT Ser46Asn aGAT-AAT 
AAAg-AAC 
ATC-AAC 
Asp603Asn 
Lys627Asn 
Ile708Asn 
PMS2 MLH1 Bowel Cancer 1 AGT-AAT Ser46Asn ATT-AAT 
aGAC-AAC 
Ile36Asn 
Asp63Asn 
 
APPENDIX 
 
 
 
169 
 
ATC-AAC 
aTAC-AAC 
gCAC-AAC 
AGT-AAT 
Ile68Asn 
Tyr126Asn 
His329Asn 
Ser406Asn 
PTEN TP53 Breast Cancer 1 aGAC-AAC 
aGAT-AAT 
aGAT-AAT 
aGAT-AAT 
Asp92Asn 
Asp107Asn 
Asp115Asn 
Asp153Asn 
aGAC-AAC Asp281Asn 
TP53 BARD1 Breast Cancer 0 aGAC-AAC Asp281Asn AAAt-AAT Lys312Asn 
Glutamate 
Node1 Node2 Cancer Match Node1 codon 
change 
Node1 Amino acid 
changes 
Node2 codon 
change 
Node2 Amino acid 
changes 
BRCA1 ATM Breast Cancer 1 GATa-GAG 
aAAG-GAG 
cAAA-GAA 
gAAA-GAA 
GTG-GAG 
GGA-GAA 
GCG-GAG 
GGA-GAA 
GATg-GAG 
GTG-GAG 
Asp67Glu 
Lys654Glu 
Lys820Glu 
Lys1606Glu 
Val1696Glu 
Gly1706Glu 
Ala1708Glu 
Gly1738Glu 
Asp1739Glu 
Val1838Glu 
GACg-GAA 
tAAG-GAG 
tCAA-GAA 
tAAA-GAA 
Asp203Glu 
Lys1964Glu 
Gln2277Glu 
Lys2431Glu 
BRCA1 PALB2 Breast Cancer 1 GATa-GAG 
aAAG-GAG 
cAAA-GAA 
gAAA-GAA 
GTG-GAG 
GGA-GAA 
GCG-GAG 
GGA-GAA 
GATg-GAG 
GTG-GAG 
Asp67Glu 
Lys654Glu 
Lys820Glu 
Lys1606Glu 
Val1696Glu 
Gly1706Glu 
Ala1708Glu 
Gly1738Glu 
Asp1739Glu 
Val1838Glu 
GGA-GAA Gly998Glu 
BRCA2 ATM Breast Cancer 1 GATa-GAG 
aAAG-GAG 
cAAA-GAA 
gAAA-GAA 
GTG-GAG 
GGA-GAA 
GCG-GAG 
GGA-GAA 
GATg-GAG 
GTG-GAG 
Asp67Glu 
Lys654Glu 
Lys820Glu 
Lys1606Glu 
Val1696Glu 
Gly1706Glu 
Ala1708Glu 
Gly1738Glu 
Asp1739Glu 
Val1838Glu 
GACg-GAA 
tAAG-GAG 
tCAA-GAA 
tAAA-GAA 
Asp203Glu 
Lys1964Glu 
Gln2277Glu 
Lys2431Glu 
BRCA2 PALB2 Breast Cancer 0 cAAG-GAG 
tCAG-GAG 
GACg-GAG 
tAAA-GAA 
Lys327Glu 
Gln2456Glu 
Asp3095Glu 
Lys3196Glu 
GGA-GAA Gly998Glu 
CHEK2 BRCA2 Breast Cancer 1 aAAA-GAA Lys224Glu GACg-GAG 
tAAA-GAA 
Asp3095Glu 
Lys3196Glu 
CHEK2 ATM Breast Cancer 1 aAAA-GAA Lys224Glu GACg-GAA 
tAAG-GAG 
tCAA-GAA 
tAAA-GAA 
Asp203Glu 
Lys1964Glu 
Gln2277Glu 
Lys2431Glu 
CHEK2 BRCA1 Breast Cancer 1 aAAA-GAA Lys224Glu GATa-GAG 
aAAG-GAG 
cAAA-GAA 
gAAA-GAA 
GTG-GAG 
GGA-GAA 
GCG-GAG 
GGA-GAA 
GATg-GAG 
GTG-GAG 
Asp67Glu 
Lys654Glu 
Lys820Glu 
Lys1606Glu 
Val1696Glu 
Gly1706Glu 
Ala1708Glu 
Gly1738Glu 
Asp1739Glu 
Val1838Glu 
EXO1 MLH1 Bowel Cancer 1 GGA-GAA Gly759Glu GCG-GAG 
GTG-GAG 
GGA-GAA 
GACa-GAA 
GGG-GAG 
tAAA-GAA 
GTG-GAG 
tAAG-GAG 
GATt-GAA 
gAAG-GAG 
Ala21Glu 
Val49Glu 
Gly54Glu 
Asp63Glu 
Gly67Glu 
Lys84Glu 
Val303Glu 
Lys416Glu 
Asp485Glu 
Lys618Glu 
EXO1 PMS2 Bowel Cancer 1 GGA-GAA Gly759Glu GGA-GAA Gly207Glu 
MLH3 MLH1 Bowel Cancer 1 cCAA-GAA 
gAAA-GAA 
Gln24Glu 
Lys412Glu 
GCG-GAG 
GTG-GAG 
GGA-GAA 
GACa-GAA 
GGG-GAG 
tAAA-GAA 
GTG-GAG 
tAAG-GAG 
GATt-GAA 
gAAG-GAG 
Ala21Glu 
Val49Glu 
Gly54Glu 
Asp63Glu 
Gly67Glu 
Lys84Glu 
Val303Glu 
Lys416Glu 
Asp485Glu 
Lys618Glu 
MSH2 MLH1 Bowel Cancer 1 GTA-GAA 
cCAA-GAA 
GGA-GAA 
tAAA-GAA 
GTA-GAA 
Val470Glu 
Gln690Glu 
Gly759Glu 
Lys845Glu 
Val923Glu 
GCG-GAG 
GTG-GAG 
GGA-GAA 
GACa-GAA 
GGG-GAG 
tAAA-GAA 
GTG-GAG 
tAAG-GAG 
GATt-GAA 
gAAG-GAG 
Ala21Glu 
Val49Glu 
Gly54Glu 
Asp63Glu 
Gly67Glu 
Lys84Glu 
Val303Glu 
Lys416Glu 
Asp485Glu 
Lys618Glu 
MSH6 MLH1 Bowel Cancer 1 tCAG-GAG 
GGG-GAG 
Gln698Glu 
Gly1069Glu 
GCG-GAG 
GTG-GAG 
GGA-GAA 
GACa-GAA 
GGG-GAG 
tAAA-GAA 
aGAG-CAG 
GTG-GAG 
tAAG-GAG 
GATt-GAA 
gAAG-GAG 
GGG-GAG 
Ala21Glu 
Val49Glu 
Gly54Glu 
Asp63Glu 
Gly67Glu 
Lys84Glu 
Glu199Gln 
Val303Glu 
Lys416Glu 
Asp485Glu 
Lys618Glu 
Gly39Glu 
MSH6 MSH2 Bowel Cancer 0 GGG-GAG 
tCAG-GAG 
GGG-GAG 
Gly39Glu 
Gln698Glu 
Gly1069Glu 
GTA-GAA 
cCAA-GAA 
GGA-GAA 
tAAA-GAA 
GTA-GAA 
Val470Glu 
Gln690Glu 
Gly759Glu 
Lys845Glu 
Val923Glu 
MUTYH MSH6 Bowel Cancer 1 GGG-GAG Gly286Glu GGG-GAG Gly39Glu 
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GGG-GAG Gly216Glu tCAG-GAG 
GGG-GAG 
Gln698Glu 
Gly1069Glu 
PMS2 MSH2 Bowel Cancer 1 GGA-GAA Gly207Glu GTA-GAA 
cCAA-GAA 
GGA-GAA 
tAAA-GAA 
GTA-GAA 
Val470Glu 
Gln690Glu 
Gly759Glu 
Lys845Glu 
Val923Glu 
PMS2 MLH1 Bowel Cancer 1 GGA-GAA Gly207Glu GCG-GAG 
GTG-GAG 
GGA-GAA 
GACa-GAA 
GGG-GAG 
tAAA-GAA 
GTG-GAG 
tAAG-GAG 
GATt-GAA 
gAAG-GAG 
Ala21Glu 
Val49Glu 
Gly54Glu 
Asp63Glu 
Gly67Glu 
Lys84Glu 
Val303Glu 
Lys416Glu 
Asp485Glu 
Lys618Glu 
Glycine 
Node1 Node2 Cancer Match Node1 codon 
change 
Node1 Amino acid 
changes 
Node2 codon 
change 
Node2 Amino acid 
changes 
ATM TP53 Breast Cancer 0 tAGT-GGT 
tAGT-GGT 
GAC-GGC 
GAC-GGC 
GAA-GGA 
GAT-GGT 
cAGA-GGA 
Ser99Gly 
Ser378Gly 
Asp1467Gly 
Asp1914Gly 
Glu2570Gly 
Asp2625Gly 
Arg2912Gly 
GTG-GGG Val122Gly 
BRCA1 TP53 Breast Cancer 1 gTGT-GGT 
tTGC-GGC 
tTGC-GGC 
gTGT-GGT 
aTGT-GGT 
aAGG-GGG 
GGTa-GGC 
GAA-GGA 
GAG-GGG 
GGTa-GGA 
GAT-GGT 
aAGA-GGA 
gCGA-GGA 
GAT-GGT 
GTC-GGC 
GTG-GGG 
gTGG-GGG 
Cys39Gly 
Cys44Gly 
Cys47Gly 
Cys61Gly 
Cys64Gly 
Arg71Gly 
Gly263Gly 
Glu421Gly 
Glu515Gly 
Gly774Gly 
Asp1344Gly 
Arg1347Gly 
Arg1443Gly 
Asp1739Gly 
Val1741Gly 
Val1810Gly 
Trp1837Gly 
GTG-GGG Val122Gly 
BRCA1 MRE11A Breast Cancer 1 gTGT-GGT 
tTGC-GGC 
tTGC-GGC 
gTGT-GGT 
aTGT-GGT 
aAGG-GGG 
GGTa-GGC 
GAA-GGA 
GAG-GGG 
GGTa-GGA 
GAT-GGT 
aAGA-GGA 
gCGA-GGA 
GAT-GGT 
GTC-GGC 
GTG-GGG 
gTGG-GGG 
Cys39Gly 
Cys44Gly 
Cys47Gly 
Cys61Gly 
Cys64Gly 
Arg71Gly 
Gly263Gly 
Glu421Gly 
Glu515Gly 
Gly774Gly 
Asp1344Gly 
Arg1347Gly 
Arg1443Gly 
Asp1739Gly 
Val1741Gly 
Val1810Gly 
Trp1837Gly 
gAGA-GGA Arg202Gly 
BRCA1 ATM Breast Cancer 1 gTGT-GGT 
tTGC-GGC 
tTGC-GGC 
gTGT-GGT 
aTGT-GGT 
aAGG-GGG 
GGTa-GGC 
GAA-GGA 
GAG-GGG 
GGTa-GGA 
GAT-GGT 
aAGA-GGA 
gCGA-GGA 
GAT-GGT 
GTC-GGC 
GTG-GGG 
gTGG-GGG 
Cys39Gly 
Cys44Gly 
Cys47Gly 
Cys61Gly 
Cys64Gly 
Arg71Gly 
Gly263Gly 
Glu421Gly 
Glu515Gly 
Gly774Gly 
Asp1344Gly 
Arg1347Gly 
Arg1443Gly 
Asp1739Gly 
Val1741Gly 
Val1810Gly 
Trp1837Gly 
tAGT-GGT 
tAGT-GGT 
GAC-GGC 
GAC-GGC 
GAA-GGA 
GAT-GGT 
cAGA-GGA 
Ser99Gly 
Ser378Gly 
Asp1467Gly 
Asp1914Gly 
Glu2570Gly 
Asp2625Gly 
Arg2912Gly 
BRCA2 ATM Breast Cancer 1 gTGT-GGT 
tTGC-GGC 
tTGC-GGC 
gTGT-GGT 
aTGT-GGT 
aAGG-GGG 
GGTa-GGC 
GAA-GGA 
GAG-GGG 
GGTa-GGA 
GAT-GGT 
aAGA-GGA 
gCGA-GGA 
GAT-GGT 
GTC-GGC 
GTG-GGG 
gTGG-GGG 
Cys39Gly 
Cys44Gly 
Cys47Gly 
Cys61Gly 
Cys64Gly 
Arg71Gly 
Gly263Gly 
Glu421Gly 
Glu515Gly 
Gly774Gly 
Asp1344Gly 
Arg1347Gly 
Arg1443Gly 
Asp1739Gly 
Val1741Gly 
Val1810Gly 
Trp1837Gly 
tAGT-GGT 
tAGT-GGT 
GAC-GGC 
GAC-GGC 
GAA-GGA 
GAT-GGT 
cAGA-GGA 
Ser99Gly 
Ser378Gly 
Asp1467Gly 
Asp1914Gly 
Glu2570Gly 
Asp2625Gly 
Arg2912Gly 
BRCA2 BRCA1 Breast Cancer 1 aTGG-GGG 
GAA-GGA 
GAA-GGA 
GAA-GGA 
GTG-GGG 
GCA-GGA 
GAT-GGT 
Trp395Gly 
Glu462Gly 
Glu2029Gly 
Glu2121Gly 
Val2280Gly 
Ala2351Gly 
Asp2811Gly 
gTGT-GGT 
tTGC-GGC 
tTGC-GGC 
gTGT-GGT 
aTGT-GGT 
aAGG-GGG 
GGTa-GGC 
GAA-GGA 
GAG-GGG 
GGTa-GGA 
GAT-GGT 
aAGA-GGA 
gCGA-GGA 
GAT-GGT 
GTC-GGC 
GTG-GGG 
gTGG-GGG 
Cys39Gly 
Cys44Gly 
Cys47Gly 
Cys61Gly 
Cys64Gly 
Arg71Gly 
Gly263Gly 
Glu421Gly 
Glu515Gly 
Gly774Gly 
Asp1344Gly 
Arg1347Gly 
Arg1443Gly 
Asp1739Gly 
Val1741Gly 
Val1810Gly 
Trp1837Gly 
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BRCA2 BRCA1 Ovarian 
Cancer 
1 GGTa-GGC 
GAA-GGA 
GAT-GGT 
Gly1552Gly 
Glu2121Gly 
Asp3142Gly 
gTGT-GGT 
tTGC-GGC 
aAGG-GGG 
GAT-GGT 
GAT-GGT 
GTG-GGG 
gTGG-GGG 
Cys39Gly 
Cys44Gly 
Arg71Gly 
Asp1344Gly 
Asp1739Gly 
Val1810Gly 
Trp1837Gly 
BRCA2 TP53 Breast Cancer 1 aTGG-GGG 
GAA-GGA 
GGTa-GGC 
GAA-GGA 
GAA-GGA 
GTG-GGG 
GCA-GGA 
GAT-GGT 
Trp395Gly 
Glu462Gly 
Gly1552Gly 
Glu2029Gly 
Glu2121Gly 
Val2280Gly 
Ala2351Gly 
Asp2811Gly 
GTG-GGG Val122Gly 
CHEK2 BRCA2 Breast Cancer 0 gAGG-GGG Arg117Gly aTGG-GGG 
GAA-GGA 
GAA-GGA 
GTG-GGG 
GCA-GGA 
GAT-GGT 
Trp395Gly 
Glu462Gly 
Glu2029Gly 
Val2280Gly 
Ala2351Gly 
Asp2811Gly 
CHEK2 ATM Breast Cancer 0 gAGG-GGG Arg117Gly tAGT-GGT 
tAGT-GGT 
GAC-GGC 
GAC-GGC 
GAA-GGA 
GAT-GGT 
cAGA-GGA 
Ser99Gly 
Ser378Gly 
Asp1467Gly 
Asp1914Gly 
Glu2570Gly 
Asp2625Gly 
Arg2912Gly 
CHEK2 TP53 Breast Cancer 0 gAGG-GGG Arg117Gly GTG-GGG Val122Gly 
CHEK2 BRCA1 Breast Cancer 0 gAGG-GGG Arg117Gly gTGT-GGT 
tTGC-GGC 
tTGC-GGC 
gTGT-GGT 
aTGT-GGT 
aAGG-GGG 
GGTa-GGC 
GAA-GGA 
GAG-GGG 
GAT-GGT 
aAGA-GGA 
gCGA-GGA 
GAT-GGT 
GTC-GGC 
GTG-GGG 
gTGG-GGG 
Cys39Gly 
Cys44Gly 
Cys47Gly 
Cys61Gly 
Cys64Gly 
Arg71Gly 
Gly263Gly 
Glu421Gly 
Glu515Gly 
Asp1344Gly 
Arg1347Gly 
Arg1443Gly 
Asp1739Gly 
Val1741Gly 
Val1810Gly 
Trp1837Gly 
EXO1 MLH1 Bowel Cancer 1 tAGT-GGT Ser610Gly  
GCT-GGT 
GAT-GGT 
cAGT-GGT 
cAGG-GGG 
GTA-GGA 
GAG-GGG 
GAA-GGA 
GCC-GGC 
GAT-GGT 
GAG-GGG 
GAT-GGT 
GAT-GGT 
gAGG-GGG 
Ala29Gly 
Asp41Gly 
Ser93Gly 
Arg182Gly 
Val185Gly 
Glu234Gly 
Glu268Gly 
Ala282Gly 
Asp304Gly 
Glu578Gly 
Asp591Gly 
Asp601Gly 
Arg755Gly 
EXO1 MSH2 Bowel Cancer 0 tAGT-GGT Ser610Gly GTT-GGT 
GAA-GGA 
GAT-GGT 
tTGT-GGT 
GAT-GGT 
GAG-GGG 
GAG-GGG 
Val163Gly 
Glu198Gly 
Asp603Gly 
Cys641Gly 
Asp660Gly 
Glu853Gly 
Glu886Gly 
MLH3 MLH1 Bowel Cancer 1 tAGT-GGT Ser817Gly GCT-GGT 
GAT-GGT 
cAGT-GGT 
cAGG-GGG 
GTA-GGA 
GAG-GGG 
GAA-GGA 
GCC-GGC 
GAT-GGT 
GAG-GGG 
GAT-GGT 
GAT-GGT 
gAGG-GGG 
Ala29Gly 
Asp41Gly 
Ser93Gly 
Arg182Gly 
Val185Gly 
Glu234Gly 
Glu268Gly 
Ala282Gly 
Asp304Gly 
Glu578Gly 
Asp591Gly 
Asp601Gly 
Arg755Gly 
MRE11A ATM Breast Cancer 1 gAGA-GGA Arg202Gly tAGT-GGT 
tAGT-GGT 
GAC-GGC 
GAC-GGC 
GAA-GGA 
GAT-GGT 
cAGA-GGA 
Ser99Gly 
Ser378Gly 
Asp1467Gly 
Asp1914Gly 
Glu2570Gly 
Asp2625Gly 
Arg2912Gly 
MSH2 MLH1 Bowel Cancer 1 GTT-GGT 
GAA-GGA 
GAT-GGT 
tTGT-GGT 
GAT-GGT 
GAG-GGG 
GAG-GGG 
Val163Gly 
Glu198Gly 
Asp603Gly 
Cys641Gly 
Asp660Gly 
Glu853Gly 
Glu886Gly 
GCT-GGT 
GAT-GGT 
cAGT-GGT 
cAGG-GGG 
GTA-GGA 
GAG-GGG 
GAA-GGA 
GCC-GGC 
GAT-GGT 
GAG-GGG 
GAT-GGT 
GAT-GGT 
gAGG-GGG 
Ala29Gly 
Asp41Gly 
Ser93Gly 
Arg182Gly 
Val185Gly 
Glu234Gly 
Glu268Gly 
Ala282Gly 
Asp304Gly 
Glu578Gly 
Asp591Gly 
Asp601Gly 
Arg755Gly 
MSH6 MLH1 Bowel Cancer 0 gAGA-GGA 
GAC-GGC 
aAGA-GGA 
Arg635Gly 
Asp803Gly 
Arg1321Gly 
GCT-GGT 
GAT-GGT 
cAGT-GGT 
cAGG-GGG 
GTA-GGA 
GAG-GGG 
GAA-GGA 
GCC-GGC 
GAT-GGT 
GAG-GGG 
GAT-GGT 
GAT-GGT 
gAGG-GGG 
GAG-GGG 
Ala29Gly 
Asp41Gly 
Ser93Gly 
Arg182Gly 
Val185Gly 
Glu234Gly 
Glu268Gly 
Ala282Gly 
Asp304Gly 
Glu578Gly 
Asp591Gly 
Asp601Gly 
Arg755Gly 
Glu229Gly 
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MSH6 MSH2 Bowel Cancer 1 GAG-GGG 
gAGA-GGA 
GAC-GGC 
aAGA-GGA 
Glu229Gly 
Arg635Gly 
Asp803Gly 
Arg1321Gly 
GTT-GGT 
GAA-GGA 
GAT-GGT 
tTGT-GGT 
GAT-GGT 
GAG-GGG 
GAG-GGG 
Val163Gly 
Glu198Gly 
Asp603Gly 
Cys641Gly 
Asp660Gly 
Glu853Gly 
Glu886Gly 
PTEN TP53 Bowel Cancer 1 GGTg-GGG 
GTG-GGG 
Gly132Gly 
Val191Gly 
GTG-GGG Val122Gly 
Histidine 
Node1 Node2 Cancer Match Node1 codon 
change 
Node1 Amino acid 
changes 
Node2 codon 
change 
Node2 Amino acid 
changes 
ATM TP53 Breast Cancer 1 aTAT-CAT 
CTC-CAC 
CGT-CAT 
CCT-CAT 
CGT-CAT 
CGT-CAT 
Tyr1442His 
Leu1555His 
Arg1575His 
Pro1785His 
Arg2719His 
Arg3008His 
CTC-CAC 
CGC-CAC 
Leu130His 
Arg181His 
BRCA1 TP53 Breast Cancer 0 CCC-CAC 
CGT-CAT 
CGT-CAT 
tAAT-CAT 
gAAT-CAT 
gTAT-CAT 
CAGg-CAT 
gTAC-CAC 
CAAg-CAC 
aGAT-CAT 
CAGc-CAT 
Pro142His 
Arg496His 
Arg504His 
Asn550His 
Asn564His 
Tyr856His 
Gln1200His 
Tyr1666His 
Gln1747His 
Asp1778His 
Gln1785His 
CTC-CAC 
CGC-CAC 
Leu130His 
Arg181His 
BRCA1 BARD1 Breast Cancer 2 CGT-CAT 
CGT-CAT 
gAAT-CAT 
Arg496His 
Arg504His 
Asn564His 
CAGc-CAC Gln564His 
BRCA1 RAD50 Breast Cancer 1 CCC-CAC 
CGT-CAT 
CGT-CAT 
tAAT-CAT 
gAAT-CAT 
gTAT-CAT 
CAGg-CAT 
gTAC-CAC 
CAAg-CAC 
aGAT-CAT 
CAGc-CAT 
Pro142His 
Arg496His 
Arg504His 
Asn550His 
Asn564His 
Tyr856His 
Gln1200His 
Tyr1666His 
Gln1747His 
Asp1778His 
Gln1785His 
CGT-CAT Arg224His 
BRCA1 ATM Breast Cancer 2 CCC-CAC 
CGT-CAT 
CGT-CAT 
tAAT-CAT 
gAAT-CAT 
gTAT-CAT 
CAGg-CAT 
gTAC-CAC 
CAAg-CAC 
aGAT-CAT 
CAGc-CAT 
Pro142His 
Arg496His 
Arg504His 
Asn550His 
Asn564His 
Tyr856His 
Gln1200His 
Tyr1666His 
Gln1747His 
Asp1778His 
Gln1785His 
aTAT-CAT 
CTC-CAC 
CGT-CAT 
CCT-CAT 
CGT-CAT 
CGT-CAT 
Tyr1442His 
Leu1555His 
Arg1575His 
Pro1785His 
Arg2719His 
Arg3008His 
BRCA1 PALB2 Breast Cancer 1 CCC-CAC 
CGT-CAT 
CGT-CAT 
tAAT-CAT 
gAAT-CAT 
gTAT-CAT 
CAGg-CAT 
gTAC-CAC 
CAAg-CAC 
aGAT-CAT 
CAGc-CAT 
Pro142His 
Arg496His 
Arg504His 
Asn550His 
Asn564His 
Tyr856His 
Gln1200His 
Tyr1666His 
Gln1747His 
Asp1778His 
Gln1785His 
aTAT-CAT Tyr408His 
BRCA2 ATM Breast Cancer 1 CGC-CAC 
aAAT-CAT 
aAAT-CAT 
tGAT-CAT 
CGT-CAT 
CGT-CAT 
tAAC-CAC 
aGAT-CAT 
tTAC-CAC 
Arg18His 
Asn289His 
Asn372His 
Asp596His 
Arg2034His 
Arg2108His 
Asn2135His 
Asp2723His 
Tyr3098His 
aTAT-CAT 
CTC-CAC 
CGT-CAT 
CCT-CAT 
CGT-CAT 
CGT-CAT 
Tyr1442His 
Leu1555His 
Arg1575His 
Pro1785His 
Arg2719His 
Arg3008His 
BRCA2 BRCA1 Breast Cancer 1 CGC-CAC 
aAAT-CAT 
aAAT-CAT 
tGAT-CAT 
CGT-CAT 
CGT-CAT 
tAAC-CAC 
aGAT-CAT 
tTAC-CAC 
Arg18His 
Asn289His 
Asn372His 
Asp596His 
Arg2034His 
Arg2108His 
Asn2135His 
Asp2723His 
Tyr3098His 
CCC-CAC 
CGT-CAT 
CGT-CAT 
tAAT-CAT 
gAAT-CAT 
gTAT-CAT 
CAGg-CAT 
gTAC-CAC 
CAAg-CAC 
aGAT-CAT 
CAGc-CAT 
Pro142His 
Arg496His 
Arg504His 
Asn550His 
Asn564His 
Tyr856His 
Gln1200His 
Tyr1666His 
Gln1747His 
Asp1778His 
Gln1785His 
BRCA2 TP53 Breast Cancer 1 CGC-CAC 
aAAT-CAT 
aAAT-CAT 
tGAT-CAT 
CGT-CAT 
CGT-CAT 
tAAC-CAC 
aGAT-CAT 
tTAC-CAC 
Arg18His 
Asn289His 
Asn372His 
Asp596His 
Arg2034His 
Arg2108His 
Asn2135His 
Asp2723His 
Tyr3098His 
CTC-CAC 
CGC-CAC 
Leu130His 
Arg181His 
CDKN2A CDK4 Melanoma 0 cGAT-CAT Asp125His CGT-CAT Arg24His 
CHEK2 BRCA2 Breast Cancer 1 aTAC-CAC 
gTAT-CAT 
Tyr159His 
Tyr424His 
CGC-CAC 
aAAT-CAT 
aAAT-CAT 
tGAT-CAT 
CGT-CAT 
CGT-CAT 
tAAC-CAC 
aGAT-CAT 
tTAC-CAC 
Arg18His 
Asn289His 
Asn372His 
Asp596His 
Arg2034His 
Arg2108His 
Asn2135His 
Asp2723His 
Tyr3098His 
CHEK2 RAD50 Breast Cancer 0 aTAC-CAC 
gTAT-CAT 
Tyr159His 
Tyr424His 
CGT-CAT Arg224His 
CHEK2 ATM Breast Cancer 0 aTAC-CAC 
gTAT-CAT 
Tyr159His 
Tyr424His 
aTAT-CAT 
CTC-CAC 
CGT-CAT 
CCT-CAT 
CGT-CAT 
Tyr1442His 
Leu1555His 
Arg1575His 
Pro1785His 
Arg2719His 
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CGT-CAT Arg3008His 
CHEK2 TP53 Breast Cancer 0 aTAC-CAC 
gTAT-CAT 
Tyr159His 
Tyr424His 
CTC-CAC 
CGC-CAC 
Leu130His 
Arg181His 
CHEK2 TP53 Breast Cancer 0 CGC-CAC 
CGT-CAT 
CGC-CAC 
Arg180His 
Arg181His 
Arg318His 
CAAc-CAT Gln136His 
CHEK2 BRCA1 Breast Cancer 1 aTAC-CAC 
gTAT-CAT 
Tyr159His 
Tyr424His 
CCC-CAC 
CGT-CAT 
CGT-CAT 
tAAT-CAT 
gAAT-CAT 
gTAT-CAT 
CAGg-CAT 
gTAC-CAC 
CAAg-CAC 
aGAT-CAT 
CAGc-CAT 
Pro142His 
Arg496His 
Arg504His 
Asn550His 
Asn564His 
Tyr856His 
Gln1200His 
Tyr1666His 
Gln1747His 
Asp1778His 
Gln1785His 
MSH2 MLH1 Bowel Cancer 1 gGAT-CAT 
CGT-CAT 
CCT-CAT 
Asp167His 
Arg382His 
Pro652His 
gAAC-CAC 
aGAT-CAT 
aGAT-CAT 
CGT-CAT 
CAGa-CAT 
tGAT-CAT 
cTAC-CAC 
CTT-CAT 
CTT-CAT 
CGC-CAC 
CCT-CAT 
Asn38His 
Asp41His 
Asp132His 
Arg265His 
Gln346His 
Asp485His 
Tyr561His 
Leu607His 
Leu622His 
Arg725His 
Pro747His 
MSH6 MLH1 Bowel Cancer 1 CGT-CAT 
CGT-CAT 
CGT-CAT 
CGC-CAC 
Arg468His 
Arg901His 
Arg976His 
Arg1095His 
gAAC-CAC 
aGAT-CAT 
aGAT-CAT 
CGT-CAT 
CAGa-CAT 
tGAT-CAT 
cTAC-CAC 
CTT-CAT 
CTT-CAT 
CGC-CAC 
CCT-CAT 
Asn38His 
Asp41His 
Asp132His 
Arg265His 
Gln346His 
Asp485His 
Tyr561His 
Leu607His 
Leu622His 
Arg725His 
Pro747His 
MSH6 MSH2 Bowel Cancer 1 CGT-CAT 
CGT-CAT 
CGC-CAC 
Arg468His 
Arg976His 
Arg1095His 
gGAT-CAT 
CGT-CAT 
CCT-CAT 
Asp167His 
Arg382His 
Pro652His 
MUTYH APEX1 Bowel Cancer 1 CAGg-CAC Gln498His CAGa-CAC Gln51His 
MUTYH MSH6 Bowel Cancer 0 CAGg-CAC Gln498His CGT-CAT 
CGT-CAT 
CGT-CAT 
CGC-CAC 
Arg468His 
Arg901His 
Arg976His 
Arg1095His 
NCOA3 BRCA1 Breast Cancer 0 CAGt-CAC Gln586His CCC-CAC 
CGT-CAT 
CGT-CAT 
tAAT-CAT 
gAAT-CAT 
gTAT-CAT 
CAGg-CAT 
gTAC-CAC 
CAAg-CAC 
aGAT-CAT 
CAGc-CAT 
Pro142His 
Arg496His 
Arg504His 
Asn550His 
Asn564His 
Tyr856His 
Gln1200His 
Tyr1666His 
Gln1747His 
Asp1778His 
Gln1785His 
OGG1 XPC Bowel Cancer 0 CGC-CAC Arg154His CGT-CAT Arg492His 
Isoleucine 
Node1 Node2 Cancer Match Node1 codon 
change 
Node1 Amino acid 
changes 
Node2 codon 
change 
Node2 Amino acid 
changes 
ATM TP53 Breast Cancer 0 ATGg-ATA 
ATGt-ATA 
Met1210Ile 
Met2482Ile 
tGTC-ATC Val97Ile 
BRCA1 TP53 Breast Cancer 0 ATGg-ATT 
cGTT-ATT 
ACA-ATA 
AGA-ATA 
AAT-ATT 
tGTT-ATT 
ATGt-ATA 
ACA-ATA 
ACT-ATT 
AGT-ATT 
AGT-ATT 
ACC-ATC 
ATGg-ATA 
ACT-ATT 
Met1Ile 
Val191Ile 
Thr374Ile 
Arg507Ile 
Asn909Ile 
Val990Ile 
Met1008Ile 
Thr1025Ile 
Thr1163Ile 
Ser1164Ile 
Ser1512Ile 
Thr1561Ile 
Met1652Ile 
Thr1685Ile 
tGTC-ATC Val97Ile 
BRCA1 BRIP1 Breast Cancer 1 ATGg-ATT 
cGTT-ATT 
ACA-ATA 
AGA-ATA 
AAT-ATT 
tGTT-ATT 
ATGt-ATA 
ACA-ATA 
ACT-ATT 
AGT-ATT 
AGT-ATT 
ACC-ATC 
ATGg-ATA 
ACT-ATT 
Met1Ile 
Val191Ile 
Thr374Ile 
Arg507Ile 
Asn909Ile 
Val990Ile 
Met1008Ile 
Thr1025Ile 
Thr1163Ile 
Ser1164Ile 
Ser1512Ile 
Thr1561Ile 
Met1652Ile 
Thr1685Ile 
ATGg-ATA Met299Ile 
BRCA1 ATM Breast Cancer 0 ATGg-ATT 
cGTT-ATT 
ACA-ATA 
AGA-ATA 
AAT-ATT 
tGTT-ATT 
ATGt-ATA 
ACA-ATA 
ACT-ATT 
AGT-ATT 
AGT-ATT 
ACC-ATC 
ATGg-ATA 
ACT-ATT 
Met1Ile 
Val191Ile 
Thr374Ile 
Arg507Ile 
Asn909Ile 
Val990Ile 
Met1008Ile 
Thr1025Ile 
Thr1163Ile 
Ser1164Ile 
Ser1512Ile 
Thr1561Ile 
Met1652Ile 
Thr1685Ile 
ATGg-ATA 
ATGt-ATA 
Met1210Ile 
Met2482Ile 
BRCA1 PALB2 Breast Cancer 1 ATGg-ATT 
cGTT-ATT 
ACA-ATA 
AGA-ATA 
AAT-ATT 
Met1Ile 
Val191Ile 
Thr374Ile 
Arg507Ile 
Asn909Ile 
ACA-ATA Thr300Ile 
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tGTT-ATT 
ATGt-ATA 
ACA-ATA 
ACT-ATT 
AGT-ATT 
AGT-ATT 
ACC-ATC 
ATGg-ATA 
ACT-ATT 
Val990Ile 
Met1008Ile 
Thr1025Ile 
Thr1163Ile 
Ser1164Ile 
Ser1512Ile 
Thr1561Ile 
Met1652Ile 
Thr1685Ile 
BRCA2 ATM Breast Cancer 1 ATGg-ATT 
cGTT-ATT 
ACA-ATA 
AGA-ATA 
AAT-ATT 
tGTT-ATT 
ATGt-ATA 
ACA-ATA 
ACT-ATT 
AGT-ATT 
AGT-ATT 
ACC-ATC 
ATGg-ATA 
ACT-ATT 
Met1Ile 
Val191Ile 
Thr374Ile 
Arg507Ile 
Asn909Ile 
Val990Ile 
Met1008Ile 
Thr1025Ile 
Thr1163Ile 
Ser1164Ile 
Ser1512Ile 
Thr1561Ile 
Met1652Ile 
Thr1685Ile 
ATGg-ATA 
ATGt-ATA 
Met1210Ile 
Met2482Ile 
BRCA2 BRCA1 Breast Cancer 2 ATGc-ATA 
ACT-ATT 
ACA-ATA 
AAC-ATC 
tGTT-ATT 
ACA-ATA 
tGTT-ATT 
ACT-ATT 
cGTC-ATC 
AAC-ATC 
Met1Ile 
Thr64Ile 
Thr200Ile 
Asn924Ile 
Val2109Ile 
Thr2515Ile 
Val2728Ile 
Thr3013Ile 
Val3091Ile 
Asn3124Ile 
ATGg-ATT 
cGTT-ATT 
ACA-ATA 
AGA-ATA 
AAT-ATT 
tGTT-ATT 
ATGt-ATA 
ACA-ATA 
ACT-ATT 
AGT-ATT 
AGT-ATT 
ACC-ATC 
ATGg-ATA 
ACT-ATT 
Met1Ile 
Val191Ile 
Thr374Ile 
Arg507Ile 
Asn909Ile 
Val990Ile 
Met1008Ile 
Thr1025Ile 
Thr1163Ile 
Ser1164Ile 
Ser1512Ile 
Thr1561Ile 
Met1652Ile 
Thr1685Ile 
BRCA2 BRCA1 Ovarian 
Cancer 
1 ACT-ATT 
ACA-ATA 
ACA-ATA 
cGTC-ATC 
Thr64Ile 
Thr200Ile 
Thr2515Ile 
Val3091Ile 
cGTT-ATT 
ACA-ATA 
AGT-ATT 
ATGg-ATA 
ACT-ATT 
Val191Ile 
Thr374Ile 
Ser1164Ile 
Met1652Ile 
Thr1685Ile 
BRCA2 PALB2 Breast Cancer 1 ATGc-ATA 
ACT-ATT 
ACA-ATA 
AAC-ATC 
tGTT-ATT 
ACA-ATA 
tGTT-ATT 
ACT-ATT 
cGTC-ATC 
AAC-ATC 
Met1Ile 
Thr64Ile 
Thr200Ile 
Asn924Ile 
Val2109Ile 
Thr2515Ile 
Val2728Ile 
Thr3013Ile 
Val3091Ile 
Asn3124Ile 
ACA-ATA Thr300Ile 
BRCA2 TP53 Breast Cancer 1 ATGc-ATA 
ACT-ATT 
ACA-ATA 
AAC-ATC 
tGTT-ATT 
ACA-ATA 
tGTT-ATT 
ACT-ATT 
cGTC-ATC 
AAC-ATC 
Met1Ile 
Thr64Ile 
Thr200Ile 
Asn924Ile 
Val2109Ile 
Thr2515Ile 
Val2728Ile 
Thr3013Ile 
Val3091Ile 
Asn3124Ile 
tGTC-ATC Val97Ile 
MET PIK3R1 Bowel Cancer 0 ACT-ATT Thr1010Ile ATGt-ATA Met326Ile 
MLH3 MLH1 Bowel Cancer 0 gGTA-ATA Val971Ile ATGt-ATA 
AGT-ATT 
ACT-ATT 
AGT-ATT 
AGC-ATC 
aTTT-ATT 
ACA-ATA 
AGA-ATA 
tTTT-ATT 
Met1Ile 
Ser46Ile 
Thr82Ile 
Ser191Ile 
Ser321Ile 
Phe396Ile 
Thr413Ile 
Arg472Ile 
Phe568Ile 
MSH2 MLH1 Bowel Cancer 1 AGC-ATC 
aGTT-ATT 
AAT-ATT 
ACC-ATC 
tGTT-ATT 
AAT-ATT 
ATGg-ATA 
ATGt-ATT 
Ser13Ile 
Val102Ile 
Asn127Ile 
Thr335Ile 
Val342Ile 
Asn583Ile 
Met688Ile 
Met729Ile 
ATGt-ATA 
AGT-ATT 
ACT-ATT 
AGT-ATT 
AGC-ATC 
aTTT-ATT 
ACA-ATA 
AGA-ATA 
tTTT-ATT 
Met1Ile 
Ser46Ile 
Thr82Ile 
Ser191Ile 
Ser321Ile 
Phe396Ile 
Thr413Ile 
Arg472Ile 
Phe568Ile 
MSH3 MLH1 Bowel Cancer 0 cGTA-ATA Val79Ile ATGt-ATA 
AGT-ATT 
ACT-ATT 
AGT-ATT 
AGC-ATC 
aTTT-ATT 
ACA-ATA 
AGA-ATA 
tTTT-ATT 
Met1Ile 
Ser46Ile 
Thr82Ile 
Ser191Ile 
Ser321Ile 
Phe396Ile 
Thr413Ile 
Arg472Ile 
Phe568Ile 
MSH3 MSH2 Bowel Cancer 0 cGTA-ATA Val79Ile AGC-ATC 
aGTT-ATT 
AAT-ATT 
ACC-ATC 
tGTT-ATT 
AAT-ATT 
ATGg-ATA 
ATGt-ATT 
Ser13Ile 
Val102Ile 
Asn127Ile 
Thr335Ile 
Val342Ile 
Asn583Ile 
Met688Ile 
Met729Ile 
MSH6 MLH1 Bowel Cancer 1 AGC-ATC 
AGT-ATT 
AGT-ATT 
aTTT-ATT 
ACT-ATT 
Ser144Ile 
Ser227Ile 
Ser285Ile 
Phe596Ile 
Thr1219Ile 
ATGt-ATA 
AGT-ATT 
ACT-ATT 
AGT-ATT 
AGC-ATC 
aTTT-ATT 
ACA-ATA 
AGA-ATA 
tTTT-ATT 
Met1Ile 
Ser46Ile 
Thr82Ile 
Ser191Ile 
Ser321Ile 
Phe396Ile 
Thr413Ile 
Arg472Ile 
Phe568Ile 
MSH6 MSH2 Bowel Cancer 1 AGC-ATC 
AGT-ATT 
AGT-ATT 
aTTT-ATT 
ACT-ATT 
Ser144Ile 
Ser227Ile 
Ser285Ile 
Phe596Ile 
Thr1219Ile 
AGC-ATC 
aGTT-ATT 
AAT-ATT 
ACC-ATC 
tGTT-ATT 
AAT-ATT 
Ser13Ile 
Val102Ile 
Asn127Ile 
Thr335Ile 
Val342Ile 
Asn583Ile 
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ATGg-ATA 
ATGt-ATT 
Met688Ile 
Met729Ile 
PMS2 MSH2 Bowel Cancer 1 ATGa-ATA Met622Ile AGC-ATC 
aGTT-ATT 
AAT-ATT 
ACC-ATC 
tGTT-ATT 
AAT-ATT 
ATGg-ATA 
ATGt-ATT 
Ser13Ile 
Val102Ile 
Asn127Ile 
Thr335Ile 
Val342Ile 
Asn583Ile 
Met688Ile 
Met729Ile 
PMS2 MLH1 Bowel Cancer 1 ATGa-ATA Met622Ile ATGt-ATA 
AGT-ATT 
ACT-ATT 
AGT-ATT 
AGC-ATC 
aTTT-ATT 
ACA-ATA 
AGA-ATA 
tTTT-ATT 
Met1Ile 
Ser46Ile 
Thr82Ile 
Ser191Ile 
Ser321Ile 
Phe396Ile 
Thr413Ile 
Arg472Ile 
Phe568Ile 
PMS2 MSH3 Bowel Cancer 0 ATGa-ATA Met622Ile cGTA-ATA Val79Ile 
TP53 PML Breast Cancer 0 tGTC-ATC Val97Ile ACC-ATC Thr28Ile 
XRCC2 RAD51C Breast Cancer 0 cCTA-ATA Leu61Ile ACC-ATC 
ACC-ATC 
Thr102Ile 
Thr102Ile 
Lysine 
Node1 Node2 Cancer Match Node1 codon 
change 
Node1 Amino acid 
changes 
Node2 codon 
change 
Node2 Amino acid 
changes 
ATM TP53 Breast Cancer 0 tCAG-AAG 
AGA-AAA 
AACa-AAG 
Gln654Lys 
Arg1437Lys 
Asn2435Lys 
aGAG-AAG Glu285Lys 
BRCA1 TP53 Breast Cancer 1 ACA-AAA 
ATA-AAA 
AGG-AAG 
tGAA-AAA 
AACc-AAA 
cGAA-AAA 
ACA-AAA 
AATa-AAG 
cGAG-AAG 
aGAG-AAG 
ACA-AAA 
tGAA-AAA 
AGA-AAA 
ATG-AAG 
Thr37Lys 
Ile68Lys 
Arg71Lys 
Glu116Lys 
Asn132Lys 
Glu575Lys 
Thr826Lys 
Asn1236Lys 
Glu1250Lys 
Glu1358Lys 
Thr1691Lys 
Glu1735Lys 
Arg1753Lys 
Met1775Lys 
aGAG-AAG Glu285Lys 
BRCA1 ATM Breast Cancer 1 ACA-AAA 
ATA-AAA 
AGG-AAG 
tGAA-AAA 
AACc-AAA 
cGAA-AAA 
ACA-AAA 
AATa-AAG 
cGAG-AAG 
aGAG-AAG 
ACA-AAA 
tGAA-AAA 
AGA-AAA 
ATG-AAG 
Thr37Lys 
Ile68Lys 
Arg71Lys 
Glu116Lys 
Asn132Lys 
Glu575Lys 
Thr826Lys 
Asn1236Lys 
Glu1250Lys 
Glu1358Lys 
Thr1691Lys 
Glu1735Lys 
Arg1753Lys 
Met1775Lys 
tCAG-AAG 
AGA-AAA 
AACa-AAG 
Gln654Lys 
Arg1437Lys 
Asn2435Lys 
BRCA1 PALB2 Breast Cancer 1 ACA-AAA 
ATA-AAA 
AGG-AAG 
tGAA-AAA 
AACc-AAA 
cGAA-AAA 
ACA-AAA 
AATa-AAG 
cGAG-AAG 
aGAG-AAG 
ACA-AAA 
tGAA-AAA 
AGA-AAA 
ATG-AAG 
Thr37Lys 
Ile68Lys 
Arg71Lys 
Glu116Lys 
Asn132Lys 
Glu575Lys 
Thr826Lys 
Asn1236Lys 
Glu1250Lys 
Glu1358Lys 
Thr1691Lys 
Glu1735Lys 
Arg1753Lys 
Met1775Lys 
tGAA-AAA Glu272Lys 
BRCA1 PALB2 Ovarian 
Cancer 
1 ATG-AAG 
ACA-AAA 
ATA-AAA 
AGG-AAG 
tGAA-AAA 
AACc-AAA 
cGAA-AAA 
AATa-AAG 
Met18Lys 
Thr37Lys 
Ile68Lys 
Arg71Lys 
Glu116Lys 
Asn132Lys 
Glu575Lys 
Asn1236Lys 
tGAA-AAA Glu272Lys 
BRCA2 ATM Breast Cancer 1 ACA-AAA 
ATA-AAA 
AGG-AAG 
tGAA-AAA 
AACc-AAA 
cGAA-AAA 
ACA-AAA 
AATa-AAG 
cGAG-AAG 
aGAG-AAG 
ACA-AAA 
tGAA-AAA 
AGA-AAA 
ATG-AAG 
Thr37Lys 
Ile68Lys 
Arg71Lys 
Glu116Lys 
Asn132Lys 
Glu575Lys 
Thr826Lys 
Asn1236Lys 
Glu1250Lys 
Glu1358Lys 
Thr1691Lys 
Glu1735Lys 
Arg1753Lys 
Met1775Lys 
tCAG-AAG 
AGA-AAA 
AACa-AAG 
Gln654Lys 
Arg1437Lys 
Asn2435Lys 
BRCA2 BRCA1 Breast Cancer 1 tGAA-AAA 
AACg-AAG 
AATa-AAG 
AGA-AAA 
tCAA-AAA 
AGA-AAA 
AGA-AAA 
aGAA-AAA 
aGAA-AAA 
Glu534Lys 
Asn1878Lys 
Asn1880Lys 
Arg2268Lys 
Gln2384Lys 
Arg2488Lys 
Arg2659Lys 
Glu2981Lys 
Glu3002Lys 
ACA-AAA 
ATA-AAA 
AGG-AAG 
tGAA-AAA 
AACc-AAA 
cGAA-AAA 
ACA-AAA 
AATa-AAG 
cGAG-AAG 
aGAG-AAG 
ACA-AAA 
tGAA-AAA 
AGA-AAA 
ATG-AAG 
Thr37Lys 
Ile68Lys 
Arg71Lys 
Glu116Lys 
Asn132Lys 
Glu575Lys 
Thr826Lys 
Asn1236Lys 
Glu1250Lys 
Glu1358Lys 
Thr1691Lys 
Glu1735Lys 
Arg1753Lys 
Met1775Lys 
BRCA2 BRCA1 Ovarian 
Cancer 
1 AACg-AAG 
AGA-AAA 
AGA-AAA 
aGAA-AAA 
Asn1878Lys 
Arg2488Lys 
Arg2659Lys 
Glu2981Lys 
ATG-AAG 
ACA-AAA 
ATA-AAA 
AGG-AAG 
Met18Lys 
Thr37Lys 
Ile68Lys 
Arg71Lys 
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tGAA-AAA 
AACc-AAA 
cGAA-AAA 
AATa-AAG 
Glu116Lys 
Asn132Lys 
Glu575Lys 
Asn1236Lys 
BRCA2 PALB2 Breast Cancer 1 tGAA-AAA 
AACg-AAG 
AATa-AAG 
AGA-AAA 
tCAA-AAA 
AGA-AAA 
AGA-AAA 
aGAA-AAA 
aGAA-AAA 
Glu534Lys 
Asn1878Lys 
Asn1880Lys 
Arg2268Lys 
Gln2384Lys 
Arg2488Lys 
Arg2659Lys 
Glu2981Lys 
Glu3002Lys 
tGAA-AAA Glu272Lys 
BRCA2 PALB2 Ovarian 
Cancer 
1 AACg-AAG 
AGA-AAA 
AGA-AAA 
aGAA-AAA 
Asn1878Lys 
Arg2488Lys 
Arg2659Lys 
Glu2981Lys 
tGAA-AAA Glu272Lys 
BRCA2 TP53 Breast Cancer 0 tGAA-AAA 
AACg-AAG 
AATa-AAG 
AGA-AAA 
tCAA-AAA 
AGA-AAA 
AGA-AAA 
aGAA-AAA 
aGAA-AAA 
Glu534Lys 
Asn1878Lys 
Asn1880Lys 
Arg2268Lys 
Gln2384Lys 
Arg2488Lys 
Arg2659Lys 
Glu2981Lys 
Glu3002Lys 
aGAG-AAG Glu285Lys 
EXO1 MLH1 Bowel Cancer 1 tGAG-AAG 
tGAG-AAG 
Glu109Lys 
Glu589Lys 
ATG-AAG 
gGAA-AAA 
ATG-AAG 
tGAG-AAG 
AACt-AAG 
cCAA-AAA 
tGAG-AAG 
AGG-AAG 
ATG-AAG 
Met1Lys 
Glu23Lys 
Met35Lys 
Glu37Lys 
Asn38Lys 
Gln62Lys 
Glu102Lys 
Arg182Lys 
Met458Lys 
EXO1 MSH2 Bowel Cancer 1 tGAG-AAG 
tGAG-AAG 
Glu109Lys 
Glu589Lys 
tGAA-AAA 
tCAG-AAG 
aCAG-AAG 
tGAA-AAA 
tGAA-AAA 
tGAA-AAA 
Glu177Lys 
Gln409Lys 
Gln419Lys 
Glu561Lys 
Glu647Lys 
Glu749Lys 
MLH3 MLH1 Bowel Cancer 1 tGAG-AAG Glu1451Lys ATG-AAG 
gGAA-AAA 
ATG-AAG 
tGAG-AAG 
AACt-AAG 
cCAA-AAA 
tGAG-AAG 
AGG-AAG 
ATG-AAG 
Met1Lys 
Glu23Lys 
Met35Lys 
Glu37Lys 
Asn38Lys 
Gln62Lys 
Glu102Lys 
Arg182Lys 
Met458Lys 
MSH2 MLH1 Bowel Cancer 1 tGAA-AAA 
tCAG-AAG 
aCAG-AAG 
tGAA-AAA 
tGAA-AAA 
tGAA-AAA 
Glu177Lys 
Gln409Lys 
Gln419Lys 
Glu561Lys 
Glu647Lys 
Glu749Lys 
ATG-AAG 
gGAA-AAA 
ATG-AAG 
tGAG-AAG 
AACt-AAG 
cCAA-AAA 
tGAG-AAG 
AGG-AAG 
ATG-AAG 
Met1Lys 
Glu23Lys 
Met35Lys 
Glu37Lys 
Asn38Lys 
Gln62Lys 
Glu102Lys 
Arg182Lys 
Met458Lys 
PTEN TP53 Breast Cancer 0 AGA-AAA Arg161Lys aGAG-AAG Glu285Lys 
Methionine 
Node1 Node2 Cancer Match Node1 codon 
change 
Node1 Amino acid 
changes 
Node2 codon 
change 
Node2 Amino acid 
changes 
BRCA1 BARD1 Breast Cancer 1 tGTG-ATG 
ATTc-ATG 
tGTG-ATG 
Val271Met 
Ile379Met 
Val1534Met 
cGTG-ATG Val507Met 
BRCA1 UBE2I Breast Cancer 1 tGTG-ATG 
ATTc-ATG 
tGTG-ATG 
Val271Met 
Ile379Met 
Val1534Met 
cGTG-ATG Val25Met 
BRCA1 ATM Breast Cancer 0 tGTG-ATG 
ATTc-ATG 
tGTG-ATG 
Val271Met 
Ile379Met 
Val1534Met 
ACG-ATG Thr1156Met 
BRCA1 PALB2 Breast Cancer 1 tGTG-ATG 
ATTc-ATG 
tGTG-ATG 
Val271Met 
Ile379Met 
Val1534Met 
cGTG-ATG 
cGTG-ATG 
Val932Met 
Val1103Met 
BRCA2 BARD1 Breast Cancer 0 ATAa-ATG 
ACG-ATG 
ACG-ATG 
ACG-ATG 
ACG-ATG 
Ile729Met 
Thr1354Met 
Thr1887Met 
Thr1915Met 
Thr3401Met 
cGTG-ATG Val507Met 
BRCA2 ATM Breast Cancer 0 tGTG-ATG 
ATTc-ATG 
tGTG-ATG 
Val271Met 
Ile379Met 
Val1534Met 
ACG-ATG Thr1156Met 
BRCA2 BRCA1 Breast Cancer 0 ATAa-ATG 
ACG-ATG 
ACG-ATG 
ACG-ATG 
ACG-ATG 
Ile729Met 
Thr1354Met 
Thr1887Met 
Thr1915Met 
Thr3401Met 
tGTG-ATG 
ATTc-ATG 
tGTG-ATG 
Val271Met 
Ile379Met 
Val1534Met 
BRCA2 BRCA1 Ovarian 
Cancer 
0 ACG-ATG Thr1887Met AGG-ATG 
tGTG-ATG 
Arg1495Met 
Val1534Met 
BRCA2 PALB2 Breast Cancer 0 ATAa-ATG 
ACG-ATG 
ACG-ATG 
ACG-ATG 
ACG-ATG 
Ile729Met 
Thr1354Met 
Thr1887Met 
Thr1915Met 
Thr3401Met 
cGTG-ATG 
cGTG-ATG 
Val932Met 
Val1103Met 
CHEK2 BRCA2 Breast Cancer 1 ATAg-ATG 
ACG-ATG 
Ile160Met 
Thr476Met 
ATAa-ATG 
ACG-ATG 
ACG-ATG 
ACG-ATG 
Ile729Met 
Thr1354Met 
Thr1915Met 
Thr3401Met 
CHEK2 ATM Breast Cancer 1 ATAg-ATG 
ACG-ATG 
Ile160Met 
Thr476Met 
ACG-ATG Thr1156Met 
CHEK2 BRCA1 Breast Cancer 0 ATAg-ATG 
ACG-ATG 
Ile160Met 
Thr476Met 
tGTG-ATG 
ATTc-ATG 
tGTG-ATG 
Val271Met 
Ile379Met 
Val1534Met 
CHEK2 BRCA1 Breast Cancer 0 ATAg-ATG 
ACG-ATG 
Ile160Met 
Thr476Met 
tGTG-ATG 
ATTc-ATG 
tGTG-ATG 
Val271Met 
Ile379Met 
Val1534Met 
MSH2 MLH1 Bowel Cancer 1 ACG-ATG 
ACG-ATG 
Thr8Met 
Thr44Met 
ACG-ATG 
cGTG-ATG 
Thr117Met 
Val213Met 
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ATTg-ATG 
AAG-ATG 
ATAa-ATG 
Ile145Met 
Lys393Met 
Ile930Met 
cCTG-ATG 
tGTG-ATG 
cTTG-ATG 
Leu317Met 
Val716Met 
Leu724Met 
MSH6 MLH1 Bowel Cancer 1 ATCt-ATG 
AAG-ATG 
ACG-ATG 
ACG-ATG 
Ile725Met 
Lys854Met 
Thr1100Met 
Thr1284Met 
ACG-ATG 
cGTG-ATG 
cCTG-ATG 
tGTG-ATG 
cTTG-ATG 
Thr117Met 
Val213Met 
Leu317Met 
Val716Met 
Leu724Met 
MSH6 MSH2 Bowel Cancer 1 ATCt-ATG 
AAG-ATG 
ACG-ATG 
ACG-ATG 
Ile725Met 
Lys854Met 
Thr1100Met 
Thr1284Met 
ACG-ATG 
ACG-ATG 
ATTg-ATG 
AAG-ATG 
ATAa-ATG 
Thr8Met 
Thr44Met 
Ile145Met 
Lys393Met 
Ile930Met 
MUTYH MSH6 Bowel Cancer 0 tGTG-ATG 
cCTG-ATG 
Val234Met 
Leu420Met 
ATCt-ATG 
AAG-ATG 
ACG-ATG 
ACG-ATG 
Ile725Met 
Lys854Met 
Thr1100Met 
Thr1284Met 
TP53 MSH2 Bowel Cancer 0 aGTG-ATG Val197Met ACG-ATG 
ACG-ATG 
ATTg-ATG 
AAG-ATG 
ATAa-ATG 
Thr8Met 
Thr44Met 
Ile145Met 
Lys393Met 
Ile930Met 
Proline 
Node1 Node2 Cancer Match Node1 codon 
change 
Node1 Amino acid 
changes 
Node2 codon 
change 
Node2 Amino acid 
changes 
ATM TP53 Breast Cancer 0 aTCT-CCT Ser707Pro CTG-CCG 
CCAg-CCG 
Leu188Pro 
Pro301Pro 
BRCA1 TP53 Breast Cancer 1 CTG-CCG 
cTCT-CCT 
CAA-CCA 
CTT-CCT 
gGCA-CCA 
CTC-CCC 
CTG-CCG 
aTCT-CCT 
CGA-CCA 
aGCA-CCA 
CTA-CCA 
CTG-CCG 
CAC-CCC 
Leu28Pro 
Ser114Pro 
Gln544Pro 
Leu623Pro 
Ala1277Pro 
Leu1407Pro 
Leu1564Pro 
Ser1577Pro 
Arg1751Pro 
Ala1752Pro 
Leu1764Pro 
Leu1780Pro 
His1805Pro 
CTG-CCG 
CCAg-CCG 
Leu188Pro 
Pro301Pro 
BRCA1 ATM Breast Cancer 1 CTG-CCG 
cTCT-CCT 
CAA-CCA 
CTT-CCT 
gGCA-CCA 
CTC-CCC 
CTG-CCG 
aTCT-CCT 
CGA-CCA 
aGCA-CCA 
CTA-CCA 
CTG-CCG 
CAC-CCC 
Leu28Pro 
Ser114Pro 
Gln544Pro 
Leu623Pro 
Ala1277Pro 
Leu1407Pro 
Leu1564Pro 
Ser1577Pro 
Arg1751Pro 
Ala1752Pro 
Leu1764Pro 
Leu1780Pro 
His1805Pro 
aTCT-CCT Ser707Pro 
BRCA1 PALB2 Breast Cancer 1 CTG-CCG 
cTCT-CCT 
CAA-CCA 
CTT-CCT 
gGCA-CCA 
CTC-CCC 
CTG-CCG 
aTCT-CCT 
CGA-CCA 
aGCA-CCA 
CTA-CCA 
CTG-CCG 
CAC-CCC 
Leu28Pro 
Ser114Pro 
Gln544Pro 
Leu623Pro 
Ala1277Pro 
Leu1407Pro 
Leu1564Pro 
Ser1577Pro 
Arg1751Pro 
Ala1752Pro 
Leu1764Pro 
Leu1780Pro 
His1805Pro 
CTT-CCT Leu1143Pro 
BRCA2 ATM Breast Cancer 1 CTG-CCG 
cTCT-CCT 
CAA-CCA 
CTT-CCT 
gGCA-CCA 
CTC-CCC 
CTG-CCG 
aTCT-CCT 
CGA-CCA 
aGCA-CCA 
CTA-CCA 
CTG-CCG 
CAC-CCC 
Leu28Pro 
Ser114Pro 
Gln544Pro 
Leu623Pro 
Ala1277Pro 
Leu1407Pro 
Leu1564Pro 
Ser1577Pro 
Arg1751Pro 
Ala1752Pro 
Leu1764Pro 
Leu1780Pro 
His1805Pro 
aTCT-CCT Ser707Pro 
BRCA2 BRCA1 Breast Cancer 1 gGCT-CCT 
tTCA-CCA 
cACT-CCT 
CGC-CCC 
CTT-CCT 
aTCA-CCA 
Ala75Pro 
Ser76Pro 
Thr582Pro 
Arg2336Pro 
Leu2653Pro 
Ser2835Pro 
CTG-CCG 
cTCT-CCT 
CAA-CCA 
CTT-CCT 
gGCA-CCA 
CTC-CCC 
CTG-CCG 
aTCT-CCT 
CGA-CCA 
aGCA-CCA 
CTA-CCA 
CTG-CCG 
CAC-CCC 
Leu28Pro 
Ser114Pro 
Gln544Pro 
Leu623Pro 
Ala1277Pro 
Leu1407Pro 
Leu1564Pro 
Ser1577Pro 
Arg1751Pro 
Ala1752Pro 
Leu1764Pro 
Leu1780Pro 
His1805Pro 
BRCA2 BRCA1 Ovarian 
Cancer 
1 tTCA-CCA 
CGC-CCC 
CTT-CCT 
Ser76Pro 
Arg2336Pro 
Leu2653Pro 
CTG-CCG 
CAA-CCA 
CTT-CCT 
CTC-CCC 
CGA-CCA 
CTA-CCA 
CTG-CCG 
CAC-CCC 
Leu28Pro 
Gln544Pro 
Leu623Pro 
Leu1407Pro 
Arg1751Pro 
Leu1764Pro 
Leu1780Pro 
His1805Pro 
BRCA2 PALB2 Breast Cancer 0 gGCT-CCT 
tTCA-CCA 
cACT-CCT 
CGC-CCC 
aTCA-CCA 
Ala75Pro 
Ser76Pro 
Thr582Pro 
Arg2336Pro 
Ser2835Pro 
CTT-CCT Leu1143Pro 
BRCA2 TP53 Breast Cancer 0 gGCT-CCT 
tTCA-CCA 
cACT-CCT 
CGC-CCC 
CTT-CCT 
aTCA-CCA 
Ala75Pro 
Ser76Pro 
Thr582Pro 
Arg2336Pro 
Leu2653Pro 
Ser2835Pro 
CTG-CCG 
CCAg-CCG 
Leu188Pro 
Pro301Pro 
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CHEK2 BRCA2 Breast Cancer 0 CGG-CCG 
tACC-CCC 
Arg145Pro 
Thr323Pro 
aTCA-CCA Ser2806Pro 
MSH2 MLH1 Bowel Cancer 2 cACA-CCA 
CTT-CCT 
aGCT-CCT 
CTA-CCA 
CTG-CCG 
CTT-CCT 
CTT-CCT 
CTT-CCT 
CTT-CCT 
CTG-CCG 
CTT-CCT 
tACT-CCT 
CGT-CCT 
tACC-CCC 
aGCA-CCA 
CGA-CCA 
CTC-CCC 
CGA-CCA 
Thr33Pro 
Leu93Pro 
Ala107Pro 
Leu173Pro 
Leu175Pro 
Leu187Pro 
Leu310Pro 
Leu341Pro 
Leu387Pro 
Leu421Pro 
Leu440Pro 
Thr441Pro 
Arg524Pro 
Thr552Pro 
Ala636Pro 
Arg680Pro 
Leu687Pro 
Arg711Pro 
CGG-CCG 
CAA-CCA 
CGA-CCA 
CAT-CCT 
gGCT-CCT 
tACA-CCA 
aGCA-CCA 
cTCA-CCA 
aTCC-CCC 
CTG-CCG 
CAC-CCC 
CGT-CCT 
CTT-CCT 
CAG-CCG 
CTT-CCT 
CTC-CCC 
CAG-CCG 
CTC-CCC 
CTC-CCC 
tGCC-CCC 
CTT-CCT 
CTT-CCT 
tGCA-CCA 
CTG-CCG 
CGA-CCA 
cACT-CCT 
CTC-CCC 
aTCT-CCT 
CAC-CCC 
CTA-CCA 
Arg27Pro 
Gln48Pro 
Arg100Pro 
His109Pro 
Ala111Pro 
Thr116Pro 
Ala128Pro 
Ser193Pro 
Ser247Pro 
Leu292Pro 
His329Pro 
Arg385Pro 
Leu393Pro 
Gln542Pro 
Leu549Pro 
Leu550Pro 
Gln562Pro 
Leu574Pro 
Leu582Pro 
Ala586Pro 
Leu588Pro 
Leu622Pro 
Ala623Pro 
Leu636Pro 
Arg659Pro 
Thr662Pro 
Leu676Pro 
Ser692Pro 
His718Pro 
Leu749Pro 
MSH6 MLH1 Bowel Cancer 1 CTG-CCG 
gTCT-CCT 
CTA-CCA 
tGCT-CCT 
Leu449Pro 
Ser666Pro 
Leu792Pro 
Ala1236Pro 
CGG-CCG 
CAA-CCA 
aGCC-CCC 
CGA-CCA 
CAT-CCT 
gGCT-CCT 
tACA-CCA 
aGCA-CCA 
cTCA-CCA 
aTCC-CCC 
CTG-CCG 
CAC-CCC 
CGT-CCT 
CTT-CCT 
CAG-CCG 
CTT-CCT 
CTC-CCC 
CAG-CCG 
CTC-CCC 
CTC-CCC 
tGCC-CCC 
CTT-CCT 
CTT-CCT 
tGCA-CCA 
CTG-CCG 
CGA-CCA 
cACT-CCT 
CTC-CCC 
aTCT-CCT 
CAC-CCC 
CTA-CCA 
Arg27Pro 
Gln48Pro 
Ala92Pro 
Arg100Pro 
His109Pro 
Ala111Pro 
Thr116Pro 
Ala128Pro 
Ser193Pro 
Ser247Pro 
Leu292Pro 
His329Pro 
Arg385Pro 
Leu393Pro 
Gln542Pro 
Leu549Pro 
Leu550Pro 
Gln562Pro 
Leu574Pro 
Leu582Pro 
Ala586Pro 
Leu588Pro 
Leu622Pro 
Ala623Pro 
Leu636Pro 
Arg659Pro 
Thr662Pro 
Leu676Pro 
Ser692Pro 
His718Pro 
Leu749Pro 
MSH6 MSH2 Bowel Cancer 1 gTCT-CCT 
CTA-CCA 
tGCT-CCT 
Ser666Pro 
Leu792Pro 
Ala1236Pro 
cACA-CCA 
CTT-CCT 
aGCT-CCT 
CTA-CCA 
CTG-CCG 
CTT-CCT 
CTT-CCT 
CTT-CCT 
CTT-CCT 
CTG-CCG 
CTT-CCT 
tACT-CCT 
CGT-CCT 
tACC-CCC 
aGCA-CCA 
CGA-CCA 
CTC-CCC 
CGA-CCA 
Thr33Pro 
Leu93Pro 
Ala107Pro 
Leu173Pro 
Leu175Pro 
Leu187Pro 
Leu310Pro 
Leu341Pro 
Leu387Pro 
Leu421Pro 
Leu440Pro 
Thr441Pro 
Arg524Pro 
Thr552Pro 
Ala636Pro 
Arg680Pro 
Leu687Pro 
Arg711Pro 
MUTYH MSH6 Bowel Cancer 0 CAA-CCA Gln454Pro CTG-CCG 
gTCT-CCT 
CTA-CCA 
tGCT-CCT 
Leu449Pro 
Ser666Pro 
Leu792Pro 
Ala1236Pro 
PMS2 MSH2 Bowel Cancer 0 CAG-CCG Gln205Pro cACA-CCA 
CTT-CCT 
aGCT-CCT 
CTA-CCA 
CTG-CCG 
CTT-CCT 
CTT-CCT 
CTT-CCT 
CTT-CCT 
CTG-CCG 
CTT-CCT 
tACT-CCT 
CGT-CCT 
tACC-CCC 
aGCA-CCA 
CGA-CCA 
CTC-CCC 
CGA-CCA 
Thr33Pro 
Leu93Pro 
Ala107Pro 
Leu173Pro 
Leu175Pro 
Leu187Pro 
Leu310Pro 
Leu341Pro 
Leu387Pro 
Leu421Pro 
Leu440Pro 
Thr441Pro 
Arg524Pro 
Thr552Pro 
Ala636Pro 
Arg680Pro 
Leu687Pro 
Arg711Pro 
PMS2 MLH1 Bowel Cancer 1 CAG-CCG Gln205Pro CGG-CCG 
CAA-CCA 
CGA-CCA 
CAT-CCT 
gGCT-CCT 
tACA-CCA 
aGCA-CCA 
cTCA-CCA 
aTCC-CCC 
CTG-CCG 
CAC-CCC 
Arg27Pro 
Gln48Pro 
Arg100Pro 
His109Pro 
Ala111Pro 
Thr116Pro 
Ala128Pro 
Ser193Pro 
Ser247Pro 
Leu292Pro 
His329Pro 
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CGT-CCT 
CTT-CCT 
CAG-CCG 
CTT-CCT 
CTC-CCC 
CAG-CCG 
CTC-CCC 
CTC-CCC 
tGCC-CCC 
CTT-CCT 
CTT-CCT 
tGCA-CCA 
CTG-CCG 
CGA-CCA 
cACT-CCT 
CTC-CCC 
aTCT-CCT 
CAC-CCC 
CTA-CCA 
Arg385Pro 
Leu393Pro 
Gln542Pro 
Leu549Pro 
Leu550Pro 
Gln562Pro 
Leu574Pro 
Leu582Pro 
Ala586Pro 
Leu588Pro 
Leu622Pro 
Ala623Pro 
Leu636Pro 
Arg659Pro 
Thr662Pro 
Leu676Pro 
Ser692Pro 
His718Pro 
Leu749Pro 
Termination 
Node1 Node2 Cancer Match Node1 codon 
change 
Node1 Amino acid 
changes 
Node2 codon 
change 
Node2 Amino acid 
changes 
ATM TP53 Breast Cancer 1 aAGA-TGA 
TGGt-TGA 
aGAA-TAA 
aGAA-TAA 
Arg1039Term 
Trp2845Term 
Glu2990Term 
Glu642Term 
cCAA-TAA 
tGAA-TAA 
TGGc-TGA 
TGG-TAG 
tGAG-TAG 
TGTc-TGA 
Gln38Term 
Glu62Term 
Trp91Term 
Trp146Term 
Glu346Term 
Cys277Term 
CHEK2 BRCA2 Prostate 
Cancer 
0 cGAG-TAG Glu239Term gCAA-TAA 
TACa-TAA 
cAAA-TAA 
TATc-TAA 
Gln84Term 
Tyr1135Term 
Lys1489Term 
Tyr1762Term 
CHEK2 BRCA2 Breast Cancer 2 aGAG-TAG 
tCGA-TGA 
aGAA-TAA 
cCAG-TAG 
Glu64Term 
Arg95Term 
Glu275Term 
Gln510Term 
tGGA-TGA 
TTA-TAA 
TGG-TAG 
TGGt-TGA 
tGAA-TAA 
aGAA-TAA 
tGAA-TAA 
aGAA-TAA 
TACg-TAG 
cGAA-TAA 
aCAA-TAA 
cAAA-TAA 
TACc-TAG 
aGAA-TAA 
TTA-TGA 
TGTc-TGA 
aCAA-TAA 
TGG-TAG 
tCAA-TAA 
aAGA-TGA 
TCA-TAA 
aAAA-TAA 
aCAA-TAA 
cAAG-TAG 
tGAA-TAA 
TTG-TAG 
cCAA-TAA 
TCA-TAA 
tAAG-TAG 
tGAA-TAA 
aGAA-TAA 
aGAA-TAA 
TTA-TGA 
TGGc-TGA 
TTG-TAG 
TCA-TAA 
cCAG-TAG 
aCAA-TAA 
TCA-TGA 
TCA-TAA 
TACa-TAA 
tCAA-TAA 
TCA-TGA 
TCA-TAA 
TGTg-TGA 
tAAA-TAA 
TTA-TGA 
aGAA-TAA 
TGGg-TGA 
TTA-TAA 
gAAG-TAG 
TTA-TGA 
tCAA-TAA 
tCAG-TAG 
gCAG-TAG 
TCA-TGA 
TCA-TGA 
cCAG-TAG 
TTA-TGA 
TCA-TGA 
cCAA-TAA 
aGAA-TAA 
tGAA-TAA 
TTA-TAA 
aCAG-TAG 
TATg-TAG 
aGAA-TAA 
TCA-TGA 
TACa-TAA 
tCAA-TAA 
aGAA-TAA 
TCA-TGA 
TCA-TGA 
gGAA-TAA 
tGAA-TAA 
gGAA-TAA 
TCA-TAA 
TCA-TGA 
cCAA-TAA 
tGAA-TAA 
TGTa-TGA 
Gly4Term 
Leu24Term 
Trp31Term 
Trp31Term 
Glu33Term 
Glu34Term 
Glu45Term 
Glu49Term 
Tyr57Term 
Glu58Term 
Gln66Term 
Lys82Term 
Tyr91Term 
Glu97Term 
Leu105Term 
Cys132Term 
Gln147Term 
Trp194Term 
Gln258Term 
Arg259Term 
Ser273Term 
Lys318Term 
Gln321Term 
Lys385Term 
Glu394Term 
Leu414Term 
Gln421Term 
Ser442Term 
Lys467Term 
Glu475Term 
Glu510Term 
Glu532Term 
Leu557Term 
Trp563Term 
Leu583Term 
Ser611Term 
Gln619Term 
Gln742Term 
Ser744Term 
Ser791Term 
Tyr792Term 
Gln819Term 
Ser846Term 
Ser871Term 
Cys916Term 
Lys944Term 
Leu971Term 
Glu984Term 
Trp993Term 
Leu997Term 
Lys1026Term 
Leu1053Term 
Gln1056Term 
Gln1089Term 
Gln1095Term 
Ser1099Term 
Ser1121Term 
Gln1148Term 
Leu1152Term 
Ser1262Term 
Gln1291Term 
Glu1308Term 
Glu1320Term 
Leu1334Term 
Gln1408Term 
Tyr1480Term 
Glu1518Term 
Ser1630Term 
Tyr1655Term 
Gln1701Term 
Glu1703Term 
Ser1760Term 
Ser1764Term 
Glu1812Term 
Glu1857Term 
Glu1876Term 
Ser1882Term 
Ser1882Term 
Gln1886Term 
Glu1912Term 
Cys1913Term 
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aGAA-TAA 
TTA-TAA 
gGAA-TAA 
TCA-TAA 
TCA-TGA 
TCA-TAA 
cCAG-TAG 
aCAA-TAA 
aCAA-TAA 
cAAA-TAA 
cGAA-TAA 
TCA-TGA 
aGAA-TAA 
cCAA-TAA 
tGGA-TGA 
TTA-TGA 
TCA-TGA 
tCAA-TAA 
aGAA-TAA 
TCA-TGA 
tGAA-TAA 
tAAA-TAA 
TCA-TAA 
tCGA-TGA 
tCAA-TAA 
tCAA-TAA 
TCA-TGA 
gAGA-TGA 
tGAA-TAA 
aCAG-TAG 
gCAA-TAA 
cAAA-TAA 
tCAG-TAG 
aCAG-TAG 
gCGA-TGA 
tCGA-TGA 
tAAA-TAA 
aCAG-TAG 
TGG-TAG 
TGGc-TGA 
TGG-TAG 
TATa-TAA 
TGGa-TGA 
TGTg-TGA 
tCAA-TAA 
TATg-TAG 
cAGA-TGA 
TCG-TAG 
TGTg-TGA 
TCA-TGA 
cCAA-TAA 
TGGt-TGA 
cCAG-TAG 
TTA-TGA 
aGAA-TAA 
TTA-TGA 
TGG-TAG 
cCAA-TAA 
aCAA-TAA 
tGAA-TAA 
aAAA-TAA 
aCAG-TAG 
gCAA-TAA 
gCAA-TAA 
aCAA-TAA 
aCAA-TAA 
aCAA-TAA 
TCA-TAA 
TCA-TGA 
TCA-TAA 
TATt-TAG 
aGGA-TGA 
TACa-TAA 
aCAG-TAG 
aCAA-TAA 
gAAA-TAA 
TATt-TAG 
cGAA-TAA 
TACa-TAA 
TACa-TAG 
TGG-TAG 
tGAG-TAG 
cCAG-TAG 
gCGA-TGA 
tCAA-TAA 
TGG-TAG 
TACg-TAG 
cGAA-TAA 
tAAA-TAA 
aCGA-TGA 
Glu1928Term 
Leu1930Term 
Glu1953Term 
Ser1955Term 
Ser1955Term 
Ser1970Term 
Gln1987Term 
Gln1994Term 
Gln1998Term 
Lys2013Term 
Glu2020Term 
Ser2022Term 
Glu2028Term 
Gln2042Term 
Gly2057Term 
Leu2080Term 
Ser2120Term 
Gln2157Term 
Glu2183Term 
Ser2219Term 
Glu2239Term 
Lys2244Term 
Ser2267Term 
Arg2318Term 
Gln2342Term 
Gln2354Term 
Ser2378Term 
Arg2394Term 
Glu2420Term 
Gln2421Term 
Gln2435Term 
Lys2459Term 
Gln2485Term 
Gln2491Term 
Arg2494Term 
Arg2520Term 
Lys2538Term 
Gln2580Term 
Trp2586Term 
Trp2586Term 
Trp2619Term 
Tyr2621Term 
Trp2626Term 
Cys2636Term 
Gln2655Term 
Tyr2660Term 
Arg2668Term 
Ser2670Term 
Cys2689Term 
Ser2695Term 
Gln2714Term 
Trp2725Term 
Gln2731Term 
Leu2732Term 
Glu2772Term 
Leu2776Term 
Trp2788Term 
Gln2858Term 
Gln2859Term 
Glu2874Term 
Lys2882Term 
Gln2893Term 
Gln2894Term 
Gln2899Term 
Gln2941Term 
Gln2957Term 
Gln2960Term 
Ser2978Term 
Ser2984Term 
Ser2993Term 
Tyr2997Term 
Gly3003Term 
Tyr3006Term 
Gln3026Term 
Gln3037Term 
Lys3083Term 
Tyr3092Term 
Glu3096Term 
Tyr3098Term 
Tyr3098Term 
Trp3106Term 
Glu3111Term 
Gln3126Term 
Arg3128Term 
Gln3156Term 
Trp3191Term 
Tyr3308Term 
Glu3309Term 
Lys3326Term 
Arg3384Term 
CHEK2 ATM Breast Cancer 1 aGAG-TAG 
tCGA-TGA 
aGAA-TAA 
cCAG-TAG 
Glu64Term 
Arg95Term 
Glu275Term 
Gln510Term 
aAGA-TGA 
TGGt-TGA 
aGAA-TAA 
aGAA-TAA 
Arg1039Term 
Trp2845Term 
Glu2990Term 
Glu642Term 
CHEK2 TP53 Breast Cancer 1 aGAG-TAG 
tCGA-TGA 
aGAA-TAA 
cCAG-TAG 
Glu64Term 
Arg95Term 
Glu275Term 
Gln510Term 
cCAA-TAA 
tGAA-TAA 
TGGc-TGA 
TGG-TAG 
tGAG-TAG 
TGTc-TGA 
Gln38Term 
Glu62Term 
Trp91Term 
Trp146Term 
Glu346Term 
Cys277Term 
CHEK2 BRCA1 Breast Cancer 2 aGAG-TAG 
tCGA-TGA 
aGAA-TAA 
cCAG-TAG 
Glu64Term 
Arg95Term 
Glu275Term 
Gln510Term 
TTA-TGA 
aCAA-TAA 
gCAG-TAG 
gGAG-TAG 
TTG-TAG 
aCAG-TAG 
TTA-TAA 
aCAA-TAA 
tCAA-TAA 
TATg-TAG 
TACa-TAA 
cGAA-TAA 
cCAA-TAA 
gCAG-TAG 
Leu3Term 
Gln12Term 
Gln19Term 
Glu29Term 
Leu30Term 
Gln60Term 
Leu63Term 
Gln74Term 
Gln81Term 
Tyr101Term 
Tyr130Term 
Glu143Term 
Gln155Term 
Gln169Term 
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aCAA-TAA 
TGTg-TGA 
tGAG-TAG 
TATc-TAG 
TCA-TGA 
TTA-TGA 
aCAG-TAG 
TGG-TAG 
aAAA-TAA 
TGG-TAG 
tAAG-TAG 
gCAG-TAG 
TCA-TGA 
TGG-TAG 
TGGa-TGA 
tCAG-TAG 
gAAA-TAA 
TCA-TAA 
gGAG-TAG 
tGAG-TAG 
TATt-TAG 
aGAG-TAG 
TTA-TGA 
TGTa-TGA 
tGAA-TAA 
TCA-TAA 
gAAG-TAG 
TTA-TGA 
aGGA-TGA 
tGAG-TAG 
aCAG-TAG 
aCAA-TAA 
tAAA-TAA 
gAGA-TGA 
TCA-TGA 
tCAA-TAA 
tCAG-TAG 
cCAA-TAA 
gCAG-TAG 
tCAA-TAA 
tGAG-TAG 
tCAG-TAG 
aGAA-TAA 
cAAA-TAA 
TTA-TGA 
TCA-TGA 
gAAG-TAG 
tGAA-TAA 
TTG-TAG 
aGAG-TAG 
aAAG-TAG 
cCAA-TAA 
tAAA-TAA 
cAAG-TAG 
aCAG-TAG 
TCA-TGA 
aGAA-TAA 
aGAG-TAG 
aGAA-TAA 
TCA-TAA 
tCAG-TAG 
TTA-TAA 
aGAA-TAA 
cAAG-TAG 
gGGA-TGA 
tCAG-TAG 
TATt-TAG 
gCAG-TAG 
TCA-TGA 
TCA-TAA 
TCA-TGA 
aGAA-TAA 
gGAA-TAA 
aCAA-TAA 
tGAA-TAA 
aCAA-TAA 
aGAA-TAA 
tCAA-TAA 
aCAG-TAG 
TCA-TAA 
tGGA-TGA 
TTA-TAA 
aCAA-TAA 
TATc-TAG 
TCA-TAA 
TCA-TGA 
aGAA-TAA 
TCA-TGA 
tGAA-TAA 
TTG-TAG 
TTA-TGA 
gCAA-TAA 
tGAA-TAA 
TATg-TAG 
tGAA-TAA 
TCA-TGA 
TTA-TGA 
aGAA-TAA 
aCAG-TAG 
tCAG-TAG 
tGAA-TAA 
gGAA-TAA 
aGAG-TAG 
TTG-TAG 
tCAG-TAG 
cCGA-TGA 
aGAG-TAG 
tGAA-TAA 
cGAG-TAG 
TGTc-TGA 
gGAG-TAG 
TTA-TGA 
TCA-TAA 
cCAG-TAG 
tCAG-TAG 
Gln206Term 
Cys226Term 
Glu255Term 
Tyr261Term 
Ser267Term 
Leu283Term 
Gln284Term 
Trp321Term 
Lys338Term 
Trp353Term 
Lys355Term 
Gln356Term 
Ser361Term 
Trp372Term 
Trp372Term 
Gln380Term 
Lys381Term 
Ser398Term 
Glu402Term 
Glu418Term 
Tyr422Term 
Glu427Term 
Leu431Term 
Cys442Term 
Glu445Term 
Ser451Term 
Lys467Term 
Leu474Term 
Gly484Term 
Glu489Term 
Gln491Term 
Gln494Term 
Lys505Term 
Arg507Term 
Ser510Term 
Gln526Term 
Gln534Term 
Gln538Term 
Gln541Term 
Gln544Term 
Glu554Term 
Gln563Term 
Glu577Term 
Lys581Term 
Leu598Term 
Ser603Term 
Lys614Term 
Glu638Term 
Leu639Term 
Glu649Term 
Lys654Term 
Gln657Term 
Lys672Term 
Lys679Term 
Gln687Term 
Ser713Term 
Glu732Term 
Glu733Term 
Glu755Term 
Ser770Term 
Gln780Term 
Leu785Term 
Glu797Term 
Lys812Term 
Gly813Term 
Gln855Term 
Tyr856Term 
Gln858Term 
Ser864Term 
Ser868Term 
Ser868Term 
Glu879Term 
Glu881Term 
Gln895Term 
Glu904Term 
Gln905Term 
Glu908Term 
Gln910Term 
Gln921Term 
Ser955Term 
Gly972Term 
Leu974Term 
Gln975Term 
Tyr978Term 
Ser988Term 
Ser1007Term 
Glu1038Term 
Ser1041Term 
Glu1060Term 
Leu1080Term 
Leu1086Term 
Gln1090Term 
Glu1107Term 
Tyr1113Term 
Glu1114Term 
Ser1130Term 
Leu1133Term 
Glu1134Term 
Gln1135Term 
Gln1144Term 
Glu1158Term 
Glu1172Term 
Glu1185Term 
Leu1198Term 
Gln1200Term 
Arg1203Term 
Glu1214Term 
Glu1221Term 
Glu1250Term 
Cys1251Term 
Glu1258Term 
Leu1261Term 
Ser1262Term 
Gln1273Term 
Gln1281Term 
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TCA-TAA 
aCAG-TAG 
cCAG-TAG 
aCAA-TAA 
cCAG-TAG 
TTG-TAG 
aGAA-TAA 
gCAA-TAA 
TGTg-TGA 
tCAG-TAG 
gCAG-TAG 
gCAA-TAA 
cCAG-TAG 
gGAA-TAA 
tGAA-TAA 
TTA-TGA 
aCAG-TAG 
TACc-TAA 
gCGA-TGA 
aCAA-TAA 
aCAG-TAG 
cCAG-TAG 
gGAA-TAA 
TCA-TGA 
TCA-TAA 
TGGt-TGA 
gGAG-TAG 
gCAA-TAA 
aCAG-TAG 
aGAG-TAG 
gGGA-TGA 
TACc-TAG 
tGAA-TAA 
TCA-TGA 
gAAA-TAA 
cCAA-TAA 
aGAA-TAA 
aGAA-TAA 
cAAG-TAG 
gAAA-TAA 
tGAG-TAG 
TATt-TAG 
aGGA-TGA 
TGGg-TGA 
TATt-TAG 
TGG-TAG 
TGGg-TGA 
aGAA-TAA 
aAAA-TAA 
gCGA-TGA 
aGAA-TAA 
cCAG-TAG 
aGAA-TAA 
TATg-TAA 
tCAA-TAA 
gGAA-TAA 
TGG-TAG 
TGGa-TGA 
aCAG-TAG 
gAAG-TAG 
gCAG-TAG 
TGG-TAG 
TGGa-TGA 
aGAG-TAG 
cCGA-TGA 
aGAG-TAG 
TGG-TAG 
TGGg-TGA 
cCAG-TAG 
TGCc-TGA 
TACc-TAG 
Ser1298Term 
Gln1299Term 
Gln1313Term 
Gln1323Term 
Gln1331Term 
Leu1351Term 
Glu1353Term 
Gln1359Term 
Cys1372Term 
Gln1395Term 
Gln1396Term 
Gln1401Term 
Gln1408Term 
Glu1410Term 
Glu1413Term 
Leu1418Term 
Gln1420Term 
Tyr1429Term 
Arg1443Term 
Gln1447Term 
Gln1458Term 
Gln1467Term 
Glu1494Term 
Ser1496Term 
Ser1503Term 
Trp1508Term 
Glu1535Term 
Gln1537Term 
Gln1538Term 
Glu1541Term 
Gly1560Term 
Tyr1563Term 
Glu1581Term 
Ser1587Term 
Lys1601Term 
Gln1604Term 
Glu1644Term 
Glu1661Term 
Lys1667Term 
Lys1690Term 
Glu1694Term 
Tyr1703Term 
Gly1710Term 
Trp1712Term 
Tyr1716Term 
Trp1718Term 
Trp1718Term 
Glu1725Term 
Lys1727Term 
Arg1751Term 
Glu1754Term 
Gln1756Term 
Glu1765Term 
Tyr1769Term 
Gln1779Term 
Glu1781Term 
Trp1782Term 
Trp1782Term 
Gln1785Term 
Lys1793Term 
Gln1811Term 
Trp1815Term 
Trp1815Term 
Glu1817Term 
Arg1835Term 
Glu1836Term 
Trp1837Term 
Trp1837Term 
Gln1846Term 
Cys1847Term 
Tyr1853Term 
MUTYH MSH6 Bowel Cancer 1 TATg-TAA 
gGAG-TAG 
gCAG-TAG 
aCAG-TAG 
cCGA-TGA 
TACg-TAA 
cCAG-TAG 
gGAA-TAA 
Tyr128Term 
Glu196Term 
Gln314Term 
Gln338Term 
Arg97Term 
Tyr104Term 
Gln267Term 
Glu480Term 
aCAG-TAG 
cGGA-TGA 
TGGg-TGA 
TCA-TGA 
TACg-TAA 
TACg-TAG 
aCAG-TAG 
aCAA-TAA 
gCGA-TGA 
TCA-TAA 
gGAA-TAA 
tCAA-TAA 
TATg-TAA 
aCGA-TGA 
aCAG-TAG 
gGAG-TAG 
aCGA-TGA 
TCA-TAA 
TCA-TGA 
TGTg-TGA 
TCA-TAA 
aCGA-TGA 
tCAG-TAG 
TTG-TAG 
tCGA-TGA 
cCAA-TAA 
TACc-TAG 
cGAG-TAG 
aCGA-TGA 
aGAA-TAA 
gCGA-TGA 
gCAG-TAG 
tCGA-TGA 
gGAA-TAA 
TACg-TAA 
TATt-TAG 
tCAA-TAA 
cCAG-TAG 
aCGA-TGA 
Gln4Term 
Gly74Term 
Trp142Term 
Ser200Term 
Tyr214Term 
Tyr214Term 
Gln232Term 
Gln236Term 
Arg240Term 
Ser252Term 
Glu272Term 
Gln344Term 
Tyr433Term 
Arg482Term 
Gln485Term 
Glu493Term 
Arg495Term 
Ser612Term 
Ser664Term 
Cys687Term 
Ser702Term 
Arg732Term 
Gln835Term 
Leu905Term 
Arg922Term 
Gln939Term 
Tyr977Term 
Glu995Term 
Arg1005Term 
Glu1023Term 
Arg1035Term 
Gln1048Term 
Arg1068Term 
Glu1119Term 
Tyr1159Term 
Tyr1256Term 
Gln1258Term 
Gln1280Term 
Arg1331Term 
PMS1 MLH1 Bowel Cancer 1 tCAG-TAG Gln233Term TCG-TAG 
cGAG-TAG 
gGAA-TAA 
cCAG-TAG 
Ser2Term 
Glu13Term 
Glu23Term 
Gln26Term 
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tGAG-TAG 
cCAA-TAA 
aGAA-TAA 
gCAG-TAG 
tGAG-TAG 
TATg-TAG 
tCGA-TGA 
tGGA-TGA 
aAAG-TAG 
TACa-TAA 
TACa-TAG 
TCA-TAA 
tGGA-TGA 
tCAA-TAA 
cCAG-TAG 
TTA-TAA 
TCA-TGA 
aAAA-TAA 
tCGA-TGA 
TACt-TAG 
TCA-TAA 
TCA-TGA 
TATg-TAA 
TTG-TAG 
TTA-TGA 
aGAA-TAA 
cCAG-TAG 
cGAG-TAG 
gCAG-TAG 
cCAG-TAG 
aCAG-TAG 
gCAG-TAG 
cAAA-TAA 
cCAG-TAG 
gCAG-TAG 
TCA-TGA 
gAAG-TAG 
cAGA-TGA 
cCGA-TGA 
cCAG-TAG 
aGAA-TAA 
gCAG-TAG 
gGGA-TGA 
tCAG-TAG 
TGGg-TGA 
aCAG-TAG 
TTA-TAA 
TACc-TAA 
tGAA-TAA 
aGAA-TAA 
TACc-TAG 
cCAG-TAG 
cAAA-TAA 
gAAG-TAG 
TATt-TAG 
tCGA-TGA 
TGGg-TGA 
TGCg-TGA 
TATt-TAG 
TCA-TGA 
cCAG-TAG 
gCAG-TAG 
TGG-TAG 
TGGa-TGA 
TGG-TAG 
TGGa-TGA 
TATa-TAA 
tAAA-TAA 
aGAA-TAA 
gCAG-TAG 
TACa-TAG 
Glu37Term 
Gln62Term 
Glu71Term 
Gln86Term 
Glu89Term 
Tyr97Term 
Arg100Term 
Gly122Term 
Lys123Term 
Tyr126Term 
Tyr126Term 
Ser131Term 
Gly133Term 
Gln146Term 
Gln149Term 
Leu166Term 
Ser193Term 
Lys196Term 
Arg226Term 
Tyr251Term 
Ser252Term 
Ser269Term 
Tyr280Term 
Leu284Term 
Leu296Term 
Glu297Term 
Gln301Term 
Glu319Term 
Gln327Term 
Gln382Term 
Gln391Term 
Gln398Term 
Lys402Term 
Gln409Term 
Gln426Term 
Ser459Term 
Lys461Term 
Arg470Term 
Arg487Term 
Gln510Term 
Glu512Term 
Gln516Term 
Gly517Term 
Gln537Term 
Trp538Term 
Gln542Term 
Leu547Term 
Tyr548Term 
Glu557Term 
Glu558Term 
Tyr561Term 
Gln562Term 
Lys604Term 
Lys618Term 
Tyr625Term 
Arg659Term 
Trp666Term 
Cys680Term 
Tyr684Term 
Ser698Term 
Gln700Term 
Gln701Term 
Trp712Term 
Trp712Term 
Trp714Term 
Trp714Term 
Tyr721Term 
Lys732Term 
Glu736Term 
Gln742Term 
Tyr750Term 
PMS2 MSH2 Bowel Cancer 1 TGTg-TGA 
gCAG-TAG 
gCAG-TAG 
tCGA-TGA 
cCAG-TAG 
tCGA-TGA 
tAAA-TAA 
gAAA-TAA 
aCGA-TGA 
gAAG-TAG 
cGAA-TAA 
Cys73Term 
Gln233Term 
Gln235Term 
Arg315Term 
Gln317Term 
Arg563Term 
Lys580Term 
Lys614Term 
Arg628Term 
Lys647Term 
Glu661Term 
gCAG-TAG 
gGAG-TAG 
cGAG-TAG 
gGAG-TAG 
cCAG-TAG 
TACa-TAG 
gCAG-TAG 
tGAA-TAA 
TATa-TAG 
tGAA-TAA 
TCA-TGA 
cCAG-TAG 
aCAG-TAG 
tGAA-TAA 
tCAG-TAG 
cCAG-TAG 
aGGA-TGA 
aGAG-TAG 
aCAG-TAG 
tCAG-TAG 
gAAA-TAA 
gCAG-TAG 
TTA-TGA 
aGAA-TAA 
TCA-TAA 
TCA-TGA 
tGGA-TGA 
aCAG-TAG 
tGAA-TAA 
cCAG-TAG 
gAAA-TAA 
TTG-TAG 
tCAG-TAG 
tGAA-TAA 
tCAG-TAG 
tAAA-TAA 
tCAA-TAA 
aGGA-TGA 
cCAG-TAG 
TGG-TAG 
TGGa-TGA 
aGAG-TAG 
gAGA-TGA 
Gln10Term 
Glu28Term 
Glu48Term 
Glu56Term 
Gln61Term 
Tyr66Term 
Gln76Term 
Glu101Term 
Tyr121Term 
Glu132Term 
Ser142Term 
Gln158Term 
Gln170Term 
Glu177Term 
Gln183Term 
Gln193Term 
Gly204Term 
Glu205Term 
Gln215Term 
Gln239Term 
Lys246Term 
Gln252Term 
Leu277Term 
Glu278Term 
Ser281Term 
Ser281Term 
Gly287Term 
Gln288Term 
Glu290Term 
Gln298Term 
Lys301Term 
Leu302Term 
Gln314Term 
Glu318Term 
Gln324Term 
Lys334Term 
Gln337Term 
Gly338Term 
Gln344Term 
Trp345Term 
Trp345Term 
Glu357Term 
Arg359Term 
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gGAA-TAA 
gCAG-TAG 
aCAA-TAA 
tCGA-TGA 
cCGA-TGA 
tCAA-TAA 
aCAA-TAA 
aCAA-TAA 
TACc-TAA 
cCGA-TGA 
tCAA-TAA 
aCAG-TAG 
gGAA-TAA 
cCAG-TAG 
gAAA-TAA 
TTA-TAA 
cAAG-TAG 
tCAG-TAG 
gGAA-TAA 
TTA-TGA 
tGAA-TAA 
TCA-TGA 
aAGA-TGA 
aGAA-TAA 
aAAG-TAG 
gCAG-TAG 
TTA-TGA 
aCAG-TAG 
TACt-TAG 
tAAA-TAA 
cCAG-TAG 
tGAA-TAA 
tAAA-TAA 
TATg-TAG 
cCAG-TAG 
TATg-TAG 
gCAG-TAG 
tCAG-TAG 
TCA-TGA 
TATg-TAG 
aCGA-TGA 
aCAA-TAA 
TACt-TAG 
aCAG-TAG 
TATa-TAA 
tCGA-TGA 
TGTg-TGA 
tGAG-TAG 
cCGA-TGA 
tCAA-TAA 
gGAA-TAA 
TCA-TAA 
TTA-TGA 
TACg-TAG 
tGGA-TGA 
TGGg-TGA 
TGCa-TGA 
tGAA-TAA 
TTA-TGA 
tCAG-TAG 
tCAA-TAA 
aCAG-TAG 
tGAG-TAG 
aGAA-TAA 
TCG-TAG 
gCAA-TAA 
gCAA-TAA 
tCAG-TAG 
tGAA-TAA 
aCGA-TGA 
Glu364Term 
Gln374Term 
Gln377Term 
Arg383Term 
Arg389Term 
Gln395Term 
Gln397Term 
Gln402Term 
Tyr405Term 
Arg406Term 
Gln413Term 
Gln419Term 
Glu422Term 
Gln429Term 
Lys430Term 
Leu431Term 
Lys449Term 
Gln451Term 
Glu452Term 
Leu458Term 
Glu467Term 
Ser473Term 
Arg482Term 
Glu483Term 
Lys490Term 
Gln493Term 
Leu496Term 
Gln518Term 
Tyr522Term 
Lys537Term 
Gln545Term 
Glu561Term 
Lys567Term 
Tyr570Term 
Gln574Term 
Tyr588Term 
Gln593Term 
Gln601Term 
Ser612Term 
Tyr619Term 
Arg621Term 
Gln629Term 
Tyr656Term 
Gln662Term 
Tyr678Term 
Arg680Term 
Cys697Term 
Glu698Term 
Arg711Term 
Gln718Term 
Glu731Term 
Ser743Term 
Leu744Term 
Tyr757Term 
Gly759Term 
Trp764Term 
Cys778Term 
Glu808Term 
Leu811Term 
Gln816Term 
Gln824Term 
Gln846Term 
Glu852Term 
Glu859Term 
Ser860Term 
Gln861Term 
Gln879Term 
Gln885Term 
Glu914Term 
Arg929Term 
PMS2 MLH1 Bowel Cancer 1 TGTg-TGA 
gCAG-TAG 
gCAG-TAG 
tCGA-TGA 
cCAG-TAG 
tCGA-TGA 
tAAA-TAA 
gAAA-TAA 
aCGA-TGA 
gAAG-TAG 
cGAA-TAA 
Cys73Term 
Gln233Term 
Gln235Term 
Arg315Term 
Gln317Term 
Arg563Term 
Lys580Term 
Lys614Term 
Arg628Term 
Lys647Term 
Glu661Term 
TCG-TAG 
cGAG-TAG 
gGAA-TAA 
cCAG-TAG 
tGAG-TAG 
cCAA-TAA 
aGAA-TAA 
gCAG-TAG 
tGAG-TAG 
TATg-TAG 
tCGA-TGA 
tGGA-TGA 
aAAG-TAG 
TACa-TAA 
TACa-TAG 
TCA-TAA 
tGGA-TGA 
tCAA-TAA 
cCAG-TAG 
TTA-TAA 
TCA-TGA 
aAAA-TAA 
tCGA-TGA 
TACt-TAG 
TCA-TAA 
TCA-TGA 
TATg-TAA 
TTG-TAG 
TTA-TGA 
aGAA-TAA 
cCAG-TAG 
cGAG-TAG 
gCAG-TAG 
cCAG-TAG 
aCAG-TAG 
gCAG-TAG 
cAAA-TAA 
cCAG-TAG 
gCAG-TAG 
TCA-TGA 
gAAG-TAG 
cAGA-TGA 
cCGA-TGA 
cCAG-TAG 
Ser2Term 
Glu13Term 
Glu23Term 
Gln26Term 
Glu37Term 
Gln62Term 
Glu71Term 
Gln86Term 
Glu89Term 
Tyr97Term 
Arg100Term 
Gly122Term 
Lys123Term 
Tyr126Term 
Tyr126Term 
Ser131Term 
Gly133Term 
Gln146Term 
Gln149Term 
Leu166Term 
Ser193Term 
Lys196Term 
Arg226Term 
Tyr251Term 
Ser252Term 
Ser269Term 
Tyr280Term 
Leu284Term 
Leu296Term 
Glu297Term 
Gln301Term 
Glu319Term 
Gln327Term 
Gln382Term 
Gln391Term 
Gln398Term 
Lys402Term 
Gln409Term 
Gln426Term 
Ser459Term 
Lys461Term 
Arg470Term 
Arg487Term 
Gln510Term 
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aGAA-TAA 
gCAG-TAG 
gGGA-TGA 
tCAG-TAG 
TGGg-TGA 
aCAG-TAG 
TTA-TAA 
TACc-TAA 
tGAA-TAA 
aGAA-TAA 
TACc-TAG 
cCAG-TAG 
cAAA-TAA 
gAAG-TAG 
TATt-TAG 
tCGA-TGA 
TGGg-TGA 
TGCg-TGA 
TATt-TAG 
TCA-TGA 
cCAG-TAG 
gCAG-TAG 
TGG-TAG 
TGGa-TGA 
TGG-TAG 
TGGa-TGA 
TATa-TAA 
tAAA-TAA 
aGAA-TAA 
gCAG-TAG 
TACa-TAG 
Glu512Term 
Gln516Term 
Gly517Term 
Gln537Term 
Trp538Term 
Gln542Term 
Leu547Term 
Tyr548Term 
Glu557Term 
Glu558Term 
Tyr561Term 
Gln562Term 
Lys604Term 
Lys618Term 
Tyr625Term 
Arg659Term 
Trp666Term 
Cys680Term 
Tyr684Term 
Ser698Term 
Gln700Term 
Gln701Term 
Trp712Term 
Trp712Term 
Trp714Term 
Trp714Term 
Tyr721Term 
Lys732Term 
Glu736Term 
Gln742Term 
Tyr750Term 
TP53 BARD1 Breast Cancer 0 cCAA-TAA 
tGAA-TAA 
TGGc-TGA 
TGG-TAG 
tGAG-TAG 
TGTc-TGA 
Gln38Term 
Glu62Term 
Trp91Term 
Trp146Term 
Glu346Term 
Cys277Term 
gCAG-TAG Gln564Term 
XRCC2 RAD51C Breast Cancer 1 cCGA-TGA Arg17Term aCAA-TAA 
cCGA-TGA 
aCAA-TAA 
cCGA-TGA 
Gln133Term 
Arg193Term 
Gln222Term 
Arg319Term 
Threonine 
Node1 Node2 Cancer Match Node1 codon 
change 
Node1 Amino acid 
changes 
Node2 codon 
change 
Node2 Amino acid 
changes 
BRCA1 BARD1 Breast Cancer 1 ATG-ACG 
ATT-ACT 
ATG-ACG 
tCCC-ACC 
AAA-ACA 
AAG-ACG 
ATA-ACA 
ATT-ACT 
ATG-ACG 
ATG-ACG 
ATG-ACG 
tGCT-ACT 
tGCA-ACA 
Met1Thr 
Ile15Thr 
Met18Thr 
Pro25Thr 
Lys45Thr 
Lys110Thr 
Ile845Thr 
Ile1391Thr 
Met1628Thr 
Met1652Thr 
Met1783Thr 
Ala1789Thr 
Ala1823Thr 
ATA-ACA Ile509Thr 
BRCA1 ATM Breast Cancer 1 ATG-ACG 
ATT-ACT 
ATG-ACG 
tCCC-ACC 
AAA-ACA 
AAG-ACG 
ATA-ACA 
ATT-ACT 
ATG-ACG 
ATG-ACG 
ATG-ACG 
tGCT-ACT 
tGCA-ACA 
Met1Thr 
Ile15Thr 
Met18Thr 
Pro25Thr 
Lys45Thr 
Lys110Thr 
Ile845Thr 
Ile1391Thr 
Met1628Thr 
Met1652Thr 
Met1783Thr 
Ala1789Thr 
Ala1823Thr 
ATG-ACG 
aGCT-ACT 
ATA-ACA 
AGG-ACG 
gGCA-ACA 
ATT-ACT 
ATG-ACG 
ATG-ACG 
ATT-ACT 
Met779Thr 
Ala1427Thr 
Ile1525Thr 
Arg2105Thr 
Ala2274Thr 
Ile2401Thr 
Met2531Thr 
Met2667Thr 
Ile2914Thr 
BRCA1 PALB2 Breast Cancer 1 ATG-ACG 
ATT-ACT 
ATG-ACG 
tCCC-ACC 
AAA-ACA 
AAG-ACG 
ATA-ACA 
ATT-ACT 
ATG-ACG 
ATG-ACG 
ATG-ACG 
tGCT-ACT 
tGCA-ACA 
Met1Thr 
Ile15Thr 
Met18Thr 
Pro25Thr 
Lys45Thr 
Lys110Thr 
Ile845Thr 
Ile1391Thr 
Met1628Thr 
Met1652Thr 
Met1783Thr 
Ala1789Thr 
Ala1823Thr 
ATA-ACA Ile1180Thr 
BRCA2 BARD1 Breast Cancer 1 cGCT-ACT 
gGCT-ACT 
ATA-ACA 
aCCC-ACC 
AAA-ACA 
ATA-ACA 
AGG-ACG 
AGA-ACA 
aGCC-ACC 
tGCT-ACT 
gGCC-ACC 
ATG-ACG 
Ala248Thr 
Ala495Thr 
Ile505Thr 
Pro920Thr 
Lys1445Thr 
Ile2490Thr 
Arg2602Thr 
Arg2659Thr 
Ala2770Thr 
Ala2786Thr 
Ala2951Thr 
Met3118Thr 
ATA-ACA Ile509Thr 
BRCA2 ATM Breast Cancer 1 ATG-ACG 
ATT-ACT 
ATG-ACG 
tCCC-ACC 
AAA-ACA 
AAG-ACG 
ATA-ACA 
ATT-ACT 
ATG-ACG 
ATG-ACG 
ATG-ACG 
tGCT-ACT 
tGCA-ACA 
Met1Thr 
Ile15Thr 
Met18Thr 
Pro25Thr 
Lys45Thr 
Lys110Thr 
Ile845Thr 
Ile1391Thr 
Met1628Thr 
Met1652Thr 
Met1783Thr 
Ala1789Thr 
Ala1823Thr 
ATG-ACG 
aGCT-ACT 
ATA-ACA 
AGG-ACG 
gGCA-ACA 
ATT-ACT 
ATG-ACG 
ATG-ACG 
ATT-ACT 
Met779Thr 
Ala1427Thr 
Ile1525Thr 
Arg2105Thr 
Ala2274Thr 
Ile2401Thr 
Met2531Thr 
Met2667Thr 
Ile2914Thr 
BRCA2 BRCA1 Breast Cancer 1 cGCT-ACT 
gGCT-ACT 
ATA-ACA 
aCCC-ACC 
Ala248Thr 
Ala495Thr 
Ile505Thr 
Pro920Thr 
ATG-ACG 
ATT-ACT 
ATG-ACG 
tCCC-ACC 
Met1Thr 
Ile15Thr 
Met18Thr 
Pro25Thr 
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AAA-ACA 
ATA-ACA 
AGG-ACG 
AGA-ACA 
aGCC-ACC 
tGCT-ACT 
gGCC-ACC 
ATG-ACG 
Lys1445Thr 
Ile2490Thr 
Arg2602Thr 
Arg2659Thr 
Ala2770Thr 
Ala2786Thr 
Ala2951Thr 
Met3118Thr 
AAA-ACA 
AAG-ACG 
ATA-ACA 
ATT-ACT 
ATG-ACG 
ATG-ACG 
ATG-ACG 
tGCT-ACT 
tGCA-ACA 
Lys45Thr 
Lys110Thr 
Ile845Thr 
Ile1391Thr 
Met1628Thr 
Met1652Thr 
Met1783Thr 
Ala1789Thr 
Ala1823Thr 
BRCA2 BRCA1 Ovarian 
Cancer 
2 ATG-ACG 
gGCT-ACT 
aCCC-ACC 
AGG-ACG 
AGA-ACA 
aGCC-ACC 
Met1Thr 
Ala495Thr 
Pro920Thr 
Arg2602Thr 
Arg2659Thr 
Ala2770Thr 
ATG-ACG 
ATT-ACT 
tCCC-ACC 
AAA-ACA 
ATA-ACA 
ATG-ACG 
ATG-ACG 
tGCT-ACT 
tGCA-ACA 
Met1Thr 
Ile15Thr 
Pro25Thr 
Lys45Thr 
Ile845Thr 
Met1652Thr 
Met1783Thr 
Ala1789Thr 
Ala1823Thr 
BRCA2 PALB2 Breast Cancer 1 cGCT-ACT 
gGCT-ACT 
ATA-ACA 
aCCC-ACC 
AAA-ACA 
ATA-ACA 
AGG-ACG 
AGA-ACA 
aGCC-ACC 
tGCT-ACT 
gGCC-ACC 
ATG-ACG 
Ala248Thr 
Ala495Thr 
Ile505Thr 
Pro920Thr 
Lys1445Thr 
Ile2490Thr 
Arg2602Thr 
Arg2659Thr 
Ala2770Thr 
Ala2786Thr 
Ala2951Thr 
Met3118Thr 
ATA-ACA Ile1180Thr 
CHEK2 ATM Breast Cancer 1 ATA-ACA Ile364Thr ATG-ACG 
aGCT-ACT 
ATA-ACA 
AGG-ACG 
gGCA-ACA 
ATT-ACT 
ATG-ACG 
ATG-ACG 
ATT-ACT 
Met779Thr 
Ala1427Thr 
Ile1525Thr 
Arg2105Thr 
Ala2274Thr 
Ile2401Thr 
Met2531Thr 
Met2667Thr 
Ile2914Thr 
CHEK2 BRCA1 Breast Cancer 1 ATA-ACA Ile364Thr ATG-ACG 
ATT-ACT 
ATG-ACG 
tCCC-ACC 
AAA-ACA 
AAG-ACG 
ATA-ACA 
ATT-ACT 
ATG-ACG 
ATG-ACG 
ATG-ACG 
tGCT-ACT 
tGCA-ACA 
Met1Thr 
Ile15Thr 
Met18Thr 
Pro25Thr 
Lys45Thr 
Lys110Thr 
Ile845Thr 
Ile1391Thr 
Met1628Thr 
Met1652Thr 
Met1783Thr 
Ala1789Thr 
Ala1823Thr 
MLH3 MLH1 Bowel Cancer 1 tGCT-ACT Ala1394Thr ATG-ACG 
ATC-ACC 
AGT-ACT 
gGCT-ACT 
tGCA-ACA 
AAC-ACC 
AAG-ACG 
aCCC-ACC 
ATC-ACC 
cGCT-ACT 
Met1Thr 
Ile25Thr 
Ser295Thr 
Ala441Thr 
Ala492Thr 
Asn551Thr 
Lys618Thr 
Pro640Thr 
Ile655Thr 
Ala681Thr 
MSH2 MLH1 Bowel Cancer 1 gGCG-ACG 
aGCA-ACA 
tGCA-ACA 
ATT-ACT 
aCCA-ACA 
ATT-ACT 
tGCT-ACT 
AAA-ACA 
Ala2Thr 
Ala72Thr 
Ala305Thr 
Ile577Thr 
Pro622Thr 
Ile691Thr 
Ala834Thr 
Lys931Thr 
ATG-ACG 
ATC-ACC 
AGT-ACT 
gGCT-ACT 
tGCA-ACA 
AAC-ACC 
AAG-ACG 
aCCC-ACC 
ATC-ACC 
cGCT-ACT 
Met1Thr 
Ile25Thr 
Ser295Thr 
Ala441Thr 
Ala492Thr 
Asn551Thr 
Lys618Thr 
Pro640Thr 
Ile655Thr 
Ala681Thr 
MSH6 MLH1 Bowel Cancer 1 cCCC-ACC 
ATA-ACA 
Pro1087Thr 
Ile1115Thr 
ATG-ACG 
ATC-ACC 
AGT-ACT 
gGCT-ACT 
tGCA-ACA 
AAC-ACC 
AAG-ACG 
aCCC-ACC 
ATC-ACC 
cGCT-ACT 
Met1Thr 
Ile25Thr 
Ser295Thr 
Ala441Thr 
Ala492Thr 
Asn551Thr 
Lys618Thr 
Pro640Thr 
Ile655Thr 
Ala681Thr 
MSH6 MSH2 Bowel Cancer 0 cCCC-ACC 
ATA-ACA 
Pro1087Thr 
Ile1115Thr 
gGCG-ACG 
aGCA-ACA 
tGCA-ACA 
ATT-ACT 
aCCA-ACA 
ATT-ACT 
tGCT-ACT 
AAA-ACA 
Ala2Thr 
Ala72Thr 
Ala305Thr 
Ile577Thr 
Pro622Thr 
Ile691Thr 
Ala834Thr 
Lys931Thr 
MUTYH MSH6 Bowel Cancer 0 tGCT-ACT 
ACGc-ACC 
Ala473Thr 
Thr477Thr 
cCCC-ACC 
ATA-ACA 
Pro1087Thr 
Ile1115Thr 
TP53 MSH2 Bowel Cancer 0 ATC-ACC Ile195Thr gGCG-ACG 
aGCA-ACA 
tGCA-ACA 
ATT-ACT 
aCCA-ACA 
ATT-ACT 
tGCT-ACT 
AAA-ACA 
Ala2Thr 
Ala72Thr 
Ala305Thr 
Ile577Thr 
Pro622Thr 
Ile691Thr 
Ala834Thr 
Lys931Thr 
PMS1 MLH1 Bowel Cancer 1 ATG-ACG Met394Thr ATG-ACG 
ATC-ACC 
AGT-ACT 
gGCT-ACT 
tGCA-ACA 
AAC-ACC 
AAG-ACG 
aCCC-ACC 
ATC-ACC 
cGCT-ACT 
Met1Thr 
Ile25Thr 
Ser295Thr 
Ala441Thr 
Ala492Thr 
Asn551Thr 
Lys618Thr 
Pro640Thr 
Ile655Thr 
Ala681Thr 
Tyrosine 
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Node1 Node2 Cancer Match Node1 codon 
change 
Node1 Amino acid 
changes 
Node2 codon 
change 
Node2 Amino acid 
changes 
BRCA1 ATM Breast Cancer 1 TGT-TAT 
TGT-TAT 
TGC-TAC 
TGC-TAC 
TGT-TAT 
TGT-TAT 
tGAT-TAT 
tAAC-TAC 
gCAC-TAC 
TCT-TAT 
gCAT-TAT 
aGAT-TAT 
Cys24Tyr 
Cys39Tyr 
Cys44Tyr 
Cys47Tyr 
Cys61Tyr 
Cys64Tyr 
Asp67Tyr 
Asn158Tyr 
His662Tyr 
Ser1253Tyr 
His1421Tyr 
Asp1739Tyr 
TGT-TAT 
tCAT-TAT 
tCAT-TAT 
aGAT-TAT 
Cys107Tyr 
His231Tyr 
His1380Tyr 
Asp1682Tyr 
BRCA2 ATM Breast Cancer 1 TGT-TAT 
TGT-TAT 
TGC-TAC 
TGC-TAC 
TGT-TAT 
TGT-TAT 
tGAT-TAT 
tAAC-TAC 
tCAC-TAC 
gCAC-TAC 
TCT-TAT 
gCAT-TAT 
aGAT-TAT 
aGAT-TAT 
Cys24Tyr 
Cys39Tyr 
Cys44Tyr 
Cys47Tyr 
Cys61Tyr 
Cys64Tyr 
Asp67Tyr 
Asn158Tyr 
His448Tyr 
His662Tyr 
Ser1253Tyr 
His1421Tyr 
Asp1739Tyr 
Asp1778Tyr 
TGT-TAT 
tCAT-TAT 
tCAT-TAT 
aGAT-TAT 
Cys107Tyr 
His231Tyr 
His1380Tyr 
Asp1682Tyr 
BRCA2 BRCA1 Breast Cancer 1 aGAT-TAT 
TGT-TAT 
TGT-TAT 
aGAT-TAT 
aAAT-TAT 
TGT-TAT 
Asp23Tyr 
Cys616Tyr 
Cys822Tyr 
Asp1420Tyr 
Asn1730Tyr 
Cys2605Tyr 
TGT-TAT 
TGT-TAT 
TGC-TAC 
TGC-TAC 
TGT-TAT 
TGT-TAT 
tGAT-TAT 
tAAC-TAC 
gCAC-TAC 
TCT-TAT 
gCAT-TAT 
aGAT-TAT 
Cys24Tyr 
Cys39Tyr 
Cys44Tyr 
Cys47Tyr 
Cys61Tyr 
Cys64Tyr 
Asp67Tyr 
Asn158Tyr 
His662Tyr 
Ser1253Tyr 
His1421Tyr 
Asp1739Tyr 
BRCA2 BRCA1 Ovarian 
Cancer 
1 aGAT-TAT 
aGAT-TAT 
Asp23Tyr 
Asp1420Tyr 
TGT-TAT 
TGC-TAC 
TGT-TAT 
tGAT-TAT 
aGAT-TAT 
Cys24Tyr 
Cys47Tyr 
Cys61Tyr 
Asp67Tyr 
Asp1778Tyr 
BRCA2 BRCA1 Prostate 
Cancer 
0 TGC-TAC Cys1290Tyr tCAC-TAC His448Tyr 
CHEK2 BRCA2 Breast Cancer 1 gAAT-TAT 
gCAC-TAC 
Asn352Tyr 
His371Tyr 
aGAT-TAT 
TGT-TAT 
TGT-TAT 
aGAT-TAT 
aAAT-TAT 
TGT-TAT 
Asp23Tyr 
Cys616Tyr 
Cys822Tyr 
Asp1420Tyr 
Asn1730Tyr 
Cys2605Tyr 
CHEK2 ATM Breast Cancer 0 gAAT-TAT 
gCAC-TAC 
Asn352Tyr 
His371Tyr 
TGT-TAT 
tCAT-TAT 
tCAT-TAT 
aGAT-TAT 
Cys107Tyr 
His231Tyr 
His1380Tyr 
Asp1682Tyr 
CHEK2 BRCA1 Breast Cancer 1 gAAT-TAT 
gCAC-TAC 
Asn352Tyr 
His371Tyr 
TGT-TAT 
TGT-TAT 
TGC-TAC 
TGC-TAC 
TGT-TAT 
TGT-TAT 
tGAT-TAT 
tAAC-TAC 
gCAC-TAC 
TCT-TAT 
gCAT-TAT 
aGAT-TAT 
Cys24Tyr 
Cys39Tyr 
Cys44Tyr 
Cys47Tyr 
Cys61Tyr 
Cys64Tyr 
Asp67Tyr 
Asn158Tyr 
His662Tyr 
Ser1253Tyr 
His1421Tyr 
Asp1739Tyr 
MSH2 MLH1 Bowel Cancer 1 tGAT-TAT 
TCT-TAT 
TGT-TAT 
gGAC-TAC 
aGAT-TAT 
gCAT-TAT 
cAAT-TAT 
aGAT-TAT 
Asp283Tyr 
Ser323Tyr 
Cys333Tyr 
Asp506Tyr 
Asp603Tyr 
His639Tyr 
Asn671Tyr 
Asp748Tyr 
TGT-TAT 
TGT-TAT 
cCAT-TAT 
aCAC-TAC 
Cys39Tyr 
Cys77Tyr 
His264Tyr 
His718Tyr 
MSH6 MLH1 Bowel Cancer 0 TACg-TAT Tyr214Tyr TGT-TAT 
TGT-TAT 
cCAT-TAT 
aCAC-TAC 
Cys39Tyr 
Cys77Tyr 
His264Tyr 
His718Tyr 
MSH6 MSH2 Bowel Cancer 0 TACg-TAT Tyr214Tyr tGAT-TAT 
TCT-TAT 
TGT-TAT 
gGAC-TAC 
aGAT-TAT 
gCAT-TAT 
cAAT-TAT 
aGAT-TAT 
Asp283Tyr 
Ser323Tyr 
Cys333Tyr 
Asp506Tyr 
Asp603Tyr 
His639Tyr 
Asn671Tyr 
Asp748Tyr 
PMS2 MLH1 Bowel Cancer 1 TGT-TAT Cys843Tyr TGT-TAT 
TGT-TAT 
cCAT-TAT 
aCAC-TAC 
Cys39Tyr 
Cys77Tyr 
His264Tyr 
His718Tyr 
Serine 
Node1 Node2 Cancer Match Node1 codon 
change 
Node1 Amino acid 
changes 
Node2 codon 
change 
Node2 Amino acid 
changes 
AR RNASEL Prostate 
Cancer 
0 gACC-TCC Thr559Ser gGGC-AGC Gly59Ser 
ATM NBN Breast Cancer 1 tCCT-TCT 
aCCT-TCT 
tCCT-TCT 
AAT-AGT 
AAC-AGC 
aCCT-TCT 
tGGT-AGT 
AAC-AGC 
ACT-AGT 
Pro604Ser 
Pro872Ser 
Pro884Ser 
Asn975Ser 
Asn2343Ser 
Pro2614Ser 
Gly2765Ser 
Asn3003Ser 
Thr2396Ser 
aCCT-TCT Pro199Ser 
AXIN2 APC Bowel Cancer 0 gGCT-TCT Ala695Ser tCCA-TCA 
TGT-TCT 
aCCT-TCT 
aGGT-AGT 
Pro870Ser 
Cys947Ser 
Pro1467Ser 
Gly1921Ser 
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AAC-AGC Asn2593Ser 
BARD1 MSH6 Breast Cancer 0 gCCC-TCC 
AAT-AGT 
AGGa-AGC 
AAT-AGT 
TGC-TCC 
Pro24Ser 
Asn295Ser 
Arg378Ser 
Asn470Ser 
Cys557Ser 
gGCC-TCC 
TTC-TCC 
Ala25Ser 
Phe340Ser 
BRCA1 MSH3 Bowel Cancer 0 gTGT-AGT Cys39Ser tCCA-TCA Pro681Ser 
BRCA1 BARD1 Breast Cancer 1 TTA-TCA 
gTGT-AGT 
tTGC-AGC 
gTGT-AGT 
TTA-TCA 
tGGC-AGC 
AGGc-AGC 
AAC-AGC 
gCCA-TCA 
TTA-TCA 
ACT-AGT 
AGAg-AGT 
aCCT-TCT 
gGGT-AGT 
tGCC-TCC 
TGG-TCG 
TTT-TCT 
ATC-AGC 
cACC-TCC 
gTGT-AGT 
tGCT-TCT 
Leu22Ser 
Cys39Ser 
Cys44Ser 
Cys61Ser 
Leu63Ser 
Gly275Ser 
Arg331Ser 
Asn656Ser 
Pro684Ser 
Leu892Ser 
Thr1051Ser 
Arg1076Ser 
Pro1150Ser 
Gly1201Ser 
Ala1669Ser 
Trp1718Ser 
Phe1734Ser 
Ile1766Ser 
Thr1773Ser 
Cys1787Ser 
Ala1789Ser 
gCCC-TCC 
AAT-AGT 
AGGa-AGC 
AAT-AGT 
TGC-TCC 
Pro24Ser 
Asn295Ser 
Arg378Ser 
Asn470Ser 
Cys557Ser 
BRCA1 MLH1 Bowel Cancer 
  
0 gTGT-AGT Cys39Ser aGCT-TCT 
AAC-AGC 
AAT-AGT 
tGGC-AGC 
aGGT-AGT 
ATT-AGT 
tCGT-AGT 
TTG-TCG 
AAT-AGT 
AAC-AGC 
aCCC-TCC 
gCCC-TCC 
TTC-TCC 
AGGt-AGC 
Ala29Ser 
Asn38Ser 
Asn64Ser 
Gly98Ser 
Gly101Ser 
Ile216Ser 
Arg265Ser 
Leu272Ser 
Asn338Ser 
Asn635Ser 
Pro640Ser 
Pro648Ser 
Phe656Ser 
Arg755Ser 
BRCA1 MSH2 Bowel Cancer 0 gTGT-AGT Cys39Ser gGGC-AGC 
AAT-AGT 
gCCA-TCA 
cCCT-TCT 
AGAt-AGT 
TAT-TCT 
AAT-AGT 
AAT-AGT 
TCA-TGA 
tGGC-AGC 
aGGT-AGT 
TTT-TCT 
TCC-TTC 
ATT-AGT 
Gly40Ser 
Asn127Ser 
Pro259Ser 
Pro336Ser 
Arg359Ser 
Tyr563Ser 
Asn583Ser 
Asn596Ser 
Ser612Term 
Gly669Ser 
Gly674Ser 
Phe694Ser 
Ser723Phe 
Ile884Ser 
BRCA1 MSH6 Breast Cancer 1 TTA-TCA 
gTGT-AGT 
tTGC-AGC 
gTGT-AGT 
TTA-TCA 
tGGC-AGC 
AGGc-AGC 
AAC-AGC 
TTA-TCA 
ACT-AGT 
AGAg-AGT 
aCCT-TCT 
gGGT-AGT 
tGCC-TCC 
TGG-TCG 
TTT-TCT 
ATC-AGC 
cACC-TCC 
gTGT-AGT 
tGCT-TCT 
Leu22Ser 
Cys39Ser 
Cys44Ser 
Cys61Ser 
Leu63Ser 
Gly275Ser 
Arg331Ser 
Asn656Ser 
Leu892Ser 
Thr1051Ser 
Arg1076Ser 
Pro1150Ser 
Gly1201Ser 
Ala1669Ser 
Trp1718Ser 
Phe1734Ser 
Ile1766Ser 
Thr1773Ser 
Cys1787Ser 
Ala1789Ser 
gGCC-TCC Ala25Ser 
BRCA1 ATM Breast Cancer 1 TTA-TCA 
gTGT-AGT 
tTGC-AGC 
gTGT-AGT 
TTA-TCA 
tGGC-AGC 
AGGc-AGC 
AAC-AGC 
gCCA-TCA 
TTA-TCA 
ACT-AGT 
AGAg-AGT 
aCCT-TCT 
gGGT-AGT 
tGCC-TCC 
TGG-TCG 
TTT-TCT 
ATC-AGC 
cACC-TCC 
gTGT-AGT 
tGCT-TCT 
Leu22Ser 
Cys39Ser 
Cys44Ser 
Cys61Ser 
Leu63Ser 
Gly275Ser 
Arg331Ser 
Asn656Ser 
Pro684Ser 
Leu892Ser 
Thr1051Ser 
Arg1076Ser 
Pro1150Ser 
Gly1201Ser 
Ala1669Ser 
Trp1718Ser 
Phe1734Ser 
Ile1766Ser 
Thr1773Ser 
Cys1787Ser 
Ala1789Ser 
tCCT-TCT 
aCCT-TCT 
tCCT-TCT 
AAT-AGT 
AAC-AGC 
aCCT-TCT 
tGGT-AGT 
AAC-AGC 
ACT-AGT 
Pro604Ser 
Pro872Ser 
Pro884Ser 
Asn975Ser 
Asn2343Ser 
Pro2614Ser 
Gly2765Ser 
Asn3003Ser 
Thr2396Ser 
BRCA1 MSH6 Bowel Cancer 0 gTGT-AGT Cys39Ser TTC-TCC 
gGGC-AGC 
Phe340Ser 
Gly1139Ser 
BRCA1 PALB2 Breast Cancer 1 TTA-TCA 
gTGT-AGT 
tTGC-AGC 
gTGT-AGT 
TTA-TCA 
tGGC-AGC 
AGGc-AGC 
AAC-AGC 
gCCA-TCA 
TTA-TCA 
ACT-AGT 
AGAg-AGT 
aCCT-TCT 
gGGT-AGT 
Leu22Ser 
Cys39Ser 
Cys44Ser 
Cys61Ser 
Leu63Ser 
Gly275Ser 
Arg331Ser 
Asn656Ser 
Pro684Ser 
Leu892Ser 
Thr1051Ser 
Arg1076Ser 
Pro1150Ser 
Gly1201Ser 
tCCC-TCC 
TTA-TCA 
AGGa-AGC 
tCCT-TCT 
tCCA-TCA 
Pro5Ser 
Leu337Ser 
Arg365Ser 
Pro864Ser 
Pro918Ser 
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tGCC-TCC 
TGG-TCG 
TTT-TCT 
ATC-AGC 
cACC-TCC 
gTGT-AGT 
tGCT-TCT 
Ala1669Ser 
Trp1718Ser 
Phe1734Ser 
Ile1766Ser 
Thr1773Ser 
Cys1787Ser 
Ala1789Ser 
BRCA2 BARD1 Breast Cancer 1 tCCT-TCT 
gCCC-TCC 
AAT-AGT 
AAT-AGT 
gGCC-TCC 
TTA-TCA 
AAT-AGT 
Pro222Ser 
Pro375Ser 
Asn588Ser 
Asn2706Ser 
Ala2717Ser 
Leu2805Ser 
Asn2930Ser 
gCCC-TCC 
AAT-AGT 
AGGa-AGC 
AAT-AGT 
TGC-TCC 
Pro24Ser 
Asn295Ser 
Arg378Ser 
Asn470Ser 
Cys557Ser 
BRCA2 ATM Breast Cancer 1 TTA-TCA 
gTGT-AGT 
tTGC-AGC 
gTGT-AGT 
TTA-TCA 
tGGC-AGC 
AGGc-AGC 
AAC-AGC 
gCCA-TCA 
TTA-TCA 
ACT-AGT 
AGAg-AGT 
aCCT-TCT 
gGGT-AGT 
tGCC-TCC 
TGG-TCG 
TTT-TCT 
aGGT-AGT 
ATC-AGC 
cACC-TCC 
gTGT-AGT 
tGCT-TCT 
Leu22Ser 
Cys39Ser 
Cys44Ser 
Cys61Ser 
Leu63Ser 
Gly275Ser 
Arg331Ser 
Asn656Ser 
Pro684Ser 
Leu892Ser 
Thr1051Ser 
Arg1076Ser 
Pro1150Ser 
Gly1201Ser 
Ala1669Ser 
Trp1718Ser 
Phe1734Ser 
Gly1748Ser 
Ile1766Ser 
Thr1773Ser 
Cys1787Ser 
Ala1789Ser 
tCCT-TCT 
aCCT-TCT 
tCCT-TCT 
AAT-AGT 
AAC-AGC 
aCCT-TCT 
tGGT-AGT 
AAC-AGC 
ACT-AGT 
Pro604Ser 
Pro872Ser 
Pro884Ser 
Asn975Ser 
Asn2343Ser 
Pro2614Ser 
Gly2765Ser 
Asn3003Ser 
Thr2396Ser 
BRCA2 PALB2 Breast Cancer 1 tCCT-TCT 
gCCC-TCC 
AAT-AGT 
AAT-AGT 
gGCC-TCC 
TTA-TCA 
AAT-AGT 
Pro222Ser 
Pro375Ser 
Asn588Ser 
Asn2706Ser 
Ala2717Ser 
Leu2805Ser 
Asn2930Ser 
tCCC-TCC 
TTA-TCA 
AGGa-AGC 
tCCT-TCT 
tCCA-TCA 
Pro5Ser 
Leu337Ser 
Arg365Ser 
Pro864Ser 
Pro918Ser 
BRCA2 BRCA1 Breast Cancer 1 tCCT-TCT 
gCCC-TCC 
AAT-AGT 
AAT-AGT 
gGCC-TCC 
TTA-TCA 
AAT-AGT 
Pro222Ser 
Pro375Ser 
Asn588Ser 
Asn2706Ser 
Ala2717Ser 
Leu2805Ser 
Asn2930Ser 
TTA-TCA 
gTGT-AGT 
tTGC-AGC 
gTGT-AGT 
TTA-TCA 
tGGC-AGC 
AGGc-AGC 
AAC-AGC 
gCCA-TCA 
TTA-TCA 
ACT-AGT 
AGAg-AGT 
aCCT-TCT 
gGGT-AGT 
tGCC-TCC 
TGG-TCG 
TTT-TCT 
ATC-AGC 
cACC-TCC 
gTGT-AGT 
tGCT-TCT 
Leu22Ser 
Cys39Ser 
Cys44Ser 
Cys61Ser 
Leu63Ser 
Gly275Ser 
Arg331Ser 
Asn656Ser 
Pro684Ser 
Leu892Ser 
Thr1051Ser 
Arg1076Ser 
Pro1150Ser 
Gly1201Ser 
Ala1669Ser 
Trp1718Ser 
Phe1734Ser 
Ile1766Ser 
Thr1773Ser 
Cys1787Ser 
Ala1789Ser 
BRCA2 BRCA1 Ovarian 
Cancer 
1 aGGC-AGC 
gGCC-TCC 
TTA-TCA 
AAT-AGT 
Gly2508Ser 
Ala2717Ser 
Leu2805Ser 
Asn2930Ser 
gTGT-AGT 
tGGC-AGC 
ACT-AGT 
AGAg-AGT 
tGCC-TCC 
TGG-TCG 
aGGT-AGT 
ATC-AGC 
cACC-TCC 
gTGT-AGT 
Cys61Ser 
Gly275Ser 
Thr1051Ser 
Arg1076Ser 
Ala1669Ser 
Trp1718Ser 
Gly1748Ser 
Ile1766Ser 
Thr1773Ser 
Cys1787Ser 
CDKN2A CDK4 Melanoma 0 gGGT-AGT 
gCCC-TCC 
ATC-AGC 
cGGC-AGC 
AAC-AGC 
gGGC-AGC 
gCCC-TCC 
Gly23Ser 
Pro38Ser 
Ile49Ser 
Gly67Ser 
Asn71Ser 
Gly111Ser 
Pro114Ser 
AAT-AGT Asn41Ser  
CHEK2 BRCA2 Breast Cancer 1 TAC-TCC 
aCCT-TCT 
Tyr390Ser 
Pro426Ser 
tCCT-TCT 
gCCC-TCC 
AAT-AGT 
AAT-AGT 
gGCC-TCC 
TTA-TCA 
AAT-AGT 
Pro222Ser 
Pro375Ser 
Asn588Ser 
Asn2706Ser 
Ala2717Ser 
Leu2805Ser 
Asn2930Ser 
CHEK2 ATM Breast Cancer 1 TAC-TCC 
aCCT-TCT 
Tyr390Ser 
Pro426Ser 
tCCT-TCT 
aCCT-TCT 
tCCT-TCT 
AAT-AGT 
AAC-AGC 
aCCT-TCT 
tGGT-AGT 
AAC-AGC 
ACT-AGT 
Pro604Ser 
Pro872Ser 
Pro884Ser 
Asn975Ser 
Asn2343Ser 
Pro2614Ser 
Gly2765Ser 
Asn3003Ser 
Thr2396Ser 
CHEK2 NBN Breast Cancer 1 TAC-TCC 
aCCT-TCT 
Tyr390Ser 
Pro426Ser 
aCCT-TCT Pro199Ser 
CHEK2 BRCA1 Breast Cancer 1 TAC-TCC 
aCCT-TCT 
Tyr390Ser 
Pro426Ser 
TTA-TCA 
gTGT-AGT 
tTGC-AGC 
gTGT-AGT 
TTA-TCA 
tGGC-AGC 
AGGc-AGC 
AAC-AGC 
gCCA-TCA 
TTA-TCA 
ACT-AGT 
AGAg-AGT 
aCCT-TCT 
gGGT-AGT 
Leu22Ser 
Cys39Ser 
Cys44Ser 
Cys61Ser 
Leu63Ser 
Gly275Ser 
Arg331Ser 
Asn656Ser 
Pro684Ser 
Leu892Ser 
Thr1051Ser 
Arg1076Ser 
Pro1150Ser 
Gly1201Ser 
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tGCC-TCC 
TGG-TCG 
TTT-TCT 
ATC-AGC 
cACC-TCC 
gTGT-AGT 
tGCT-TCT 
Ala1669Ser 
Trp1718Ser 
Phe1734Ser 
Ile1766Ser 
Thr1773Ser 
Cys1787Ser 
Ala1789Ser 
MET CDH1 Stomach 
Cancer 
1 cCCA-TCA Pro1009Ser aGGT-AGT 
tCCA-TCA 
aACT-TCT 
Gly274Ser 
Pro429Ser 
Thr599Ser 
MLH3 MLH1 Bowel Cancer 1 AAT-AGT 
cGGT-AGT 
AAT-AGT 
Asn499Ser 
Gly981Ser 
Asn1007Ser 
aGCT-TCT 
AAC-AGC 
AAT-AGT 
tGGC-AGC 
aGGT-AGT 
ATT-AGT 
tCGT-AGT 
TTG-TCG 
AAT-AGT 
AAC-AGC 
aCCC-TCC 
gCCC-TCC 
TTC-TCC 
AGGt-AGC 
Ala29Ser 
Asn38Ser 
Asn64Ser 
Gly98Ser 
Gly101Ser 
Ile216Ser 
Arg265Ser 
Leu272Ser 
Asn338Ser 
Asn635Ser 
Pro640Ser 
Pro648Ser 
Phe656Ser 
Arg755Ser 
MSH2 MLH1 Bowel Cancer 1 gGGC-AGC 
AAT-AGT 
gCCA-TCA 
cCCT-TCT 
AGAt-AGT 
AAT-AGT 
AAT-AGT 
tGGC-AGC 
aGGT-AGT 
TTT-TCT 
ATT-AGT 
Gly40Ser 
Asn127Ser 
Pro259Ser 
Pro336Ser 
Arg359Ser 
Asn583Ser 
Asn596Ser 
Gly669Ser 
Gly674Ser 
Phe694Ser 
Ile884Ser 
aGCT-TCT 
AAC-AGC 
AAT-AGT 
tGGC-AGC 
aGGT-AGT 
ATT-AGT 
tCGT-AGT 
TTG-TCG 
AAT-AGT 
AAC-AGC 
aCCC-TCC 
gCCC-TCC 
TTC-TCC 
AGGt-AGC 
Ala29Ser 
Asn38Ser 
Asn64Ser 
Gly98Ser 
Gly101Ser 
Ile216Ser 
Arg265Ser 
Leu272Ser 
Asn338Ser 
Asn635Ser 
Pro640Ser 
Pro648Ser 
Phe656Ser 
Arg755Ser 
MSH3 MLH1 Bowel Cancer 0 tCCA-TCA Pro681Ser aGCT-TCT 
AAC-AGC 
AAT-AGT 
tGGC-AGC 
aGGT-AGT 
ATT-AGT 
tCGT-AGT 
TTG-TCG 
AAT-AGT 
AAC-AGC 
aCCC-TCC 
gCCC-TCC 
TTC-TCC 
AGGt-AGC 
Ala29Ser 
Asn38Ser 
Asn64Ser 
Gly98Ser 
Gly101Ser 
Ile216Ser 
Arg265Ser 
Leu272Ser 
Asn338Ser 
Asn635Ser 
Pro640Ser 
Pro648Ser 
Phe656Ser 
Arg755Ser 
MSH3 MSH2 Bowel Cancer 1 tCCA-TCA Pro681Ser gGGC-AGC 
AAT-AGT 
gCCA-TCA 
cCCT-TCT 
AGAt-AGT 
TAT-TCT 
AAT-AGT 
AAT-AGT 
tGGC-AGC 
aGGT-AGT 
TTT-TCT 
ATT-AGT 
Gly40Ser 
Asn127Ser 
Pro259Ser 
Pro336Ser 
Arg359Ser 
Tyr563Ser 
Asn583Ser 
Asn596Ser 
Gly669Ser 
Gly674Ser 
Phe694Ser 
Ile884Ser 
MSH6 MLH1 Bowel Cancer 1 TTC-TCC 
gGGC-AGC 
Phe340Ser 
Gly1139Ser 
aGCT-TCT 
AAC-AGC 
AAT-AGT 
cAGT-GGT 
tGGC-AGC 
aGGT-AGT 
ATT-AGT 
tCGT-AGT 
TTG-TCG 
AAT-AGT 
AAC-AGC 
aCCC-TCC 
gCCC-TCC 
TTC-TCC 
AGGt-AGC 
Ala29Ser 
Asn38Ser 
Asn64Ser 
Ser93Gly 
Gly98Ser 
Gly101Ser 
Ile216Ser 
Arg265Ser 
Leu272Ser 
Asn338Ser 
Asn635Ser 
Pro640Ser 
Pro648Ser 
Phe656Ser 
Arg755Ser 
MSH6 MSH2 Bowel Cancer 1 gGGC-AGC Gly1139Ser gGGC-AGC 
AAT-AGT 
gCCA-TCA 
cCCT-TCT 
AGAt-AGT 
TAT-TCT 
AAT-AGT 
AAT-AGT 
tGGC-AGC 
aGGT-AGT 
TTT-TCT 
ATT-AGT 
Gly40Ser 
Asn127Ser 
Pro259Ser 
Pro336Ser 
Arg359Ser 
Tyr563Ser 
Asn583Ser 
Asn596Ser 
Gly669Ser 
Gly674Ser 
Phe694Ser 
Ile884Ser 
MSH6 MSH2 Bowel Cancer 1 gGGC-AGC Gly1139Ser gGGC-AGC 
AAT-AGT 
gCCA-TCA 
cCCT-TCT 
AGAt-AGT 
TAT-TCT 
AAT-AGT 
AAT-AGT 
tGGC-AGC 
aGGT-AGT 
TTT-TCT 
ATT-AGT 
Gly40Ser 
Asn127Ser 
Pro259Ser 
Pro336Ser 
Arg359Ser 
Tyr563Ser 
Asn583Ser 
Asn596Ser 
Gly669Ser 
Gly674Ser 
Phe694Ser 
Ile884Ser 
MUTYH MSH6 Bowel Cancer 0 TAT-TCT 
AAC-AGC 
Tyr180Ser 
Asn238Ser 
TTC-TCC 
gGGC-AGC 
Phe340Ser 
Gly1139Ser 
MYC BRCA1 Breast_Cancer 1 AAC-AGC Asn26Ser TTA-TCA 
gTGT-AGT 
tTGC-AGC 
gTGT-AGT 
TTA-TCA 
tGGC-AGC 
AGGc-AGC 
AAC-AGC 
Leu22Ser 
Cys39Ser 
Cys44Ser 
Cys61Ser 
Leu63Ser 
Gly275Ser 
Arg331Ser 
Asn656Ser 
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gCCA-TCA 
TTA-TCA 
ACT-AGT 
AGAg-AGT 
aCCT-TCT 
gGGT-AGT 
tGCC-TCC 
TGG-TCG 
TTT-TCT 
ATC-AGC 
cACC-TCC 
gTGT-AGT 
tGCT-TCT 
Pro684Ser 
Leu892Ser 
Thr1051Ser 
Arg1076Ser 
Pro1150Ser 
Gly1201Ser 
Ala1669Ser 
Trp1718Ser 
Phe1734Ser 
Ile1766Ser 
Thr1773Ser 
Cys1787Ser 
Ala1789Ser 
XRCC2 RAD51C Breast_Cancer 0 tGCC-TCC Ala16Ser TTA-TCA Leu219Ser 
Aspartate 
Node1 Node2 Cancer Match Node1 codon 
change 
Node1 Amino acid 
changes 
Node2 codon 
change 
Node2 Amino acid 
changes 
ATM TP53 Breast Cancer 0 GGT-GAT 
aAAT-GAT 
aCAT-GAT 
GGT-GAT 
Gly301Asp 
Asn1356Asp 
His2887Asp 
Gly2891Asp 
GGC-GAC Gly244Asp 
BRCA1 TP53 Breast Cancer 1 GGC-GAC 
cTAT-GAT 
GAAg-GAC 
GGC-GAC 
GAGg-GAC 
GAAg-GAC 
GGT-GAT 
GGT-GAT 
GAGc-GAT 
Gly275Asp 
Tyr465Asp 
Glu827Asp 
Gly960Asp 
Glu1219Asp 
Glu1581Asp 
Gly1748Asp 
Gly1788Asp 
Glu1794Asp 
GGC-GAC Gly244Asp 
BRCA1 CREBBP Ovarian 
Cancer 
0 GGT-GAT 
GTC-GAC 
Gly1788Asp 
Val1804Asp 
cAAC-GAC Asn1978Asp 
BRCA1 ATM Breast Cancer 1 GGC-GAC 
cTAT-GAT 
GAAg-GAC 
GGC-GAC 
GAGg-GAC 
GAAg-GAC 
GGT-GAT 
GGT-GAT 
GAGc-GAT 
Gly275Asp 
Tyr465Asp 
Glu827Asp 
Gly960Asp 
Glu1219Asp 
Glu1581Asp 
Gly1748Asp 
Gly1788Asp 
Glu1794Asp 
GGT-GAT 
aAAT-GAT 
aCAT-GAT 
GGT-GAT 
Gly301Asp 
Asn1356Asp 
His2887Asp 
Gly2891Asp 
BRCA1 PALB2 Breast Cancer 1 GGC-GAC 
cTAT-GAT 
GAAg-GAC 
GGC-GAC 
GAGg-GAC 
GAAg-GAC 
GGT-GAT 
GGT-GAT 
GAGc-GAT 
Gly275Asp 
Tyr465Asp 
Glu827Asp 
Gly960Asp 
Glu1219Asp 
Glu1581Asp 
Gly1748Asp 
Gly1788Asp 
Glu1794Asp 
GAGg-GAC 
GAGt-GAC 
Glu1018Asp 
Glu1083Asp 
BRCA2 ATM Breast Cancer 1 GGC-GAC 
cTAT-GAT 
GAAg-GAC 
GGC-GAC 
GAGg-GAC 
GAAg-GAC 
GGT-GAT 
GGT-GAT 
GAGc-GAT 
Gly275Asp 
Tyr465Asp 
Glu827Asp 
Gly960Asp 
Glu1219Asp 
Glu1581Asp 
Gly1748Asp 
Gly1788Asp 
Glu1794Asp 
GGT-GAT 
aAAT-GAT 
aCAT-GAT 
GGT-GAT 
Gly301Asp 
Asn1356Asp 
His2887Asp 
Gly2891Asp 
BRCA2 TP53 Breast Cancer 1 GGT-GAT 
GGC-GAC 
aTAT-GAT 
GGT-GAT 
Gly1771Asp 
Gly2544Asp 
Tyr2660Asp 
Gly2748Asp 
GGC-GAC Gly244Asp 
BRCA2 BRCA1 Breast Cancer 1 GGT-GAT 
GGC-GAC 
aTAT-GAT 
GGT-GAT 
Gly1771Asp 
Gly2544Asp 
Tyr2660Asp 
Gly2748Asp 
GGC-GAC 
cTAT-GAT 
GAAg-GAC 
GGC-GAC 
GAGg-GAC 
GAAg-GAC 
GGT-GAT 
GGT-GAT 
GAGc-GAT 
Gly275Asp 
Tyr465Asp 
Glu827Asp 
Gly960Asp 
Glu1219Asp 
Glu1581Asp 
Gly1748Asp 
Gly1788Asp 
Glu1794Asp 
BRCA2 BRCA1 Ovarian 
Cancer 
1 GGT-GAT 
GGC-GAC 
GGT-GAT 
GGT-GAT 
Gly1771Asp 
Gly2544Asp 
Gly2748Asp 
Gly2901Asp 
GGT-GAT 
GTC-GAC 
Gly1788Asp 
Val1804Asp 
BRCA2 PALB2 Breast Cancer 0 GGT-GAT 
GGC-GAC 
aTAT-GAT 
GGT-GAT 
Gly1771Asp 
Gly2544Asp 
Tyr2660Asp 
Gly2748Asp 
GAGg-GAC 
GAGt-GAC 
Glu1018Asp 
Glu1083Asp 
MSH6 MLH1 Bowel Cancer 1 GAAg-GAC 
GCT-GAT 
tCAC-GAC 
Glu619Asp 
Ala1021Asp 
His1248Asp 
GAAg-GAT 
gAAC-GAC 
GGC-GAC 
GGT-GAT 
GAGg-GAT 
GCT-GAT 
GTT-GAT 
GGT-GAT 
gTAT-GAT 
gTAC-GAC 
GTT-GAT 
GCC-GAC 
GCC-GAC 
GCC-GAC 
GCT-GAT 
GAGg-GAT 
Glu23Asp 
Asn38Asp 
Gly65Asp 
Gly101Asp 
Glu102Asp 
Ala111Asp 
Val113Asp 
Gly244Asp 
Tyr280Asp 
Tyr293Asp 
Val384Asp 
Ala539Asp 
Ala586Asp 
Ala589Asp 
Ala608Asp 
Glu663Asp 
MSH6 MSH2 Bowel Cancer 0 GAAg-GAC 
GCT-GAT 
tCAC-GAC 
Glu619Asp 
Ala1021Asp 
His1248Asp 
GGT-GAT 
GTT-GAT 
GTT-GAT 
gTAT-GAT 
GGC-GAC 
GAAa-GAT 
GGC-GAC 
GGT-GAT 
GAGc-GAC 
Gly149Asp 
Val161Asp 
Val163Asp 
Tyr165Asp 
Gly322Asp 
Glu464Asp 
Gly669Asp 
Gly674Asp 
Glu878Asp 
PMS2 MSH2 Bowel Cancer 1 GGC-GAC Gly750Asp GGT-GAT 
GTT-GAT 
GTT-GAT 
gTAT-GAT 
GGC-GAC 
GAAa-GAT 
Gly149Asp 
Val161Asp 
Val163Asp 
Tyr165Asp 
Gly322Asp 
Glu464Asp 
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GGC-GAC 
GGT-GAT 
GAGc-GAC 
Gly669Asp 
Gly674Asp 
Glu878Asp 
PMS2 MLH1 Bowel Cancer 1 GGC-GAC Gly750Asp GAAg-GAT 
gAAC-GAC 
GGC-GAC 
GGT-GAT 
GAGg-GAT 
GCT-GAT 
GTT-GAT 
GGT-GAT 
gTAT-GAT 
gTAC-GAC 
GTT-GAT 
GCC-GAC 
GCC-GAC 
GCC-GAC 
GCT-GAT 
GAGg-GAT 
Glu23Asp 
Asn38Asp 
Gly65Asp 
Gly101Asp 
Glu102Asp 
Ala111Asp 
Val113Asp 
Gly244Asp 
Tyr280Asp 
Tyr293Asp 
Val384Asp 
Ala539Asp 
Ala586Asp 
Ala589Asp 
Ala608Asp 
Glu663Asp 
TP53 MSH2 Bowel Cancer 1 GGC-GAC Gly244Asp GGT-GAT 
GTT-GAT 
GTT-GAT 
gTAT-GAT 
GGC-GAC 
GAAa-GAT 
GGC-GAC 
GGT-GAT 
GAGc-GAC 
Gly149Asp 
Val161Asp 
Val163Asp 
Tyr165Asp 
Gly322Asp 
Glu464Asp 
Gly669Asp 
Gly674Asp 
Glu878Asp 
Cysteine 
Node1 Node2 Cancer Match Node1 codon 
change 
Node1 Amino acid 
changes 
Node2 codon 
change 
Node2 Amino acid 
changes 
ATM TP53 Breast Cancer 1 cCGT-TGT 
tCGT-TGT 
TTC-TGC 
aCGT-TGT 
tCGT-TGT 
TTT-TGT 
TCT-TGT 
tCGC-TGC 
gCGC-TGC 
Arg13Cys 
Arg337Cys 
Phe627Cys 
Arg720Cys 
Arg981Cys 
Phe1463Cys 
Ser2592Cys 
Arg2691Cys 
Arg2854Cys 
gCGC-TGC Arg181Cys 
ATM TOPBP1 Breast Cancer 1 cCGT-TGT 
tCGT-TGT 
TTC-TGC 
aCGT-TGT 
tCGT-TGT 
TTT-TGT 
TCT-TGT 
tCGC-TGC 
gCGC-TGC 
Arg13Cys 
Arg337Cys 
Phe627Cys 
Arg720Cys 
Arg981Cys 
Phe1463Cys 
Ser2592Cys 
Arg2691Cys 
Arg2854Cys 
tCGT-TGT Arg309Cys 
BRCA1 TP53 Breast Cancer 1 TAT-TGT 
TAC-TGC 
TGCa-TGT 
gCGT-TGT 
gGGT-TGT 
tAGT-TGT 
gCGT-TGT 
TTC-TGC 
gCGC-TGC 
TCT-TGT 
TAC-TGC 
TAC-TGC 
tAGC-TGC 
TAC-TGC 
Tyr105Cys 
Tyr179Cys 
Cys197Cys 
Arg252Cys 
Gly263Cys 
Ser264Cys 
Arg496Cys 
Phe861Cys 
Arg866Cys 
Ser1241Cys 
Tyr1522Cys 
Tyr1666Cys 
Ser1715Cys 
Tyr1853Cys 
gCGC-TGC Arg181Cys 
BRCA1 TOPBP1 Breast Cancer 1 TAT-TGT 
TAC-TGC 
TGCa-TGT 
gCGT-TGT 
gGGT-TGT 
tAGT-TGT 
gCGT-TGT 
TTC-TGC 
gCGC-TGC 
TCT-TGT 
TAC-TGC 
TAC-TGC 
tAGC-TGC 
TAC-TGC 
Tyr105Cys 
Tyr179Cys 
Cys197Cys 
Arg252Cys 
Gly263Cys 
Ser264Cys 
Arg496Cys 
Phe861Cys 
Arg866Cys 
Ser1241Cys 
Tyr1522Cys 
Tyr1666Cys 
Ser1715Cys 
Tyr1853Cys 
tCGT-TGT Arg309Cys 
BRCA1 TOPBP1 Ovarian 
Cancer 
1 TGCa-TGT 
gCGT-TGT 
TTC-TGC 
gCGC-TGC 
gAGT-TGT 
tAGC-TGC 
TAC-TGC 
Cys197Cys 
Arg496Cys 
Phe861Cys 
Arg866Cys 
Ser1613Cys 
Ser1715Cys 
Tyr1853Cys 
tCGT-TGT Arg309Cys 
BRCA1 PALB2 Breast Cancer 1 TAT-TGT 
TAC-TGC 
TGCa-TGT 
gCGT-TGT 
gGGT-TGT 
tAGT-TGT 
gCGT-TGT 
TTC-TGC 
gCGC-TGC 
TCT-TGT 
TAC-TGC 
TAC-TGC 
tAGC-TGC 
TAC-TGC 
Tyr105Cys 
Tyr179Cys 
Cys197Cys 
Arg252Cys 
Gly263Cys 
Ser264Cys 
Arg496Cys 
Phe861Cys 
Arg866Cys 
Ser1241Cys 
Tyr1522Cys 
Tyr1666Cys 
Ser1715Cys 
Tyr1853Cys 
TAC-TGC Tyr28Cys 
BRCA2 ATM Breast Cancer 1 TAT-TGT 
TAC-TGC 
gCGT-TGT 
gGGT-TGT 
tAGT-TGT 
gCGT-TGT 
TTC-TGC 
gCGC-TGC 
TCT-TGT 
TAC-TGC 
gAGT-TGT 
TAC-TGC 
tAGC-TGC 
TAC-TGC 
Tyr105Cys 
Tyr179Cys 
Arg252Cys 
Gly263Cys 
Ser264Cys 
Arg496Cys 
Phe861Cys 
Arg866Cys 
Ser1241Cys 
Tyr1522Cys 
Ser1613Cys 
Tyr1666Cys 
Ser1715Cys 
Tyr1853Cys 
cCGT-TGT 
tCGT-TGT 
TTC-TGC 
aCGT-TGT 
tCGT-TGT 
TTT-TGT 
TCT-TGT 
tCGC-TGC 
gCGC-TGC 
Arg13Cys 
Arg337Cys 
Phe627Cys 
Arg720Cys 
Arg981Cys 
Phe1463Cys 
Ser2592Cys 
Arg2691Cys 
Arg2854Cys 
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BRCA2 BRCA1 Breast Cancer 1 TAT-TGT 
TCT-TGT 
aCGT-TGT 
TCC-TGC 
TAT-TGT 
tCGT-TGT 
TAC-TGC 
TAT-TGT 
aCGC-TGC 
TAT-TGT 
TAT-TGT 
gAGT-TGT 
Tyr42Cys 
Ser1261Cys 
Arg2034Cys 
Ser2072Cys 
Tyr2094Cys 
Arg2108Cys 
Tyr2222Cys 
Tyr2363Cys 
Arg2502Cys 
Tyr3035Cys 
Tyr3092Cys 
Ser3303Cys 
TAT-TGT 
TAC-TGC 
gCGT-TGT 
gGGT-TGT 
tAGT-TGT 
gCGT-TGT 
TTC-TGC 
gCGC-TGC 
TCT-TGT 
TAC-TGC 
TAC-TGC 
tAGC-TGC 
TAC-TGC 
Tyr105Cys 
Tyr179Cys 
Arg252Cys 
Gly263Cys 
Ser264Cys 
Arg496Cys 
Phe861Cys 
Arg866Cys 
Ser1241Cys 
Tyr1522Cys 
Tyr1666Cys 
Ser1715Cys 
Tyr1853Cys 
BRCA2 BRCA1 Ovarian 
Cancer 
1 aCGT-TGT 
tCGT-TGT 
aCGC-TGC 
Arg2034Cys 
Arg2108Cys 
Arg2502Cys 
TGCa-TGT 
gCGT-TGT 
TTC-TGC 
gCGC-TGC 
gAGT-TGT 
tAGC-TGC 
TAC-TGC 
Cys197Cys 
Arg496Cys 
Phe861Cys 
Arg866Cys 
Ser1613Cys 
Ser1715Cys 
Tyr1853Cys 
BRCA2 PALB2 Breast Cancer 1 TAT-TGT 
TCT-TGT 
aCGT-TGT 
TCC-TGC 
TAT-TGT 
tCGT-TGT 
TAC-TGC 
TAT-TGT 
aCGC-TGC 
TAT-TGT 
TAT-TGT 
gAGT-TGT 
Tyr42Cys 
Ser1261Cys 
Arg2034Cys 
Ser2072Cys 
Tyr2094Cys 
Arg2108Cys 
Tyr2222Cys 
Tyr2363Cys 
Arg2502Cys 
Tyr3035Cys 
Tyr3092Cys 
Ser3303Cys 
TAC-TGC Tyr28Cys 
BRCA2 TP53 Breast Cancer 1 TAT-TGT 
TCT-TGT 
aCGT-TGT 
TCC-TGC 
TAT-TGT 
tCGT-TGT 
TAC-TGC 
TAT-TGT 
aCGC-TGC 
TAT-TGT 
TAT-TGT 
gAGT-TGT 
Tyr42Cys 
Ser1261Cys 
Arg2034Cys 
Ser2072Cys 
Tyr2094Cys 
Arg2108Cys 
Tyr2222Cys 
Tyr2363Cys 
Arg2502Cys 
Tyr3035Cys 
Tyr3092Cys 
Ser3303Cys 
gCGC-TGC Arg181Cys 
CDKN2A CDK4 Melanoma 1 gGGT-TGT 
gCGC-TGC 
tCGC-TGC 
Gly23Cys 
Arg107Cys 
Arg124Cys 
cCGT-TGT Arg24Cys 
CHEK2 BRCA2 Breast Cancer 1 cCGT-TGT Arg346Cys TAT-TGT 
TCT-TGT 
aCGT-TGT 
TCC-TGC 
TAT-TGT 
tCGT-TGT 
TAC-TGC 
TAT-TGT 
aCGC-TGC 
TAT-TGT 
TAT-TGT 
gAGT-TGT 
Tyr42Cys 
Ser1261Cys 
Arg2034Cys 
Ser2072Cys 
Tyr2094Cys 
Arg2108Cys 
Tyr2222Cys 
Tyr2363Cys 
Arg2502Cys 
Tyr3035Cys 
Tyr3092Cys 
Ser3303Cys 
CHEK2 BRCA2 Breast Cancer 1 cCGT-TGT Arg346Cys TAT-TGT 
TCT-TGT 
aCGT-TGT 
TCC-TGC 
TAT-TGT 
tCGT-TGT 
TAC-TGC 
TAT-TGT 
aCGC-TGC 
TAT-TGT 
TAT-TGT 
gAGT-TGT 
Tyr42Cys 
Ser1261Cys 
Arg2034Cys 
Ser2072Cys 
Tyr2094Cys 
Arg2108Cys 
Tyr2222Cys 
Tyr2363Cys 
Arg2502Cys 
Tyr3035Cys 
Tyr3092Cys 
Ser3303Cys 
CHEK2 ATM Breast Cancer 1 cCGT-TGT Arg346Cys cCGT-TGT 
tCGT-TGT 
TTC-TGC 
aCGT-TGT 
tCGT-TGT 
TTT-TGT 
TCT-TGT 
tCGC-TGC 
gCGC-TGC 
Arg13Cys 
Arg337Cys 
Phe627Cys 
Arg720Cys 
Arg981Cys 
Phe1463Cys 
Ser2592Cys 
Arg2691Cys 
Arg2854Cys 
CHEK2 TP53 Breast Cancer 0 cCGT-TGT Arg346Cys gCGC-TGC Arg181Cys 
CHEK2 BRCA1 Breast Cancer 1 cCGT-TGT Arg346Cys TAT-TGT 
TAC-TGC 
TGCa-TGT 
gCGT-TGT 
gGGT-TGT 
tAGT-TGT 
gCGT-TGT 
TTC-TGC 
gCGC-TGC 
TCT-TGT 
TAC-TGC 
TAC-TGC 
tAGC-TGC 
TAC-TGC 
Tyr105Cys 
Tyr179Cys 
Cys197Cys 
Arg252Cys 
Gly263Cys 
Ser264Cys 
Arg496Cys 
Phe861Cys 
Arg866Cys 
Ser1241Cys 
Tyr1522Cys 
Tyr1666Cys 
Ser1715Cys 
Tyr1853Cys 
MLH3 MLH1 Bowel Cancer 1 aCGT-TGT 
tGGT-TGT 
Arg647Cys 
Gly933Cys 
cCGC-TGC 
tCGC-TGC 
tCGT-TGT 
TAT-TGT 
tCGT-TGT 
TCT-TGT 
TAT-TGT 
gCGC-TGC 
Arg18Cys 
Arg217Cys 
Arg265Cys 
Tyr379Cys 
Arg385Cys 
Ser420Cys 
Tyr646Cys 
Arg725Cys 
MSH2 MLH1 Bowel Cancer 1 TAT-TGT 
TAT-TGT 
TCT-TGT 
tGGT-TGT 
TAT-TGT 
Tyr43Cys 
Tyr98Cys 
Ser323Cys 
Gly548Cys 
Tyr619Cys 
cCGC-TGC 
tCGC-TGC 
tCGT-TGT 
TAT-TGT 
tCGT-TGT 
TCT-TGT 
TAT-TGT 
gCGC-TGC 
Arg18Cys 
Arg217Cys 
Arg265Cys 
Tyr379Cys 
Arg385Cys 
Ser420Cys 
Tyr646Cys 
Arg725Cys 
MSH6 MLH1 Bowel Cancer 1 TCC-TGC 
TAC-TGC 
Ser503Cys 
Tyr850Cys 
cCGC-TGC 
tCGC-TGC 
Arg18Cys 
Arg217Cys 
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TAT-TGT 
tCGC-TGC 
Tyr969Cys 
Arg1076Cys 
tCGT-TGT 
TAT-TGT 
tCGT-TGT 
TCT-TGT 
TAT-TGT 
gCGC-TGC 
Arg265Cys 
Tyr379Cys 
Arg385Cys 
Ser420Cys 
Tyr646Cys 
Arg725Cys 
MSH6 MSH2 Bowel Cancer 1 TAC-TGC 
TAT-TGT 
tCGC-TGC 
Tyr850Cys 
Tyr969Cys 
Arg1076Cys 
TAT-TGT 
TAT-TGT 
TCT-TGT 
tGGT-TGT 
TAT-TGT 
Tyr43Cys 
Tyr98Cys 
Ser323Cys 
Gly548Cys 
Tyr619Cys 
MUTYH MSH6 Bowel Cancer 0 cCGT-TGT Arg245Cys TAC-TGC 
TAT-TGT 
tCGC-TGC 
Tyr850Cys 
Tyr969Cys 
Arg1076Cys 
OGG1 XPC Lung Cancer 0 TCC-TGC Ser326Cys tCGT-TGT Arg671Cys 
TP53 MSH2 Gastric Cancer 0 gCGC-TGC Arg283Cys TAT-TGT Tyr408Cys 
XRCC2 RAD51C Breast Cancer 0 TGGc-TGT Trp231Cys tCGT-TGT Arg249Cys 
Glutamine 
Node1 Node2 Cancer Match Node1 codon 
change 
Node1 Amino acid 
changes 
Node2 codon 
change 
Node2 Amino acid 
changes 
AR SMAD4 Breast Cancer 0 CGA-CAA Arg608Gln CAGg-CAA Gln450Gln 
AR BRCA1 Breast Cancer 1 CGA-CAA Arg608Gln cAAG-CAG 
CGG-CAG 
cAAG-CAG 
CATg-CAA 
gAAA-CAA 
CGG-CAG 
CGA-CAA 
Lys519Gln 
Arg841Gln 
Lys918Gln 
His1686Gln 
Lys1690Gln 
Arg1699Gln 
Arg1751Gln 
AR TP53 Breast Cancer 1 CGA-CAA Arg608Gln CGA-CAA 
CGG-CAG 
Arg306Gln 
Arg267Gln 
ATM TP53 Breast Cancer 1 CGA-CAA 
CGG-CAG 
CGA-CAA 
Arg805Gln 
Arg924Gln 
Arg250Gln 
CGA-CAA 
CGG-CAG 
Arg306Gln 
Arg267Gln 
ATM RAD51 Breast Cancer 1 CGA-CAA 
CGG-CAG 
CGA-CAA 
Arg805Gln 
Arg924Gln 
Arg250Gln 
CGG-CAG Arg150Gln 
BRCA1 RAD51 Breast Cancer 1 cAAG-CAG 
cAAG-CAG 
CATg-CAA 
gAAA-CAA 
CGG-CAG 
CGA-CAA 
Lys519Gln 
Lys918Gln 
His1686Gln 
Lys1690Gln 
Arg1699Gln 
Arg1751Gln 
CGG-CAG Arg150Gln 
BRCA1 AURKA Breast Cancer 0 GATa-GAG 
aAAG-GAG 
cAAA-GAA 
gAAA-GAA 
GTG-GAG 
GGA-GAA 
GCG-GAG 
GGA-GAA 
GATg-GAG 
GTG-GAG 
Asp67Glu 
Lys654Glu 
Lys820Glu 
Lys1606Glu 
Val1696Glu 
Gly1706Glu 
Ala1708Glu 
Gly1738Glu 
Asp1739Glu 
Val1838Glu 
GTA-GAA Val377Glu 
BRCA1 TP53 Breast Cancer 1 CAGg-CAA 
cAAG-CAG 
CGG-CAG 
cAAG-CAG 
CATg-CAA 
gAAA-CAA 
CGG-CAG 
CGA-CAA 
Gln262Gln 
Lys519Gln 
Arg841Gln 
Lys918Gln 
His1686Gln 
Lys1690Gln 
Arg1699Gln 
Arg1751Gln 
CGA-CAA 
CGG-CAG 
Arg306Gln 
Arg267Gln 
BRCA1 SMAD4 Breast Cancer 1 CAGg-CAA 
cAAG-CAG 
CGG-CAG 
cAAG-CAG 
CATg-CAA 
gAAA-CAA 
CGG-CAG 
CGA-CAA 
Gln262Gln 
Lys519Gln 
Arg841Gln 
Lys918Gln 
His1686Gln 
Lys1690Gln 
Arg1699Gln 
Arg1751Gln 
CAGg-CAA Gln450Gln 
BRCA1 BRIP1 Breast Cancer 0 GATa-GAG 
aAAG-GAG 
cAAA-GAA 
gAAA-GAA 
GTG-GAG 
GGA-GAA 
GCG-GAG 
GGA-GAA 
GATg-GAG 
GTG-GAG 
Asp67Glu 
Lys654Glu 
Lys820Glu 
Lys1606Glu 
Val1696Glu 
Gly1706Glu 
Ala1708Glu 
Gly1738Glu 
Asp1739Glu 
Val1838Glu 
cCAG-GAG Gln944Glu 
BRCA1 PALB2 Breast Cancer 0 CAGg-CAA 
cAAG-CAG 
CGG-CAG 
cAAG-CAG 
CATg-CAA 
gAAA-CAA 
CGG-CAG 
CGA-CAA 
Gln262Gln 
Lys519Gln 
Arg841Gln 
Lys918Gln 
His1686Gln 
Lys1690Gln 
Arg1699Gln 
Arg1751Gln 
aGAA-CAA Glu672Gln 
BRCA1 ATM Breast Cancer 1 CAGg-CAA 
cAAG-CAG 
CGG-CAG 
cAAG-CAG 
CATg-CAA 
gAAA-CAA 
CGG-CAG 
CGA-CAA 
Gln262Gln 
Lys519Gln 
Arg841Gln 
Lys918Gln 
His1686Gln 
Lys1690Gln 
Arg1699Gln 
Arg1751Gln 
CGA-CAA 
CGG-CAG 
CGA-CAA 
Arg805Gln 
Arg924Gln 
Arg250Gln 
BRCA2 ATM Breast Cancer 1 CAGg-CAA 
cAAG-CAG 
CGG-CAG 
cAAG-CAG 
CGA-CAA 
CATg-CAA 
gAAA-CAA 
CGG-CAG 
CGA-CAA 
Gln262Gln 
Lys519Gln 
Arg841Gln 
Lys918Gln 
Arg1203Gln 
His1686Gln 
Lys1690Gln 
Arg1699Gln 
Arg1751Gln 
CGA-CAA 
CGG-CAG 
CGA-CAA 
Arg805Gln 
Arg924Gln 
Arg250Gln 
BRCA2 RAD51 Breast Cancer 1 cGAG-CAG 
tAAA-CAA 
CGA-CAA 
CGG-CAG 
CGG-CAG 
Glu1895Gln 
Lys2150Gln 
Arg2318Gln 
Arg2784Gln 
Arg3052Gln 
CGG-CAG Arg150Gln 
BRCA2 BRCA1 Breast Cancer 1 cGAG-CAG 
tAAA-CAA 
Glu1895Gln 
Lys2150Gln 
CAGg-CAA 
cAAG-CAG 
Gln262Gln 
Lys519Gln 
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CGA-CAA 
CGG-CAG 
CGG-CAG 
Arg2318Gln 
Arg2784Gln 
Arg3052Gln 
CGG-CAG 
cAAG-CAG 
CATg-CAA 
gAAA-CAA 
CGG-CAG 
CGA-CAA 
Arg841Gln 
Lys918Gln 
His1686Gln 
Lys1690Gln 
Arg1699Gln 
Arg1751Gln 
BRCA2 BRCA1 Ovarian 
Cancer 
1 CGA-CAA Arg2318Gln cAAG-CAG 
CGG-CAG 
cAAG-CAG 
CATg-CAA 
CGG-CAG 
CGA-CAA 
Lys519Gln 
Arg841Gln 
Lys918Gln 
His1686Gln 
Arg1699Gln 
Arg1751Gln 
BRCA2 BRCA1 Prostate 
Cancer 
0 CCA-CAA Pro2347Gln CGA-CAA Arg1203Gln 
BRCA2 PALB2 Breast Cancer 0 cGAG-CAG 
tAAA-CAA 
CGA-CAA 
CGG-CAG 
CGG-CAG 
Glu1895Gln 
Lys2150Gln 
Arg2318Gln 
Arg2784Gln 
Arg3052Gln 
aGAA-CAA Glu672Gln 
BRCA2 TP53 Breast Cancer 1 cGAG-CAG 
tAAA-CAA 
CGA-CAA 
CGG-CAG 
CGG-CAG 
Glu1895Gln 
Lys2150Gln 
Arg2318Gln 
Arg2784Gln 
Arg3052Gln 
CGA-CAA 
CGG-CAG 
Arg306Gln 
Arg267Gln 
CHD1L XRCC1 Lung Cancer 0 CACc-CAG His350Gln CGG-CAG Arg399Gln 
CHEK2 MSH2 Bowel Cancer 1 CGG-CAG Arg145Gln CCG-CAG 
CACg-CAG 
CGG-CAG 
gAAA-CAA 
CATg-CAA 
Pro5Gln 
His46Gln 
Arg243Gln 
Lys246Gln 
His639Gln 
CHEK2 TP53 Breast Cancer 1 CGA-CAA Arg137Gln CGA-CAA 
CGG-CAG 
Arg306Gln 
Arg267Gln 
CHEK2 BRCA1 Breast Cancer 1 CGA-CAA Arg137Gln cAAG-CAG 
CGG-CAG 
cAAG-CAG 
CATg-CAA 
gAAA-CAA 
CGG-CAG 
CGA-CAA 
Lys519Gln 
Arg841Gln 
Lys918Gln 
His1686Gln 
Lys1690Gln 
Arg1699Gln 
Arg1751Gln 
EXO1 MSH2 Bowel Cancer 2 GGA-GAA Gly759Glu GTA-GAA 
cCAA-GAA 
GGA-GAA 
tAAA-GAA 
GTA-GAA 
Val470Glu 
Gln690Glu 
Gly759Glu 
Lys845Glu 
Val923Glu 
MLH3 MLH1 Bowel Cancer 0 aGAA-CAA Glu624Gln aGAG-CAG 
CGA-CAA 
cAAA-CAA 
CGG-CAG 
cAAA-CAA 
CGG-CAG 
CGA-CAA 
CTA-CAA 
Glu199Gln 
Arg226Gln 
Lys286Gln 
Arg389Gln 
Lys443Gln 
Arg474Gln 
Arg659Gln 
Leu749Gln 
MSH2 MLH1 Gastric Cancer 0 tCAA-GAA Gln824Glu CATg-CAG 
tGAA-CAA 
His109Gln 
Glu433Gln 
MSH2 MLH1 Bowel Cancer 1 CCG-CAG 
CACg-CAG 
CGG-CAG 
gAAA-CAA 
CATg-CAA 
Pro5Gln 
His46Gln 
Arg243Gln 
Lys246Gln 
His639Gln 
aGAG-CAG 
CGA-CAA 
cAAA-CAA 
CGG-CAG 
cAAA-CAA 
CGG-CAG 
CGA-CAA 
CTA-CAA 
Glu199Gln 
Arg226Gln 
Lys286Gln 
Arg389Gln 
Lys443Gln 
Arg474Gln 
Arg659Gln 
Leu749Gln 
MSH3 MLH1 Bowel Cancer 1 CGG-CAG Arg949Gln aGAG-CAG 
CGA-CAA 
cAAA-CAA 
CGG-CAG 
cAAA-CAA 
CGG-CAG 
CGA-CAA 
CTA-CAA 
Glu199Gln 
Arg226Gln 
Lys286Gln 
Arg389Gln 
Lys443Gln 
Arg474Gln 
Arg659Gln 
Leu749Gln 
MSH3 MSH2 Bowel Cancer 1 CGG-CAG Arg949Gln CCG-CAG 
CACg-CAG 
CGG-CAG 
gAAA-CAA 
CATg-CAA 
Pro5Gln 
His46Gln 
Arg243Gln 
Lys246Gln 
His639Gln 
MSH6 MLH1 Bowel Cancer 0 tCAG-GAG 
CTG-CAG 
Gln698Glu 
Leu1354Gln 
CATg-CAG 
aGAG-CAG 
CGA-CAA 
cAAA-CAA 
CGG-CAG 
tGAA-CAA 
cAAA-CAA 
CGG-CAG 
CGA-CAA 
CTA-CAA 
His109Gln 
Glu199Gln 
Arg226Gln 
Lys286Gln 
Arg389Gln 
Glu433Gln 
Lys443Gln 
Arg474Gln 
Arg659Gln 
Leu749Gln 
MSH6 MSH2 Bowel Cancer 0 CTG-CAG Leu1354Gln CCG-CAG 
CACg-CAG 
CGG-CAG 
gAAA-CAA 
CATg-CAA 
Pro5Gln 
His46Gln 
Arg243Gln 
Lys246Gln 
His639Gln 
MUTYH MSH6 Bowel Cancer 0 CGG-CAG Arg184Gln CTG-CAG Leu1354Gln 
PMS2 MSH2 Bowel Cancer 1 CGG-CAG Arg20Gln CCG-CAG 
CACg-CAG 
CGG-CAG 
gAAA-CAA 
CATg-CAA 
Pro5Gln 
His46Gln 
Arg243Gln 
Lys246Gln 
His639Gln 
PMS2 MLH1 Bowel Cancer 1 CGG-CAG Arg20Gln aGAG-CAG 
CGA-CAA 
cAAA-CAA 
CGG-CAG 
cAAA-CAA 
CGG-CAG 
CGA-CAA 
CTA-CAA 
Glu199Gln 
Arg226Gln 
Lys286Gln 
Arg389Gln 
Lys443Gln 
Arg474Gln 
Arg659Gln 
Leu749Gln 
PMS2 MSH3 Bowel Cancer 1 CGG-CAG Arg20Gln CGG-CAG Arg949Gln 
TP53 RAD51 Breast Cancer 1 CGA-CAA 
CGG-CAG 
Arg306Gln 
Arg267Gln 
CGG-CAG Arg150Gln 
TP53 CDKN1A Breast Cancer 1 CGA-CAA 
CGG-CAG 
Arg306Gln 
Arg267Gln 
CGA-CAA Arg84Gln 
Leucine 
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Node1 Node2 Cancer Match Node1 codon 
change 
Node1 Amino acid 
changes 
Node2 codon 
change 
Node2 Amino acid 
changes 
AR RNASEL Prostate 
Cancer 
0 CGC-CTC Arg727Leu tATC-CTC Ile97Leu 
ATM TP53 Breast Cancer 1 tGTT-CTT 
aTTC-CTC 
tGTG-TTG 
CCT-CTT 
TCG-TTG 
aTTT-CTT 
Val182Leu 
Phe582Leu 
Val613Leu 
Pro1112Leu 
Ser1383Leu 
Phe858Leu 
CCG-CTG 
CCT-CTT 
Pro82Leu 
Pro278Leu 
ATM NBN Breast Cancer 0 tGTT-CTT 
aTTC-CTC 
tGTG-TTG 
CCT-CTT 
TCG-TTG 
aTTT-CTT 
Val182Leu 
Phe582Leu 
Val613Leu 
Pro1112Leu 
Ser1383Leu 
Phe858Leu 
CCG-CTG Pro266Leu 
BRCA1 FANCD2 Breast Cancer 0 CCA-CTA 
aTTT-CTT 
TTTg-TTA 
CCT-CTT 
aGTA-CTA 
CCT-CTT 
cATA-TTA 
TTTg-TTA 
tGTG-CTG 
CGG-CTG 
Pro359Leu 
Phe461Leu 
Phe486Leu 
Pro1099Leu 
Val1116Leu 
Pro1238Leu 
Ile1593Leu 
Phe1695Leu 
Val1696Leu 
Arg1699Leu 
CTTt-CTG Leu1366Leu 
BRCA1 TP53 Breast Cancer 1 CCA-CTA 
aTTT-CTT 
TTTg-TTA 
CCT-CTT 
aGTA-CTA 
CCT-CTT 
cATA-TTA 
TTTg-TTA 
tGTG-CTG 
CGG-CTG 
Pro359Leu 
Phe461Leu 
Phe486Leu 
Pro1099Leu 
Val1116Leu 
Pro1238Leu 
Ile1593Leu 
Phe1695Leu 
Val1696Leu 
Arg1699Leu 
CCG-CTG 
CCT-CTT 
Pro82Leu 
Pro278Leu 
BRCA1 RAD50 Breast Cancer 0 CCA-CTA 
aTTT-CTT 
TTTg-TTA 
CCT-CTT 
aGTA-CTA 
CCT-CTT 
cATA-TTA 
TTTg-TTA 
tGTG-CTG 
CGG-CTG 
Pro359Leu 
Phe461Leu 
Phe486Leu 
Pro1099Leu 
Val1116Leu 
Pro1238Leu 
Ile1593Leu 
Phe1695Leu 
Val1696Leu 
Arg1699Leu 
tATA-CTA Ile94Leu 
BRCA1 RAD50 Ovarian 
Cancer 
0 aGTA-CTA 
CCT-CTT 
CAT-CTT 
cATA-TTA 
CCA-CTA 
tGTG-CTG 
CGG-CTG 
Val1116Leu 
Pro1238Leu 
His1421Leu 
Ile1593Leu 
Pro1637Leu 
Val1696Leu 
Arg1699Leu 
tATA-CTA Ile94Leu 
BRCA1 ATM Breast Cancer 0 CCA-CTA 
aTTT-CTT 
TTTg-TTA 
CCT-CTT 
aGTA-CTA 
CCT-CTT 
cATA-TTA 
TTTg-TTA 
tGTG-CTG 
CGG-CTG 
Pro359Leu 
Phe461Leu 
Phe486Leu 
Pro1099Leu 
Val1116Leu 
Pro1238Leu 
Ile1593Leu 
Phe1695Leu 
Val1696Leu 
Arg1699Leu 
tGTT-CTT 
aTTC-CTC 
tGTG-TTG 
CCT-CTT 
TCG-TTG 
aTTT-CTT 
Val182Leu 
Phe582Leu 
Val613Leu 
Pro1112Leu 
Ser1383Leu 
Phe858Leu 
BRCA1 ATM Breast Cancer 1 CCA-CTA 
aTTT-CTT 
TTTg-TTA 
CCT-CTT 
aGTA-CTA 
CCT-CTT 
cATA-TTA 
TTTg-TTA 
tGTG-CTG 
CGG-CTG 
Pro359Leu 
Phe461Leu 
Phe486Leu 
Pro1099Leu 
Val1116Leu 
Pro1238Leu 
Ile1593Leu 
Phe1695Leu 
Val1696Leu 
Arg1699Leu 
tGTT-CTT 
aTTC-CTC 
tGTG-TTG 
CCT-CTT 
TCG-TTG 
aTTT-CTT 
Val182Leu 
Phe582Leu 
Val613Leu 
Pro1112Leu 
Ser1383Leu 
Phe858Leu 
BRCA1 PALB2 Breast Cancer 0 CCA-CTA 
aTTT-CTT 
TTTg-TTA 
CCT-CTT 
aGTA-CTA 
CCT-CTT 
cATA-TTA 
TTTg-TTA 
tGTG-CTG 
CGG-CTG 
Pro359Leu 
Phe461Leu 
Phe486Leu 
Pro1099Leu 
Val1116Leu 
Pro1238Leu 
Ile1593Leu 
Phe1695Leu 
Val1696Leu 
Arg1699Leu 
CCC-CTC Pro8Leu 
BRCA2 FANCD2 Breast Cancer 0 gTTT-CTT 
aTTC-CTC 
CAG-CTG 
gCTC-GTC 
TTA-TGA 
TCG-TTG 
TCA-TTA 
aATG-TTG 
gGTA-TTA 
tTTT-CTT 
TCG-TTG 
Phe32Leu 
Phe81Leu 
Gln713Leu 
Leu1019Val 
Leu1152Term 
Ser1172Leu 
Ser1271Leu 
Met1272Leu 
Val2166Leu 
Phe2234Leu 
Ser2670Leu 
CTTt-CTG Leu1366Leu 
BRCA2 ATM Breast Cancer 1 CCA-CTA 
aTTT-CTT 
TTTg-TTA 
CCG-CTG 
CCT-CTT 
aGTA-CTA 
CCT-CTT 
CAT-CTT 
cATA-TTA 
CCA-CTA 
tGTG-CTG 
CGG-CTG 
Pro359Leu 
Phe461Leu 
Phe486Leu 
Pro871Leu 
Pro1099Leu 
Val1116Leu 
Pro1238Leu 
His1421Leu 
Ile1593Leu 
Pro1637Leu 
Val1696Leu 
Arg1699Leu 
tGTT-CTT 
aTTC-CTC 
tGTG-TTG 
CCT-CTT 
TCG-TTG 
aTTT-CTT 
TCA-TTA 
Val182Leu 
Phe582Leu 
Val613Leu 
Pro1112Leu 
Ser1383Leu 
Phe858Leu 
Ser2394Leu 
BRCA2 BRCA1 Breast Cancer 1 gTTT-CTT 
aTTC-CTC 
CAG-CTG 
TCG-TTG 
TCA-TTA 
aATG-TTG 
Phe32Leu 
Phe81Leu 
Gln713Leu 
Ser1172Leu 
Ser1271Leu 
Met1272Leu 
CCA-CTA 
aTTT-CTT 
TTTg-TTA 
CCT-CTT 
aGTA-CTA 
CCT-CTT 
Pro359Leu 
Phe461Leu 
Phe486Leu 
Pro1099Leu 
Val1116Leu 
Pro1238Leu 
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gGTA-TTA 
tTTT-CTT 
TCG-TTG 
Val2166Leu 
Phe2234Leu 
Ser2670Leu 
cATA-TTA 
TTTg-TTA 
tGTG-CTG 
CGG-CTG 
Ile1593Leu 
Phe1695Leu 
Val1696Leu 
Arg1699Leu 
BRCA2 BRCA1 Ovarian 
Cancer 
0 TCA-TTA 
tTTT-CTT 
TCG-TTG 
Ser1271Leu 
Phe2234Leu 
Ser2670Leu 
aGTA-CTA 
CCT-CTT 
CAT-CTT 
cATA-TTA 
CCA-CTA 
tGTG-CTG 
CGG-CTG 
Val1116Leu 
Pro1238Leu 
His1421Leu 
Ile1593Leu 
Pro1637Leu 
Val1696Leu 
Arg1699Leu 
BRCA2 PALB2 Breast Cancer 0 gTTT-CTT 
aTTC-CTC 
CAG-CTG 
TCG-TTG 
TCA-TTA 
gGTA-TTA 
TCG-TTG 
Phe32Leu 
Phe81Leu 
Gln713Leu 
Ser1172Leu 
Ser1271Leu 
Val2166Leu 
Ser2670Leu 
CCC-CTC Pro8Leu 
BRCA2 TP53 Breast Cancer 0 gTTT-CTT 
aTTC-CTC 
CAG-CTG 
TCG-TTG 
TCA-TTA 
aATG-TTG 
gGTA-TTA 
tTTT-CTT 
TCG-TTG 
Phe32Leu 
Phe81Leu 
Gln713Leu 
Ser1172Leu 
Ser1271Leu 
Met1272Leu 
Val2166Leu 
Phe2234Leu 
Ser2670Leu 
CCG-CTG 
CCT-CTT 
Pro82Leu 
Pro278Leu 
CHEK2 BRCA2 Breast Cancer 0 TTCt-TTA 
CCG-CTG 
Phe427Leu 
Pro484Leu 
gTTT-CTT 
aTTC-CTC 
CAG-CTG 
TCG-TTG 
TCA-TTA 
aATG-TTG 
gGTA-TTA 
tTTT-CTT 
TCG-TTG 
Phe32Leu 
Phe81Leu 
Gln713Leu 
Ser1172Leu 
Ser1271Leu 
Met1272Leu 
Val2166Leu 
Phe2234Leu 
Ser2670Leu 
CHEK2 BRCA2 Breast Cancer 0 TTCt-TTA 
CCG-CTG 
Phe427Leu 
Pro484Leu 
gTTT-CTT 
aTTC-CTC 
CAG-CTG 
TCG-TTG 
TCA-TTA 
aATG-TTG 
gGTA-TTA 
tTTT-CTT 
TCG-TTG 
Phe32Leu 
Phe81Leu 
Gln713Leu 
Ser1172Leu 
Ser1271Leu 
Met1272Leu 
Val2166Leu 
Phe2234Leu 
Ser2670Leu 
CHEK2 RAD50 Breast Cancer 0 TTCt-TTA 
CCG-CTG 
Phe427Leu 
Pro484Leu 
tATA-CTA Ile94Leu 
CHEK2 ATM Breast Cancer 0 TTCt-TTA 
CCG-CTG 
Phe427Leu 
Pro484Leu 
tGTT-CTT 
aTTC-CTC 
tGTG-TTG 
CCT-CTT 
TCG-TTG 
aTTT-CTT 
Val182Leu 
Phe582Leu 
Val613Leu 
Pro1112Leu 
Ser1383Leu 
Phe858Leu 
CHEK2 NBN Breast Cancer 1 TTCt-TTA 
CCG-CTG 
Phe427Leu 
Pro484Leu 
CCG-CTG Pro266Leu 
CHEK2 TP53 Breast Cancer 1 TTCt-TTA 
CCG-CTG 
Phe427Leu 
Pro484Leu 
CCG-CTG 
CCT-CTT 
Pro82Leu 
Pro278Leu 
CHEK2 BRCA1 Breast Cancer 0 TTCt-TTA 
CCG-CTG 
Phe427Leu 
Pro484Leu 
CCA-CTA 
aTTT-CTT 
TTTg-TTA 
CCT-CTT 
aGTA-CTA 
CCT-CTT 
cATA-TTA 
TTTg-TTA 
tGTG-CTG 
CGG-CTG 
Pro359Leu 
Phe461Leu 
Phe486Leu 
Pro1099Leu 
Val1116Leu 
Pro1238Leu 
Ile1593Leu 
Phe1695Leu 
Val1696Leu 
Arg1699Leu 
EXO1 MLH1 Bowel Cancer 1 CCT-CTT 
CCG-CTG 
Pro757Leu 
Pro770Leu 
CCA-CTA 
CGA-CTA 
cATA-TTA 
CCC-CTC 
CAG-CTG 
CCG-CTG 
CCC-CTC 
CCC-CTC 
CCT-CTT 
CGA-CTA 
Pro28Leu 
Arg226Leu 
Ile246Leu 
Pro496Leu 
Gln542Leu 
Pro581Leu 
Pro640Leu 
Pro648Leu 
Pro654Leu 
Arg659Leu 
EXO1 PMS2 Bowel Cancer 0 CCT-CTT 
CCG-CTG 
Pro757Leu 
Pro770Leu 
CGA-CTA 
TCG-TTG 
Arg563Leu 
Ser815Leu 
EXO1 MSH2 Bowel Cancer 1 CCT-CTT 
CCG-CTG 
Pro757Leu 
Pro770Leu 
cATG-CTG 
cATG-TTG 
CCT-CTT 
TCA-TTA 
CGT-CTT 
aTTG-CTG 
CCA-CTA 
CCC-CTC 
CCA-CTA 
Met1Leu 
Met1Leu 
Pro349Leu 
Ser473Leu 
Arg524Leu 
Leu556Leu 
Pro622Leu 
Pro670Leu 
Pro696Leu 
FANCD2 NBN Breast Cancer 0 CTTt-CTG Leu1366Leu CCG-CTG Pro266Leu 
FANCD2 ATM Breast Cancer 0 CTTt-CTG Leu1366Leu tGTT-CTT 
aTTC-CTC 
tGTG-TTG 
CCT-CTT 
TCG-TTG 
aTTT-CTT 
Val182Leu 
Phe582Leu 
Val613Leu 
Pro1112Leu 
Ser1383Leu 
Phe858Leu 
MET CDH1 Gastric Cancer 1 CCG-CTG Pro791Leu CCG-CTG 
cATA-CTA 
Pro373Leu 
Ile415Leu 
MSH2 MLH1 Bowel Cancer 1 cATG-CTG 
cATG-TTG 
CCT-CTT 
TCA-TTA 
CGT-CTT 
aTTG-CTG 
CCA-CTA 
CCC-CTC 
CCA-CTA 
Met1Leu 
Met1Leu 
Pro349Leu 
Ser473Leu 
Arg524Leu 
Leu556Leu 
Pro622Leu 
Pro670Leu 
Pro696Leu 
CCA-CTA 
CGA-CTA 
cATA-TTA 
CCC-CTC 
CAG-CTG 
CCG-CTG 
CCC-CTC 
CCC-CTC 
CCT-CTT 
CGA-CTA 
Pro28Leu 
Arg226Leu 
Ile246Leu 
Pro496Leu 
Gln542Leu 
Pro581Leu 
Pro640Leu 
Pro648Leu 
Pro654Leu 
Arg659Leu 
MSH6 MLH1 Bowel Cancer 1 TCG-TTG 
CCC-CTC 
gGTT-CTT 
Ser580Leu 
Pro656Leu 
Val800Leu 
CCA-CTA 
CGA-CTA 
cATA-TTA 
CCC-CTC 
CAG-CTG 
Pro28Leu 
Arg226Leu 
Ile246Leu 
Pro496Leu 
Gln542Leu 
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CCG-CTG 
CCC-CTC 
CCC-CTC 
CCT-CTT 
CGA-CTA 
Pro581Leu 
Pro640Leu 
Pro648Leu 
Pro654Leu 
Arg659Leu 
MSH6 MSH2 Bowel Cancer 1 TCG-TTG 
CCC-CTC 
gGTT-CTT 
Ser580Leu 
Pro656Leu 
Val800Leu 
cATG-CTG 
cATG-TTG 
CCT-CTT 
TCA-TTA 
CGT-CTT 
aTTG-CTG 
CCA-CTA 
CCC-CTC 
CCA-CTA 
Met1Leu 
Met1Leu 
Pro349Leu 
Ser473Leu 
Arg524Leu 
Leu556Leu 
Pro622Leu 
Pro670Leu 
Pro696Leu 
MSH6 MSH2 Bowel Cancer 1 TCG-TTG 
CCC-CTC 
gGTT-CTT 
Ser580Leu 
Pro656Leu 
Val800Leu 
cATG-CTG 
cATG-TTG 
CCT-CTT 
TCA-TTA 
CGT-CTT 
aTTG-CTG 
CCA-CTA 
CCC-CTC 
CCA-CTA 
Met1Leu 
Met1Leu 
Pro349Leu 
Ser473Leu 
Arg524Leu 
Leu556Leu 
Pro622Leu 
Pro670Leu 
Pro696Leu 
MUTYH MSH6 Bowel Cancer 0 CCA-CTA Pro295Leu TCG-TTG 
CCC-CTC 
gGTT-CTT 
Ser580Leu 
Pro656Leu 
Val800Leu 
PMS2 MSH2 Bowel Cancer 0 CGA-CTA 
TCG-TTG 
Arg563Leu 
Ser815Leu 
cATG-CTG 
cATG-TTG 
CCT-CTT 
TCA-TTA 
CGT-CTT 
aTTG-CTG 
CCA-CTA 
CCC-CTC 
CCA-CTA 
Met1Leu 
Met1Leu 
Pro349Leu 
Ser473Leu 
Arg524Leu 
Leu556Leu 
Pro622Leu 
Pro670Leu 
Pro696Leu 
PMS2 MLH1 Bowel Cancer 1 CGA-CTA 
TCG-TTG 
Arg563Leu 
Ser815Leu 
CCA-CTA 
CGA-CTA 
cATA-TTA 
CCC-CTC 
CAG-CTG 
CCG-CTG 
CCC-CTC 
CCC-CTC 
CCT-CTT 
CGA-CTA 
Pro28Leu 
Arg226Leu 
Ile246Leu 
Pro496Leu 
Gln542Leu 
Pro581Leu 
Pro640Leu 
Pro648Leu 
Pro654Leu 
Arg659Leu 
TP53 MSH2 Bowel Cancer 1 CCC-CTC Pro250Leu CCT-CTT 
TCA-TTA 
CGT-CTT 
aTTG-CTG 
CCA-CTA 
CCC-CTC 
CCA-CTA 
Pro349Leu 
Ser473Leu 
Arg524Leu 
Leu556Leu 
Pro622Leu 
Pro670Leu 
Pro696Leu 
Phenylalanine 
Node1 Node2 Cancer Match Node1 codon 
change 
Node1 Amino acid 
changes 
Node2 codon 
change 
Node2 Amino acid 
changes 
ATM TP53 Breast Cancer 1 TCT-TTT 
TTGc-TTT 
cATT-TTT 
TGT-TTT 
tCTT-TTT 
Ser151Phe 
Leu1574Phe 
Ile1804Phe 
Cys2488Phe 
Leu1420Phe 
cCTC-TTC 
tCTT-TTT 
Leu130Phe 
Leu194Phe 
ATM NBN Breast Cancer 0 TCT-TTT 
TTGc-TTT 
cATT-TTT 
TGT-TTT 
tCTT-TTT 
Ser151Phe 
Leu1574Phe 
Ile1804Phe 
Cys2488Phe 
Leu1420Phe 
cCTT-TTT Leu150Phe 
BRCA1 TP53 Breast Cancer 1 TGC-TTC 
TGC-TTC 
tCTC-TTC 
TCT-TTT 
TCT-TTT 
gGTT-TTT 
Cys44Phe 
Cys47Phe 
Leu52Phe 
Ser186Phe 
Ser1655Phe 
Val1809Phe 
cCTC-TTC 
tCTT-TTT 
Leu130Phe 
Leu194Phe 
BRCA1 ATM Breast Cancer 0 TGC-TTC 
TGC-TTC 
tCTC-TTC 
TCT-TTT 
TCT-TTT 
gGTT-TTT 
Cys44Phe 
Cys47Phe 
Leu52Phe 
Ser186Phe 
Ser1655Phe 
Val1809Phe 
TCT-TTT 
TTGc-TTT 
cATT-TTT 
TGT-TTT 
tCTT-TTT 
Ser151Phe 
Leu1574Phe 
Ile1804Phe 
Cys2488Phe 
Leu1420Phe 
BRCA1 NBN Breast Cancer 0 TGC-TTC 
TGC-TTC 
tCTC-TTC 
TCT-TTT 
TCT-TTT 
gGTT-TTT 
Cys44Phe 
Cys47Phe 
Leu52Phe 
Ser186Phe 
Ser1655Phe 
Val1809Phe 
cCTT-TTT Leu150Phe 
BRCA1 MSH6 Breast Cancer 1 TGC-TTC 
TGC-TTC 
tCTC-TTC 
TCT-TTT 
TCT-TTT 
gGTT-TTT 
Cys44Phe 
Cys47Phe 
Leu52Phe 
Ser186Phe 
Ser1655Phe 
Val1809Phe 
TCT-TTT Ser682Phe 
BRCA1 PALB2 Breast Cancer 0 TGC-TTC 
TGC-TTC 
tCTC-TTC 
TCT-TTT 
TCT-TTT 
gGTT-TTT 
Cys44Phe 
Cys47Phe 
Leu52Phe 
Ser186Phe 
Ser1655Phe 
Val1809Phe 
aCTT-TTT Leu100Phe 
BRCA2 BRCA1 Breast Cancer 1 TTAg-TTT 
TCC-TTC 
TTGg-TTT 
TCT-TTT 
gATC-TTC 
TCT-TTT 
gATC-TTC 
Leu24Phe 
Ser384Phe 
Leu1522Phe 
Ser2522Phe 
Ile2627Phe 
Ser2704Phe 
Ile2944Phe 
TGC-TTC 
TGC-TTC 
tCTC-TTC 
TCT-TTT 
TCT-TTT 
gGTT-TTT 
Cys44Phe 
Cys47Phe 
Leu52Phe 
Ser186Phe 
Ser1655Phe 
Val1809Phe 
BRCA2 ATM Breast Cancer 1 TGC-TTC 
TGC-TTC 
tCTC-TTC 
TCT-TTT 
TCT-TTT 
gGTT-TTT 
Cys44Phe 
Cys47Phe 
Leu52Phe 
Ser186Phe 
Ser1655Phe 
Val1809Phe 
TCT-TTT 
TTGc-TTT 
cATT-TTT 
TGT-TTT 
tCTT-TTT 
Ser151Phe 
Leu1574Phe 
Ile1804Phe 
Cys2488Phe 
Leu1420Phe 
BRCA2 BRCA1 Ovarian 
Cancer 
1 TTAg-TTT 
tTTT-CTT 
TCT-TTT 
Leu24Phe 
Phe2234Leu 
Ser2522Phe 
TGC-TTC 
TGC-TTC 
TCT-TTT 
Cys44Phe 
Cys47Phe 
Ser186Phe 
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gATC-TTC 
aCTT-TTT 
Ile2627Phe 
Leu2686Phe 
TCT-TTT 
gGTT-TTT 
Ser1655Phe 
Val1809Phe 
BRCA2 PALB2 Breast Cancer 0 TTAg-TTT 
TCC-TTC 
TTGg-TTT 
TCT-TTT 
gATC-TTC 
TCT-TTT 
gATC-TTC 
Leu24Phe 
Ser384Phe 
Leu1522Phe 
Ser2522Phe 
Ile2627Phe 
Ser2704Phe 
Ile2944Phe 
aCTT-TTT Leu100Phe 
BRCA2 TP53 Breast Cancer 0 TTAg-TTT 
TCC-TTC 
TTGg-TTT 
TCT-TTT 
gATC-TTC 
TCT-TTT 
gATC-TTC 
Leu24Phe 
Ser384Phe 
Leu1522Phe 
Ser2522Phe 
Ile2627Phe 
Ser2704Phe 
Ile2944Phe 
cCTC-TTC 
tCTT-TTT 
Leu130Phe 
Leu194Phe 
CHEK2 BRCA2 Ovarian 
Cancer 
1 TCT-TTT Ser357Phe TTAg-TTT 
TCT-TTT 
gATC-TTC 
aCTT-TTT 
Leu24Phe 
Ser2522Phe 
Ile2627Phe 
Leu2686Phe 
CHEK2 BRCA2 Breast Cancer 1 gCTT-TTT 
TCT-TTT 
Leu174Phe 
Ser428Phe 
TTAg-TTT 
TCC-TTC 
TTGg-TTT 
TCT-TTT 
gATC-TTC 
TCT-TTT 
gATC-TTC 
Leu24Phe 
Ser384Phe 
Leu1522Phe 
Ser2522Phe 
Ile2627Phe 
Ser2704Phe 
Ile2944Phe 
CHEK2 BRCA2 Prostate 
Cancer 
0 cATC-TTC Ile251Phe cCTT-TTT Leu3055Phe 
CHEK2 ATM Breast Cancer 1 gCTT-TTT 
TCT-TTT 
Leu174Phe 
Ser428Phe 
TCT-TTT 
TTGc-TTT 
cATT-TTT 
TGT-TTT 
tCTT-TTT 
Ser151Phe 
Leu1574Phe 
Ile1804Phe 
Cys2488Phe 
Leu1420Phe 
CHEK2 NBN Breast Cancer 1 gCTT-TTT 
TCT-TTT 
Leu174Phe 
Ser428Phe 
cCTT-TTT Leu150Phe 
CHEK2 TP53 Breast Cancer 1 gCTT-TTT 
TCT-TTT 
Leu174Phe 
Ser428Phe 
cCTC-TTC 
tCTT-TTT 
Leu130Phe 
Leu194Phe 
CHEK2 BRCA1 Breast Cancer 1 gCTT-TTT 
TCT-TTT 
Leu174Phe 
Ser428Phe 
TGC-TTC 
TGC-TTC 
tCTC-TTC 
TCT-TTT 
TCT-TTT 
gGTT-TTT 
Cys44Phe 
Cys47Phe 
Leu52Phe 
Ser186Phe 
Ser1655Phe 
Val1809Phe 
CHEK2 BRCA1 Ovarian 
Cancer 
1 TCT-TTT Ser357Phe TGC-TTC 
TGC-TTC 
TCT-TTT 
TCT-TTT 
gGTT-TTT 
Cys44Phe 
Cys47Phe 
Ser186Phe 
Ser1655Phe 
Val1809Phe 
MSH2 MLH1 Bowel Cancer 1 tCTT-TTT 
aCTT-TTT 
TGT-TTT 
TCC-TTC 
Leu93Phe 
Leu390Phe 
Cys697Phe 
Ser723Phe 
cATC-TTC 
tATC-TTC 
TCC-TTC 
TTAa-TTC 
cATT-TTT 
gCTC-TTC 
Ile19Phe 
Ile25Phe 
Ser44Phe 
Leu166Phe 
Ile565Phe 
Leu582Phe 
MSH6 MLH1 Bowel Cancer 0 TAT-TTT Tyr397Phe cATC-TTC, 
tATC-TTC 
TCC-TTC, 
TTAa-TTC, 
cATT-TTT, 
gCTC-TTC 
Ile19Phe 
Ile25Phe 
Ser44Phe 
Leu166Phe 
Ile565Phe 
Leu582Phe 
MSH6 MSH2 Breast Cancer 0 TAT-TTT Tyr397Phe tCTT-TTT 
aCTT-TTT 
TGT-TTT 
TCC-TTC 
Leu93Phe 
Leu390Phe 
Cys697Phe 
Ser723Phe 
Tryptophan 
Node1 Node2 Cancer Match Node1 codon 
change 
Node1 Amino acid 
changes 
Node2 codon 
change 
Node2 Amino acid 
changes 
BRCA1 TP53 Breast Cancer 1 TGTg-TGG 
TTG-TGG 
aCGG-TGG 
Cys91Trp 
Leu523Trp 
Arg1699Trp 
aCGG-TGG Arg267Trp 
BRCA1 MLH1 Breast Cancer 0 TGTg-TGG 
TTG-TGG 
Cys91Trp 
Leu523Trp 
cCGG-TGG Arg389Trp 
BRCA1 MLH1 Breast Cancer 1 aCGG-TGG Arg1699Trp cCGG-TGG Arg389Trp 
BRCA1 MSH2 Bowel Cancer 0 aCGG-TGG Arg1699Trp tGGG-TGG Gly164Trp 
CHEK2 BRCA2 Breast Cancer 1 tCGG-TGG Arg3Trp TGTg-TGG 
TGTc-TGG 
aCGG-TGG 
Cys161Trp 
Cys554Trp 
Arg3052Trp 
MSH2 MLH1 Bowel Cancer 1 tGGG-TGG Gly164Trp cGGG-TGG 
cCGG-TGG 
cCGG-TGG 
gAGG-TGG 
Gly67Trp 
Arg389Trp 
Arg687Trp 
Arg755Trp 
MSH3 MLH1 Bowel Cancer 0 TTG-TGG Leu911Trp cGGG-TGG 
cCGG-TGG 
cCGG-TGG 
gAGG-TGG 
Gly67Trp 
Arg389Trp 
Arg687Trp 
Arg755Trp 
MSH6 MLH1 Bowel Cancer 1 TGCc-TGG 
gCGG-TGG 
Cys765Trp 
Arg772Trp 
cGGG-TGG 
cCGG-TGG 
cCGG-TGG 
gAGG-TGG 
Gly67Trp 
Arg389Trp 
Arg687Trp 
Arg755Trp 
MSH6 MSH2 Bowel Cancer 0 gCGG-TGG Arg772Trp tGGG-TGG Gly164Trp 
BRCA1 MSH3 Bowel Cancer 0 aCGG-TGG Arg1699Trp TTG-TGG Leu911Trp 
BRCA1 MRE11A Ovarian 
Cancer 
1 TGTt-TGG 
tCGG-TGG 
Cys644Trp 
Arg841Trp 
gCGG-TGG Arg305Trp 
BRCA1 MSH6 Bowel Cancer 1 aCGG-TGG Arg1699Trp TGCc-TGG 
gCGG-TGG 
Cys765Trp 
Arg772Trp 
BRCA1 PALB2 Breast Cancer 1 TGTg-TGG 
TTG-TGG 
aCGG-TGG 
Cys91Trp 
Leu523Trp 
Arg1699Trp 
TTG-TGG Leu939Trp 
BRCA2 BRCA1 Breast Cancer 1 TGTg-TGG 
TGTc-TGG 
aCGG-TGG 
Cys161Trp 
Cys554Trp 
Arg3052Trp 
TGTg-TGG 
TTG-TGG 
aCGG-TGG 
Cys91Trp 
Leu523Trp 
Arg1699Trp 
BRCA2 BRCA1 Ovarian 
Cancer 
1 TGTg-TGG Cys161Trp TGTt-TGG 
tCGG-TGG 
Cys644Trp 
Arg841Trp 
BRCA2 PALB2 Breast Cancer 0 TGTg-TGG 
TGTc-TGG 
aCGG-TGG 
Cys161Trp 
Cys554Trp 
Arg3052Trp 
TTG-TGG Leu939Trp 
BRCA2 TP53 Breast Cancer 1 TGTg-TGG Cys161Trp aCGG-TGG Arg267Trp 
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TGTc-TGG 
aCGG-TGG 
Cys554Trp 
Arg3052Trp 
CHEK2 BRCA1 Breast Cancer 1 tCGG-TGG Arg3Trp TGTg-TGG 
TTG-TGG 
aCGG-TGG 
Cys91Trp 
Leu523Trp 
Arg1699Trp 
CHEK2 TP53 Breast Cancer 1 tCGG-TGG Arg3Trp aCGG-TGG Arg267Trp 
MSH3 MSH2 Bowel Cancer 0 TTG-TGG Leu911Trp tGGG-TGG Gly164Trp 
BRCA1 MLH1 Bowel Cancer 1 aCGG-TGG Arg1699Trp cCGG-TGG Arg389Trp 
Valine 
Node1 Node2 Cancer Match Node1 codon 
change 
Node1 Amino acid 
changes 
Node2 codon 
change 
Node2 Amino acid 
changes 
ATM TP53 Breast Cancer 0 aCTG-GTG 
tATA-GTA 
tCTG-GTG 
tTTG-GTG 
cCTT-GTT 
cATT-GTT 
cCTA-GTA 
GCA-GTA 
aATG-GTG 
GAT-GTT 
Leu546Val 
Ile550Val 
Leu702Val 
Leu1255Val 
Leu1493Val 
Ile2030Val 
Leu2330Val 
Ala2466Val 
Met3011Val 
Asp1853Val 
GCC-GTC Ala138Val 
BRCA1 ACACA Ovarian 
Cancer 
0 aATG-GTG 
tTTG-GTG 
cATG-GTG 
GAT-GTT 
GCG-GTG 
GAT-GTT 
GGT-GTT 
Met1Val 
Leu246Val 
Met1400Val 
Asp1692Val 
Ala1708Val 
Asp1739Val 
Gly1788Val 
GCG-GTG Ala2271Val 
BRCA1 AURKA Breast Cancer 0 aATG-GTG 
aATC-GTC 
tTTG-GTG 
GGT-GTT 
GGT-GTT 
GCG-GTG 
gATT-GTT 
cATG-GTG 
aATG-GTG 
GCG-GTG 
Met1Val 
Ile21Val 
Leu246Val 
Gly263Val 
Gly552Val 
Ala622Val 
Ile1318Val 
Met1400Val 
Met1628Val 
Ala1708Val 
GCA-GTA Ala213Val 
BRCA1 TP53 Breast Cancer 0 aATG-GTG 
aATC-GTC 
tTTG-GTG 
GGT-GTT 
GGT-GTT 
GCG-GTG 
gATT-GTT 
cATG-GTG 
aATG-GTG 
GCG-GTG 
Met1Val 
Ile21Val 
Leu246Val 
Gly263Val 
Gly552Val 
Ala622Val 
Ile1318Val 
Met1400Val 
Met1628Val 
Ala1708Val 
GCC-GTC Ala138Val 
BRCA1 ATM Breast Cancer 1 aATG-GTG 
aATC-GTC 
tTTG-GTG 
GGT-GTT 
GGT-GTT 
GCG-GTG 
gATT-GTT 
cATG-GTG 
aATG-GTG 
GCG-GTG 
Met1Val 
Ile21Val 
Leu246Val 
Gly263Val 
Gly552Val 
Ala622Val 
Ile1318Val 
Met1400Val 
Met1628Val 
Ala1708Val 
aCTG-GTG 
tATA-GTA 
tCTG-GTG 
tTTG-GTG 
cCTT-GTT 
cATT-GTT 
cCTA-GTA 
GCA-GTA 
aATG-GTG 
GAT-GTT 
Leu546Val 
Ile550Val 
Leu702Val 
Leu1255Val 
Leu1493Val 
Ile2030Val 
Leu2330Val 
Ala2466Val 
Met3011Val 
Asp1853Val 
BRCA1 MSH6 Breast Cancer 0 aATG-GTG 
aATC-GTC 
tTTG-GTG 
GGT-GTT 
GGT-GTT 
GCG-GTG 
gATT-GTT 
cATG-GTG 
aATG-GTG 
GCG-GTG 
Met1Val 
Ile21Val 
Leu246Val 
Gly263Val 
Gly552Val 
Ala622Val 
Ile1318Val 
Met1400Val 
Met1628Val 
Ala1708Val 
cATA-GTA Ile251Val 
BRCA2 ATM Breast Cancer 1 aATG-GTG 
aATC-GTC 
tTTG-GTG 
GGT-GTT 
GGT-GTT 
GCG-GTG 
gATT-GTT 
cATG-GTG 
aATG-GTG 
GCG-GTG 
Met1Val 
Ile21Val 
Leu246Val 
Gly263Val 
Gly552Val 
Ala622Val 
Ile1318Val 
Met1400Val 
Met1628Val 
Ala1708Val 
aCTG-GTG 
tATA-GTA 
tCTG-GTG 
tTTG-GTG 
cCTT-GTT 
cATT-GTT 
cCTA-GTA 
GCA-GTA 
aATG-GTG 
GAT-GTT 
Leu546Val 
Ile550Val 
Leu702Val 
Leu1255Val 
Leu1493Val 
Ile2030Val 
Leu2330Val 
Ala2466Val 
Met3011Val 
Asp1853Val 
BRCA2 FANCE Breast Cancer 0 GAT-GTT 
GAT-GTT 
GTAa-GTT 
cATG-GTG 
gCTC-GTC 
aATG-GTG 
tCTT-GTT 
aATT-GTT 
GGC-GTC 
GCA-GTA 
GAA-GTA 
GAT-GTT 
cATA-GTA 
cATG-GTG 
aATT-GTT 
Asp191Val 
Asp224Val 
Val465Val 
Met784Val 
Leu1019Val 
Met1272Val 
Leu1904Val 
Ile1929Val 
Gly2044Val 
Ala2466Val 
Glu2663Val 
Asp2723Val 
Ile2840Val 
Met2952Val 
Ile3412Val 
tCTG-GTG Leu1143Val 
BRCA2 BRCA1 Breast Cancer 1 GAT-GTT 
GAT-GTT 
cATG-GTG 
gCTC-GTC 
aATG-GTG 
tCTT-GTT 
aATT-GTT 
GGC-GTC 
GCA-GTA 
GAA-GTA 
GAT-GTT 
cATA-GTA 
cATG-GTG 
aATT-GTT 
Asp191Val 
Asp224Val 
Met784Val 
Leu1019Val 
Met1272Val 
Leu1904Val 
Ile1929Val 
Gly2044Val 
Ala2466Val 
Glu2663Val 
Asp2723Val 
Ile2840Val 
Met2952Val 
Ile3412Val 
aATG-GTG 
aATC-GTC 
tTTG-GTG 
GGT-GTT 
GGT-GTT 
GCG-GTG 
gATT-GTT 
cATG-GTG 
aATG-GTG 
GCG-GTG 
Met1Val 
Ile21Val 
Leu246Val 
Gly263Val 
Gly552Val 
Ala622Val 
Ile1318Val 
Met1400Val 
Met1628Val 
Ala1708Val 
BRCA2 BRCA1 Ovarian 
Cancer 
1 GAT-GTT 
GTAa-GTT 
GAA-GTA 
GAT-GTT 
Asp191Val 
Val465Val 
Glu2663Val 
Asp2723Val 
aATG-GTG 
tTTG-GTG 
cATG-GTG 
GAT-GTT 
Met1Val 
Leu246Val 
Met1400Val 
Asp1692Val 
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GCG-GTG 
GAT-GTT 
GGT-GTT 
Ala1708Val 
Asp1739Val 
Gly1788Val 
BRCA2 TP53 Breast Cancer 0 GAT-GTT 
GAT-GTT 
GTAa-GTT 
cATG-GTG 
gCTC-GTC 
aATG-GTG 
tCTT-GTT 
aATT-GTT 
GGC-GTC 
GCA-GTA 
GAA-GTA 
GAT-GTT 
cATA-GTA 
cATG-GTG 
aATT-GTT 
Asp191Val 
Asp224Val 
Val465Val 
Met784Val 
Leu1019Val 
Met1272Val 
Leu1904Val 
Ile1929Val 
Gly2044Val 
Ala2466Val 
Glu2663Val 
Asp2723Val 
Ile2840Val 
Met2952Val 
Ile3412Val 
GCC-GTC Ala138Val 
CHEK2 BRCA2 Breast Cancer 1 aATT-GTT Ile189Val GAT-GTT 
cATG-GTG 
gCTC-GTC 
aATG-GTG 
tCTT-GTT 
aATT-GTT 
GGC-GTC 
GCA-GTA 
cATA-GTA 
cATG-GTG 
aATT-GTT 
Asp224Val 
Met784Val 
Leu1019Val 
Met1272Val 
Leu1904Val 
Ile1929Val 
Gly2044Val 
Ala2466Val 
Ile2840Val 
Met2952Val 
Ile3412Val 
CHEK2 ATM Breast Cancer 1 aATT-GTT Ile189Val aCTG-GTG 
tATA-GTA 
tCTG-GTG 
tTTG-GTG 
cCTT-GTT 
GTT-GCT 
GTT-GCT 
cATT-GTT 
cCTA-GTA 
GTA-GCA 
GCA-GTA 
aATG-GTG 
GAT-GTT 
Leu546Val 
Ile550Val 
Leu702Val 
Leu1255Val 
Leu1493Val 
Val1570Ala 
Val1729Ala 
Ile2030Val 
Leu2330Val 
Val2439Ala 
Ala2466Val 
Met3011Val 
Asp1853Val 
CHEK2 TP53 Breast Cancer 0 aATT-GTT Ile189Val GCC-GTC Ala138Val 
CHEK2 BRCA1 Breast Cancer 1 aATT-GTT Ile189Val aATG-GTG 
aATC-GTC 
tTTG-GTG 
GGT-GTT 
GGT-GTT 
GCG-GTG 
gATT-GTT 
cATG-GTG 
aATG-GTG 
GCG-GTG 
Met1Val 
Ile21Val 
Leu246Val 
Gly263Val 
Gly552Val 
Ala622Val 
Ile1318Val 
Met1400Val 
Met1628Val 
Ala1708Val 
FANCA BRCA1 Breast Cancer 0 tCTG-GTG Leu1143Val aATG-GTG 
aATC-GTC 
tTTG-GTG 
GGT-GTT 
GGT-GTT 
GCG-GTG 
gATT-GTT 
cATG-GTG 
aATG-GTG 
GCG-GTG 
Met1Val 
Ile21Val 
Leu246Val 
Gly263Val 
Gly552Val 
Ala622Val 
Ile1318Val 
Met1400Val 
Met1628Val 
Ala1708Val 
MLH3 MLH1 Bowel Cancer 0 tATG-GTG Met809Val GCG-GTG 
gTTC-GTC 
GCT-GTT 
aCTG-GTG 
GCC-GTC 
cATC-GTC 
GGT-GTT 
cTTG-GTG 
GCA-GTA 
GAT-GTT 
GCT-GTT 
tCTG-GTG 
gCTT-GTT 
gCTC-GTC 
GCT-GTT 
tCTG-GTG 
GAT-GTT 
Ala21Val 
Phe80Val 
Ala111Val 
Leu135Val 
Ala160Val 
Ile219Val 
Gly244Val 
Leu272Val 
Ala281Val 
Asp304Val 
Ala353Val 
Leu400Val 
Leu555Val 
Leu582Val 
Ala681Val 
Leu729Val 
Asp737Val 
MSH2 MLH1 Bowel Cancer 2 cATG-GTG 
GCG-GTG 
GAC-GTC 
tCTT-GTT 
cATA-GTA 
gATA-GTA 
GCG-GTG 
aCTC-GTC 
GGT-GTT 
aCTT-GTT 
GAG-GTG 
GCT-GTT 
GGG-GTG 
GCT-GTT 
tATG-GTG 
Met1Val 
Ala45Val 
Asp49Val 
Leu92Val 
Ile169Val 
Ile216Val 
Ala272Val 
Leu279Val 
Gly315Val 
Leu390Val 
Glu562Val 
Ala600Val 
Gly692Val 
Ala714Val 
Met813Val 
GCG-GTG 
gTTC-GTC 
GCT-GTT 
aCTG-GTG 
GCC-GTC 
cATC-GTC 
GGT-GTT 
cTTG-GTG 
GCA-GTA 
GAT-GTT 
GCT-GTT 
tCTG-GTG 
gCTT-GTT 
gCTC-GTC 
GCT-GTT 
tCTG-GTG 
GAT-GTT 
Ala21Val 
Phe80Val 
Ala111Val 
Leu135Val 
Ala160Val 
Ile219Val 
Gly244Val 
Leu272Val 
Ala281Val 
Asp304Val 
Ala353Val 
Leu400Val 
Leu555Val 
Leu582Val 
Ala681Val 
Leu729Val 
Asp737Val 
MSH6 MLH1 Bowel Cancer 1 GCC-GTC 
cATA-GTA 
cATC-GTC 
gATG-GTG 
GCT-GTT 
GAA-GTA 
Ala20Val 
Ile251Val 
Ile425Val 
Met492Val 
Ala787Val 
Glu1163Val 
 
GCG-GTG 
gTTC-GTC 
GCT-GTT 
aCTG-GTG 
GCC-GTC 
cATC-GTC 
GGT-GTT 
cTTG-GTG 
GCA-GTA 
GAT-GTT 
GCT-GTT 
tCTG-GTG 
gCTT-GTT 
gCTC-GTC 
tATC-GTC 
Ala21Val 
Phe80Val 
Ala111Val 
Leu135Val 
Ala160Val 
Ile219Val 
Gly244Val 
Leu272Val 
Ala281Val 
Asp304Val 
Ala353Val 
Leu400Val 
Leu555Val 
Leu582Val 
Ile655Val 
Ala681Val 
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GCT-GTT 
tCTG-GTG 
GAT-GTT 
Leu729Val 
Asp737Val 
MSH6 MLH1 Womb Cancer 1 GCC-GTC 
cATA-GTA 
cATC-GTC 
gATG-GTG 
GCT-GTT 
GAA-GTA 
Ala20Val 
Ile251Val 
Ile425Val 
Met492Val 
Ala787Val 
Glu1163Val 
GCG-GTG 
gTTC-GTC 
GCT-GTT 
aCTG-GTG 
GCC-GTC 
cATC-GTC 
GGT-GTT 
cTTG-GTG 
GCA-GTA 
GAT-GTT 
GCT-GTT 
tCTG-GTG 
gCTT-GTT 
gCTC-GTC 
tATC-GTC 
GCT-GTT 
tCTG-GTG 
GAT-GTT 
Ala21Val 
Phe80Val 
Ala111Val 
Leu135Val 
Ala160Val 
Ile219Val 
Gly244Val 
Leu272Val 
Ala281Val 
Asp304Val 
Ala353Val 
Leu400Val 
Leu555Val 
Leu582Val 
Ile655Val 
Ala681Val 
Leu729Val 
Asp737Val 
MSH6 MSH2 Bowel Cancer 1 cATC-GTC 
gATG-GTG 
GCT-GTT 
GAA-GTA 
Ile425Val 
Met492Val 
Ala787Val 
Glu1163Val 
cATG-GTG 
GCG-GTG 
GAC-GTC 
tCTT-GTT 
cATA-GTA 
gATA-GTA 
GCG-GTG 
aCTC-GTC 
GGT-GTT 
aCTT-GTT 
GAG-GTG 
GCT-GTT 
GGG-GTG 
GCT-GTT 
tATG-GTG 
Met1Val 
Ala45Val 
Asp49Val 
Leu92Val 
Ile169Val 
Ile216Val 
Ala272Val 
Leu279Val 
Gly315Val 
Leu390Val 
Glu562Val 
Ala600Val 
Gly692Val 
Ala714Val 
Met813Val 
MUTYH MSH6 Bowel Cancer 1 GCC-GTC Ala373Val GCC-GTC 
cATC-GTC 
gATG-GTG 
GCT-GTT 
GAA-GTA 
Ala20Val 
Ile425Val 
Met492Val 
Ala787Val 
Glu1163Val 
PMS2 MSH2 Bowel Cancer 2 cATG-GTG Met1Val cATG-GTG 
GCG-GTG 
GAC-GTC 
tCTT-GTT 
cATA-GTA 
gATA-GTA 
GCG-GTG 
aCTC-GTC 
GGT-GTT 
aCTT-GTT 
GAG-GTG 
GCT-GTT 
GGG-GTG 
GCT-GTT 
tATG-GTG 
Met1Val 
Ala45Val 
Asp49Val 
Leu92Val 
Ile169Val 
Ile216Val 
Ala272Val 
Leu279Val 
Gly315Val 
Leu390Val 
Glu562Val 
Ala600Val 
Gly692Val 
Ala714Val 
Met813Val 
PMS2 MLH1 Bowel Cancer 0 cATG-GTG Met1Val GCG-GTG 
gTTC-GTC 
GCT-GTT 
aCTG-GTG 
GCC-GTC 
cATC-GTC 
GGT-GTT 
cTTG-GTG 
GCA-GTA 
GAT-GTT 
GCT-GTT 
tCTG-GTG 
gCTT-GTT 
gCTC-GTC 
GCT-GTT 
tCTG-GTG 
GAT-GTT 
Ala21Val 
Phe80Val 
Ala111Val 
Leu135Val 
Ala160Val 
Ile219Val 
Gly244Val 
Leu272Val 
Ala281Val 
Asp304Val 
Ala353Val 
Leu400Val 
Leu555Val 
Leu582Val 
Ala681Val 
Leu729Val 
Asp737Val 
RAD23B XPC Lung Cancer 0 GCT-GTT Ala249Val GCG-GTG Ala499Val 
TP53 AURKA Breast Cancer 0 GCC-GTC Ala138Val GCA-GTA Ala213Val 
XRCC2 RAD51C Breast Cancer 0 aATT-GTT 
tTTT-GTT 
Ile95Val 
Phe270Val 
GGT-GTT 
aTTA-GTA 
Gly125Val 
Leu262Val 
 
 
 
 
